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 Summary   
 Due to the large surface area of the gut and its continual exposure to a wide 
variety of agents including dietary constituents, commensal bacteria and 
pathogens, the intestinal arm of the immune system has evolved to be the largest 
component of the immune system. It must be able to discriminate between 
harmless and harmful antigens, so that it can induce tolerance to harmless 
commensal, self or dietary antigens, but active immunity against pathogens. As 
the sentinels of the immune system, intestinal dendritic cells (DCs) are central to 
these processes, continually sampling antigen in the environment and migrating to 
the mesenteric lymph nodes (MLNs), where they present the antigen to naïve T 
cells and induce appropriate T cell responses. However the nature and functions 
of DCs in the intestine remains a topic of debate. Their characterisation has been 
hampered by the use of non-specific and overlapping markers which has led to 
intestinal DCs being confused with other cells of the mononuclear phagocyte 
system, especially macrophages (mφs) which vastly outnumber DCs in the 
intestinal mucosa. While considerable progress has been made in recent years 
with the identification of CD103 and CX3CR1 as mutually exclusive markers of 
DCs and mφs respectively, it has become assumed that CD103+ DCs are 
intrinsically tolerogenic and thus it remains unclear how DCs contribute to active 
immunity in the intestine. Furthermore it is unknown whether CD103 is sufficient to 
define all intestinal DCs, or whether bona fide CD103- DCs may also exist. Thus a 
major aim of my project was to develop methods that allowed precise 
characterisation of the mononuclear phagocytes in the intestinal lamina propria 
(LP) and examine the functions of phenotypically defined subsets. As part of this, I 
also examined the contribution of the inhibitory signalling receptor, signal 
regulatory protein alpha (SIRPα) co-expressed by CD11b+ DCs, in regulating 
intestinal DC function. 
In Chapter 3, I set out to examine the phenotype of mononuclear 
phagocytes in the small intestine lamina propria (SI LP). Initially I confirmed 
previous studies that CD103 and CX3CR1 were mutually exclusive markers of 
DCs and mφs respectively. This identified 2 populations of DCs separated on the 
basis of CD11b expression, together with two populations of mφs distinguished by 
22 
 
 
their levels of CX3CR1. However, further experiments examining F4/80 expression 
in combination with the recently identified mφ-specific marker CD64 showed that 
the CX3CR1int CD103- MPs were heterogeneous. Although the majority were 
F4/80+CD64+CD11b+ mφs, I could also identify two additional populations that 
were F4/80-CD64- and could be separated on the basis of CD11b expression. I 
hypothesised these were DCs and this was supported by the fact that all 4 subsets 
of putative DCs could also be found amongst CD11c+MHCIIhi migratory DCs in the 
MLNs and in pseudo-afferent intestinal lymph. All the subsets also expressed 
genes and markers of DCs but not mφs and were dependent on Flt3L in vivo. 
Unlike CD64+ mφs, the DC subsets had no ability to phagocytose E. coli particles.  
Four similar subsets were also identified in the colonic LP, however the 
proportions of the subsets in this location were distinct from those seen in the SI 
LP. While the CD103+CD11b+ DCs were the main subset in the SI LP, in the 
colonic LP the CD103+CD11b- DCs dominated.  
Having identified two novel populations of genuine CD103- DCs in the 
intestinal LP, in Chapter 4 I went on to examine their origin. Previous reports had 
shown that CD103+ LP DCs were derived from DC-committed precursors (pre-
DCs), whereas CD103- MPs were reported to be of monocyte origin. However as I 
had shown the CD103- MPs to include both DCs and mφs, it was necessary to re-
examine their origin using appropriate gating strategies.  Adoptive transfer of pre-
DCs from the BM into resting WT mice generated all subsets of DCs in the LP, 
including the two novel populations of CD103- DCs I had identified. In contrast 
adoptive transfer of Ly6Chi monocytes into monocytopenic CCR2-/- recipients 
generated mφs exclusively. By comparing the small intestine, colon and spleen, I 
could show that the development of pre-DCs was determined by the tissue they 
entered, as the progeny took on the same subset profiles as seen in the 
endogenous DC populations. Thus the differentiation of pre-DCs appears to be 
driven by the local microenvironment. By tracking the appearance of donor-derived 
DCs over time, I could monitor their differentiation in situ. These studies and 
experiments using BrdU incorporation showed that all DC subsets turned over 
much more rapidly in vivo than mφs and that a significant proportion were actively 
dividing in situ. No clear differences suggesting a precursor-product relationship 
between any of the DC subsets could be seen in these kinetic experiments.  To 
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gain a better idea of how the DC subsets might develop, I also examined them in 
neonatal animals and examined the effects of administering broad-spectrum 
antibiotics. These studies demonstrated that the CD103+CD11b+ DCs were likely 
regulated by the presence of specific microbiota as they did not develop in the 
neonatal animals until day 7 after birth and were increased in proportion following 
administration of antibiotics.  
In Chapter 5, I examined how the DC populations might behave during 
inflammation, using DSS colitis, post-operative ileus and infection with Citrobacter 
rodentium as models. DSS-colitis caused considerable inflammatory infiltrate and 
the number of DCs was increased, however there were no subset specific 
differences. Post-operative ileus also caused inflammation characterised by 
monocyte and neutrophil infiltration, but had few effects on the DC populations.  
Infection with C. rodentium resulted in a selective increase in the number of 
CD103- DCs in the colonic LP, suggesting these may be involved in modulating 
the Th17 response which characterises the protective immune response in this 
infection. By transferring pre-DCs into colitic mice, I found that these still gave rise 
to all the DC subsets during inflammation. 
In Chapter 6, I examined the functions of the phenotypically defined subsets 
of LP DCs by pulsing them with ovalbumin (OVA) protein in vitro and culturing 
them with OVA-specific CD4+ or CD8+ T cells. Consistent with their expression of 
CD8α and XCR1, I found the CD103+CD11b- DCs to be the most efficient at 
cross-presenting antigen to naïve CD8+ T cells and they were also the most 
efficient inducers of IFNγ-producing CD4+ T cells. All populations of DCs could 
induce FoxP3+ TReg cells, but consistent with their ability to produce retinoic acid 
as measured by the ALDEFLUOR assay, the CD103+ DC subsets were most 
efficient at this. The CD103+CD11b- subset also expressed the TGFβ-activating 
integrin αvβ8. In contrast, induction of IL17a-producing CD4+ T cells was a 
function of CD103+CD11b+ and CD103-CD11b+ DCs, with the latter being the most 
efficient.  
In Chapters 7 and 8, I examined the role of the inhibitory molecule SIRPα in 
intestinal DC behaviour by examining the DC populations in SIRPα mutant (mt) 
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mice, which have a truncated cytoplasmic domain and hence cannot signal 
intracellularly. Despite being expressed by most myeloid cells including all CD11b+ 
DC subsets and CD64+ mφs, SIRPα mt mice had a selective defect in the number 
of CD103+CD11b+ DCs in the LP and MLN. This correlated with a reduction in the 
number of Th17 cells in the LP of steady state SIRPα mt mice and these mice 
showed reduced levels of Th17 cell induction after antigen-specific immunisation 
and infection by C. rodentium. In parallel, SIRPα mt mice had impaired clearance 
of C. rodentium infection. T cells from SIRPα mt mice did not have an intrinsic 
defect in their ability to be polarised to the Th17 phenotype and CD103+CD11b+ 
DCs from SIRPα mt LP were fully capable of priming Th17 cells in vitro. They also 
produced normal amounts of the Th17 inducing cytokines IL1β and IL6. As total 
DCs from SIRPα mt mice produced lower than normal levels of these cytokines, 
these findings suggest that the defective induction of Th17 responses in vivo 
reflects the lower numbers of CD103+CD11b+ DC in these mice, rather than a 
defect in their function. However, preliminary studies investigating the role of 
CD103-CD11b+ DCs from these mice in the induction of Th17 responses suggests 
that lack of SIRPα signalling in these cells may also contribute to the reduced Th17 
cell population observed in the LP. 
Having identified these defects in Chapter 7, in Chapter 8 I went on to 
examine how the SIRPα mutation might be affecting the homeostasis of 
CD103+CD11b+ DCs. By competitively transferring pre-DCs from WT and SIRPα 
mt mice into WT recipients, I found that the SIRPα mt precursors generated 
CD103+CD11b+ DCs in the LP more rapidly than WT pre-DCs. Although this 
seemed to be at odds with the reduced numbers of these DCs in the SIRPα mt 
intestine, further work revealed that the CD103+CD11b+ DCs from SIRPα mt LP 
expressed higher basal levels of CD86 than their WT counterparts, while Annexin 
V staining suggested that these DCs were apoptosing more rapidly in SIRPα mt 
MLN. As these results suggested that the lack of CD103+CD11b+ DCs in SIRPα 
mt mice might reflect increased activation and susceptibility to death because of 
the absence of SIRPα’s inhibitory signal, I examined whether this would also lead 
to more efficient migration into afferent lymph. However there were no differences 
in the proportions of CD103+CD11b+ DCs found in pseudo-afferent intestinal 
lymph from SIRPα mt and WT mice. Thus more rapid departure into lymph may be 
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sufficiently marked to counterbalance the decreased population in the mucosa. 
Further experiments are clearly needed to test the hypothesis that lack of SIRPα 
mediated inhibitory signalling allows hyperactivation of CD103+CD11b+ DCs and 
subsequent poor survival, as well as to determine why it is restricted to this subset.  
Finally in Chapter 9, I examined the role of CCR2 in intestinal DC behaviour, 
aiming to follow up a recent report which had suggested that CD103- Zbtb46-
expressing DCs in the LP were monocyte-derived based on their depletion 
following administration of an anti-CCR2 antibody. I found CCR2-/- mice had a 
selective reduction in the number of CD103-CD11b+ DCs in the LP and amongst 
migratory DCs in MLN, as well as amongst CD11b+ DCs in the spleen. 
Competitive WT:CCR2-/- BM chimeras experiments demonstrated that the 
requirement for CCR2 in DC development was cell intrinsic. Although antibody 
staining, fluorescent CCL2-uptake and RFP expression in CCR2+/RFP mice 
revealed different levels of CCR2 expression, each method showed there was a 
proportion of CD103-CD11b+ DCs expressing CCR2. The CCR2+ subset of 
CD103-CD11b+ DCs in LP expressed similar levels of the DC markers Zbtb46, 
CCR7 and Flt3 to the other bona fide intestinal DCs and were generated by 
adoptive transfer of pre-DCs, a proportion of which also expressed CCR2. A 
similar pattern of expression was found on CD103-SIRPα+ DCs isolated from the 
human colonic LP. The CCR2+CD103-CD11b+ DCs were the most efficient 
inducers of Th17 responses by naïve CD4+ T cells in vitro and CCR2-/- mice had 
reduced generation of Th17 responses after antigen specific immunisation and C. 
rodentium infection in vivo. This enhanced ability of CCR2+CD103-CD11b+ DCs to 
induce Th17 responses correlated with higher constitutive and LPS induced 
expression of IL12/IL23p40, which was presumed to be IL23. Together these 
findings reveal an entirely novel population of CCR2+ and CCR2-dependent, 
genuine DCs which have a selective ability to drive Th17 responses. 
Taken together, the data in this thesis represent an important step forward 
in our understanding of intestinal dendritic cells. By developing rigorous gating 
strategies, I have been able to distinguish accurately between the various 
populations of intestinal mononuclear phagocytes and have identified two novel 
populations of CD103- conventional DCs that are derived from DC committed 
precursors rather than monocytes as previously assumed. Furthermore, by 
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showing there is a population of bona fide intestinal DC which expresses CCR2 
and is dependent on this receptor in vivo, my project may help explain why 
previous studies have concluded that intestinal DCs may be derived from 
Ly6ChiCCR2+ monocytes. Importantly, the phenotypic subsets I identified appear 
to have functional consequences, although my work on SIRPα mt mice and on 
CCR2 expression have generated somewhat contradictory results on exactly how 
the different subsets of CD11b+ DCs contribute to Th17 polarisation. One 
explanation for this may be that these subsets are related members of a linear 
differentiation pathway, in which CD103-CD11b+ DCs precede the development of 
the CD103+CD11b+ subset. Further work on the nature of the precursors of these 
subsets at the single cell level will be required to shed light on this possibility, while 
it will also be important to investigate the nature of the local factors which 
determine the unique differentiation pathways of intestinal DCs. 
   
 
 
 
 
 
 Chapter 1 General Introduction 
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1.1 Introduction 
The innate and adaptive arms of the immune system have evolved complex 
and distinct mechanisms to ensure that harmful agents are eradicated from the 
body, while preventing excessive damage and chronic inflammation in host tissues. 
The innate immune system provides a rapid non-specific response to pathogens 
and tissue damage, whereas the adaptive immune system responds in a delayed 
antigen-specific manner resulting in the generation of immunological memory that 
allows rapid and specific responses to be initiated upon re-exposure to the same 
harmful agents. Although the immune system must act to eliminate pathogens, it 
must also prevent unnecessary responses to both self and innocuous foreign 
antigens, such as dietary constituents, commensal and mutualistic bacteria. This 
crucial balance between immunity and tolerance is most apparent in the intestine, 
which encounters more foreign antigen than any other part of the immune system. 
The intestine represents one of the main routes of entry for pathogens, while also 
being home to an extensive and complex microbiota and being exposed 
continuously to an array of harmless dietary antigens. Dendritic cells (DCs) in the 
intestine are critical in this process, sampling the intestinal environment and 
subsequently migrating to the mesenteric lymph nodes (MLN) where they present 
antigen to naïve T cells. These T cells then proliferate and differentiate into gut 
homing effector or regulatory T cells allowing for active immunity or tolerance to be 
induced as required. 
1.2 Dendritic Cells 
Dendritic cells are myeloid cells named after their characteristic morphology, 
consisting of numerous long and dynamic finger-like cytoplasmic processes 
resembling the dendrites of nerve cells. They were first described by Ralph 
Steinman and Zanvil Cohn in 1973 (Steinman, 1973) and act as specialised 
sentinel cells that survey tissues, sampling the environment by ingesting large 
amounts of the extracellular fluid and its components through a process known as 
macropinocytosis. Like other innate immune cells such as macrophages and 
neutrophils, DCs can degrade any pathogens they engulf, but in contrast to these 
cells, the main role of DCs is not pathogen clearance, but rather to activate naïve 
T lymphocytes in the draining lymph nodes (LNs). By doing so, DCs form the 
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crucial link between the innate and adaptive arms of the immune system, with their 
importance recognised in 2011, when the late Ralph Steinman was awarded the 
Nobel Prize for their discovery. After sampling material from the environment, DCs 
process proteins into small peptides, which they then display on their cell surface 
in combination with major histocompatibility complex molecules (MHC) and 
migrate to the T cell zones of the lymph nodes (LNs). There they present the 
antigenic peptides to naïve T lymphocytes, inducing their proliferation and 
polarisation into antigen specific effector or regulatory T cells. The activated T 
lymphocytes subsequently home to the tissue of the DC origin and orchestrate the 
immune response through their production of a collection of immunomodulatory 
cytokines such as IL17, IFNγ, IL4, IL5, IL10 and others (Banchereau and 
Steinman, 1998).  
1.2.1 Identifying Dendritic Cells 
Given their role as linkers of the innate and adaptive immune systems, 
considerable research has gone into the accurate identification and 
characterisation of DCs. This is especially important given the significant 
phenotypic overlap between DCs and other mononuclear phagocytes such as 
macrophages (mφs), which is described in detail below.  DCs can be classified into 
two distinct groups, classical or conventional DCs (referred to here as DCs) as 
described originally by Ralph Steinman and Zanvil Cohn (Steinman, 1973; 
Steinman and Cohn, 1974; Steinman et al., 1974) and plasmacytoid DCs (pDCs), 
first identified by Lennert and Remmele (Lennert and Remmele, 1958), although 
these were not referred to as pDCs until later (Facchetti et al., 2003). Classical 
DCs of various subtypes in the intestine are the focus of this thesis. 
In addition to their characteristic morphology, DCs, like other bone marrow 
(BM) derived leukocytes, express the haematopoietic marker CD45, while lacking 
expression of T and B cell, granulocyte, NK cell and erythrocyte lineage markers 
(Merad et al., 2013). Surface expression of the integrin CD11c and major 
histocompatibility complex class II molecules (MHCII) (Shortman and Liu, 2002) 
have been used extensively to identify DCs. However, despite its continued use to 
identify DCs, the discovery of the CD11c antigen (Metlay et al., 1990) has only 
served to complicate the specific identification of these cells. Although antibodies 
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raised against this molecule bound splenic DCs with high affinity, it was also found 
to bind peritoneal macrophages and T cells (Metlay et al., 1990; Rogler et al., 
1998) (and reviewed in (Hume, 2008)). Despite this, CD11c still became the 
definitive ‘DC’ marker and the CD11c-DTR mice (Jung et al., 2002) and CD11c-cre 
mice (Caton et al., 2007) became popular tools for examining the in vivo role of 
DCs. Unfortunately, in reality, these tools only enable the examination of the role 
of CD11c-expressing cells and thus these tools have led to a number of functions 
being attributed incorrectly to DCs. Although DCs can be identified by their 
expression of CD11c and MHCII in lymphoid tissues, it is now clear that these 
markers alone are not sufficient for DC identification in most non-lymphoid tissues, 
as some mφs, such as those in the intestine (P Pavli, 1990) and liver (Kupffer 
cells) (You et al., 2008) also express these molecules. Furthermore, alveolar mφs 
in the lung (Plantinga et al., 2013), as well as plasma cells and T cells can also 
express CD11c (Caton et al., 2007; Postigo et al., 1991). The complexity involved 
in identifying bona fide DCs is further seen when Langerhans cells in the skin are 
considered. These cells express CD11c and MHCII and so are commonly referred 
to as DCs, but these also express the macrophage marker F4/80 and appear to 
derive independently from DC-committed precursors (discussed in detail below) 
(Ghigo et al., 2013; Ginhoux et al., 2006; Hoeffel et al., 2012).  
Based on these findings, it has become clear that surface phenotyping 
alone may not be sufficient for the accurate identification of DCs and instead a 
combination of phenotypical and functional analysis is required to discriminate 
them from mφs. While I was carrying out my work, a major advance came from the 
identification of a novel zinc finger transcription factor Zbtb46 (herein referred to as 
zDC), whose expression is restricted to cells of the DC lineage within the immune 
system. Although also expressed by endothelial cells and erythroid progenitors, 
zDC is absent from mφs, pDCs and all other CD45+ cells (Meredith et al., 2012a; 
Satpathy et al., 2012). Thus zDC expression seems to provide a unique way for 
researchers to identify DCs accurately and with the generation of mice with cre 
recombinase or the human diphtheria toxin receptor (DTR) under the control of the 
zDC promoter, this will become the conventional way to assess the biology of 
bona fide DCs without contamination by other mononuclear phagocytes (MPs) 
such as mφs. The accurate identification of DCs has also been aided by recent 
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studies in which the transcriptomes of DCs and mφs in many different tissues have 
been compared, resulting in the identification of a provisional molecular signature 
for DCs (Gautier et al., 2012; Miller et al., 2012). In addition to zDC, these studies 
identified CD26 and CD272 as DC-specific markers (Miller et al., 2012), while 
CD64, CD14 and MerTK have been identified as monocyte/mφ-specific markers 
(Bain et al., 2013; Gautier et al., 2012; Tamoutounour et al., 2012). Given the 
difficulties associated with the specific identification of DCs and the continued 
confusion surrounding what constitutes a DC in the intestine (discussed below), 
accurately identifying DC populations from mφs in the intestine was a specific aim 
of this thesis. 
While having a similar origin to classical DCs (discussed in detail below) 
pDCs lack the characteristic DC morphology and indeed as their name suggests, 
these rather resemble plasma cells. pDCs can be discriminated from classical DCs 
by their expression of a number of surface markers such as B220, Ly6C, CCR9 
and Siglec-H. Furthermore, pDCs also express lower levels of CD11c and MHCII 
than classical DCs (Nakano et al., 2001). The principal function of pDCs is to 
produce large quantities of type 1 interferon (IFN)-α in response to viral infection. 
However, their ability to present viral antigens to naïve T cells and subsequently 
induce their proliferation remains controversial (Colonna et al., 2004).  
1.2.2 Classical Dendritic Cell Function 
1.2.2.1 Antigen Acquisition by DCs  
Given the complications associated with identifying DCs on the basis of 
their surface phenotype, identification of DCs on the basis of their function has 
become crucial. In order to fulfil their function as antigen presenting cells, DCs 
must first acquire antigen from the tissue. When they first enter the tissues from 
the bloodstream, DCs are classified as immature and have a high ability to acquire 
material from their environment mainly by endocytosis and fluid phase 
macropinocytosis, with little or no phagocytic ability (Sallusto et al., 1995). 
Immature DCs are estimated to take up approximately 96 times their own volume 
each day and this material is delivered into the intracellular compartments of the 
endocytic pathway (Norbury, 2006; Sallusto et al., 1995).  As immature DCs are 
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also constantly recycling MHCII molecules through this pathway, any antigenic 
peptides generated through the degradation of endocytosed material can be 
loaded onto these MHCII molecules, with the potential to be transported to the cell 
surface for presentation to naïve T lymphocytes (Pinet et al., 1995).  
Table 1.1: Mammalian Pattern Recognition Receptors 
Protein/domain family PRR Ligands 
C-type Lectin 
DC-SIGN Mannose Oligosaccharides 
Dectin-1 b-glucans from fungi 
Mannose 
receptor Terminal mannose residues 
TLRs TLRs Lipopeptides, LPS, Flagellin, dsDNA, ssRNA, rRNA, CpG DNA, uropathogenic bacteria* 
Caspase Recruiting Domain 
(CARD) Helicases 
RIG1 dsRNA, Viral RNA 
MDA-5 Poly(I:C) 
NODs 
NOD1 Intestinal epithelial g-D-glutamyl-meso-diaminopimelic acid (DAP) 
NOD2 Muramyl dipeptide (MDP) 
Scavenger Receptors 
SRA Modified low density lipoprotein (LDL), apoptotic cells 
MARCO Modified LDL, gram+ and gram- bacteria 
NOD, nucleotide-binding oligomerisation domain; SRA, scavenger receptor A; MARCO, 
macrophage receptor with collagenous structure; *Refer to Figure 1.1. 
In the steady state, the generation of stable peptide-MHCII complexes by 
immature DCs is inefficient and these cells are thus thought to play a role in 
tolerance to self and innocuous antigen (Steinman et al., 2003). However, in the 
presence of pathogenic infection or tissue damage, DCs recognise conserved 
structures on microbes or damaged cells via a plethora of pattern recognition 
receptors (PRRs), such as Toll-like receptors (TLRs), lectins and Fc receptors 
(Table 1.1). The most extensively studied of these PRRs is the TLR family of 
receptors, which recognise microbial products. TLRs were first identified in 
Drosophila (Hashimoto et al., 1988) and to date ten human and thirteen murine 
TLRs have been identified (Kawai and Akira, 2009), each recognising distinct non-
self microbial patterns (PAMPs; pathogen associated molecular patterns) found 
outside or inside the cell (Fig. 1.1) (Medzhitov, 2001; O'Neill et al., 2013).  
Triggering of PRR on immature DCs causes them to become activated and 
mature, resulting in the stabilisation of peptide-MHCII complexes on the cell 
surface due to reduced MHCII recycling (Cella et al., 1997; Sallusto et al., 1995). 
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At the same time, the DCs become less able to sample the surrounding 
environment by endocytosis and upregulate their expression of co-stimulatory 
molecules, such as CD80 (Larsen et al., 1992) and CD86 (Lenschow et al., 1993), 
which are ligands for CD28 expressed by T cells. Additionally, activated DCs 
increase their locomotive activity and upregulate their expression of the chemokine 
receptor CCR7 (Dieu et al., 1998; Sallusto et al., 1998; Sozzani et al., 1998; 
Yanagihara et al., 1998), allowing them to enter afferent lymphatics and migrate to 
the draining LNs along a CCL19/CCL21 chemokine gradient (Forster et al., 1999; 
MartIn-Fontecha et al., 2003; Ohl et al., 2004).  
 
Figure 1.1: Ligand specificities of TLRs 
TLRs recognise a variety of pathogen associated molecular patterns (PAMPs). TLR5, TLR11 and 
heterodimers of TLR1:TLR2 and TLR1:TLR6 bind their respective ligands at the cell surface. TLR3, 
TLR7, TLR8, TLR9 and TLR13 are localised in the endosome to allow binding of intracellular 
PAMPs. TLR4 localises at both the plasma membrane and endosomes. TLR1:TLR2, TLR1: TLR6 
bind di- or tri-acetylated lipopeptides, TLR3 recognises double-stranded DNA (dsDNA), TLR4 binds 
LPS, TLR5 binds bacterial flagellin, TLR7 and TLR8 recognise single stranded RNA (ssRNA), 
TLR9 binds to unmethylated CpG motifs in DNA, TLR11 recognises uropathogenic bacteria while 
TLR13 is a receptor for ribosomal RNA (rRNA). Adapted from (O'Neill et al., 2013). 
1.2.2.2 Priming of Naïve T Lymphocytes 
Once DCs have migrated to the LNs, they move towards the T cell area in 
the paracortex. Here, DCs meet constantly recirculating naïve T cells which have 
entered via high endothelial venules (HEVs) and present antigen on MHCII 
molecules, inducing T cell proliferation and polarisation. DCs interact very 
efficiently with naïve T cells via several ligand receptor pairs such as ICAM-
1/ICAM-2:LFA-1, CD58:CD2 and DC-SIGN:ICAM-3. In addition to presenting 
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antigen to CD4+ T cells on MHCII molecules, DCs can also present antigens to 
naïve CD8+ T cells on MHC class I molecules (MHCI), in a process known as 
cross-presentation. This is crucial for the generation of cytotoxic T lymphocytes 
(CTLs) against antigens not synthesised by the DCs themselves and appears to 
be a property of a particular subset of DCs (discussed below) (Bevan, 1995; 
Huang et al., 1994; Reis e Sousa and Germain, 1995; Shen et al., 1997). When a 
naïve T cell recognises a specific peptide antigen displayed on a DC expressing 
co-stimulatory molecules, it produces IL2 and enters cell cycle, a process known 
as clonal expansion (Guermonprez et al., 2002; Mellman and Steinman, 2001; 
Thery and Amigorena, 2001). After several rounds of cell division, the activated T 
cells differentiate into the effector cells needed to eliminate infectious organisms. 
CD8+ T cells differentiate into cytotoxic T lymphocytes (CTLs), which kill cells 
infected with viruses and other intracellular pathogens, while CD4+ T cells 
differentiate into Th1, Th2 or Th17 cells, defined on the basis of the cytokines they 
secrete (Glimcher and Murphy, 2000; Harrington et al., 2005; Park et al., 2005). 
Effector T cell differentiation is driven by the expression of additional co-
stimulatory molecules on activated DCs including CD40 and OX40, as well as 
cytokines such as IL12, IL6, IL1β, TGF-β and IL23 (Fig. 1.2). IL12 is a heterodimer 
composed of IL12p35 and IL12/IL23p40 subunits (Gubler et al., 1991), which is 
produced by DCs following TLR and/or CD40 ligation, leading to the generation of 
IFNγ-producing Th1 cells (De Becker et al., 1998). DC production of IL6, TGFβ, 
IL1β and IL23, a heterodimer of IL12/IL23p40 and IL23p19 subunits (Oppmann et 
al., 2000), results in the induction of IL17-producing Th17 cells (Aggarwal, 2002; 
Bettelli et al., 2006; Langrish et al., 2005; Mangan et al., 2006; Veldhoen et al., 
2006). IL1β, IL6 and TGF-β act early in Th17 cell differentiation, while IL23 acts 
once activated T cells express the IL23 receptor (IL23R) and is thought to be most 
important in maintaining Th17 cells (Aggarwal, 2002; Oppmann et al., 2000; 
Parham et al., 2002). IL4 production is required to induce a Th2 response from 
naïve T cells, but is produced by a number of other immune cells including T cells, 
eosinophils, NKT cells and basophils rather than DCs (O'Garra, 1998). These 
cytokines act by inducing lineage specific transcription factors (Fig. 1.2). Th1 cells 
require the transcription factor T-bet (Szabo et al., 2000), Th2 cells depend upon 
GATA-3, Stat-6 and c-Maf (Agarwal and Rao, 1998; Zhang et al., 1997; Zheng and 
Flavell, 1997), while Th17 differentiation requires the transcription factor, RORγt 
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(Ivanov et al., 2006). The various T cell subsets play distinct roles in the immune 
response (Abbas et al., 1996) with Th1 cells producing IFNγ that activates mφs to 
kill intracellular pathogens, as well as stimulating the production of IgG2a 
antibodies by B cells (Snapper et al., 1988b). Th2 cells produce IL4 which also 
activates naïve B cells and induces class switching, in this case generating IgE 
and IgG1 responses (Finkelman et al., 1988; Katona et al., 1991; Snapper et al., 
1988a). The third, most recently described, effector T cell population, the IL17 and 
IL22 producing Th17 cells, appear to function in the control of extracellular bacteria 
(Happel et al., 2005) but are also implicated in causing tissue inflammation (Park 
et al., 2005). Importantly, the largest population of Th17 cells are found in the 
intestine, but their exact role in this location remains unclear (Maloy and Kullberg, 
2008).  
1.2.2.3 DCs in Tolerance 
Although DCs are responsible for the initiation of active adaptive immunity 
(Hagnerud et al., 2006; Hildner et al., 2008; Jung et al., 2002; Lewis et al., 2011; 
Persson et al., 2013b; Satpathy et al., 2013; Schlitzer et al., 2013), they are also 
essential for the induction of both central and peripheral tolerance. DCs have been 
shown to be involved in the induction of central tolerance to self-antigens in the 
thymus, either by inducing clonal deletion of self-reactive T cells or by generating 
FoxP3+ natural TReg cells (nTReg) (Derbinski and Kyewski, 2010; Hori et al., 2003; 
McCaughtry and Hogquist, 2008; Proietto et al., 2008). This may occur by antigen-
loaded DCs from peripheral tissues migrating to the thymus (Bonasio et al., 2006) 
or alternatively thymic-resident DCs can acquire self-antigen from medullary 
thymic epithelial cells (mTECs) expressing the transcription factor autoimmune 
regulator (AIRE), which drives promiscuous expression of peripheral antigens in 
the thymus. The antigen acquired in this manner is then cross-presented to T cells 
(Gallegos and Bevan, 2004; Hubert et al., 2011) inducing negative selection or 
nTReg polarisation.  
In addition to central tolerance, mechanisms exist to allow tolerance to also 
be induced in the periphery after T cells have left the thymus. Known as peripheral 
tolerance, this phenomenon involves the generation of suppressive induced 
regulatory FoxP3+ T cells (iTReg) and specific immunological hyporesponsiveness 
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or anergy towards antigens. In addition to their role in central tolerance, DCs play 
a key role in peripheral tolerance. iTReg cell induction by DCs is mediated by TGFβ 
and the vitamin A metabolite, retinoic acid (RA) (Mucida et al., 2007) (Fig. 1.2). T 
cell anergy occurs when naïve T cells are presented with specific antigen by 
immature or semi-mature DCs, which lack effective levels of costimulatory 
molecules. Anergy can also occur when DCs present antigen in the presence of 
the anti-inflammatory cytokine IL-10 (Schwartz, 2003). 
 
 
Figure 1.2: Outcomes of DC:T cell interactions 
Depending on the signals received during antigen acquisition, DCs can be programmed to produce 
a variety of cytokines, which promote the polarisation of naïve T cells to distinct subsets of effector 
or regulatory T cells. Signals from outwith the DCs can also influence the outcomes of the DC:T 
cell interactions. Each distinct lineage of T cells is controlled by specific transcription factors. 
1.2.3 Phenotypic subsets of DCs 
It has long been an attractive idea that different DC subsets may exist to fulfil 
the different functions proposed for DCs. Early studies in mice indicated that there 
were two main populations, one expressing CD4 or CD11b, but lacking CD8α 
(CD11b+ DCs) and a second, expressing CD8α but lacking CD4 and CD11b 
(CD8+ DCs). These subsets were first identified in lymphoid organs, but similar 
subsets are also present in all non-lymphoid tissues, except the CNS, although 
this is currently being investigated further (M. Guilliams, personal communication). 
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In most tissues, expression of the αE integrin CD103 overlaps with CD8α 
expression (Ginhoux et al., 2009), but as I will show, in the intestine a population 
of CD103+CD11b+ DCs is also present (Bogunovic et al., 2009; Denning et al., 
2007; Varol et al., 2009) (Fig. 1.3). Initially these subsets, which were thought to 
be hard-wired to perform distinct functions, were also thought to derive from 
different lineages, with CD8+ DCs being of lymphoid origin, while CD11b+ DCs 
were thought to be of myeloid origin (Wu et al., 2001). However, as discussed 
below, it is now clear that both DC subsets arise from myeloid progenitors and that 
they are likely to show at least some functional overlap.  
 
Figure 1.3: DC subsets in different locations in the mouse 
CD11b+ and CD8α+ (or CD103+ equivalents in non-lymphoid tissue) DC subsets are present in 
each tissue in the mouse in varying proportions. + Denotes presence in tissue, while ++ marks the 
predominant DC population. pDCs are also present in each tissue however, in some tissues they 
only form a significant population during inflammation (Inf.). ** Langerhans cells (LC) are only 
found in the epidermis and the skin draining lymph node. * In the small intestine CD11b+ DCs 
predominate while in the large intestine the main DC population is the CD8α+ DCs. Furthermore, 
throughout the intestine, a proportion of CD11b+ DCs also express CD103.  Adapted from (Merad 
and Manz, 2009). 
These two DC subsets also differ in their expression of a number of other 
surface markers (Table 1.2), which have recently proved useful in defining 
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functional properties. SIRPα (CD172a) is a signalling transmembrane receptor 
expressed by myeloid cells that is found on CD11b+ DCs (Adams et al., 1998). As 
is discussed below, its role on CD11b+ DCs is currently unclear and thus one of 
the aims of this thesis was to address its role on intestinal CD11b+ DCs. The 
chemokine receptor XCR1 and the lectin-like receptor Clec9A (DNGR-1) are 
expressed solely by CD8+ DCs and appear to define those DCs capable of cross-
presenting antigen to CD8+ T cells (Bachem et al., 2010; 2012; Caminschi et al., 
2008; Crozat et al., 2011; Huysamen et al., 2008; Poulin et al., 2012; 2010; 
Zelenay et al., 2012). However, more recently expression of DNGR-1 has been 
described on all DC-committed progenitors and has been used to track their fate in 
vivo (Schraml et al., 2013).  
Table 1.2: Phenotype of murine DCs 
Surface Marker CD8α+ CD11b+ pDCs 
CD45 + + + 
CD11c ++ ++ + 
MHCII ++ ++ + 
CD8α + - +/- 
CD11b - + - 
CD4 - +/- + 
CD103 + +/-* - 
F4/80 - +/-* - 
SIRPα (CD172a) - + + 
B220 - - + 
Ly6C - +/- ++ 
CD205 ++ +/ND - 
CD209 - +/- ++ 
Clec9A (DNGR1) ++ - + 
XCR1 + - - 
CD24 ++ +/- ND 
CX3CR1 - +/- - 
* Expression amongst these cells are only reported in the intestine 
ND; not determined 
Much of what is known about DC subsets originates from murine studies 
and many of the markers are species-specific. However more recently, 
considerable progress has been made in identifying human DC subsets. Initially 
three main subsets were described in human blood on the basis of CD141, CD1c 
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and CD16 expression, with an additional population of CD123+CD303+CD304+ 
pDCs being described (MacDonald et al., 2002). However, subsequent studies 
have demonstrated that CD16+ DCs arise from distinct precursors to the others 
(Lindstedt et al., 2005) and in tissue, CD16+ ‘DCs’ appear to be indistinguishable 
from mφs. Thus, they are unlikely to represent bona fide DCs. Recent 
transcriptional studies suggest that the CD141+ DCs may be the equivalent of the 
mouse CD8+ DCs (Haniffa et al., 2012), while the CD1c+ DCs are related to the 
CD11b+ subset (Robbins et al., 2008). These computational studies have been 
confirmed by the finding that Clec9A and XCR1 are found on human CD141+ DCs 
(Bachem et al., 2010; Caminschi et al., 2008; Huysamen et al., 2008; Poulin et al., 
2010; Sancho et al., 2008) (Table 1.3), while SIRPα expression is found only on 
CD1c+ DCs (Persson et al., 2013b; Schlitzer et al., 2013). CD103 expression has 
also been found on human DCs and as in the mouse, it is expressed by both 
CD1c and CD141 DCs in the gut (Beitnes et al., 2011; Jaensson et al., 2008; 
Persson et al., 2013b). Collectively, these studies suggest a high degree of 
evolutionary conservation of the DC populations between mice and men.  
Table 1.3: Murine and Human DC subsets 
DC Subset Phenotype 
Mice Human 
CD8+ DCs 
CD11c+, MHCII+, CD8+, 
XCR1+, Clec9A+, 
CD103+/- 
CD11c+, MHCII+, CD141+, 
XCR1+, Clec9A+, CD103+/- 
CD11b+ DCs 
CD11c+, MHCII+, 
CD11b+, CD103+/-*, 
SIRPα+ 
CD11c+, MHCII+, CD11b+, 
CD1c+, CD103+/-*, SIRPα+ 
pDCs CD11c
int, MHCIIint, B220+, 
Ly6C+, Siglec H+ 
CD11c-, MHCIIint, CD123+, 
CD303+, CD304+ 
* Expression reported in intestine (Persson et al., 2013b). 
1.2.4 Function of DC subsets 
DCs are the only APCs which can prime naïve T cells. Initially it was 
proposed that the phenotypic subsets had distinct functions, with the CD11b+ DCs 
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preferentially inducing CD4+ effector T cell responses (Pooley et al., 2001) and the 
CD8+ DCs inducing CD8+ T cell responses or tolerance (Bonifaz et al., 2002; Haan 
et al., 2000; Hawiger et al., 2001; Kurts et al., 2001; 1996; Pooley et al., 2001). 
However it is now clear that both DC subsets can induce most T cell responses 
under different conditions, the exception to this being the selective ability of CD8+ 
DC to cross-present antigen to CD8+ T cells in the steady state (Bachem et al., 
2010; Bedoui et al., 2009; Haan et al., 2000; Haniffa et al., 2012; Hildner et al., 
2008; Pooley et al., 2001; Poulin et al., 2010; Zelenay et al., 2012), mainly 
because they have receptors like DNGR-1 which take antigen into the 
phagosomes and have appropriate processing machinery. CD8+ DCs are also 
effective inducers of Th1 responses, via an enhanced ability to produce the 
bioactive IL12p70 (Maldonado-López et al., 1999; Pulendran et al., 1999). 
Whether the two DC subsets play distinct roles in inducing specific effector 
CD4+ T cell responses or tolerance remains unclear. While much remains to be 
understood about the roles played by CD11b+ DCs, their selective loss in vivo has 
recently been shown to affect Th17 differentiation (Lewis et al., 2011; Persson et 
al., 2013b; Schlitzer et al., 2013). The nature of the DCs responsible for tolerance 
is not entirely clear. As mentioned above, CD8+ DCs were originally thought to be 
the tolerogenic subset in both LNs and thymus, based on studies demonstrating 
that cross-presentation was crucial for tolerance to self-antigens (Kurts et al., 
1996; 2001) and that targeting DEC-205 on CD8+ DCs induced tolerance (Bonifaz 
et al., 2002; Hawiger et al., 2001). Given the link between CD103+ and CD8+ DCs, 
additional evidence that CD8+ DCs may be involved in tolerance came from 
studies identifying intestinal CD103+ DCs to be potent inducers of FoxP3+ TReg 
cells (Coombes et al., 2007; Sun et al., 2007) (and reviewed in (Scott et al., 2011)). 
However, as previously mentioned CD103+ DCs in the gut can be CD11b+ or 
CD8α+ (Denning et al., 2011; Fujimoto et al., 2011). In addition, SIRPα+ DCs exist 
in the thymus and these along with CD8+ DCs can induce central tolerance 
through the mechanisms described above (Hsieh et al., 2012; Klein et al., 2009). 
Furthermore, recent studies have shown that the selective depletion of CD8+ or 
CD11b+ DCs does not affect TReg cell populations (Edelson et al., 2010; Persson 
et al., 2013b; Welty et al., 2013). However, when both populations are 
simultaneously depleted a reduction in TReg cells is observed suggesting a degree 
of redundancy between the populations (Welty et al., 2013). Thus further studies 
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are required to assess the functionality of the distinct DC populations and 
investigating the specific functions of intestinal DC populations was one aim of this 
thesis. Additionally a number of studies have proposed that a specific population 
of TNF and iNOS producing inflammatory DCs (Tip-DCs) may be recruited during 
inflammation (Serbina et al., 2003). Whether these cells are indeed bona fide DCs 
remains to be determined. Tip-DCs are derived from distinct progenitors 
(monocytes) compared with the other DC populations (see below), their 
identification is controversial and furthermore it is yet unclear if they are capable of 
migrating in lymph to the draining lymph nodes.  
1.3 DC Ontogeny and Development 
DCs are classified along with macrophages and monocytes as mononuclear 
phagocytes. The mononuclear phagocyte system (MPS) was first described in 
1972 by van Furth and colleagues as a system of phagocytic cells located in 
reticular connective tissue arising from a common bone marrow (BM) progenitor 
(van Furth et al., 1972). As discussed above, the surface phenotype of the cells of 
the MPS is overlapping despite the presence of a number of cell types (Table 1.4).  
Although arising from a common BM progenitor, DCs and mφs follow distinct 
pathways of development ultimately deriving from distinct precursors (Liu et al., 
2009). These distinct lineages will be used in this thesis, in combination with 
surface phenotype and functionality as an aid to definitively distinguish between 
DCs and mφs in the intestine. Additionally, distinct cytokines and transcription 
factors have been implicated in the development of mφs and DCs and a 
considerable degree of heterogeneity has also been reported regarding the 
transcriptional factor requirements of the DC subsets. This will also be investigated 
for the DC subsets in the intestine as part of this thesis. 
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Table 1.4: Cells of the Steady-State MPS 
Cell Tissue Marker Expression 
CD11c MHCII F4/80 CD11b 
DCs Intestine, Lung, Liver, Spleen, Blood, Kidney, Heart, Thymus 
+ + - -/+ 
pDCs 
Intestine, Lung, Liver, Spleen, 
Blood, Kidney, Heart, 
Thymus, BM 
Int. - - - 
Intestinal mφs Intestine + + + + 
Kupffer cells Liver Int. + + - 
Alveolar mφs Lung + - + - 
Peritoneal mφs Peritoneum +/- - + + 
Monocytes 
Intestine, Lung, Liver, Spleen, 
Blood, Kidney, Heart, 
Thymus, BM 
Int. -/+ -/+ + 
Langerhans cells Skin + + + + 
 
1.3.1 Bone Marrow Precursors for Cells of the MPS 
In adult mice, progenitors of the MPS arise from haematopoietic stem cells 
(HSCs) through a series of intermediate stages in the BM. Each stage in 
development is accompanied by a progressive lineage commitment, in which cells 
lose the ability to generate certain cell types (Liu et al., 2009) (Fig. 1.4). The first 
stage results in the generation of the common myeloid progenitor (CMP) and the 
common lymphoid progenitor (CLP) from the HSC. CMPs have the potential to 
generate all myeloid cells, including DCs, mφs, granulocytes, neutrophils and 
eosinophils (Akashi et al., 2000), whereas CLPs generate T cells, B cells and NK 
cells (Kondo et al., 1997). As discussed above, initial studies suggested that CLPs 
may also retain some potential to generate CD8+ DCs but this remains 
controversial (Manz et al., 2001; Wu et al., 2001). CMPs then differentiate into 
mφ/DC progenitors (MDPs) or granulocyte/mφ progenitors (GMPs), the latter 
retaining the potential to generate DCs, but preferentially differentiating into 
granulocytes and monocytes/mφs (Auffray et al., 2009; D'Amico and Wu, 2003). In 
contrast, MDPs have the potential to generate DCs and monocytes/mφs only 
(Fogg et al., 2006). MDPs are characterised by their expression of CX3CR1, 
CD135, CD115 and CD117 while lacking expression of MHCII, T cell, B cell, 
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erythrocyte and NK cell lineage markers (Fogg et al., 2006). At the next stage of 
differentiation, the MDP generates either CD117- CX3CR1+ CD115+ CD135- 
CD11b+ Ly6Chi monocytes or CD117lo CX3CR1+ CD135+ CD115+ DC committed 
progenitors, termed common DC progenitors (CDPs) (Onai et al., 2007b) or pro-
DCs (Naik et al., 2007). The Ly6Chi monocytes generated from MDPs are short-
lived and have the ability to mature into Ly6Clo monocytes which circulate in the 
blood (Yona et al., 2013), or give rise to tissue-resident mφs (Bain et al., 2013; 
Ginhoux et al., 2006; Tamoutounour et al., 2012). However, it is interesting to note 
that a number of recent studies have demonstrated that most tissue-resident mφs 
are the progeny of primitive yolk-sac mφs or foetal liver monocytes (Guilliams et 
al., 2013b; Hoeffel et al., 2012; Schulz et al., 2012; Yona et al., 2013) rather than 
being continually replenished by BM monocytes, the key exceptions to this being 
the gut (Bain et al., 2013; Tamoutounour et al., 2012) and skin (S. Tamoutounour, 
in press). Additionally during inflammation monocytes have been proposed to 
generate Tip-DCs (Serbina et al., 2003), although as discussed above the nature 
of these cells remains controversial. The CDPs generated from MDPs lose their 
potential to generate cells of the monocyte/mφ lineage and then differentiate into 
either CD117-CX3CR1- CD135+ CD115- CCR9+ CD11cint B220+ Ly6C+ pDCs or into 
CD117-CX3CR1+ CD135+ CD115- CD11cint CD11b- precursors of conventional DCs 
(pre-DCs) (Naik et al., 2007). While mature pDCs develop from CDPs in the BM, 
pre-DCs exit the BM and traffic in blood to tissues before maturing into 
conventional DCs subsequently proliferating in situ (Liu et al., 2009). More recently, 
an additional stage of differentiation has been described in which CDPs may 
generate a CCR9- pDC-like progenitor (pDC progenitor) which retains both DC 
and pDC potential (Schlitzer et al., 2012; 2011).  
It remains unclear if there are distinct subsets of pre-DCs that are pre-
programmed to generate CD8+ or CD11b+ DCs, or if the same progenitors can 
differentiate into either DC subset once in the tissue. Recently it has been 
suggested that there is considerable heterogeneity in these cells, for instance Naik 
and colleagues demonstrated that pre-DCs could be divided into three populations 
based on CD24 expression, CD24hi, CD24int and CD24lo. They found that whereas 
the CD24int cells could generate both subsets, the CD24hi and CD24lo cells 
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preferentially generated CD8+ or CD11b+ DCs respectively, suggesting a degree 
of lineage commitment within the BM (Naik et al., 2007; 2006).  
 
Figure 1.4: DCs develop from HSCs through a series of intermediate precursors stage in the 
BM 
Progenitors restricted to the DC lineage arise in the bone marrow from HSCs. Firstly HSCs 
generate CMPs which in turn differentiate into MDPs and then into either monocytes or CDP/pro-
DCs. Monocytes then enter the bloodstream and under inflammatory conditions eventually 
peripheral where they give rise to inflammatory mφs. In the steady state, monocytes can also enter 
the skin and gut where they generate tissue resident mφs. In other tissues, tissue-resident mφs 
arise from foetal liver monocytes or primitive yolk-sac mφs. The pro-DCs further differentiate in the 
bone marrow into pre-DCs or pDCs. pDCs then directly enter peripheral tissues through the 
bloodstream where they produce high levels of type 1 interferon in response to viral infections. 
Similarly pre-DCs also enter tissues but subsequently differentiate into both CD11b+ and CD8+ DCs. 
A pDC progenitor has also been reported, which lacks CCR9 expression that traffics to tissues 
retaining the potential to generate either DCs or pDCs depending on the environmental stimuli 
received. The HSCs also give rise to CLPs, which are reported to have the potential to generate 
CD8+ DCs, however the intermediate stages in this process as well as the relative contribution of 
this pathway to the CD8+ DC population remain unclear.  
 
Additionally it is unclear if there are distinct subsets of pre-DCs which traffic 
to specific tissues. A recent study has identified a novel DC and pDC progenitor 
with apparent intestinal specificity (Zeng et al., 2013). However, how this CCR9- 
B220+ CD11cint α4β7+ progenitor relates to the MDP:CDP:pre-DC system remains 
to be determined, but these may represent the plastic pDC-like progenitor recently 
described by Schlitzer and coworkers which retained the ability to generate pDCs 
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as well as DCs (Schlitzer et al., 2011; 2012; Zeng et al., 2013). Whether additional 
precursors exist with other tissue-specificities remains to be reported. However, it 
is important to note that in the Butcher study (Zeng et al., 2013) donor-derived 
cells could also be found in the spleen demonstrating that these are not 
completely imprinted with the decision to migrate to the intestine. 
1.3.2 Role of Growth Factors in DC Development 
The development of all haematopoietic cells is controlled by precursor 
and/or lineage-specific growth factors. Fms-like tyrosine kinase 3 (Flt3; also known 
as CD135, Flk-2 and STK-1) (Karsunky et al., 2003; Liu et al., 2009) is expressed 
by several haematopoietic progenitors, but unlike other lineages, DCs retain Flt3 
expression throughout their maturation process. Mice lacking its ligand, Flt3L 
(Flt3L-/- mice), or mice receiving Flt3L inhibitors show a dramatic reduction of DCs 
and pDCs (McKenna et al., 2000; Tussiwand et al., 2005). In parallel, 
administration or conditional expression of Flt3L stimulates preferential expansion 
of DC-committed progenitors and both CD8+ and CD11b+ DCs (Björck, 2001; 
Karsunky et al., 2003; Maraskovsky et al., 1996). Flt3L can also be used to 
generate CDPs, pre-DCs and mature DCs from BM cells in vitro, providing a 
useful source of such cells for study (Brasel et al., 2000; Naik et al., 2007) and 
Flt3L has similar effects in humans (Pulendran et al., 2000). Importantly, 
expansion of DCs with Flt3L does not appear to alter their functionality, but simply 
increases their numbers (Shurin et al., 1997; Viney et al., 1998). Flt3L production 
is regulated in response to DC depletion in vivo, ensuring adequate replenishment 
of DCs in both the steady state and during inflammation (Birnberg et al., 2008). 
Thus it is clear that Flt3 and its ligand play a non-redundant role in DC 
development. Importantly and consistent with the confusion surrounding their 
identification, Langerhans cells and Tip-DCs are not dependent upon Flt3L.  Thus I 
will use Flt3L dependence to identify bona fide DC populations in the intestine as 
part of this thesis. 
Granulocyte/mφ colony stimulating factor (GM-CSF or CSF-2), was the first 
growth factor used to generate DCs from murine haematopoietic progenitors and 
from human monocytes in vitro (Caux et al., 1992; Inaba et al., 1992; Sallusto and 
Lanzavecchia, 1994). Despite this, DC numbers are normal in the lymphoid organs 
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of mice lacking CSF-2 or its receptor and administration of exogenous CSF-2 or 
overexpression of CSF-2 in transgenic mice only marginally increases the DC 
populations in lymphoid organs (Maraskovsky et al., 1996; Vremec et al., 1997). 
CSF-2 appears to play a more important role in the development of DCs in non-
lymphoid tissues, with the presence of CD103+CD11b+ DCs in the intestine and 
CD103+CD11b- DCs in the lung, liver, kidney and dermis being dependent on 
CSF-2 (Bogunovic et al., 2009; Greter et al., 2012; King et al., 2010; Varol et al., 
2009). Despite CD103 expression itself being regulated by CSF-2 (Zhan et al., 
2011), the apparent role of CSF-2 in the development of CD103+ DCs cannot be 
explained by its effects on CD103 expression because when CD24 is used as a 
surrogate marker for CD103 similar defects were observed (Greter et al., 2012). 
However, this approach remains to be validated and re-examining the role of CSF-
2 in gut DC ontogeny was one aim of this thesis.  
Mφ colony stimulating factor (M-CSF or CSF-1) is a key cytokine involved in 
monocyte and mφ differentiation and survival, with mice lacking CSF-1 or its 
receptor, CSF-1R (CD115) lacking most mφ populations and developing 
osteopetrosis due to the lack of osteoclasts (Dai et al., 2002; Yoshida et al., 1990). 
Neither DCs nor pDCs appear to require CSF-1 for their development (Witmer-
Pack et al., 1993) and the fact that it may be required for the development of Tip-
DCs and Langerhans cells is further evidence against these being bona fide DCs 
(Ginhoux et al., 2006; Greter et al., 2012).  
1.3.3 Transcription factors 
A number of transcription factors have been associated with the 
development, homeostasis and function of murine and human DC subsets (Fig. 
1.5). Interferon regulatory factor 4 (IRF4) is expressed by CD11b+ but not by CD8+ 
DCs and loss of this transcription factor leads to a selective defect in the ability to 
generate CD11b+ DCs from BM cells in vitro as well as a reduction in the 
proportion and number of CD4+ splenic DCs (Suzuki et al., 2004). More recently, it 
has been reported that absence of IRF4 leads to a reduced population of CD11b+ 
DCs in the lung and CD103+CD11b+ DCs in the intestine (Persson et al., 2013b; 
Schlitzer et al., 2013). Although the role of IRF4 was initially assumed to be in DC 
development (Suzuki et al., 2004), more recently it has been implicated in 
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promoting CD11b+ DC survival (Persson et al., 2013b). At this time no mechanism 
has been proposed, however as IRF4 functions as a negative regulator of pro-
inflammatory cytokine production in response to TLR ligation (Honma, 2005), it is 
possible that absence of this transcription factor leads to aberrant activation 
contributing to the decreased survival of IRF4-deficient DCs. IRF4 is also 
expressed by mφs and lymphocytes (Brüstle et al., 2007; Celada et al., 1996; 
Cretney et al., 2011; DeKoter et al., 1998; Henkel et al., 1996; Klein et al., 2009; 
McKercher et al., 1996; Mudter et al., 2011; Zheng et al., 2009). Thus studies of 
IRF4 function in DCs need to exclude potentially confounding effects on other 
leukocyte populations.  
In addition to IRF4, CD11b+ DCs are also regulated by Notch RBP-J, RelB 
and TRAF6 (Kobayashi et al., 2003; Lewis et al., 2011; Wu et al., 1998). Deletion 
of Notch, leads to a selective reduction in CD11b+ DCs in the spleen and 
CD103+CD11b+ DCs in the intestine (Lewis et al., 2011; Satpathy et al., 2013), 
although its effects in the spleen are limited to the CD11b+ DCs expressing the 
endothelial cell – selective adhesion molecule (ESAM). The relevance and 
functional implications of this remain unclear.  
IRF8 (also known as IFN consensus sequence-binding protein, ICSBP) is 
expressed by CD8+, but not CD11b+ DCs, and has been implicated in the 
development and homeostasis of CD8+ DCs and pDCs, in both lymphoid and non-
lymphoid tissues (Edelson et al., 2010; Ginhoux et al., 2009; Schiavoni et al., 
2002; Tamura et al., 2005; Tsujimura et al., 2003), however its role in the gut is yet 
to be examined. IRF8 has also been implicated in mφ differentiation (Holtschke et 
al., 1996; Li et al., 2011). Although, basic leucine zipper ATF-like 3 (Batf3) is 
expressed by all DCs, it is specifically associated with the development of CD8+ 
DCs, with Batf3-/- mice on the 129S6/SvEv background lacking CD8+/CD103+ DCs 
(Edelson et al., 2010; Hildner et al., 2008). The effect of this defect is strain-
dependent and can be overcome in mice on the C57Bl/6 background by IL12/IFNγ 
production during infection driving compensatory Batf1 and/or Batf2 expression 
(Tussiwand et al., 2012). Inhibitor of DNA binding protein 2 (Id2) is another 
transcription factor associated with CD8+ DC development and mice lacking Id2 
display marked reductions in CD8+/CD103+ DCs in the lung, liver, kidney, spleen 
and intestine (Ginhoux et al., 2009; Hacker et al., 2003; Kusunoki et al., 2003).  
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The recently discovered zinc finger transcription factor, zDC, specifically 
marks all cells of the DC lineage (Meredith et al., 2012a; Satpathy et al., 2012), but 
its absence skews DC populations towards the CD8+ DC phenotype suggesting its 
role may be lineage dependent (Meredith et al., 2012a; 2012b; Satpathy et al., 
2012). zDC has also been shown to be a negative regulator of DC activation, thus 
perhaps its role in maintaining the CD11b+ DCs may be liked to their activation 
status rather than being directly involved in their development (Meredith et al., 
2012b).  
 
Figure 1.5: Expression and dependence of DC subsets on specific growth and transcription 
factors 
CD11b+ DCs develop from pre-DCs in peripheral tissues in an Flt3L dependent manner and has 
been shown to involve IRF4, Notch-RBJ, RelB and TRAF-6 signalling. * CD11b+ DCs develop 
independently of CSF-2 apart from intestinal CD103+CD11b+ DCs, which similar to CD8+/CD103+ 
DCs in other tissues require CSF-2. CD8+/CD103+ DCs (CD8+ DCs) develop from pre-DCs in an 
Flt3L and CSF-2 dependent manner. Their development is regulated by the transcription factors 
Batf3, Id2 and IRF8. Both classical DC subsets express the zinc finger transcription factor, zDC. 
 
1.4 The Intestinal Immune System 
The intestine represents a key immune site in the body. In order to allow for 
efficient absorption of water and nutrients, the single layer of intestinal epithelium 
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has to allow access by the contents of the lumen to the interior. As this renders it 
susceptible to invasion by pathogens, the intestinal immune system has to be able 
to mount protective responses against any harmful pathogens it encounters. At the 
same time, the gut is home to a large and diverse array of commensal bacteria, 
many of which are mutualistic symbionts (Sonnenburg et al., 2004), as well as 
being continuously exposed to a variety of foreign antigens in the diet. As it would 
be wasteful and dangerous to mount active immunity against these materials, the 
intestinal immune system induces a state of immunological hyporesponsiveness 
(tolerance) to such harmless antigens. This is no easy feat given the large surface 
area of the gut and that the intestinal microbiota outnumbers the total cells in the 
human body by 10-fold (Macpherson et al., 2009). Inappropriate responses to food 
proteins and commensal bacteria result in disorders such as coeliac disease and 
inflammatory bowel disease (IBD) respectively (Mowat, 2005). The decision 
making mechanisms that underlie this dichotomy are still to be elucidated fully, but 
DCs are likely to play a key role due to their ability to induce effector and 
regulatory T cells as well, as gut-specific IgA secreting plasma cells (Bergtold et 
al., 2005; Castigli et al., 2005; Massacand et al., 2008).  
1.4.1 Components of the Intestinal Immune System 
The gastrointestinal (GI) tract consists of the stomach, small intestine, 
caecum, large intestine (colon) and rectum and the largest compartment of the 
immune system has evolved in these tissues (Mowat, 2003). Immune cells are 
found in the mucosa itself, as well as in the organised lymphoid tissues associated 
with it. These organs are responsible for the induction of immune responses and 
they include the MLNs, Peyer’s patches (PPs), which are scattered along the anti-
mesenteric side of the small intestine, and the smaller isolated lymphoid follicles 
(ILFs), which have the appearance of microscopic PPs and are distributed 
throughout the walls of the small and large intestine (Mowat, 2003). The mucosa 
contains a large range of immune cells including lymphocytes, plasma cells, mφs, 
DCs, ILCs and eosinophils, as well as a few mast cells.  
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1.4.1.1 Peyer’s patches and ILFs 
Peyer’s patches (PPs) are macroscopic lymphoid aggregates found in the 
submucosa of the small intestine, particularly at the two ends. These consist of 
collections of large B cell follicles and intervening T-cell areas, together with the 
subepithelial dome (SED) which is the area directly below the epithelium. A single 
layer of columnar epithelial cells, known as the follicle-associated epithelium (FAE) 
separates the PPs from the intestinal lumen (Hamada et al., 2002; Mowat and 
Viney, 1997). The FAE contains specialised enterocytes called microfold (M) cells. 
As well as lacking a thick mucus layer immediately above them, M cells have 
distinct oligosaccharide epitopes on their surface, which allow the adhesion of 
invasive pathogens and other particulate antigens (Neutra et al., 1996). Antigen 
from these M cells is then delivered to DCs in the SED, which then interact with 
naïve T and B cells deeper in the PPs (Newberry and Lorenz, 2005). It is currently 
unclear if DCs in the PPs are solely responsible for priming T and B cells in situ or 
if these DCs can also migrate to the MLNs to carry out these functions. The exact 
need for the PPs remains unclear, as experiments using mice deficient in PPs and 
M cells have produced conflicting results with some groups reporting no effects on 
immunity and/or oral tolerance, while others suggest there are defects in these 
processes (Alpan et al., 2001; Fujihashi et al., 2001; Spahn et al., 2001). ILFs are 
microscopic lymphoid aggregates found throughout the length of both the small 
and large intestines. Similar to PPs, ILFs have both FAE and M cells, however 
consist of only 1 or 2 B cell follicles (Eberl and Lochner, 2009). 
1.4.1.2 Mesenteric lymph nodes 
In contrast to the discrepant findings on the role of PPs, the MLNs are 
clearly essential for the induction of all immune responses in the intestine. Just as 
the intestinal immune system is the largest component of the immune system, the 
mesenteric lymph nodes are the largest lymph nodes in the body. DCs from 
throughout the mucosa and possibly PPs and ILFs migrate to the MLNs via 
afferent lymphatics in a CCR7 dependent manner (Jang et al., 2006; Worbs et al., 
2006). As in other LNs, migratory DCs in the MLNs can be identified as MHCIIhi 
cells (Henri et al., 2001), while LN resident DCs (identified as MHCIIint) enter from 
bloodstream via high endothelial venules (HEVs). Both DC subsets can present 
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antigen to naïve T cells within the MLN allowing for a diverse array of responses to 
a variety of antigen. LN resident DCs acquire soluble antigen from afferent lymph 
draining the intestine in addition to blood for presentation to naïve T cells, which 
occurs more rapidly than when DC migration from the intestine is required (Sixt et 
al., 2005). In addition to the induction of protective immune responses, the MLNs 
play a critical role in the induction of oral tolerance as demonstrated by the loss of 
this phenomenon in mice that have had their MLNs surgically removed (Worbs et 
al., 2006), in lymphotoxin α (LTα)-/- mice or in the progeny of pregnant mice 
treated with an anti-LTβR antibody to block the formation of MLNs (Spahn et al., 
2002). 
Once T and B cells encounter antigen on migratory DCs, they become 
imprinted with the specific ability to return to the small intestinal mucosa due to 
expression of α4β7 integrin and the chemokine receptor CCR9 (Agace, 2008; 
Johansson-Lindbom and Agace, 2007). The ligand for α4 β7 integrin mucosal 
addressin cell-adhesion molecule (MAdCAM)-1 which is expressed constitutively 
by postcapillary endothelial cells in mucosal tissues (Berlin et al., 1993; Hamann et 
al., 1994; Picarella et al., 1997). Consistent with its role as a gut homing receptor, 
mice lacking β7 integrin lack mucosal T cells (Artis et al., 2000; Wagner et al., 
1996). The ligand for CCR9 is CCL25, a chemokine expressed by small intestinal 
epithelial cells (Bowman et al., 2002; Kunkel et al., 2000; Pabst et al., 2004; 
Svensson et al., 2008) and as a result, the migration of activated T and B cells to 
the small intestine is highly dependent on CCR9, although this is more marked for 
CD8+ T cells in the epithelium than CD4+ T cells in the LP. Importantly, the CCL25-
CCR9 axis is not needed for entry of lymphocytes to other parts of the gut such as 
the colon, where instead it has been proposed GPR15 may control T cell 
trafficking to this site (Kim et al., 2013). The imprinting of gut homing molecules on 
lymphocytes depends on the production of retinoic acid (RA) by DCs (Iwata et al., 
2004; Jaensson-Gyllenbäck et al., 2011). RA is a metabolite of dietary vitamin A, 
generated through the action of two enzyme families, aldehyde dehydrogenases 
(ALDHs) and retinaldehyde dehydrogenases (RALDHs). Vitamin A is first oxidised 
to retinaldehyde by ALDHs, which is subsequently oxidised to RA by RALDHs 
(Duester, 2000; Maden, 2002). As discussed below, production of RA has been 
shown to be a function of CD103+ DCs in the LP, PPs and MLNs. 
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Figure 1.6: Schematic representation of intestine and gut-associated lymphoid tissues  
DCs in the LP migrate through the afferent lymphatics to the MLNs, which are the crucial site for 
the induction of tolerance and immunity. PPs and ILFs represent additional priming sites and DCs 
in this location may also drain to the MLNs, although this remains to be shown.   
 
1.4.1.3 Lamina propria 
The lamina propria (LP) is a thin layer of loose connective tissue (Mowat, 
2003) that together with its overlying epithelium, constitutes the mucosa. As 
mentioned above, the LP is home to a number of immune cells including 
lymphocytes, macrophages, DCs, eosinophils and ILCs. There are more 
lymphocytes in the mucosa than in any other part of the body, with the LP 
containing CD4+ and CD8+ T cells, NKT cells as well as a large population of 
plasma cells, which produce IgA, the dominant antibody isotype in the intestine. 
Following its transcytosis into the lumen, IgA functions to neutralise pathogens and 
their products (Cerutti and Rescigno, 2008). The majority of T cells in the LP are 
CD4+ T cells and all subtypes of these can be found in the LP, including IFNγ-
producing Th1, cells, the suppressive FoxP3+ TReg cells and Th17 cells. A sizeable 
population of cytotoxic CD8+ T cells is also present in the LP. The presence of 
Th17 cells in the steady state LP has caused some confusion, as these cells are 
usually absent from the periphery in the absence of inflammation. Notably, Th17 
cells represent the majority of CD4+ T cells in the steady state LP (Ivanov et al., 
2006; Mangan et al., 2006). Several investigators have argued that their presence 
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in the absence of pathological inflammation suggests these may be protective. 
Consistent with this, IL17A-/- mice are more susceptible to dextran sodium 
sulphate (DSS) induced colitis (Yang et al., 2008). However, contrary to the idea 
that Th17 cells are protective, similar to their roles in other tissues, Th17 cells have 
also been associated with pathology. One explanation may come from the 
different effects of individual forms of the IL17 protein. Whereas IL17F has been 
implicated in the role of Th17 cells in gut pathology, IL17A appears to play a more 
anti-inflammatory role (Yang et al., 2008). Nevertheless, additional studies are 
required to delineate the role of Th17 cells in the steady state LP (Maloy and 
Kullberg, 2008). In addition to lymphocytes, the LP is home to a considerable 
number of mononuclear phagocytes such as DCs and mφs. As alluded to earlier, 
the correct identification of these cells is the cause of continued debate and this is 
described in detail below. 
1.4.2 Regulation of Tolerance vs. Immunity in the Intestine 
Most individuals do not develop intestinal inflammation in response to the 
diverse array of harmless antigens encountered on a daily basis, yet are capable 
of clearing intestinal pathogens when necessary. In order to achieve this level of 
regulation, the intestinal immune system has evolved sophisticated processes 
which balance protective immunity and tolerance.  
A number of mechanisms are designed to prevent the entry of pathogenic 
microbes into the intestine, including physical, biochemical and mechanical 
barriers, together with a diverse array of innate and adaptive immune cells at the 
mucosal surface. Despite only being one cell thick, the intestinal epithelium 
provides a physical barrier against the entry of potential pathogens. The barrier 
function of the intestinal epithelium is ensured by complex mechanisms acting on 
multiple levels. Commensal microbes themselves represent one arm of this 
defence, preventing potential pathogens from attaching and invading (Swidsinski 
et al., 2005). In addition to its barrier function, the epithelium can also initiate 
inflammatory responses as a result of intracellular and surface expression of PRR 
by enterocytes (Rakoff-Nahoum et al., 2004; Vaishnava et al., 2008). Furthermore, 
much of the epithelium is coated with a thick mucus layer, resulting from mucin 
production by goblet cells. This mucus layer is essential for host protection as 
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evidenced by the spontaneous development of colitis and impaired protection from 
DSS colitis in Muc2 knock out mice (van der Sluis and van Seuningen, 2006; van 
der Sluis et al., 2006; Van der Sluis et al., 2006). Trefoil factors are further agents 
produced by enterocytes which protect the barrier against invasion (Mashimo et 
al., 1996). Further protection against pathogenic bacteria comes from the MyD88-
dependent production of anti-microbial peptides such as defensins and RegIIIγ by 
Paneth cells present in the crypts of the small intestine (Hooper et al., 2003; 
Ouellette and Bevins, 2001; Vaishnava et al., 2008). 
Despite the presence of these surface defences, a number of microbes can 
breach the epithelium and communicate with the innate immune cells located in 
the lamina propria including the largest population of macrophages in the body, 
neutrophils, eosinophils, natural killer (NK) cells and innate lymphoid cells (ILCs). 
As well as producing pro-inflammatory mediators and being able to kill pathogens, 
some of these innate cells such as ILCs, produce mediators like IL22 which drives 
the production of anti-microbial peptides and enhances barrier integrity (Cella et 
al., 2009; Harrison and Maloy, 2011; Sanos et al., 2009; Sonnenberg et al., 2011; 
Zheng et al., 2008). If the innate response is overcome, uptake of invading 
microbes by DCs in LP or PPs leads to antigen specific immune responses via 
priming of T and B cells in PP or MLNs, as discussed in detail below.  
A rather similar battery of innate and adaptive immune responses is now 
thought to also limit the uptake and penetration of commensal bacteria across the 
epithelium. However the main consequence in the adaptive immune system of 
exposure to harmless antigens such as commensal bacteria and food proteins is 
the induction of tolerance, which ensures that effector T cell responses are not 
generated inappropriately. In the case of food proteins, this tolerance affects both 
systemic and local immune responses, a phenomenon known as “oral tolerance” 
(Pabst and Mowat, 2012). The generalised effects of oral tolerance may reflect the 
fact that orally administered proteins may disseminate via the blood and lymph into 
systemic lymphoid tissue, as well as the liver, which receives blood from the 
intestine via the portal vein (Thomson and Knolle, 2010). In contrast, tolerance to 
commensal bacteria only affects mucosal immunity and the systemic immune 
system remains ignorant of the antigens. In addition, IgA production is stimulated 
in response to commensal bacteria, but not food proteins (Pabst and Mowat, 2012; 
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Pabst, 2012). The exact mechanisms of tolerance induced in the intestine remain 
unclear, with a number of different mechanisms being implicated, including the 
induction of TReg cells, clonal deletion and T cell anergy, with each mechanism 
possibly related to the nature and dose of the antigen (Chen and Weiner, 1996; 
Chen et al., 1995; Hadis et al., 2011; Pabst and Mowat, 2012). 
When the intestinal immune system fails to induce tolerance, inappropriate 
inflammatory reactions against food proteins and commensal bacteria can lead to 
disorders such as coeliac disease, food allergies and inflammatory bowel diseases. 
There are two main forms of IBD, Crohn’s disease (CD) and ulcerative colitis (UC), 
both of which are chronic, relapsing and remitting diseases which result in the loss 
of intestinal architecture and tissue destruction (Baumgart and Sandborn, 2007). 
Crohn’s disease has become a major health problem in industrialised countries, 
being difficult to treat and with a rapidly increasing incidence in recent years 
(Lakatos, 2006; Molodecky et al., 2012). There is considerable evidence that IBD 
results from aberrant responses to the host microbiota in genetically susceptible 
individuals (Xavier and Podolsky, 2007). Many of the factors that underlie 
susceptibility to IBD are related to mechanisms of local bacterial defence, 
including barrier defects (Xavier and Podolsky, 2007), defects in Paneth cells and 
anti-microbial peptide production (Wehkamp et al., 2005), autophagy (Henry et al., 
2009) and PRRs such as Nod2 (Kobayashi et al., 2005). These associations are 
underlined by the genetic linkage between Crohn’s disease and polymorphism in 
the IL23R (Duerr et al., 2006; Kobayashi et al., 2008; Sarra et al., 2010), as well 
as the evidence that Th17 responses are important for the pathology. Furthermore, 
murine models of IBD cannot be established in germ-free animals (Sellon et al., 
1998) and can be transferred by microbes from the gut of an IBD mouse into a 
healthy animal (Garrett et al., 2007) and as a result both antibiotic and probiotic 
treatments have been used to treat IBD (Gionchetti et al., 2003; Khan et al., 2011). 
How the intestinal immune system decides between inducing tolerance or active 
immunity remains a matter of debate. However it seems very likely that dendritic 
cells play a central role, being the principal cells in the immune system which can 
distinguish between harmless and pathogenic antigens and translate this 
information into appropriate priming of naïve T cells. Which intestinal DCs are 
involved in these responses, whether different DC subsets are required for each 
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aspect of immunity and how they react to different kinds of antigen are among the 
questions I sought to address in my project.  
1.4.3 Intestinal MPs  
Mononuclear phagocytes play several important roles in maintaining the 
balance between tolerance and immunity in the intestine. DCs and mφs are 
abundant in the mucosa, while PPs and ILFs also contain many DCs as well as 
some mφs. As mentioned above, DCs are also present in the MLNs, where they 
either derive from the blood or have migrated to the MLNs from the intestine. 
Contrary to this, mφs are absent from the steady state MLNs. Defining the exact 
roles of these cell types has been difficult especially in the mucosa where the use 
of overlapping markers has created many problems.  
The intestinal LP was one of the first non-lymphoid tissues in which MHCII+ 
cells with classical DC morphology were identified by immunohistochemistry 
(Mayrhofer et al., 1983). The idea that these may be involved with inducing 
antigen specific responses was supported by the identification of cells with a 
similar appearance in intestinal lymph from rats (Pugh et al., 1983). However it 
was soon realised that intestinal mφs were also MHCII+ (Janossy et al., 1986; 
Mayrhofer et al., 1983; Spencer et al., 1987), meaning that mere expression of 
MHCII could not discriminate between DC and mφs.  
When CD11c became established as the ‘definitive’ marker of DCs, this 
also became the convention for identifying these cells in the intestinal LP. Indeed 
from the late 1990s onwards, DCs were routinely identified solely on the basis of 
CD11c surface expression, with MHCII expression being largely ignored (Chirdo et 
al., 2005; Monteleone et al., 2008; Rescigno et al., 2001). Following the 
identification of CD11b+ and CD11b- DC subsets, it became routine for co-
expression of CD11c and CD11b to be used for the identification of LP DCs, and 
many groups have used this approach until fairly recently (Anjuère et al., 2004; 
Chirdo et al., 2005; Denning et al., 2007; 2011; Jang et al., 2006; Krajina et al., 
2003). The development of more sophisticated multi-parameter flow cytometers 
has now shown that several other myeloid cells in the LP express CD11b, and 
many of these can co-express CD11c, such as mφs and eosinophils (Bain et al., 
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2013; Mowat and Bain, 2010; Pabst and Bernhardt, 2010). As discussed in more 
detail below, it is also now clear that the CD8α+ DCs are present in the villous LP 
and not mere contaminants of intestinal lymphoid structures (Cerovic et al., 2013) 
as previously assumed (Anjuère et al., 1999; Bogunovic et al., 2009; Vremec et 
al., 1997; 2000; 1992). 
  A major advance in the identification of LP DCs came from the identification 
of CD103 (OX-62), which was suggested to be a specific marker of intestinal DCs. 
Although CD103 was first identified as a marker of intraepithelial lymphocytes 
(IELs), early work found CD103 to be expressed on DCs migrating in rat intestinal 
lymph (Brenan and Puklavec, 1992; Kilshaw, 1993). It was later shown to identify 
a proportion of CD11c+ DCs in the LP and MLN, which induced gut homing 
receptors on interacting naïve T cells. Furthermore these DCs were also shown to 
play a role in the regulation of T cell mediated colitis (Annacker et al., 2005; 
Johansson-Lindbom et al., 2005), by driving TReg responses (Coombes et al., 
2007; Sun et al., 2007). CD103+ DCs in the intestine have been shown to consist 
of CD11b+ and CD11b- fractions with the latter being outnumbered by 
CD103+CD11b+ DCs which appear to be specific to the intestine (Fujimoto et al., 
2011; Sun et al., 2007).  
The inadequacy of using CD11c and MHCII to specifically identify DCs was 
exemplified by reports that a population of LP ‘DCs’ could extend dendrites across 
the epithelium to sample antigen in the lumen (Rescigno et al., 2001). These MPs 
were shown to express the chemokine receptor CX3CR1 and CD11b, but not 
CD103, and as such were classified as CD103- DC (Niess et al., 2005; Vallon-
Eberhard et al., 2006). Thus it was proposed that there were 3 distinct populations 
of intestinal DCs, CD103+CD11b-, CD103+CD11b+ and CD103-CD11b+ DCs 
(Table 1.5) (Bogunovic et al., 2009; Varol et al., 2009). Additional characterisation 
of these MP populations found the two CD103+ MP populations to derive from pre-
DCs in an Flt3L-dependent manner, with the CD103+CD11b+ DCs showing an 
additional dependence on CSF-2 (Bogunovic et al., 2009; Greter et al., 2012). 
Contrary to this, the CD103- DCs were reported to derived from Ly6Chi monocytes 
in a CSF-1-dependent, Flt3L-independent manner (Bogunovic et al., 2009; Greter 
et al., 2012; Varol et al., 2009). However work published at the same time from the 
Pabst and Agace groups challenged the lineage designation of CX3CR1-
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expressing cells (Schulz et al., 2009). Consistent with their derivation from pre-
DCs and dependence upon Flt3L, Schulz et al. showed that the CD103+ cells 
appeared to be genuine DCs, migrating in lymph and inducing proliferation of 
naïve T cells (Schulz et al., 2009), a finding confirmed by several groups since 
(Denning et al., 2011; Fujimoto et al., 2011; Uematsu et al., 2008). In direct 
contrast, the CD103-CX3CR1+ cells were not found in lymph and could not induce 
the proliferation of naïve T cells (Schulz et al., 2009). These findings coupled with 
their expression of F4/80 and CD115 resulted in these cells being redefined as a 
population of CD11c+MHCII+ mφs (Schulz et al., 2009). 
Interestingly, Schulz and colleagues also found that the CD103-CX3CR1+ 
MP population could be further divided on the basis of levels of CX3CR1 
expression into a population of CX3CR1int and CX3CR1hi cells. Although they 
concluded that both these were likely to be tissue-resident mφs, the CD103-
CX3CR1int cells, unlike their CD103-CX3CR1hi counterparts were slightly increased 
following exogenous administration of Flt3L and were able to induce some 
proliferation of naïve T cells although at a much lower level than those induced by 
the genuine CD103+ DCs (Schulz et al., 2009). These cells were not characterised 
further and several subsequent studies have grouped all CD103-CX3CR1-
expressing MPs together. Other studies, including those from our lab, have 
suggested that the CX3CR1int cells comprise monocytes maturing into tissue 
resident CX3CR1hi mφs as well as a minor putative population of DCs (Bain et al., 
2013; Rivollier et al., 2012; Tamoutounour et al., 2012). In addition, preliminary 
work from the Milling group had identified CD103- DCs in pseudo-afferent 
intestinal lymph. This was the position when I began my project, with considerable 
confusion over how to identify DCs and mφs in the LP. In particular, there was no 
definitive evidence for a bona fide population of CD103- DCs, therefore this was 
the principal aim of my work. To do this, I adopted phenotyping strategies that had 
been used in our lab in conjunction with collaborators in Bernard Malissen’s 
laboratory in Marseille which had found CD64 (FcγRI) and F4/80 expression to 
specifically mark mφs amongst the CD11c+MHCII+ intestinal MPs (Bain et al., 
2013; Tamoutounour et al., 2012).  
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Table 1.5: Intestinal Mononuclear Phagocyte Subsets as defined in 2009 
MP Subset Phenotype Precursor Growth Factor 
CD103+CD11b+ 
CD11c+, MHCII+, 
F4/80-, CX3CR1-, 
SIRPα+, XCR1- 
Pre-DCs Flt3L, CSF-2 
CD103+CD11b- 
CD11c+, MHCII+, 
F4/80-, CX3CR1-, 
SIRPα-, XCR1+ 
Pre-DCs Flt3L 
CD103-CD11b+ SIRPα+, XCR1- Monocytes CSF-1 
 
1.4.4 Functions of Intestinal DCs 
1.4.4.1 Antigen Acquisition by Intestinal DCs 
As discussed above, DCs are involved in acquiring antigen from their local 
environment and transporting it to the draining lymph nodes, where they initiate 
adaptive immune responses. In the intestine, one way this could occur is that DCs 
in the SED of PPs may acquire antigen and subsequently migrate to the T cell 
areas of the PPs or potentially migrate in lymph to the MLNs (Mowat, 2003). 
However, the evidence discussed above that PPs may be dispensable for the 
induction of immunity and tolerance especially to soluble antigen suggests that 
additional antigen entry must occur across the villous epithelium into the LP. How 
this happens and what cells are involved are largely unknown. Pathogenic 
microbes may achieve this by invading the epithelium rendering them susceptible 
to engulfment by APCs in the LP. Additionally, M cells have been described in the 
villous epithelium (Jang et al., 2004), however these are likely to be rare 
occurrences. The suggestions that CX3CR1+CD11c+MHCII+ cells could extend 
transepithelial dendrites (TEDs) through tight junctions in the epithelium to capture 
luminal bacteria seemed to offer one possible explanation (Chieppa et al., 2006; 
Niess et al., 2005; Rescigno et al., 2001). However, these TED-generating DCs 
were never shown to migrate to MLNs or present antigen and, as discussed above, 
most CX3CR1-expressing cells in the intestine are considered to be macrophages 
rather than DCs (Schulz et al., 2009). In addition, it is even uncertain if TEDs are 
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required because although Niess and coworkers demonstrated that CX3CR1-
dependent TEDs were involved in the uptake of invasion-deficient Salmonella 
(Niess et al., 2005), invasive Salmonella usually gain entry to the intestine via M 
cells in PPs and ILFs (Carter et al., 1975; Halle et al., 2007; Jones et al., 1994) 
and CX3CR1-dependent TEDs were not required for uptake of such invasive 
strains. In the same vein, non-invasive Aspergillus spores were also found to gain 
access to the LP in a TED-independent fashion. However formation of TEDs has 
only been shown to occur in the terminal ileum and only in some strains of mice 
(Vallon-Eberhard et al., 2006). 
More recently, two multi-photon in vivo microscopy studies attempted to 
address this issue using more rigorous approaches to identify the APCs involved. 
Using CD11c+/YFP x CX3CR1+/GFP mice in which CX3CR1+CD11c+ cells are 
assumed to be mφs and CX3CR1-CD11c+ cells are assumed to be DCs, two 
studies failed to detect CX3CR1-expressing intestinal MPs extending TEDs into 
the lumen (Farache et al., 2013; McDole et al., 2012). Instead McDole and 
coworkers identified goblet cell associated antigen passages (GAPs) that 
appeared to pass soluble dextran and proteins from the lumen to underlying GFP-
YFPhi (CD11c+CX3CR1-) cells. This route is unlikely to be involved in the uptake of 
particulate antigen such as bacteria, as beads >0.02µm diameter could not transit 
through GAPs (McDole et al., 2012). In contrast, Farache and colleagues could 
not find a role for GAPs, but noted a small population of CD103+ DCs present 
within the epithelium which could extend dendrites into the lumen. Notably this 
phenomenon was increased during Salmonella infection (Farache et al., 2013). 
Although these latter findings need to be confirmed, they are in agreement with 
previous reports suggesting that low numbers of CD103+ DCs were present in the 
steady state epithelium and could increase during inflammation (Anjuère et al., 
1999; Bogunovic et al., 2009; Cruickshank et al., 2009). Interestingly however, the 
idea that mφs may be involved in the initial capture of soluble antigen from the 
lumen is supported by an earlier report suggesting CX3CR1+ MPs preferentially 
take up orally administered soluble antigen (Schulz et al., 2009). Clearly more 
work is required to determine the nature of cells taking up antigen and how DCs 
acquire antigen for subsequent presentation to naïve T cells.  
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1.4.4.2 Migration of Intestinal DC to MLNs 
After acquiring antigen, intestinal DCs migrate to the draining MLNs in a 
CCR7 dependent manner (Forster et al., 1999; Jang et al., 2006; Johansson-
Lindbom et al., 2005; Worbs et al., 2006) carrying both soluble and particulate 
antigen (Bogunovic et al., 2009; Jaensson et al., 2008; Macpherson and Uhr, 
2004). Antigen laden intestinal DCs were first demonstrated to be present in 
pseudo-afferent lymph of rats and pigs which had undergone mesenteric 
lymphadenectomy, followed by thoracic duct cannulation (Bimczok et al., 2005; 
Cerovic et al., 2009; Liu and MacPherson, 1991; Macpherson and Uhr, 2004; 
Mayrhofer et al., 1983; 1986; Milling et al., 2010; Pugh et al., 1983; Yrlid et al., 
2006b) and more recently, these findings have been extended to mice (Bain et al., 
2013; Cerovic et al., 2013; Schulz et al., 2009). The earliest studies of these in rats 
used CD103 to identify them, thus providing the first evidence that migration and 
APC activity were intrinsic properties of CD103+ DCs in the gut (Brenan and 
Puklavec, 1992). Their importance was underlined by studies which showed 
similar DCs in the MLNs and that the generation of gut tropic T cells in the MLNs 
after oral administration of antigen was CCR7 dependent (Johansson-Lindbom et 
al., 2005). As CD103+ DCs are selectively absent from CCR7-/- MLNs, these 
results indicate that migration of intestinal DCs is crucial in establishing immune 
responses (Worbs et al., 2006). Further studies using BrdU incorporation showed 
that the accumulation of BrdU+CD103+ DCs in the MLN was delayed compared 
with that in the LP, suggesting they were derived from the LP (Jaensson et al., 
2008). Ex vivo confocal imaging of intestinal lymphatics and sampling of intestinal 
draining lymph then identified CD103+ DCs directly as the major migratory DC 
population in intestinal lymph (Schulz et al., 2009). By adapting the lymph 
cannulation technique to mice, Cerovic and colleagues recently confirmed that 
CD103+ DCs are the major population in intestinal lymph and that the CX3CR1hi 
MPs do not migrate, consistent with their lack of CCR7 expression and 
classification as tissue-resident mφs (Cerovic et al., 2013). However, their work 
also showed a population of CD103-CX3CR1int MPs which in addition to migrating 
in lymph, had APC capabilities and were Flt3L dependent demonstrating them to 
be bona fide DCs (Cerovic et al., 2013). This finding suggests a similar DC 
population should also be present in the LP and thus one aim of my project was to 
investigate their presence. Intriguingly, the migration of DCs from the LP appears 
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to be a constitutive process occurring in the absence of both overt inflammation 
and commensal bacteria and MyD88-signalling (Wilson et al., 2008). However, the 
number of DCs migrating can be increased following TLR ligation or TNFα 
(Turnbull et al., 2005; Yrlid et al., 2006b; 2006a). 
1.4.4.3 Presentation of Antigen to T Cells 
As discussed above the MLNs are essential for the development of both 
immunity and tolerance in the intestine (Mowat, 2003; Spahn et al., 2002; Worbs 
et al., 2006) and the ultimate fate of DCs migrating from the SI LP is the MLN, as 
few DCs are detectable in the thoracic duct without prior mesenteric 
lymphadenectomy (Cerovic et al., 2013). CD103+ DCs are the only DC subset in 
the MLNs of mice fed soluble antigen that can induce antigen specific proliferation 
of CD4+ and CD8+ T cells ex vivo (Coombes et al., 2007; Jaensson et al., 2008). 
However as noted above, it has proved difficult to show these DCs taking up 
antigen directly from the lumen and it remains unclear how and where they first 
acquire antigen for presentation in the MLN.  
One of the unique features of CD103+ DCs in the intestine is their ability to 
generate RA from dietary vitamin A (Coombes et al., 2007; Iwata et al., 2004; Sun 
et al., 2007). This is most marked with CD103+ DCs from the LP and MLNs, 
however it is also found with CD103+ DCs isolated from the PPs and CD103+ LP, 
MLN and PP DCs have been shown to express both Aldh1a1 and Aldh1a2 
(Coombes et al., 2007; Yokota et al., 2009) and have considerable ALDH activity 
as assessed using the commercially available ALDEFLUOR assay (Schulz et al., 
2009; Yokota et al., 2009). Importantly, CD103- MPs from the gut do not share this 
property and typically nor do CD103+ DCs from other sites, however it can be 
upregulated in other DCs by CSF-2, IL4 and TLR signalling (Yokota et al., 2009). 
However, more recently, CD103+ and CD103- DCs from the lung have also been 
reported to have ALDEFLUOR activity and be capable of inducing gut homing 
molecules on naïve T cells, suggesting some overlap between mucosal surfaces 
(Ruane et al., 2013). There also appears to be a feedback loop in which ALDH 
activity requires the presence of vitamin A, either directly from the diet or after 
excretion from the liver in bile (Jaensson-Gyllenbäck et al., 2011; Molenaar et al., 
2011). Importantly, there may also be other sources of RA in the intestine, 
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including epithelial cells (Bhat, 1998; Lampen et al., 2000) and mesenteric stromal 
cells (Hammerschmidt et al., 2008; Molenaar et al., 2011). These cells themselves 
can induce gut homing molecule expression on naïve T cells (Agace and Persson, 
2012; Annacker et al., 2005; Hammerschmidt et al., 2008; Jaensson et al., 2008; 
Jaensson-Gyllenbäck et al., 2011; Johansson-Lindbom et al., 2005; Svensson et 
al., 2008) and may cooperate with migratory DCs in this.  
The other function of CD103+ intestinal DCs, which was identified in early 
studies, was a preferential ability to drive the differentiation of FoxP3+ TReg cells 
under steady state conditions. Again, this function was restricted to this subset 
from the gut and was related to the production of RA which cooperated with 
exogenous TGFβ (Coombes et al., 2007; Sun et al., 2007). Many cells in the 
intestine can produce TGFβ, including DCs. However, TGFβ is produced in an 
inactive form that has to be cleaved to allow it to mediate its biological effects 
(Annes et al., 2003). One molecule that can activate TGFβ is the integrin αvβ8 (Mu 
et al., 2002). Interestingly CD103+ DCs express αvβ8 at high levels and mice that 
lack integrin αvβ8 expression on CD11c+ or CD11b+ cells have reduced numbers 
of FoxP3+ TReg cells and develop intestinal pathology (Lacy-Hulbert et al., 2007; 
Travis et al., 2007; Worthington et al., 2011).  
As a result of these studies, a paradigm has arisen that the principal 
function of CD103+ DCs in the steady state intestine is the generation of gut 
homing TReg cells and that this is how tolerance is maintained. However, the 
contributions of each CD103+ DC subset to TReg cell induction remain unclear. 
Batf3-/- mice, which lack intestinal CD103+CD11b- DCs, have normal numbers of 
intestinal FoxP3+ TReg cells (Edelson et al., 2010), as do mice with a severe and 
selective reduction in migratory MLN CD103+CD11b+ DCs  (Lewis et al., 2011). 
Although this apparent contradiction could reflect that these studies did not 
distinguish natural thymus-derived TReg cells (nTReg) from intestinally induced TReg 
cells (iTReg) and the majority of TReg cells in the intestine represent nTReg cells 
(Cebula et al., 2013; Weiss et al., 2012), a recent study by the Agace lab, 
demonstrated that mice with a significant reduction in the CD103+CD11b+ DC 
population had normal proportions of both natural and induced TReg cells (Persson 
et al., 2013b). As I was finalising this thesis, a report came out demonstrating a 
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degree of redundancy between the CD103+ intestinal DC subsets and effects on 
TReg populations were only apparent following deletion of both CD103+ DC subsets 
(Welty et al., 2013). In direct contrast to these results implicating CD103+ DCs as 
the tolerogenic APCs, two reports from Denning and colleagues have suggested 
that mφs are responsible for priming TReg cells (Denning et al., 2007; 2011). 
However, given the inability of these cells to migrate to the draining MLN and the 
fact that the intestinal mucosa is devoid of naïve T cells, it is difficult to see where 
this would be physiologically relevant. One explanation for this apparent 
discrepancy could come from studies from the Pabst lab showing that IL10 
producing mφs in the LP are crucial for the in situ secondary expansion of FoxP3+ 
TReg cells which were primed initially by DCs in the MLNs (Hadis et al., 2011). 
Thus this may be site-specific cooperation between intestinal MPs in immune 
regulation.  
Considerable research effort has concentrated on intestinal CD103+ DCs as 
mediators of tolerance, but the APCs involved in active immunity in the intestine 
are less well characterised. Because it was assumed that CD103+ DCs were 
intrinsically tolerogenic, it was hypothesised that a separate population of CD103- 
pro-inflammatory DCs of monocyte-origin may exist in the LP (Rivollier et al., 
2012; Siddiqui et al., 2010; Varol et al., 2009; 2007; Zigmond et al., 2012). 
However, these studies were carried out using phenotyping strategies which could 
not discriminate DCs from mφs (Rivollier et al., 2012; Varol et al., 2007; 2009). 
Thus one aim of this thesis was to determine if a population of genuine CD103- 
DCs exist in the intestinal LP and explore their functions and origins. While the 
idea of distinct subsets of cells inducing either tolerance or active immunity is 
attractive, the presence of a CD103- DC population would not fit the current 
paradigm that only intestinal CD103+ DCs can induce gut tropisms, as the 
generation of intestinal effector T cells would require the induction of the gut 
homing molecules CCR9 and α4β7 expression on the T cells.  
An alternative possibility is that the CD103+ DCs are not inherently 
tolerogenic, but instead can adapt to the local environment to induce either 
tolerance or protective immunity as required. During T-cell mediated colitis, 
CD103+ MLN DCs have reduced ability to drive the differentiation of TReg cells, a 
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finding that correlated with decreased ALDH expression and activity and instead 
CD103+ DCs during inflammation induced Th1 and Th17 responses (Laffont et al., 
2010). Moreover, it appears that the individual subsets of intestinal CD103+ DCs 
may play distinct roles in promoting different arms of the adaptive immune 
response even in the steady state. In vitro studies indicate that both 
CD103+CD11b+ and CD103+CD11b- DCs can drive IFNγ production from CD4+ T 
cells (Fujimoto et al., 2011), while CD103+CD11b- SI DCs excel at priming CD8+ T 
cells (Cerovic et al., 2013; Fujimoto et al., 2011). Conversely CD103+CD11b+ DCs 
appear to be more efficient at inducing Th17 polarization than their CD103+CD11b- 
counterparts (Denning et al., 2011; Fujimoto et al., 2011; Lewis et al., 2011; 
Persson et al., 2013b; Schlitzer et al., 2013; Uematsu et al., 2008), and it is 
suggested that this reflects their production of IL6 (Persson et al., 2013b). Both 
properties are enhanced by ligation of TLRs including TLR2, TLR5 and TLR9 
(Fujimoto et al., 2011; Persson et al., 2013b; Uematsu et al., 2008). Thus CD103+ 
DCs may be able to become pro-inflammatory under some conditions and given 
that CD103+CD11b+ and CD103+CD11b- DCs express a partially distinct array of 
TLRs (Fujimoto et al., 2011; Kinnebrew et al., 2012; Miller et al., 2012; Uematsu et 
al., 2008), they may react differently depending on the context of their immediate 
environment. In my project, I investigated the T cell priming properties of intestinal 
DC subsets in vitro and in vivo.  
1.4.5 DC Conditioning Factors in the Gut 
Intestinal DCs have many unusual properties including the expression of 
CD103 on CD11b+ DCs and the production of retinoic acid (RA). Most evidence 
suggests that these properties result from the local ‘conditioning’ effect on DC 
precursors and mature DCs in the mucosa and a number of such factors have 
been identified. These include dietary constituents and neuroendocrine factors, as 
well as factors produced by intestinal epithelial cells (IECs), luminal bacteria, other 
leukocytes and stromal cells (Figure 1.7).  
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Figure 1.7: Conditioning of DCs by the intestinal environment 
A number of different factors might act in concert to condition mucosal DCs with their unique 
properties. These include dietary metabolites, microbial-derived products, epithelial cell factors, 
neuropeptides produced by enteroendocrine cells, IL10 from CX3CR1hi mφs and IL10 and TGFβ 
from gut-homing TReg cells. Adapted from (Scott et al., 2011). 
 
1.4.5.1  Epithelial Cell Derived and Other Cytokines 
DCs are situated close to IECs and the interaction between these two cell 
types is thought to be integral for the conditioning of DCs to their local environment. 
The first evidence for this came from co-culture studies with epithelial cells and 
human monocyte derived DCs (mo-DCs), whereby epithelial cells treated with 
different bacterial strains produced different pro-inflammatory mediators which 
modulated mo-DC function (Rimoldi et al., 2005a). Later, IEC-specific knock out 
(KO) of NF-kB signalling was reported to result in the dysregulated production of 
pro-inflammatory cytokines by DCs and the subsequent development of intestinal 
inflammation (Nenci et al., 2007; Zaph et al., 2007). Exactly how IECs modulate 
DCs is unclear but one mechanism is through their secretion of several 
immunoregulatory factors, such as thymic stromal lymphopoietin (TSLP), TGFβ 
and prostaglandin E2. Perhaps the best characterised of these is TSLP, which 
although constitutively expressed can be upregulated in response to infection, 
inflammation and tissue injury (Allakhverdi et al., 2007; Bogiatzi et al., 2007; Kato 
et al., 2007; Lee and Ziegler, 2007; Li et al., 2006; Rimoldi et al., 2005a; Zaph et 
al., 2007). TSLP appears to mediate its effects through modulating the expression 
of pro-inflammatory cytokines by DCs subsequently affecting their ability to induce 
naïve T cell polarisation. Consistent with the role of TSLP in the skin and lung 
(Holgate, 2007), IEC-derived TSLP has been shown to condition DCs to drive Th2-
like anti-inflammatory T cell differentiation, while limiting their production of IL12 
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(Rimoldi et al., 2005a; 2005b; Zeuthen et al., 2008), Furthermore, deletion of the 
TSLP receptor in mice leads to overexpression of IL12/IL23p40 and the inability to 
induce protective Th2 responses to Trichuris muris infection (Zaph et al., 2007). 
Additionally, TSLP drives DC-dependent differentiation of nTReg cells in thymus 
(Watanabe et al., 2005), as well as inducing CD103 expression by monocyte-
derived DCs, which then have enhanced ability to induce FoxP3+ TReg 
differentiation (Iliev et al., 2009a; 2009b). Interestingly, DCs themselves may also 
produce TSLP in response to MyD88 signalling controlling T cell polarisation 
(Spadoni et al., 2012). 
In addition to TSLP, TGFβ production by IECs contributes to the ability of 
these cells to condition DCs to drive FoxP3+ TReg cell differentiation (Iliev et al., 
2009a; 2009b). However, as mentioned above, several other cell types may also 
contribute to TGFβ production in vivo, including CD4+ T cells (Fukaura et al., 1996; 
Gonnella et al., 1998) and macrophages (Gonnella et al., 1998; Weber et al., 
2011). 
1.4.5.2  Intestinal microbes  
Although effects of the microbiota on immune function are well known and 
these can influence the differentiation of individual T cell subsets including TReg 
and Th17 cells (Ivanov et al., 2009; 2008), very few of these studies have shown 
that this is the result of altered DC behaviour. Examples of direct effects on DCs 
come from studies where DCs isolated from mice sourced from different vendors, 
and therefore with distinct microbiota, induce differential T cell responses following 
ex vivo co-culture (Denning et al., 2011). Similarly, microbiota signals through TLR 
ligation can induce expression of the enzymes required for synthesis of RA (retinal 
dehydrogenases) by DCs, thus conferring upon the DC the ability to induce gut 
homing molecules on differentiating T cells (Johansson-Lindbom et al., 2005). This 
idea is supported by the fact that MyD88-/- mice express lower levels of retinal 
dehydrogenases compared with WT controls (Wang et al., 2011). Furthermore, 
several commensal Bacteroides and Bifidobacteria strains can directly induce a 
tolerogenic phenotype on monocyte-derived DCs (Baba et al., 2008). Zymosan, a 
component of yeast cell wall recognised through TLR2 and dectin-1, shapes the 
immune response by inducing DCs to produce IL10 and express Aldh1a2, 
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contributing to the ability of intestinal DCs to drive TReg cell differentiation (Dillon et 
al., 2006; Manicassamy et al., 2009; Zhou et al., 2004).  
The presence of specific microbes can also contribute to the activation state 
of DCs. For example, polysaccharide A (PSA) from Bacteroides fragilis, associates 
with CD11c+ cells in the MLN driving a mixture of Th1 systemic responses and IL-
10 producing TReg cells in the colonic LP (Mazmanian et al., 2005). Segmented 
filamentous bacteria (SFB) have recently been shown to induce Th17 and inhibit 
FoxP3+ TReg cell differentiation in the mucosa (Ivanov et al., 2009) presumably 
through its effects on DCs and mφs in the LP which have been shown to regulate 
Th17 differentiation and maintenance (Denning et al., 2011; Lewis et al., 2011; 
Persson et al., 2013b; Satpathy et al., 2013; Schlitzer et al., 2013; Shaw et al., 
2012) although exactly how SFB affects the MPs remains to be determined.  
1.4.5.3  Role of dietary constituents 
Intestinal DCs are continuously exposed to foreign dietary constituents 
which may have immunomodulatory properties. As discussed earlier, vitamin A is 
perhaps the most studied of these, and its only source in mammals is from the diet. 
CD103+ DCs themselves have the ability to metabolise vitamin A to RA and this 
has been linked to their ability to induce FoxP3+ TReg cells (Coombes et al., 2007; 
Jaensson et al., 2008; Johansson-Lindbom and Agace, 2007; Johansson-Lindbom 
et al., 2005; Molenaar et al., 2011; Sun et al., 2007). Indeed, depletion of vitamin A 
from the diet impairs the ability of MLN CD103+ DCs to induce TReg cell 
differentiation and imprint gut homing receptors on lymphocytes (Jaensson-
Gyllenbäck et al., 2011; Molenaar et al., 2011). Interestingly, persistent infection 
with T. muris has recently been shown to abrogate the capacity of intestinal MPs 
to metabolise vitamin A until clearance of the infection, suggesting that the 
generation of RA is not required for the efficient clearance of this pathogen (Hurst 
and Else, 2013).  Other cells including intestinal epithelial cells and MLN stromal 
cells are also likely to contribute to vitamin A metabolism (Agace and Persson, 
2012). 
Tryptophan, which is the substrate for indoleamine 2,3-dioxygenase (IDO), 
is also found in the diet. Removal of this hydrophobic amino acid from the 
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environment, through its metabolism into kyneurenines or tryptophan starvation 
can inhibit the generation of effector T cells instead promoting TReg cell 
differentiation (Belladonna et al., 2006; Fallarino et al., 2006b; 2006a). Similarly to 
retinal dehydrogenases, IDO is produced by CD103+ DCs (Matteoli et al., 2010). 
Other dietary metabolites which have immunomodulatory effects, include 
prostaglandins, which are derived enzymatically from fatty acids. These lipid 
mediators activate the anti-inflammatory peroxisome-proliferative-activated 
receptor-γ (PPARγ) which is expressed by DCs, in addition to a variety of other 
cells types, augmenting RA production in the ligated DCs (Szatmari et al., 2006; 
Varga and Nagy, 2008). Additionally ligands of the aryl hydrocarbon receptor 
(AhR), including tryptophan, bilirubin, lipoxin A4 and prostaglandin G can induce 
IL6 production from CD103+ DCs and promote Th17 cell differentiation (Chmill et 
al., 2010). Furthermore, curcumin, a spice that has a long history of medical use in 
India and Southeast Asia has been shown to modulate immune responses. 
Curcumin-treated DCs acquire a tolerogenic phenotype, expressing aldh1a2, 
producing IL-10 and inducing the differentiation of FoxP3+ TReg (Bereswill et al., 
2010; Cong et al., 2009).  
1.4.5.4  Neuroendocrine pathways and mucosal DC function 
One of the best-described examples of neuropeptide-regulation of the 
immune system is vasoactive intestinal peptide (VIP). This product of intestinal 
enteroendocrine cells is a vasodilator and regulator of epithelial permeability. It is 
also produced by several immune cells and has anti-inflammatory properties 
(Bellinger et al., 1996). VIP suppresses LPS-induced CCR7 expression by DC, 
inducing IL10 production, preventing the establishment of an inflammatory immune 
response and promoting tolerance (Weng et al., 2007). Additionally, VIP-pulsed 
DCs preferentially induce naïve T cells to differentiate into TReg cells (Delgado et 
al., 2005a; 2005b) and in parallel VIP-treated DCs can prevent TNBS-induced 
colitis (Gonzalez-Rey and Delgado, 2006).  
1.5 Signal Regulatory Protein α  (SIRPα) 
Many immune cells, including DCs, express inhibitory or activating receptors, 
which may determine or tune their functions. These include the signal inhibitory 
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regulatory protein family (SIRP) (Barclay and Brown, 2006), the CD200 receptor 
(CD200R) family (Gorczynski, 2012) and triggering receptors expressed by 
myeloid cells (TREM) (Colonna, 2003).  
1.5.1 The SIRP Family 
The SIRP family consists of three proteins, SIRPα, SIRPβ and SIRPγ, 
which all have similar extracellular regions, comprising three immunoglobulin 
superfamily (IgSF) domains (Nakaishi et al., 2008) (Fig.1.8). SIRPα, which is also 
known as CD172a, SHPS1, P84 or PTPNS1, was the first member of the family to 
be discovered. It is an inhibitory signalling receptor expressed predominantly by 
myeloid cells including CD11b+ DCs, mφs, eosinophils, monocytes and neutrophils. 
It is also found on neuronal cells (Adams et al., 1998; Fujioka et al., 1996; 
Kharitonenkov et al., 1997; Yamao et al., 1997). SIRPα is particularly relevant to 
intestinal DCs, since it can be used as a marker to distinguish between the two 
populations of CD103+ DCs in the intestine of various species including mice, pigs 
and humans (Bimczok et al., 2005; Persson et al., 2013b; Saito et al., 2010).  
SIRPα binds the ubiquitously expressed ligand, CD47, also known as 
integrin associated protein (IAP) (Vernon-Wilson et al., 2000), a transmembrane 
receptor with intracellular signalling capacity. The cytoplasmic region of SIRPα is 
highly conserved between mice, rats, pigs and humans, and contains an 
immunoreceptor tyrosine-based inhibition motif (ITIM), which is phosphorylated 
upon ligation of SIRPα. This leads to the recruitment of SH2-domain containing 
protein tyrosine phosphatase (SHP) 2 and SHP1, thereby inhibiting several 
tyrosine kinase dependent pathways (Barclay and Brown, 2006; Fujioka et al., 
1996; Kharitonenkov et al., 1997; Ohnishi et al., 1996; Oshima et al., 2002; 
Veillette et al., 1998). SIRPβ does not bind CD47 and has the ability to relay a 
positive signal, as it associates with DAP12, a transmembrane adaptor protein 
containing an immunoreceptor tyrosine-based activation motif (ITAM) (Dietrich et 
al., 2000; Seiffert et al., 2001). The third member of the family, SIRPγ, is capable 
of binding CD47, but the strength of this binding is weaker than the SIRPα/CD47 
interaction. In addition, SIRPγ also lacks an extensive cytoplasmic region and 
hence is unlikely to signal intracellularly (Brooke et al., 2004; Ichigotani et al., 
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2000). As SIRPα expression is used to define DC populations in the gut, I 
concentrated on its potential role in regulating DC function in this thesis.  
 
Figure 1.8: SIRP family of receptors with their associated ligands  
Schematic representation of the SIRP family of signalling receptors depicting their extracellular 
regions and their signalling potentials. The IgSF domains are shown as purple ovals. CD47 
contains one IgSF domains. Cartoon also demonstrates the bidirectional signalling of SIRPα 
through its interaction with CD47.  
1.5.2 SIRPα Ligands 
As detailed above, the predominant ligand for SIRPα is CD47, named for its 
ability to associate with integrins at the cell surface. CD47 is a transmembrane 
receptor, with five transmembrane regions and a single IgSF extracellular domain 
(Nakaishi et al., 2008) (Fig.1.8). As well as triggering SIRPα signalling, ligation of 
CD47 also activates an intracellular signalling cascade, although the details of this 
pathway remain be fully characterised. In neurons, ligation of CD47 by SIRPα 
activates a member of the Rho family of GTP-binding proteins, but whether this is 
involved in CD47 function in the immune system remains to be seen (Matozaki et 
al., 2009; Murata et al., 2006).  As a result, the interaction between SIRPα and 
CD47 can lead to bidirectional signalling. CD47 is expressed by many cell types 
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including haematopoietic cells such as lymphocytes, red blood cells, endothelial 
and epithelial cells (Matozaki et al., 2009) in most tissues, although the exact 
pattern of expression in the intestine remains to be examined and this represents 
one aim of this thesis.  
SIRPα also binds to the lung surfactant proteins SP-A and SP-D (Gardai et 
al., 2003; Janssen et al., 2008), which belong to the collectin family containing a 
C-type carbohydrate-recognition (lectin) domain coupled to a collagen-like tail 
(Håkansson and Reid, 2000). These ligands outcompete CD47 for binding to 
SIRPα in the lung and it is thought that they may hold SIRPα in a constitutively 
phosphorylated state which prevents immune activation until such time as an 
inflammatory response is required. Release of the cytoplasmic domain of SIRPα 
and surfactant protein binding to Calreticulin/CD91 subsequently inducing the p38 
pathway and immune stimulation (Gardai et al., 2003). SP-D expression has been 
reported in the intestine (Akiyama et al., 2002; Lin and Floros, 2002; Madsen et 
al., 2000; Soerensen et al., 2005), but the roles of the surfactant proteins in the 
intestine have not been addressed.  
1.5.3 Functions of the SIRPα/CD47 interaction 
The SIRPα/CD47 axis has been proposed to influence a number of 
biological processes including phagocytosis and the functions of both the central 
nervous and immune systems. Perhaps the best characterised function of 
SIRPα/CD47 interaction is as a ‘don’t eat me’ signal, whereby CD47-expressing 
cells are recognised as self by SIRPα+ mφs and phagocytosis is inhibited 
(Oldenborg et al., 2000; Olsson et al., 2007; Wang et al., 2007). As a result, CD47-
deficient red blood cells are cleared much more quickly from the bloodstream 
compared with wild-type cells (Oldenborg et al., 2000). This phenomenon also has 
important implications for organ transplantation as human SIRPα does not 
recognise porcine CD47 and thus the use of porcine organs for transplants may be 
limited (Subramanian et al., 2006).  
In addition to inhibiting the phagocytic activity of mφs (Oldenborg et al., 
2000; Olsson et al., 2007; Wang et al., 2007), ligation of SIRPα induces nitric 
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oxide production from mφs (Alblas et al., 2005; Bogdan, 2001), although it has 
also been reported to prevent TNFα production from human peripheral blood 
mononuclear cells (PBMCs) in response to a variety of pathogen products (Smith 
et al., 2003). Ligation of SIRPα also prevents the upregulation of co-stimulatory 
molecules and cytokine production following exposure of human DCs to 
Staphlococcus aureus cowan I strain (SAC) (Latour et al., 2001), while pre-
treatment with either an anti-SIRPα mAb or ligating CD47-Fc fusion protein 
prevented the maturation of Langerhans cells in response to 2,4-dinitro-1-
fluorobenzene (DNFB) or TNFα (Fukunaga et al., 2006). Ligation of CD47 on 
human DCs also resulted in the inhibition of human DC maturation in response to 
SAC, confirming the bidirectional role of this interaction (Demeure et al., 2000).  
Despite the evidence suggesting a predominantly inhibitory role of SIRPα 
on individual cells, mice with a non-signalling truncated form of the cytoplasmic 
domain of SIRPα (SIRPα mt mice) are less susceptible to a wide variety of 
autoimmune diseases, including experimental autoimmune encephalomyelitis 
(EAE) (Tomizawa et al., 2007), collagen-induced arthritis (CIA) (Okuzawa et al., 
2008), contact hypersensitivity (CHS) (Fukunaga et al., 2006; Motegi et al., 2008) 
and colitis resulting from IL10 deficiency (Kanazawa et al., 2010). In parallel, 
CD47KO mice are less susceptible to trinitrobenzene sulfonic acid (TNBS) 
induced colitis (Fortin et al., 2009), although they are more susceptible to 
Escherchia coli peritonitis (Lindberg et al., 1996). Several early studies suggested 
that SIRPα on DCs acted as a co-stimulatory molecule in the induction of 
proliferation and differentiation of naïve T cells (Latour et al., 2001; Tomizawa et 
al., 2007; Waclavicek et al., 1997). This may be particularly important for the 
generation of Th17 effector cells, given the paucity of these cells in SIRPα mt mice 
during the aforementioned diseases and the associated protection of these mice 
from autoimmunity (Fortin et al., 2009; Fukunaga et al., 2006; Kanazawa et al., 
2010; Okuzawa et al., 2008; Tomizawa et al., 2007). SIRPα/CD47 signalling has 
also been suggested to be required for the migration of DCs to draining LNs 
(Hagnerud et al., 2006; Raymond et al., 2009; Van et al., 2006), with SIRPα mt 
mice having reduced numbers of SIRPα+CD11b+ DCs in the LNs compared with 
WT controls (Iwamura et al., 2010). However, others have suggested that impaired 
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survival may explain the reduced numbers of SIRPα+ DCs observed in the skin 
and spleen of SIRPα mutant mice (Iwamura et al., 2010; Saito et al., 2010).  
The precise role of the SIRPα/CD47 axis in regulating immune responses 
remains unclear and very little is known about how it might affect the intestine. As 
discussed above, SIRPα mutant and CD47KO mice appear to be less susceptible 
to various models of IBD and this has been associated with a reduced number of 
Th17 cells (Fortin et al., 2009; Kanazawa et al., 2010). A further study has shown 
that CD47KO mice have reduced levels of intestinal IgA in response to orally 
administered antigen, but this did not result in any defect in their ability to induce 
oral tolerance to the protein (Westlund et al., 2011). However, these studies have 
not shown how SIRPα and CD47 signalling contributes to these phenotypes. In 
addition, the reports which associated IBD with the reduced numbers of Th17 cells 
simply implicated a role for SIRPα+CD11c+ MPs which were also reduced in 
SIRPα mutant and CD47KO mice, but did not identify these cells more precisely 
(Fortin et al., 2009; Kanazawa et al., 2010). As both SIRPα and CD11c are also 
expressed by eosinophils and mφs in the intestine, clearly further investigation is 
required, especially as SIRPα signalling has recently been implicated in intestinal 
eosinophil homeostasis (Verjan Garcia et al., 2011). While the more recent study 
by Westlund and colleagues published during my PhD suggested that CD47 
signalling was involved in the homeostasis of well-defined CD103+CD11b+ DCs in 
the intestine and MLN (Westlund et al., 2011), these authors did not study the 
functional consequences of CD47 ablation on DCs or on the generation of Th17 
cells. Thus one of the aims of this thesis was to investigate the role of SIRPα and 
CD47 signalling in DC homeostasis and function in the intestine using more 
precise analytical methods. 
1.6 Thesis Aims 
It is evident that DCs play a fundamental role in maintaining the balance 
between tolerance and immunity in the intestine. Despite this, there is still 
considerable confusion regarding the identification of DCs in the gut, including how 
they can be distinguished from other CD11c-expressing cells such as mφs and 
eosinophils. As a result, it has been difficult to determine exactly which population 
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of intestinal DCs are responsible for inducing different aspects of the immune 
response.  
Therefore the main aims of this thesis were to first develop a strategy using 
multi-parameter flow cytometry which would allow the accurate identification of 
DCs in the intestine LP and MLN in the steady state. Having identified putative DC 
populations, I then set out to examine the ontogeny, kinetics and growth factor 
dependence of these cells, focussing on a novel population of bona fide CD103- 
DCs that I discovered in the steady state LP. I then examined the functions of the 
various DC subsets in terms of their ability to induce naïve T cell proliferation and 
polarisation. I also explored the role of the chemokine receptor CCR2 and SIRPα 
in regulating DC development and function. 
Chapter 3 of this thesis introduces the heterogeneity of the intestinal 
mononuclear phagocyte system and describes how CD103+ and CD103- DCs can 
be discriminated accurately from CD11c+MHCII+ intestinal mφs on the basis of 
CD64 and zDC expression, and growth factor dependence. Having identified bona 
fide DC populations in the LP and MLNs, Chapter 4 goes on to assess the 
ontogeny of these cells using adoptive transfer of pre-DC and monocyte 
precursors. In Chapter 5, the proportions and numbers of these DC populations 
are examined during active immune responses, including DSS-induced colitis, 
post-operative ileus and Citrobacter rodentium infection. The aim of Chapter 6 was 
to determine the ability of each DC population to present antigen to naïve CD4+ 
and CD8+ T cells and induce their differentiation into regulatory or effector cell 
populations. In Chapter 7, I explored the role of the SIRPα/CD47 axis in regulating 
intestinal DC function and in Chapter 8, I examined how SIRPα and CD47 
signalling contributed to the homeostasis of CD103+CD11b+ intestinal DCs. Finally 
in Chapter 9, I describe the discovery of a novel subset of CD103-CD11b+ DCs 
which expresses CCR2 and is dependent on CCR2 for their development, but 
which are genuine DC, based on their expression of zDC and derivation from DC-
committed progenitors.  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 Chapter 2 Materials and Methods 
2.1 Mice 
All mice were maintained under specific pathogen free (SPF) conditions at 
the Central Research Facility (CRF) or Veterinary Research Facility (VRF) at the 
University of Glasgow and were used between 6 and 12 weeks of age, unless 
otherwise specified.  Table 2.1 details the mouse strains used throughout these 
studies.  All strains were on the C57/Bl6 background. All procedures were carried 
out in accordance with UK Home Office regulations.   
Table 2.1: Mice Strains 
Strain Source 
C57Bl/6 (CD45.2) Harlan Olac (Bicester, Oxfordshire) 
C57Bl/6.SJL (CD45.1) Kindly provided by Prof. W. Agace (Lund University, 
Sweden) 
C57Bl/6 (CD45.1/CD45.2) Generated by crossing C57Bl/6 with C57Bl/6.SJL 
SIRPα Mutant (CD45.2) Kindly provided by Prof. P.A. Oldenburg (Umeå University, 
Sweden) with kind permission from Prof. T. Matozaki 
(University of Tokyo, Japan) (Inagaki, Yamao et al. 2000) 
CD47KO (CD45.2) Jackson Laboratories (Maine, USA) (Lindberg et al., 1996) 
Flt3L-/- (CD45.2) Used in collaboration with Prof. B. Lambrecht (Ghent 
University, Belgium). Mice maintained at VIB, University of 
Ghent, Belgium with WT (C57Bl/6) controls (McKenna et al., 
2000) 
Csf2rb-/- (CD45.2) Jackson Laboratories (Maine, USA). Used in collaboration 
with Fiona Powrie (University of Oxford, UK). Mice 
maintained in Oxford with WT (C57Bl/6) controls (Robb et 
al., 1995) 
CX3CR1gfp/gfp  
(B6.129P-CX3CR1tm1Litt/J) 
(CD45.2) 
Kindly provided by Prof. W. Agace (Lund University, 
Sweden) (Jung et al., 2000) 
CX3CR1+/gfp (CD45.2+) Generated by crossing CX3CR1gfp/gfp with C57Bl/6 mice. 
CX3CR1+/gfp 
(CD45.1+/CD45.2+) 
Generated by crossing CX3CR1gfp/gfp with C57Bl/6.SJL. 
CCR2-/- (CD45.2) Kindly provided by Dr Robert Nibbs (University of Glasgow) 
(Boring et al., 1997) 
CD11c-DTR-GFP (CD45.2) Kindly provided by Prof. Paul Garside (University of 
Glasgow)  (Jung et al., 2002) 
OT-I (CD45.2) Jackson Laboratories (Maine USA) (Hogquist et al., 1995) 
OT-II (CD45.2) Jackson Laboratories (Maine USA) (Barnden et al., 1998) 
OT-I (CD45.1/CD45.2) Generated by crossing OT-I with C57Bl/6.SJL 
OT-II (CD45.1/CD45.2) Generated by crossing OT-II with C57Bl/6.SJL 
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CCR2+/RFP Jackson Laboratories, (Maine, USA) used in collaboration 
with Dr. Barry McColl, Roslin Institute, Edinburgh (Saederup 
et al., 2010) 
 
2.2 Genotyping Mice 
2.2.1 Genomic DNA Isolation 
Tail tips were collected from mice to be genotyped and frozen at -20°C until 
use. DNA was isolated using the DNeasy Blood and Tissue Kit (Qiagen) as per the 
manufacturer’s guidelines. Briefly, 25mg of each tail tip was digested overnight at 
56°C with Proteinase K. The following day, DNA was purified by binding to the 
spin column membrane provided, washing and finally eluting in the elution buffer 
supplied. Genomic DNA was frozen and stored at -20°C until needed. 
 
Table 2.2 Primers for Genotyping 
Gene Sense Antisense 
SIRP WT ATACCATTGGCTGAGCCCACTGGGAAAGAA TAGTACAGACCACAGCCCCATTCACTTCCT 
SIRP MT TCGTGCTTTACGGTATCGCCGCTCCCGAAT TAGTACAGACCACAGCCCCATTCACTTCCT 
CD47 WT CAAGCATAAATGAACAGTTGCAG CACGTTTCAAAACAGGCAAA 
CD47 KO CTTGGGTGGAGAGGCTATTC AGGTGAGATGACAGGAGATC 
CD11c-DTR GCCACCATGAAGCTGCTGCGG TCAGTGGGAATTAGTCATGCC 
 
2.2.2 Genotyping 
SIRPα mutant (mt), CD47KO and CD11c-DTR-GFP mice were genotyped 
before use in all experiments. Genomic DNA isolated from tail tips was diluted 1:2 
prior to use in polymerase chain reaction (PCR).  The primers (Integrated DNA 
Technologies, IDT) used for genotyping these strains are detailed in Table 2.2.  
Each PCR mix had a final volume of 20µl and contained 1µl diluted 
genomic DNA, 0.2µl 10µM sense and anti-sense primers, 0.4µl 10µM dNTPs, 
0.1µl 5U/µl Go Taq polymerase, 4µl 5X reaction buffer and 14.1µl nuclease free 
water (all Life Technologies, Paisley, UK). The PCR consisted of one cycle of 
denaturation at 95°C for 5 minutes, thirty-five cycles of denaturation at 95°C for 1 
minute, annealing at the desired temperature (Table 2.3) and elongation at 72°C 
for 2 minutes, followed by one cycle of elongation at 72°C for 10 minutes. 
Table 2.3: Annealing Temperatures 
Primer Pair Annealing Temperature (°C) 
CD47 WT & KO 61 
SIRP WT & MT 58 
CD11c-DTR 58 
 
Following PCR, the products were visualised using agarose gel 
electrophoresis on a 2% agarose gel (Sigma-Aldrich, Poole, UK) in 1X TAE with 
3µl ethidium bromide (Life Technologies) per 100ml gel. 10µl of PCR reaction 
along with 2µl of 6X loading dye (Life Technologies) were loaded onto the gel with 
5µl DNA ladder (Life Technologies) and 1µl 6X loading dye. Gels were run in 1X 
TAE for approximately 1 hour at 100mV. Gels were visualised by UV. 
2.3 Isolation of Leukocytes from Tissue 
2.3.1 Isolation of Lamina Propria Cells 
Murine small intestines (SI) were excised and soaked in PBS (Gibco, Life 
Technologies). Peyer’s patches and excess fat were removed and the intestines 
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opened longitudinally. Faeces were removed by washing in calcium/magnesium 
free (CMF) Hank’s balanced salt solution (HBSS; Gibco) supplemented with 2% 
foetal calf serum (FCS; Gibco) and the intestines were cut into 0.5cm segments. 
Tissue was shaken vigorously in HBSS/2% FCS and the supernatant removed by 
pouring tissue and supernatant onto Nitex mesh (Cadisch and Sons, London, UK) 
and subsequently collecting the tissue sections. The epithelial layer was removed 
by incubating the tissue at 37°C with shaking in 10ml pre-warmed HBSS 
supplemented with 2mM EDTA (Sigma-Aldrich, Poole, UK) for 20 minutes. 
Following this the tubes were shaken vigorously, supernatants discarded and the 
tissue was washed in pre-warmed HBSS before a second incubation in 
HBSS/2mM EDTA for a further 20 minutes. Following repetition of the wash step, 
the tissue was digested in 10ml pre-warmed complete RPMI (RPMI 1640, 50µM 2-
β-mercaptethanol, 2mM L-glutamine, 100µg/ml penicillin, 100µg/ml streptomycin, 
1.25µg/ml Fungizone, and 10% FCS; all Gibco) supplemented with 1mg/ml 
collagenase VIII (Sigma), by incubation at 37°C with shaking for 20-30 minutes. To 
aid digestion, tubes were shaken vigorously every 5 minutes. Following digestion, 
the cell suspensions were passed through a 100µm filter (BD Falcon), followed by 
a 40µm filter (BD Falcon) washed twice in complete RPMI to remove any residual 
enzyme, resuspended in complete RPMI, counted and kept on ice until use. 
Colonic LP cells were isolated in a similar fashion except that the 
HBSS/2mM EDTA incubations are 15 minutes and 30 minutes in duration, while 
the digestion step involved a 30-45 minute incubation in complete RPMI 
supplemented with an enzyme cocktail containing 1.25mg/ml collagenase D 
(Roche; Roche Diagnostics GmbH, Mannheim, Germany), 0.85mg/ml collagenase 
V (Sigma), 1mg/ml dispase (Gibco), and 30U/ml DNase (Roche).  
2.3.2 Isolation of Lymph Node Cells and Splenocytes 
Lymph nodes and/or spleens were excised from mice and excess fat was 
removed. The tissues were washed in HBSS and cut into small fragments. To 
isolate T and B lymphocytes, tissue was mashed between two pieces of Nitex 
mesh and filtered through a fresh piece of Nitex before being resuspended in 
complete RPMI, counted and left on ice until use. To isolate DCs, tissues were 
digested by incubating at 37°C with shaking in HBSS supplemented with 1mg/ml 
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collagenase D for 45 minutes. Following the digestion, any remaining tissue was 
passed through a 100µm filter, washed twice in complete RPMI to remove any 
residual enzyme, resuspended in complete RPMI, counted and left on ice until use. 
Red blood cells in the spleen preparations were lysed by incubation for 6 minutes 
on ice with ammonium chloride solution (0.8% NH4Cl/0.1mM EDTA, Stem Cell 
Technologies, Grenoble, France) prior to resuspension in complete RPMI and 
counting. 
2.3.3 Isolation of Liver Leukocytes 
CO2-euthanised mice were perfused through the heart with 10ml CMF PBS 
and the livers were excised. These were subsequently cut into small pieces 
(<2mm) and placed in HBSS supplemented with 2% FCS. Tissue was shaken 
vigorously in HBSS/2% FCS and the supernatant removed by pouring tissue and 
supernatant onto Nitex mesh and subsequently collecting the tissue sections. 
Livers were then digested in complete RPMI supplemented with an enzyme 
cocktail containing 0.75mg/ml collagenase D, 0.425mg/ml collagenase V, 1mg/ml 
dispase, and 30U/ml DNase at 37oC with shaking for 20 minutes. Following 
digestion, the cell suspensions were passed through a 40µm filter washed twice in 
complete RPMI to remove any residual enzyme and red blood cells were lysed by 
incubation for 6 minutes on ice with ammonium chloride solution, before being 
resuspended in complete RPMI, counted and kept on ice until use. 
2.3.4 Isolation of Lung Leukocytes 
CO2-euthanised mice were perfused with 10ml CMF PBS and the lungs 
were excised. These were subsequently cut into small pieces (<2mm) and 
digested in complete RPMI supplemented with 1mg/ml Collagenase D (Roche) at 
37oC with shaking for 45minutes. Following digestion, the cell suspensions were 
passed through a 40µm filter washed twice in complete RPMI to remove any 
residual enzyme and red blood cells were lysed by incubation for 6 minutes on ice 
with ammonium chloride solution before being resuspended in complete RPMI, 
counted and kept on ice until use. 
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2.3.5 Whole Blood Isolation 
Whole blood was obtained from mice by cardiac puncture. Red blood cells 
(RBCs) were lysed by incubating heparinised blood on ice with ammonium 
chloride solution for 10 minutes and subsequently washed twice in PBS. Cells 
were counted and left on ice until use.  
2.3.6 Isolation of Bone Marrow Cells 
Femurs and tibiae were isolated from mice and the bone marrow was flushed 
out using RPMI 1640 and filtered through Nitex. If cells were to be used for flow 
cytometric analysis, RBCs were lysed as described above and cells were 
subsequently washed twice in RPMI 1640. If cells were to be used for culture, 
RBC lysis was omitted. Cells were then counted and left on ice until required.  
2.4 Flow Cytometry 
2.4.1 Cell Surface Staining: 
Freshly isolated cells were resuspended in FACS buffer (CMF PBS, 2% 
FCS, 2mM EDTA) and 2.5-5x106 cells were added to 12x75mm polystyrene tubes 
(BD falcon). Non-specific binding of antibodies to Fc receptors was prevented by 
incubation of the cells with anti-CD16/CD32 (‘Fc Block’; BD Biosciences) at 4°C for 
15-20 minutes. Cells were then washed in FACS buffer and incubated with 
required antibodies or isotype controls at a dilution of 1:200 unless otherwise 
specified by manufacturer (Table 2.4) at 4°C for 20-30 minutes. Cells were then 
washed twice and incubated with streptavidin conjugates if biotinylated antibodies 
were used at 4°C for a further 20 minutes and washed twice more. Just prior to 
analysis, 15µl of 7-aminoactinomycin D (7-AAD; Biolegend) was added to the cells 
to allow dead cell exclusion. Cells were acquired on BD LSRII or BD FACSAriaI 
with Diva software. Cells were analysed using FlowJo Software (Treestar Inc., 
USA). 
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Table 2.4: Antibodies and Isotype Controls 
Antibody Clone Isotype Source 
Annexin V n/a n/a BD Biosciences 
β7 M293 Rat IgG2a BD Biosciences 
CD3 145-2C11 Ham IgG Biolegend 
CD4 GK1.5 Rat IgG2b Biolegend 
CD8 53-6.7 Rat IgG2a Biolegend 
CD11b M1/70 Rat IgG2b Biolegend 
CD11c HL3 Ham IgG1 BD Biosciences 
CD11c N418* Ham IgG Biolegend 
CD14 Sa2-8 Rat IgG2a eBioscience 
CD19 1D3 Rat IgG2a BD Biosciences 
CD25 7D4 Rat IgM BD Biosciences 
CD26 (DPP4) H194-112 Rat IgG2a Biolegend 
CD40 3/23 Rat IgG2a BD Biosciences 
CD45 30-F11 Rat IgG2b Biolegend 
CD45.1 A20 Ms IgG2a Biolegend 
CD45.2 104 Ms IgG2a Biolegend 
CD45R (B220) RA3-6B2 Rat IgG2a Biolegend 
CD47 B6H12 Ms IgG1 BD Biosciences 
CD49b DX5 Rat IgM BD Biosciences 
CD62L MEL-14 Rat IgG2a BD Biosciences 
CD64 X54-5/7.1 Ms IgG1 Biolegend 
CD80 16-10A1 Ham IgG1 BD Biosciences 
CD86 GL1 Rat IgG2a BD Biosciences 
CD103 M2/90 Rat IgG2a BD Biosciences 
CD103 2E7 Ham IgG Biolegend 
CD115 AFS98 Rat IgG2a eBioscience 
CD117 2B8 Rat IgG2b BD Biosciences 
CD135 A2F10.1 Rat IgG2a BD Biosciences 
CD172a P84 Rat IgG1 BD Biosciences 
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CD192 (CCR2) 475301 Rat IgG2b R & D Systems 
CD193 (CCR3) 83103 Rat IgG2a BD Biosciences 
CD197 (CCR7) 4B12 Rat IgG2b Biolegend 
CD199 (CCR9) CW-1.2 Ms IgG2a Biolegend 
CD272 6F7 Ms IgG1 eBioscience 
F4/80 BM8 Rat IgG2a eBioscience 
FoxP3 FJK-16s Rat IgG2a eBioscience 
IFNg 
IL6 
IL12/IL23p40 
XMG1.2 
MP5-20F3 
C15.6 
Rat IgG1 
Rat IgG1 
Rat IgG1 
BD Biosciences 
Biolegend 
Biolegend 
IL17a TC11-18H10.1 Rat IgG1 Biolegend 
Ki67 B56 Ms IgG1 BD Biosciences 
Ly6C AL-21 Rat IgM BD Biosciences 
Ly6G 1A8 Rat IgG2a BD Biosciences 
MerTK - Goat IgG R & D Systems 
MHCII (IA-IE) M5/114.15.2 Rat IgG2b eBiosciences 
Siglec F E50-2440 Rat IgG2b BD Biosciences 
TNFa MP-6XT22 Rat IgG1 BD Biosciences 
XCR1 Marx10 Rat IgG2a Kroczek lab 
Streptavidin BV605 Biolegend 
Streptavidin QDot 605 Molecular Probes 
 * N418 clone gave superior staining and was the only clone used after its introduction. 
2.4.2 Intracellular Staining: 
When staining for intracellular cytokines or transcription factors, the staining 
protocol was adapted slightly to be compatible with the fixable dead cell exclusion 
dyes used.  4x106 cells were incubated in complete RPMI for 4.5hrs in 5ml 
polystyrene tubes in the presence of 1µM Monensin and 1µM Brefeldin A (both 
Biolegend) to prevent cytokine secretion. In most experiments stimulants such as 
phorbol 12-myristate 13-acetate (PMA) and ionomycin (Cell stimulation cocktail 
plus protein transport inhibitors, eBioscience) or the TLR4 ligand, LPS (100ng/ml; 
Sigma-Aldrich) were added to restimulate T cells or stimulate MP cells respectively. 
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Cells were washed in CMF PBS and then incubated for 20-30minutes protected 
from light at 4oC with LIVE/DEAD® fixable dead cell stain kits (eBioscience) as per 
the manufacturer's guidelines. Cells were then washed in FACS buffer, incubated 
with purified anti-CD16/CD32 and stained with the appropriate antibodies for cell 
surface antigens as described above, before being washed three times in FACS 
buffer. Cells were then fixed and permeabilised using the eBioscience Flow Kit 
according to manufacturer’s instructions. Cells were subsequently incubated with 
purified anti CD16/CD32 and stained with appropriate antibodies to stain for 
intracellular cytokines or transcription factors in permeabilisation buffer for 20mins 
at 4oC protected from light, washed in permeabilisation buffer and subsequently 
resuspended in FACS buffer and analysed by flow cytometry. 
2.4.3 CCL2 Uptake Assay 
2-3x106 cells resuspended in complete RPMI were incubated, protected 
from light, in a 96-well polypropylene plate (Fischer Scientific, UK) with 25nM 
CCL2-AF647 (Almac) at 37oC for 60 minutes. Cells were washed in FACS buffer 
and stained for surface markers as indicated in section 2.4.1. 
2.4.4 Fluorescence Activated Cell Sorting 
Cells were prepared for FACS as described above but under sterile 
conditions, before being sorted using a BD FACSAria I cell sorter and were 
typically 94-99% pure.  
2.5 In Vitro Cell Culture 
2.5.1 In Vitro Stimulation of Isolated Leukocytes 
Following isolation of leukocytes from tissues, cells were resuspended in 
complete RPMI and 5x106 cells in a final volume of 1ml complete RPMI were 
incubated in 5ml polystyrene tubes for 4.5 hours in the presence of absence of 
100ng/ml lipopolysaccharide (LPS) from Salmonella typhimurium (Sigma-Aldrich), 
with 1µM Brefeldin A and 1µM Monensin to block protein secretion, before being 
stained for intracellular cytokines as indicated above. 
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2.5.2 DC:T Cell Co-cultures 
To assess the ability of intestinal APC populations to prime naïve T cells, 
populations of DC and mφ were FACS-purified from the LP as indicated above and 
co-cultured with FACS-purified naïve (CD62L+CD25-) CD4+ or CD8+ T cells from 
lymph nodes of OTII or OTI mice respectively. Prior to co-culture, T cells were 
labelled with 5mM Carboxyfluorescein diacetate succinimidyl ester (CFSE, Life 
Technologies) by incubating at room temperature for 10 minutes before washing in 
complete RPMI. The APC populations were pulsed with 1-2mg/ml Ovalbumin for 2 
hours and then co-cultured at various ratios with 100,000 T cells for 3-4 days at 
37oC with 5% CO2. Following co-culture, supernatants were removed for CBA 
analysis described in section 2.7.1 and the cells were stimulated with fresh 
complete RPMI supplemented with 1X cell stimulation cocktail + protein transport 
inhibitors (eBioscience) for 4.5hrs. The cells were stained for expression of 
intracellular cytokines and FoxP3 by flow cytometry as described above. Dilution 
of CFSE dye on the T cells was also assessed.  
2.5.3 Th17 Differentiation In Vitro 
24-well ultra low adherence plates were coated with 1.5µg/ml anti-CD3 and 
1.5µg/ml anti-CD28 (BD Biosciences) in CMF PBS for 6 hours at 4°C. The plates 
were then washed once with CMF PBS and 8x105 FACS-purified naïve CD4+ 
CD62Lhi CD25- T cells from mesenteric lymph nodes (MLN) were added in 1ml 
complete RPMI supplemented with 10µg/ml anti-IFNγ, 10µg/ml anti-IL4, 10µg/ml 
anti-IL2, 20ng/ml IL6, 20ng/ml IL23, 20ng/ml IL1β (all BD Biosciences) and 
2.5ng/ml recombinant human TGFβ (Peprotech, London, UK). Cells were 
incubated at 37°C with 5% CO2 for 4 days and supplemented with 500µl complete 
RPMI on day 3. On day 4 cells were harvested by flushing the wells before being 
washed in complete RPMI, resuspended in 1ml complete RPMI supplemented 
with 1X cell stimulation cocktail + protein transport inhibitors (eBioscience) 
containing Brefeldin A, Monensin, PMA and Ionomycin, in 12x75mm polystyrene 
tubes and incubated for 4.5 hours at 37°C with 5% CO2. The cells were then 
harvested and stained for intracellular IL17A and RORγt as described above. 
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2.6 Transcriptional Analysis of Cell Populations 
2.6.1 RNA Extraction 
Single cell suspensions (FACS-sorted cells or BMDC/BMMφ) were washed 
twice with PBS, spun down and the supernatant discarded.  RNA was then 
isolated using the RNeasy Micro or Mini Kit (Qiagen) (depending on cell number) 
according to the manufacturer’s guidelines. Contaminating genomic DNA was 
removed on-column during RNA isolation with the RNase-free DNase Set 
(Qiagen) according to the manufacturer’s instructions. The RNA was quantified 
using a nanodrop spectrophotometer (Amersham Biosciences) and RNA was 
stored at –20oC until use. 
2.6.2 cDNA Synthesis 
cDNA was reverse transcribed from DNase-treated RNA using Superscript 
III Reverse Transcriptase (RT) (Life Technologies) according to the manufacturer’s 
instructions. Briefly, 10ng of RNA, 1µl Oligo(dT)12-18 (500µg/ml; Life Technologies), 
1µl dNTP mix (25mM each; Life Technologies), and nuclease-free water were 
added to a nuclease-free microcentrifuge tube (ABgene, Surrey, UK) in a total 
volume of 10µl. The mixture was heated at 65°C for 5 minutes, and then chilled on 
ice. 4µl 5X First-Strand Buffer, 2µl 0.1M DTT, and 1µl RNaseOUT (40 units/ml) 
were added and incubated at 42°C for 2 minutes. 1µl (200 units) Superscript III RT 
was then added and the RNA was reverse transcribed at 42°C for 50 minutes. The 
Superscript III RT was inactivated by heating at 70°C for 15 minutes and RNA was 
degraded using Escherchia coli RNase H (10units) at 37°C for 20 minutes. 
Negative control samples were incubated in the absence of Superscript III and all 
cDNA was stored at –20°C until use. 
 
Table 2.5 Primers for qRT-PCR 
Gene Sense Antisense 
HPRT GCTGACCTGCTGGATTACATTAA TGATCATTACAGTAGCTCTTCAGTCTGA 
Il1β CTGGTGTGTGACGTTCCCATTA CCGACAGCACGACGCTTT 
Ccr2 ATCCACGGCATACTATCAACATC CAAGGCTCACCATCATCGTAG 
Il10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG 
Il6 CCAGTTGCCTTCTTGGGACT GGTCTGTTGGGAGTGGTATCC 
Caspase 3 ACGCGCACAAGCTAGAATTT CTTTGCGTGGAAAGTGGAGT 
Bcl2 TGTGTGTGGAGAGCGTCAACA TGCCGGTTCAGGTACTCAGTC 
Batf3 CAGACCCAGAAGGCTGACAAG CTGCGCAGCACAGAGTTCTC 
Id2 TCCTGTCCTTGCAGGCATCTGAAT AACGTGTTCTCCTGGTGAAATGGC 
Irf8 GAGCGAAGTTCCTGAGATGG TGGGCTCCTCTTGGTCATAC 
Zbtb46 TCACATACTGGAGAGCGGC CCTCATCCTCATCCTCAACC 
Irf4 TCTCTGAGGGTCTGGAAACT GCCCAAGCTAGAAAG 
Integrin β8 GGGTGTGGAAACGTGACAAGCAAT TCTGTGGTTCTCACACTGGCAACT 
90 
 
 
Csf2RA CGTGGCGCGATGCAT TCACGACCAAGTAGGCCTCACT 
Tlr1 TGGACACCCCTACAGAAACGT AATTTGGTTTAGTCATTGTATGGCC 
Tlr2 CTGGAGCATCCGAATTGCA CATCCTCTGAGATTTGACTT 
Tlr3 CCAGAAGAATCTAATCAAATTAGATTTGTC TTTTGCTAAGAGCAGTTCTTGGAG 
Tlr4 GGCAACTTGGACCTGAGGAG CATGGGCTCTCGGTCCATAG 
Tlr5 CACTCCCTCGGAGAACCCA GGCCTTGAAAAACATCCCAAC 
Tlr6 AAAGTCCCTCTGGGATAGCCTCT TGCTTCCGACTATTAAGGCCA 
Tlr7 ACAGAAATCCCTGAGGGCATT CAGATGGTTCAGCCTACGGAAG 
Tlr9 GGGCCCATTGTGATGAACC CTTGGTCTGCACCTCCAACA 
Il12p35 TACTAGAGAGACTTCTTCCACAACAAGAG TCTGGTACATCTTCAAGTCCTCATAGA 
Il12p40 GACCATCACTGTCAAAGAGTTTCTAGAT AGGAAAGTCTTGTTTTTGAAATTTTTTAA 
Il23p19 AGCGGGACATATGAATCTACTAAGAGA GTCCTAGTAGGGAGGTGTGAAGTTG 
Il17a GCTCCAGAAGGCCCTCAG CTTTCCCTCCGCATTGACA 
Il22 CATGCAGGAGGTGGTGCCTT CAGACGCAAGCATTTCTCAG 
Cd115 GCATACAGCATTACAACTGGACCTACC CAGGACATCAGAGCCATTCACAG 
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Ccr7 ATTGCTGCTGAGGGAAGAG ACTTTTGGCTGTCGTTTTGG 
Cd135 GGTTTAAAGCGTACCCACGA GAACTGGGCGTCATCATTTT 
 
 2.6.3 Real-Time PCR  
Gene expression was assayed by quantitative reverse transcription PCR 
(qRT-PCR) using Brilliant III Ultra Fast SYBR qPCR master mix (Agilient 
Technologies) on the 7900HT Fast system (Applied Biosystems). Primers (Table 
2.5) were designed using Primer Express software (Applied Biosystems, Life 
Technologies) and purchased from IDT (Iowa, USA). cDNA samples were 
assayed in triplicate and gene expression levels were normalised to hypoxanthine 
phosphoribosyltransferase (HPRT) as a housekeeping gene. The mean relative 
gene expression was calculated using the 2-ΔΔC(t) method. 
2.6.4 Microarray 
Microarray analyses were performed in collaboration with the groups of Toby 
Lawrence, Bernard Malissen and Marc Dalod (Marseille, France). RNA was 
isolated from sorted SI LP cells as described above and sent for microarray 
analysis at the IGBMC facility in Strasbourg using the GeneChip Mouse Gene 
1.0ST with single amplification using the Nugen Protocol. Analysis was performed 
at the CIML, Marseille, France by Marc Dalod. 
2.7 Measurement of Proteins in Serum, Faeces and Culture 
Supernatants 
2.7.1 Cytokine Bead Array 
Cytokine bead array (CBA) assays were carried out by Knut Kotarsky, 
Biomedical Centre, University of Lund, Sweden. Culture supernatants were 
removed and frozen at -20oC before being analysed using the CBA kit (BD 
Biosciences) as per manufacturers instructions. 
2.7.2 Isolation and measurement of intestinal IgA by ELISA 
Faeces were removed from the colon and transferred to eppendorfs 
containing ice cold CMF PBS with 0.1mg/ml soybean trypsin inhibitor type II 
(Sigma) and 50mM EDTA. Tubes were centrifuged at 1500g for 10 minutes at 4°C 
and the supernatants collected into fresh eppendorfs, to which 10µl of 100mM 
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phenylmethylsulfonyl (PMSF) (Sigma) in 95% ethanol solution was added before 
being centrifuged at 14000g for 30 minutes at 4°C. 10µl PMSF solution, 10µl of 
1% sodium azide (Sigma) solution and 50µl FCS were then added to the resulting 
supernatants which were stored at –20°C until required. The total protein content 
was determined using the BCA assay kit (Pierce, Loughborough, UK) according to 
the manufacturer’s guidelines and using two-fold dilutions of bovine serum albumin 
(BSA; Sigma) as standards. To measure total IgA, Immulon-4 ELISA plates 
(Corning) were coated overnight at 4°C with 50µl per well purified rat anti-mouse 
IgA (BD Biosciences) diluted at 1:500. The next day, the plates were washed a 
minimum of five times with PBS/0.05% Tween 20, before blocking with PBS/3% 
BSA for 1 hour at 37°C. Plates were washed and 50µl of neat faecal samples 
added in duplicate for 1 hour at 37°C. The plates were then washed and 75µl 
biotin conjugated rat anti-mouse IgA (BD Biosciences) diluted at 1:500 was added 
before being incubated at room temperature for 1 hour. Plates were then washed 
and incubated with 1:1000 extravidinperoxidase (Sigma) for 1 hour at room 
temperature before washing. The ELISA plates were then washed and 
subsequently developed using tetramethylbenzidine (TMB) substrate (Biolegend) 
before the reaction was stopped by adding 15-20µl stop solution (R & D Systems) 
and read at 450nm using a MRX II microplate reader (Dynex).  
2.8 In Vivo Models of Inflammation, Infection, Priming and 
Tolerance 
2.8.1 DSS Colitis 
To induce acute colitis, mice received 1 or 2% dextran sodium sulphate 
(DSS) salt (reagent grade; MW 36,000-50,000 kDa; MP Biomedicals, Ohio, USA), 
ad libitum in sterile drinking water for up to 9 days. Mice were monitored daily for 
weight change, rectal bleeding and diarrhoea and a clinical score generated 
(Table 2.6).  Mice that lost >20% of their initial bodyweight were sacrificed 
immediately in accordance with Home Office regulations.  Water intake was 
measured daily for each group and the volume of water consumed per mouse was 
estimated by dividing the total volume of water consumed per cage by the number 
of animals in the cage.   
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Table 2.6: Clinical disease score criteria used during DSS-induced colitis studies 
Score Weight Loss Rectal Bleeding Stools 
0 0% None Well-formed pellet 
1 5-9.9% Blood around anus Pasty soft pellets 
2 10-14.9% Bleeding Faeces around anus 
3 15-19.9% Gross Bleeding Diarrhoea 
4 >20% N/A N/A 
 
2.8.2 Post-Operative Ileus 
To induce transient inflammation of the SI, a model of post-operative Ileus 
(POI) was utilised. POI experiments were carried out in collaboration with Dr 
Simon Milling, University of Glasgow. Mice were anaesthetised, laparotomy 
performed to expose the SI and inflammation was induced by rubbing the length of 
the SI with a cotton bud. 24 hours after surgery mice were culled and SI LP MP 
populations were assessed by flow cytometry. 
2.8.3 Citrobacter Rodentium Infection 
Citrobacter rodentium infection was carried out in collaboration with Drs Gill 
Douce and Andrew Roe, University of Glasgow. Mice were infected with 10x107 
luminescent Citrobacter Rodentium by oral gavage. Infection was monitored by 
faecal colony forming unit (CFU) counts and by in vivo (IVIS) imaging. Mice were 
culled at various time points during infection and leukocyte populations in the 
colon were assessed by flow cytometry. 
2.8.4 In Vivo T Cell Priming Following Oral Administration of Antigen 
To assess antigen specific oral priming, 5x106 CD45.1/CD45.2 OTII cells 
isolated from LNs were labelled with CSFE (Life Technologies) as described 
above and transferred into CD45.1+ WT or CD45.2+ SIRPα mt mice. 24 hours later 
mice received 10mg OVA protein by oral gavage in 200ml PBS. 3 days later mice 
were sacrificed and proliferation and polarisation of donor T cells were assessed 
by dilution of CSFE and IFNγ, IL17a and FoxP3 staining respectively in MLNs and 
SI LP as described above. 
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2.8.5 In Vivo T Cell Priming Following Systemic Administration of 
Antigen and Adjuvants 
Mice were transferred with 5x106 CFSE-labelled CD45.1/CD45.2 OTII cells 
isolated from LNs. 24 hours later mice received 25µg anti-CD40 (Biolegend, clone 
1C10), 15µg LPS (Sigma) and 0.5mg OVA protein (Sigma) i.p in 100µL PBS 
(Sigma) and 1 and 3 days later received i.p. 1mg/kg bodyweight FTY720 (Cayman, 
Michigan, USA) in 0.9% NaCl (VWR, Leuven, Belgium). 5 days after T cell transfer 
mice were sacrificed and transferred T cells in MLN were examined for CSFE 
dilution and polarisation towards Th17, Th1 or TReg cell phenotypes as described 
above. 
2.8.6 Induction of Oral Tolerance by Oral Administration of Antigen 
To induce tolerance, mice were fed a single 25mg dose of OVA dissolved in 
0.2ml sterile CMF PBS using a rigid steel curved gavage tube. Control mice 
received 0.2ml sterile CMF PBS alone. One week after feeding, all mice were 
immunized in the right hind footpad with 100µg OVA in complete Freund’s 
adjuvant (CFA; Sigma) and 3 weeks later, OVA specific DTH responses were 
assessed by measuring the increase in thickness of the opposite footpad 24 hours 
after challenge with 100µg heat aggregated OVA (HAO) in 50µl sterile CMF PBS 
using calipers (Kroeplin, Hertfordshire, UK). HAO was prepared by heating a 2% 
solution of OVA in sterile PBS at 70°C for an hour. The precipitated OVA formed 
was then centrifuged for 10 minutes at 400G at 4°C and the supernatant discarded. 
HAO pellets were suspended in sterile PBS at a concentration of 20mg/ml until 
further use.  
2.8.7 Antibiotic Treatment 
Mice received 500mg/kg ampicillin, gentamycin, metranidazole, neomycin 
(Roche) and 250mg/kg vancomycin (Hospira, UK) for 2 weeks in their drinking 
water, which was sweetened (Swetex, Reckitt Benckiser Household, UK) to 
encourage drinking. Control mice received sweetened water only. Antibiotic 
solutions were made up immediately before administration and were replaced 
every other day. 
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2.9 Measurement of Cell Turnover by BrdU Incorporation 
2.9.1 Short-Term Pulse-Chase 
Mice were injected i.p. with 1mg 5-bromo-2'-deoxyuridine (BrdU; BD 
Biosciences) and then sacrificed at different time points thereafter.  The 
incorporation of BrdU by isolated cells was assessed using the BD BrdU Flow Kit 
(BD Biosciences) as per manufacturers instructions.  
2.9.2 Long-term BrdU Feeding 
Mice were injected i.p. with 1mg BrdU and before receiving 0.8mg/ml BrdU 
(Sigma) in the drinking water for 3 days. Mice were culled immediately after 
cessation of feeding or at various time-points thereafter. As per section 2.9.1, 
BrdU incorporation was assessed using the BD BrdU Flow kit as per 
manufacturers instructions. 
2.10 Adoptive Transfer of Progenitor Cells 
2.10.1 Pre-DC Transfers 
Donor mice were injected subcutaneously at the scruff of the neck with 
2x106 Flt3L secreting B16 tumour cells 10 days prior to pre-DC isolation to expand 
the number of pre-DC in the BM. On the day of the transfer, mice were culled and 
bone marrow was obtained as described in section 2.3.6, before red blood cells 
were lysed by incubation with ammonium chloride solution for 5 minutes on ice. 
The remaining cells were stained with efluor 450 violet proliferation dye 
(eBioscience) as per manufacturer’s instructions and then stained for lineage 
markers (CD3, CD19, CD49b, CD11b and MHCII), CD11c, CCR9 and B220. Pre-
DC (Lineage- CD11c+ CCR9- B220-/lo) were then sorted into complete RPMI. The 
purity was routinely >97%. Sorted pre-DC were washed twice in sterile PBS and 
7x105 were injected intravenously into congenic recipient mice in 0.1ml CMF PBS. 
The fate of donor cells was assessed by flow cytometry 1, 3, 5 and 7 days after 
transfer. 
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2.10.2 Transfer of Ly6Chi Monocytes 
Bone marrow was obtained as described in section 2.3.8 from CX3CR1+/gfp 
CD45.2+ mice, RBCs lysed and the remaining cells were stained for CD11b, 
CD117, Ly6G and Ly6C to allow the identification of Ly6Chi monocytes (CD11b+ 
CD117- Ly6G- Ly6Chi CX3CR1int), which were then sorted into complete RPMI. The 
purity of these monocyte populations was routinely >97%. Sorted monocytes were 
washed twice in sterile PBS and then 1x106 cells were transferred intravenously, in 
a volume of 0.1ml CMF PBS into congenic recipients. The fate of the donor cells 
was assessed 5 days after transfer by flow cytometry. 
2.11 Generation of BM Chimeras 
8 week old Ly5xC57Bl/6 (CD45.1/CD45.2) mice were irradiated with 2 doses 
of 5 Gy 2 hrs apart using the Cobalt source at the Beatson Institute, Glasgow, UK. 
Mice then received 1x107 BM cells in a 50:50 ratio of WT (CD45.1+) mice and 
either SIRP mutant (CD45.2+) mice or CCR2null (CD45.2+) mice. Recipient mice 
were left for 8 weeks to allow BM engraftment.  
2.12 Parabiosis 
WT:WT (CD45.1:CD45.2) and WT:CCR2null (CD45.1:CD45.2) parabiotic 
mice were generated by Sandrine Henri (Marseille-Luminy University, France). 
Briefly 8 week old male mice were surgically joined following exposure of the skin 
from the forearm to hindleg and left for 12 weeks to allow revascularisation. The 
mice were then culled and degree of chimersim determined by flow cytometry.  
2.13 Administration of Growth Factors in vivo 
2.13.1 Recombinant Human Flt3L 
To assess DC expansion, CX3CR1+/gfp mice were injected i.p. with 10µg 
human recombinant CHO-derived flt3L (a kind gift of Amgen Corp, Seattle, USA) 
in 0.2ml sterile PBS for 8 consecutive days to achieve maximal cell expansion, as 
previously optimised in the Mowat lab. The extent of expansion was assessed by 
comparison with non-injected resting CX3CR1+/gfp mice. 
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2.13.2 B16 CSF-2 Secreting Melanoma Cells 
To assess DC expansion, WT mice were injected subcutaneously in the 
scruff of the neck with 2x106 B16 melanoma cells secreting CSF-2 (a kind gift from 
Dr. Oliver Pabst, Hannover Medical School, Hannover, Germany). 10 days later 
mice were culled and the extent of expansion assessed by comparison to non-
injected resting mice. 
2.14 Functional Analysis 
2.14.1 Phagocytosis Assay 
To measure the phagocytic activity, total SI LP cells were isolated and 
phagocytosis was assessed using the pHrodo assay according to the 
manufacturer's guidelines. Briefly, 3x106 cells were incubated with 10µl pHrodo E. 
coli bioparticles (Molecular Probes) for 15mins at 37°C or at 4°C as a control, 
washed in Buffer C and analysed in Buffer C by flow cytometry. Results were 
expressed as ΔMFI (MFI 37oC- MFI 4oC). 
2.14.2 DCs in Pseudo-Afferent Lymph 
To assess the nature of the cells migrating from the SI LP to MLNs, pseudo-
afferent lymph was collected by thoracic duct cannulation in mice, which had 
undergone mesenteric lymphadenectomy 6-8 weeks earlier. DCs in lymph were 
analysed by flow cytometry. These experiments were carried out in collaboration 
with Drs Simon Milling and Vuk Cerovic, University of Glasgow, UK 
2.15 Statistical analysis 
Results are presented as means ±1 standard deviation unless otherwise 
stated and groups were compared using a Student’s t test, Mann Whitney or for 
multiple groups, a one-way or two-way ANOVA followed by a Bonferroni post test 
using Prism Software (GraphPad Software Inc., USA). Values of less than p<0.05 
were considered significant. 
   
  
  
  
  
  
  
 Chapter 3 Phenotypic Characterisation of Intestinal 
Dendritic Cells 
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3.1 Introduction 
As described in Chapter 1, the precise characterisation of intestinal DCs has 
been difficult. In part this has been due to the laborious processes required to 
isolate these cells from the intestinal LP. However, a major problem has been the 
use of traditional DC markers such as CD11c and MHCII, which do not 
discriminate between DCs and other cells such as mφs in non-lymphoid tissues. 
Prior to starting my PhD, a post-doc in the lab had spent a considerable amount of 
time optimising protocols for isolating leukocytes from the small intestinal LP, while 
a PhD student had established multi-parameter flow cytometry techniques for 
characterising myeloid cells in the colonic LP. Thus when I began my project, the 
lab was ideally set up to start characterising intestinal DCs in more rigorous ways 
and this first chapter sets out my experiments designed to explore DC populations 
in the steady state intestinal LP. 
3.2 Characterisation of intestinal DCs by surface phenotype 
When I began, work in both our lab and others, was making it increasingly obvious 
that the use of the traditional markers such as CD11c, MHCII and F4/80 in 
isolation was insufficient to differentiate DCs from mφs in the intestine. To begin to 
overcome these issues, a gating strategy had been developed in which mutually 
exclusive expression of CD103 and CX3CR1 defined DCs and mφs respectively 
(Coombes et al., 2007; Jaensson et al., 2008; Schulz et al., 2009) and I adopted 
this strategy in my initial experiments. Using CX3CR1+/GFP mice, total mononuclear 
phagocytes (MPs) were identified amongst single live leukocytes (CD45+ 7AAD-) 
as CD11c+ MHCII+ cells (Fig. 3.1A) and DCs and mφs  within these MPs were then 
distinguished on the basis of CD103 and CX3CR1 expression respectively (Fig. 
3.1B). This showed the majority of MPs to be CX3CR1+, all of which were CD103-
F4/80+, consistent with them being mφs. A much smaller population was 
CD103+CX3CR1- and did not express F4/80, suggesting they were DCs (Fig. 
3.1C). Although my initial results supported the paradigm that these markers could 
be used to discriminate DCs and mφs other experiments going on in the lab at the 
time were suggesting that CX3CR1 expression by intestinal MPs was 
heterogeneous and that CD103- DCs may also exist. Furthermore, much of my 
project planned to use non-CX3CR1+/GFP mice and given that there was no anti-
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CX3CR1 antibody commercially available, it was necessary to modify the gating 
strategy so that DC and mφs could be discriminated in such mice. 
To overcome these issues, I developed a new gating strategy in which no a 
priori assumptions were made regarding CD103 and CX3CR1 expression. At this 
time, a PhD student in the lab investigating mφs in the colonic lamina propria in 
collaboration with the lab of Bernard Malissen in Marseille found that expression of 
CD64 (FcγRI) appeared to be specific for mφs (Bain et al., 2013; Tamoutounour et 
al., 2012). Therefore, I decided to investigate this marker in combination with the 
pan mφ marker F4/80, as a potential means of discriminating intestinal DCs and 
mφs. To this end, total MPs were first identified amongst single live leukocytes as 
CD11c+MHCII+ and contaminating B cells were excluded as B220+ cells (Fig. 
3.2A). The remaining MPs were analysed for expression of CD103 and CD11b. 
This analysis revealed the presence of 4 discrete subsets of MPs (CD103+CD11b+, 
CD103+CD11b-, CD103-CD11b+ and CD103-CD11b-) (Fig. 3.2B). To determine if 
these subsets were likely to represent DCs or mφs,  I next analysed expression of 
F4/80 and CD64 on each of the populations. Consistent with their previous 
identification as genuine DCs, neither the CD103+CD11b+ nor CD103+CD11b- 
populations expressed either F4/80 or CD64. Additionally, the novel CD103-
CD11b- MP population lacked both F4/80 and CD64 expression suggesting these 
to also be a bona fide DC population (Fig. 3.2C). In contrast, the CD103-CD11b+ 
MPs consisted of two distinct populations, with the overwhelming majority (~80%) 
expressing both CD64 and F4/80, suggesting they were mφs. The remaining 
~20% were negative for both these markers and I hypothesised that these may 
also be a novel population of genuine DCs (Fig. 3.2C). By applying this analysis to 
multiple mice, I found that the CD64+F4/80+CD103-CD11b+ mφ population was 
clearly the largest subset of MPs in the small intestinal LP, representing 73.85 ± 
2.01% of MPs. CD103+CD11b+ MPs were the most abundant CD64-F4/80- MP 
population comprising 6.07 ± 0.52%, while there were similar proportions of 
CD103+CD11b- MPs and CD64-F4/80-CD103-CD11b+ MPs (~2.5 ± 0.25% and 
~3.28 ± 0.15% respectively). The CD103-CD11b- MPs comprised a small minority 
population at 0.84 ± 0.24% of all MPs (Fig. 3.2D). 
My identification of novel putative CD103- DCs suggested that the current 
convention of discriminating DCs and mφs on the basis of CD103 and CX3CR1 
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expression was insufficient. To explore this in more detail, I next examined 
CX3CR1 expression by the various populations I had defined by applying the 
phenotyping strategy to CX3CR1+/GFP mice. To reflect the above finding that CD64 
and F4/80 are either co-expressed or both absent from the MP populations 
defined above, I modified the gating strategy slightly. Thus, total MPs were 
examined for CD64 expression prior to analysis of CD103 and CD11b expression 
on the CD64-B220- MPs (Fig. 3.3A). This analysis revealed the same subsets of 
CD64- MPs based on CD103 and CD11b expression (Fig. 3.3A).  As expected, the 
two CD103+ DC populations were negative for CX3CR1, while the CD64+ mφ 
population mostly expressed high levels of this chemokine receptor. However, the 
CD64-CD103- putative DCs were heterogeneous for CX3CR1. Whereas the CD64-
CD103-CD11b+ MPs expressed intermediate levels, some of the CD64-CD103-
CD11b- MPs lacked CX3CR1 expression while others expressed intermediate 
levels (Fig 3.3B). Thus, neither CD103 nor CX3CR1 are completely reliable for 
distinguishing DCs from mφs in the LP. I next went on to examine the expression 
of other DC and myeloid markers on the various MP populations. As described 
previously and consistent with this population in other tissues, the CD103+CD11b- 
DCs expressed CD8α, whereas neither the CD103+CD11b+ DCs, the CD103-
CD11b+ putative DCs nor the CD103-CD11b+ mφs were CD8α+. The CD103-
CD11b- putative DCs expressed heterogeneous levels of CD8α (Fig. 3.3C). The 
myeloid cell marker, signal regulatory protein α (SIRPα) was expressed by all 
intestinal MP populations except for the CD103+CD11b- DCs and a proportion of 
the CD103-CD11b- putative DCs (Fig. 3.3D).  
Previous studies have suggested that the relative proportions of 
CD103+CD11b+ and CD103+CD11b- DCs depend on the part of the 
gastrointestinal (GI) tract examined, with CD103+CD11b+ DCs predominating in 
the SI duodenum and CD103+CD11b- predominating in the colon (Denning et al., 
2011). Having identified two novel populations of CD103- putative DCs in the 
whole SI LP, I next investigated if the frequencies of these cells were also 
dependent upon location throughout the GI tract. To do this, I examined the 
proportions of CD64- DC subsets in the duodenum, jejunum, ileum and colon. This 
analysis revealed a marked and progressive decrease in the proportion of 
CD103+CD11b+ DCs going down the length of the intestine from the duodenum to 
the colon, with significantly fewer in the colon (~4%) compared with the duodenum 
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(~15%). The other CD64- MP populations examined remained constant throughout 
the length of the small intestine but were significantly increased in proportion in the 
colon, this being most apparent for the CD103+CD11b- DCs which constituted 
~14% in the colon and only ~3% in the duodenum of the SI (Fig. 3.4A). Total mφs 
were also examined throughout the length of the intestine. However, as the level 
of CD11c on intestinal mφs is not uniform, to ensure all mφs were included in this 
analysis, they were identified amongst live leukocytes as CD11b+ and CD64+ cells 
(Fig. 3.4B) rather than pre-gating on CD11c and MHCII. The proportion of mφs 
was shown to increase progressively from the duodenum (~38%) to the colon 
(~50%) (Fig. 3.4C). 
As the ability to migrate to the draining lymph node is a definitive property of 
DCs, I next examined whether the putative DC subsets I had identified in the gut 
could be found in the mesenteric lymph nodes (MLNs). To do this, live leukocytes 
were first identified and then B cells were excluded as B220+ cells (Fig. 3.5A). 
Analysis of the remaining cells for CD11c and MHCII expression revealed two 
distinct populations, a CD11c+MHCIIint population and a CD11c+MHCIIhi population 
(Fig. 3.5B). Recent work on DCs in the skin and lung draining lymph nodes, as 
well as in pseudo-afferent intestinal lymph (Cerovic et al., 2013; Guilliams et al., 
2010b; Plantinga et al., 2013) has concluded that the CD11c+MHCIIhi cells are 
migratory DCs which have entered lymph nodes from tissues via lymph. In 
contrast, the CD11c+MHCIIint population is thought to be blood-derived, lymph 
node resident DCs. Consistent with the non-migratory nature of mφs, very few of 
the cells in the migratory gate identified in the MLNs expressed CD64 (Fig. 3.6A) 
and CD64+ cells were also rare amongst the resident DC gate (Fig. 3.6B). Analysis 
of CD103 and CD11b expression by the CD64- cells amongst the migratory DC 
gate revealed four populations that were phenotypically similar to those I found in 
the LP (Fig. 3.6A). While phenotypically similar, the proportions of the 
CD103+CD11b- and CD103-CD11b+ DC subsets differed slightly to those seen in 
LP (compare Fig. 3.3B with Fig. 3.6A). Consistently, the frequency of 
CD103+CD11b- DCs tended to be higher in the MLNs than in the LP (~20-30% of 
migratory DC compared with ~15-18% in the SI LP) and this was coupled with a 
trend towards a lower frequency of CD103-CD11b+ DCs in the MLNs compared 
with the LP (~10-12% in the MLNs and ~15-18% in the SI LP). In contrast there 
were only three populations of CD64- MPs amongst the resident DC gate, with the 
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CD103+CD11b+ subset being absent (Fig. 3.6B). This is consistent with the 
designation of the DCs within the CD11c+MHCIIint gate as LN resident, as the 
CD103+CD11b+ DCs have, to date, only been described in the intestine. Indeed, I 
could not find any CD103+CD11b+ DCs outwith the intestinal mucosa in either 
lymphoid tissues such as the spleen (Fig. 3.7A), or non-lymphoid tissues such as 
the lung, liver or kidney (Fig. 3.7B-D).  
 The expression of CD11c and MHCII, but not CD64 or F4/80, coupled with 
the presence of phenotypically similar cells in the migratory subset of MLN DCs, 
suggested that the four populations of MP I had identified in the LP are indeed 
genuine DCs. To confirm this, I next set out to determine if the MP populations 
conformed to the core gene signatures recently identified by the Immunological 
Genome Consortium as being typical of DCs and mφs (Gautier et al., 2012; Miller 
et al., 2012). First I examined expression of CD26 and CD272 as DC-specific 
markers and CD14 and MerTK as mφ−specific. Consistent with their designation 
as DCs, all CD11c+CD64- populations expressed CD26 and CD272, but lacked 
MerTK and CD14 (Fig. 3.8). On the other hand, the CD11c+CD64+ MPs lacked 
expression of the DC-specific markers, but expressed both CD14 and MerTK, 
confirming their identification as mφs (Fig. 3.8). 
3.3 Transcription factor expression by intestinal MP subsets 
To explore further the nature of the MP populations I had 
identified, I next FACS-purified the individual subsets (Fig. 3.9) and examined the 
expression of the transcription factors associated with the development and 
differentiation of DCs and mφs. 
I first examined the expression of Zbtb46, the recently reported DC-specific 
transcription factor (Meredith et al., 2012a; Satpathy et al., 2012). Confirming my 
earlier phenotypic analysis all four populations of CD64- putative DCs expressed 
mRNA for Zbtb46 at equivalent levels, while the CD64+ mφs did not (Fig. 3.10A). 
The other transcription factors I analysed were Batf3, IRF4, IRF8 and Id2. Batf3 is 
considered to be specific for CD8α+ DCs and Batf3-/- mice have been shown to 
lack CD103+CD11b- DCs in the intestine (Edelson et al., 2010). Despite this, 
similar levels of Batf3 mRNA were observed in all intestinal DC subsets, as well as 
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in the mφ population (Fig. 3.10B). IRF4 and IRF8 are interferon regulatory factors 
associated with the development of CD11b+ and CD11b- DCs respectively 
(Edelson et al., 2010; Ginhoux et al., 2009; Persson et al., 2013b; Schlitzer et al., 
2013). Consistent with this, IRF4 mRNA was detected at similar levels in 
CD103+CD11b+ and CD103-CD11b+ DCs, as well as in mφs. IRF4 mRNA was also 
detected in the CD103-CD11b- DCs (Fig. 3.10C). On the other hand, IRF8 mRNA 
was detected at the highest level in CD103+CD11b- DCs, with very little being 
found in CD103+CD11b+ DCs. The CD103-CD11b+ and CD103-CD11b- DCs also 
expressed IRF8 mRNA; although at levels about 10-fold lower than seen in the 
CD103+CD11b- DC (Fig. 3.10D). Interestingly, mφs expressed similar levels of 
IRF8 to the CD103+CD11b- DCs, but the relevance of this remains unclear. Id2 
was originally thought to control the differentiation of CD8α+ lineage of DCs, but it 
has since been shown to be expressed by both CD11b+ and CD11b-CD8α+ DCs 
(Jackson et al., 2011). Consistent with this, all intestinal DC subsets expressed Id2 
mRNA, although this was approximately 2-fold lower in the two subsets of CD103- 
DCs compared with the CD103+ subsets. Mφs also expressed Id2 at levels 
equivalent to CD103+ DCs (Fig. 3.10E). 
3.4 Transcriptional profile of intestinal MP populations 
I next set out to determine how similar or otherwise these cells were in terms 
of their complete transcriptional profiles. For this, I FACS-purified the MP 
populations from the SI LP and sent RNA samples for microarray. The analysis of 
the microarray data is currently being performed in collaboration with Drs. Toby 
Lawrence, Bernard Malissen and Marc Dalod (CIML, Marseille, France). 
3.5 Growth factor dependence of intestinal MP subsets 
So far my data suggest that all four populations of CD11c+CD64- MP are 
bona fide DCs, while the CD11c+CD64+ MP are mφs. As DCs and mφs  require 
distinct growth factors for their development, I next investigated the dependency of 
each intestinal MP population on Flt3L, CSF-1 and CSF-2. DC development has 
been shown to require Flt3L and CSF-2, while mφ development is known to 
depend on CSF-1 (Helft et al., 2010; MacDonald et al., 2010; Merad and Manz, 
2009; Waskow et al., 2008). To investigate the role of these growth factors, I first 
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examined the expression of their receptors on sorted populations of intestinal MPs 
(Fig. 3.11). Consistent with their designation as DCs, all four populations of 
CD11c+CD64- cells expressed high levels of mRNA for CD135 (Flt3), the receptor 
for Flt3L, while the mφs lacked expression of this receptor (Fig. 3.11A). 
Interestingly all intestinal MP subsets expressed similar levels of mRNA for CD116, 
the α chain of the receptor for CSF-2 (Fig. 3.11B). Conversely and consistent with 
their known requirement for CSF-1R signalling, the mφs expressed the highest 
levels of the receptor for this factor, CD115 (CSF-1R). In comparison, both 
subsets of CD103+ DCs expressed very low levels of CD115 and although the two 
CD103- DC subsets expressed intermediate amounts of CD115 mRNA, this was at 
a level about 10-fold lower than that of the mφs (Fig. 3.11C).  
Given these results, I next decided to investigate how the intestinal MP 
populations were affected in mice lacking growth factors or their receptors. 
Although I did not have access to any of these mice in Glasgow, I was able to 
establish collaborations that allowed me to investigate Flt3L-/- mice (in 
collaboration with Prof. Bart Lambrecht and Dr. Martin Guilliams, University of 
Ghent) and CSF-2R2b-/- mice (in collaboration with Prof. Fiona Powrie and Dr. 
Thibault Griseri, University of Oxford). In both cases I travelled to their labs and 
compared MP populations in the SI LP of the KO mice with co-housed WT mice as 
controls. Importantly, I found the same populations of DCs and mφs in both groups 
of WT mice that I had identified in Glasgow.  
As reported previously (Tamoutounour et al., 2012), the proportion of total 
CD64-CD11c+MHCII+ DCs was severely reduced in the SI LP of Flt3L-/- mice (Fig. 
3.12A). Subsequent analysis of the remaining DCs in these mice for expression of 
CD103 and CD11b demonstrated that there was no selective effect of Flt3L 
deficiency and that all four putative DC populations were virtually absent in the 
Flt3L-/- mice (Fig. 3.12B). In contrast, the relative proportion of mφs was 
unchanged in these mice indicating their independence of Flt3L (Fig. 3.12C). 
To complement these studies I examined the effects of exogenous 
recombinant murine Flt3L on the numbers of MP subsets in the intestine of WT 
mice in Glasgow. For this, mice received 10µg Flt3L i.p. for 8 days, or PBS as a 
control. Flt3L administration led to a dramatic expansion in the numbers of 
CD11c+MHCII+ MPs, which now comprised 40-45% of live leukocytes, compared 
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with 12-16% in the PBS treated controls (Fig. 3.13A). Upon examination of CD11c 
and F4/80 expression, it was clear that this expansion was due to a preferential 
increase in CD11c+F4/80- DCs (Fig. 3.13B). This was most marked in the 
CD103+CD11b- DC population, but the relative increases in numbers of CD103-
CD11b+ and CD103-CD11b- DCs were almost as marked and the numbers of 
CD103+CD11b+ DCs were also significantly increased compared with controls (Fig. 
3.13C-E). Although the numbers of CD64+ mφs were not altered by administration 
of Flt3L, there was a slight but significant reduction in the proportion of mφs (Fig. 
3.13C-F).  
There were no differences in the relative proportion of CD11c+CD64- DCs 
and CD11c+CD64+ mφs in the SI LP of CSF-2R2b-/- mice compared with WT mice 
 (Fig. 3.14A), but, there was a significant defect in the proportion of 
CD103+CD11b+ DCs in CSF-2R2b-/- mice compared with controls. However, it 
should be noted that a number of cells in the KO mice fell outside the CD103 gate 
set using WT controls, suggesting generally lower levels of CD103 expression. 
This is consistent with previous suggestions that CSF-2 is needed for CD103 
expression (Edelson et al., 2010; Greter et al., 2012; Zhan et al., 2011). As a result, 
it is difficult to make conclusions about the involvement of CSF-2 in intestinal DC 
development when using CD103 as a marker. There were no significant 
differences in the other MP populations in the CSF-2R2b-/- mice (Fig. 3.14B,C).  
As with Flt3L, I attempted to complement the studies in the CSF-2R2b-/- mice 
by giving WT mice in Glasgow exogenous CSF-2. Initially, I attempted to do this by 
administration of recombinant CSF-2, but this was unsuccessful due to the limited 
amounts available. Therefore I used an alternative approach, in which mice were 
inoculated with CSF-2 secreting B16 melanoma cells for 10 days. This led to a 
dramatic increase in the proportion of CD11c+MHCII+ cells, with a marked 
upregulation of CD11c expression so that almost all of the cells within the 
CD11c+MHCII+ gate expressed high levels of CD11c (Fig. 3.15A). CD64 
expression was also upregulated on CD11c+MHCII+ cells from CSF-2 treated 
animals compared with those from WT controls (Fig. 3.15B), although expression 
of F4/80 was not affected by the administration of CSF-2 (Fig. 3.15B). As a result 
of their high expression of CD11c and lack of F4/80, for the purposes of this 
analysis, I assumed the F4/80+ cells to be mφs while the F4/80-CD64int cells were 
analysed as DCs. On this basis CSF-2 administration resulted in an expansion of 
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all DC populations, while F4/80+ mφs were unaffected (Fig. 3.15C-E). The greatest 
increase in DC number was observed amongst the CD103-CD11b+ DC population 
(Fig. 3.15E) with decreases in the proportion of the other DC subsets (Fig. 
3.15C.D). Unfortunately I did not have time to repeat this experiment or to confirm 
the nature of these cells induced by CSF-2 by more detailed analysis. Thus further 
investigation is required to determine the role of CSF-2 in intestinal DC 
development. 
3.6 Population kinetics of intestinal MP populations in vivo 
As intestinal DCs are short-lived cells that sample antigen in the LP and 
migrate constitutively to the MLNs, I hypothesised that they would have distinct 
kinetics to intestinal mφs, which are long-lived and sessile in the LP. Therefore as 
a final means of distinguishing DCs and mφs amongst intestinal MPs, I examined 
their kinetics in vivo using BrdU pulse-chase, in which mice were given a single 
dose of BrdU i.p. and then fed BrdU in the drinking water for 3 days. BrdU+ cells 
amongst the MP in the SI LP were then assessed immediately after cessation of 
BrdU feeding and again at 3, 6 and 9 days after withdrawing BrdU. I also 
examined BrdU incorporation by DCs in the MLNs to determine if any of the LP 
DCs had migrated to the MLNs.  
After 3 days of BrdU feeding, all the CD64- DC populations in the SI LP were 
~65-80% BrdU+, whereas only ~20% of the CD64+ mφs were BrdU+ (Fig. 3.16A,B). 
After withdrawal of BrdU, the proportion of BrdU+ DCs in the LP decreased over 
time, until few BrdU+ cells remained in any DC population 9 days after cessation of 
BrdU feeding (Fig. 3.16B). No differences were observed in the rate of BrdU+ cell 
loss between the different subsets of DCs. The loss of BrdU+ cells from the LP 
correlated with an increase in the proportion of BrdU+ cells amongst the migratory 
CD11c+MHCIIhi DCs within the MLNs which rose from ~40% immediately after 
BrdU administration to 60-70% 3 days after BrdU withdrawal (Fig. 3.16C). This 
increase was observed for all DC populations except for the CD103-CD11b- DCs, 
where the proportion of BrdU+ cells fell progressively from ~40% after cessation of 
BrdU feeding. The proportion of BrdU+ cells amongst the other migratory DC 
subsets in the MLNs fell slightly from 3-6 days after BrdU withdrawal and 
decreased further by day 9 (Fig. 3.16C). Conversely, the number of BrdU+ cells 
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amongst the CD64+ mφs remained at similar levels throughout the study with the 
exception of 3 days after cessation of BrdU, which likely represents a technical 
issue as all MP populations had a slightly lower than expected proportion of BrdU+ 
cells (Fig. 3.16B). This analysis thus confirms the extended half-life of the mφs and 
their inability to migrate to the MLNs compared with the DCs.  
3.7 Summary 
In this chapter I set out to characterise intestinal DCs using multi-parameter 
flow cytometry, transcriptional analysis, growth factor dependence and kinetic 
studies. I first made use of recent developments in our lab and elsewhere in which 
CD64 was found to be a useful means of distinguishing DCs and mφs (Bain et al., 
2013; Tamoutounour et al., 2012). By exploiting this, I was able to characterise 
total CD11c+MHCII+ MPs in the small intestinal LP without relying on CD103 and 
CX3CR1, two markers which had become the convention in the field for 
distinguishing between DCs and mφs in the intestinal lamina propria. This analysis 
allowed me to define mφs as CD64+ and to identify four subsets of CD64- MPs, 
based on the expression of CD103 and CD11b, which I proposed to be genuine 
DCs. In addition to the well-characterised populations of CD103+CD11b+ and 
CD103+CD11b- DCs, I also found equivalent subsets of CD103- DCs whose 
existence had been contentious, often resulting in their inclusion amongst mφs. All 
these CD64- DC subsets could also be found in the colonic LP and amongst 
migratory populations of DCs in the MLNs. 
 I went on to demonstrate definitively that the novel CD103-CD64- MPs were 
indeed DCs, as they expressed CD26, CD272 and the recently defined DC-
specific transcription factor, Zbtb46, but lacked expression of the mφ markers; 
MerTk and CD14. Additionally, all the CD103- and CD103+ DCs expressed similar 
levels of the transcription factors and growth factor receptors associated with DC 
development, which was were quite distinct from the CD64+ mφs. In parallel, all 
the DC subsets but not mφs were absent in Flt3L-/- mice and their numbers 
increased in response to in vivo administration of Flt3L. Additionally, all CD64- 
DCs were shown to expand in response to exogenous CSF-2 in vivo with apparent 
preferential increase in the numbers of CD103-CD11b+ DCs, although the effects 
of CD11c and CD64 expression made these results more difficult to interpret. In 
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vivo kinetic studies demonstrated similar BrdU incorporation by the CD103+ and 
CD103- DC subsets in the SI LP, all of which showed rapid turnover from 
precursors and efficient migration to the MLNs. In contrast the CD64+ mφs were 
comparatively long-lived and sessile.  
 Together these experiments allowed me to establish reliable techniques for 
distinguishing DCs and mφs in the steady state intestine and to identify two novel 
bona fide populations of CD103- DCs. In the next chapter, I set out to examine the 
ontogeny of these cells, and more specifically to determine whether they were the 
progeny of common DC precursors or if monocytes also played a role in their 
replenishment. 
 
Figure 3.1: Initial gating strategy for identification of SI mononuclear phagocytes 
SI LP cells were isolated from CX3CR1+/GFP mice and analysed for CD103 and CX3CR1-GFP 
expression by flow cytometry. A. Representative dot plots showing the identification of single cells 
based on FSC-A and FSC-H profiles. Live leukocytes were identified amongst single cells as 
CD45+7-AAD- cells and mononuclear phagocytes identified as CD11c+MHCII+ cells. B. 
Representative dot plots showing expression of CD103 and CX3CR1-GFP by mononuclear 
phagocytes as gated in A. C. Expression of the pan mφ marker F4/80 by CD103+ MP (black line) 
and CX3CR1+ MP (purple line) compared with isotype control (shaded grey line). Results are 
representative of at least 10 individual experiments.  
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Figure 3.2: Characterisation of intestinal MP populations in non CX3CR1+/GFP mice 
A. Representative dot and contour plots showing the gating used to define MPs in SI LP digests. 
After selection of single, live (7-AAD-) leukocytes (CD45+) as shown in Fig 3.1, MPs were 
identified as CD11c+MHCII+ and any contaminating B cells were excluded as B220+ cells. B. 
Representative dot plots showing expression of CD103 and CD11b on B220- MPs. C. Expression 
of F4/80 and CD64 on the four populations of MPs identified in B. D. Proportion of each MP 
subset as a percentage of total CD11c+MHCII+ cells. Data are representative of at least 20 
independent experiments with n =3/4 per experiment. 
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Figure 3.3: Expression of CX3CR1, CD8α and SIRPα by intestinal MPs 
A. Representative dot plot showing identification of total DCs as CD64-CD11chiB220- cells and 
mφs as CD11c+CD64+ cells amongst single live CD45+CD11c+MHCII+ MPs in SI LP digests from 
CX3CR1+/GFP mice. Total DCs were divided into four distinct subsets on the basis of their 
expression of CD103 and CD11b. B. Proportion of each DC subset as a percentage of total DCs 
as gated in A. C-E. Representative histogram showing expression of CX3CR1-GFP (B), CD8α (C) 
and SIRPα  (D) on the four DC subsets and CD64+ mφs with isotype controls shown in grey. Data 
are representative of at least 10 independent experiments with n =3/4 per experiment. 
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Figure 3.4: MP populations throughout the GI tract 
A. DC populations were identified in the duodenum, jejunum and ileum of the small intestine LP 
and colonic LP as shown in Fig. 3.3. The results shown are the frequencies of each DC subset as 
a percentage of total CD11c+MHCII+ cells. B.  Total mφs were identified in the different parts of the 
GI tract as CD11b+CD64+ amongst single live CD45+ cells as shown in Fig. 3.1. Data shown is 
from Ileum. C. Mφs were identified in the duodenum, jejunum and ileum of the small intestine LP 
and colonic LP as shown in B. The results shown are the frequencies of mφs as a percentage of 
live CD45+CD11b+ cells. Data are from a single experiment with n=3/4 *p<0.05, **p<0.01, 
***p<0.005, versus equivalent population in duodenum. One way ANOVA with Bonferroni post-
test.  
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Figure 3.5: Migratory and resident DCs in the MLN 
A. Representative dot plots showing the gating strategy used to define single live B220- CD45+ 
cells amongst MLN cells. B. Expression of CD11c and MHCII by live-gated B220- CD45+ cells 
defining migratory and resident DCs as CD11c+MHCIIhi and CD11c+MHCIIint respectively. Data are 
representative of at least 20 independent experiments with n =3/4 per experiment. 
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Figure 3.6: Subsets of migratory and resident DCs in the MLN 
Migratory (CD11c+MHCIIhi) and resident (CD11c+MHCIIint) cells were identified in the MLN 
amongst live B220- CD45+ cells and analysed for expression of CD64, CD103 and CD11b. A. 
Representative dot plots showing expression of CD64, CD103 and CD11b by migratory DCs in 
MLN gated as in Fig. 3.5. Scatter plot shows proportion of each DC subset as a percentage of 
total migratory DCs. B. Representative dot plots showing expression of CD64, CD103 and CD11b 
by resident MLN DCs gated as in Fig 3.5. Scatter plot shows proportion of each DC subset as a 
percentage of total resident DC. Data are representative of at least 20 independent experiments 
with n =3/4 per experiment. 
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Figure 3.7: DC populations in non-intestinal tissues 
Non-intestinal tissues were digested, DCs were identified as live CD45+ CD11c+ MHCII+ CD64- 
cells and analysed for CD103 and CD11b expression compared with the SI LP. A-E. 
Representative dot plots showing expression of CD103 and CD11b by DCs in (A) spleen, (B) lung, 
(C) liver, (D) kidney and (E) SI LP. Data are from 1-2 independent experiments with n =2/3 per 
experiment. 
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Figure 3.8: Expression of DC and mφ specific markers by intestinal MPs 
The subsets of DCs and mφs from SI LP were identified as described in Fig. 3.3 and analysed for 
expression of DC and mφ specific markers. Representative histograms shows the expression of 
CD272, CD26, MerTK and CD14 compared with isotype (CD272, CD26, CD14) or streptavidin 
only controls (MerTK) (shaded grey histograms).   
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Figure 3.9: Purification of intestinal MP subsets by FACS 
Subsets of CD64- DCs and CD64+ mφs were identified amongst live gated single CD45+CD11c
+MHCI+B220- in SI LP digests as shown in Fig. 3.3. A. Representative plots showing the 
proportion of each DC subset (left panel) and mφs (right panel) as a percentage of total cells prior 
to sorting. B. Representative plots showing the proportion of each cell type as a percentage of 
sorted cells. Data are representative of at least 20 independent experiments with 9-12 mice 
pooled per experiment. 
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Figure 3.10: Transcription factor expression by intestinal MP subsets 
A-E. SI LP DCs and mφs were FACS-purified from whole digests as described in Fig. 3.9 and 
analysed by qRT-PCR for expression of mRNA for (A) Zbtb46, (B) Batf3, (C) Irf4, (D) Irf8 and (E) 
Id2. Results shown are relative to HPRT using the 2-ΔΔct method with mφs set to 1. Data are pooled 
from 2 independent experiments with cells pooled from 9-12 mice per experiment.  
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Figure 3.11: Growth factor receptor expression by intestinal MP subsets 
A-C. SI LP DCs and mφs were FACS-purified from whole digests as described in Fig. 3.9 and 
analysed by qRT-PCR for expression of mRNA for (A) Flt3, (B) Csf-2Ra and (C) Csf-1R. Results 
shown are relative to HPRT using the 2-ΔΔct method with mφs set to 1. Data are pooled from 1/2 
independent experiments with cells pooled from 9-12 mice per experiment.  
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Figure 3.12: Role of Flt3L in development of intestinal MPs 
A. Representative plots showing CD11c and CD64 expression on live gated CD45+CD11c+MHCII+ 
in SI LP digests from Flt3L-/- and WT control mice. Numbers indicate percentage of live CD45+ 
cells. B. Representative dot plots showing CD103 and CD11b expression on CD11chiCD64- DCs 
in Flt3L-/-  and WT mice gated in A. C. Proportion of each MP subtype as a percentage of total live 
leukocytes in LP of  Flt3L-/- and WT controls. Data are from two independent experiments with 
n=3/4 per group per experiment. ***p<0.001 Student’s t test. 
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Figure 3.13: Effects of recombinant Flt3L on intestinal MP populations in vivo 
Mice received PBS or 10µg of recombinant Flt3L i.p. daily for 8 days and DC and mφ populations 
were analysed in SI LP. A. Representative dot plots showing CD11c and MHCII expression by live 
gated CD45+ single cells in control and Flt3L-treated mice. B. Representative dot plots showing 
CD11c and F4/80 expression on total MPs in control and Flt3L-treated mice. C. Representative 
dot plots showing CD103 and CD11b expression on CD11c+F4/80- DCs in control and Flt3L-
treated mice. D. Proportion of each MP subtype as a percentage of total live CD45+ cells in control 
and Flt3L-treated mice. E. Absolute number of each MP subset in control and Flt3L-treated mice. 
Data are representative of three independent experiments with n=3 per group. *p,0.05, **p<0.005, 
***p<0.001 Student’s t test. 
A 
MHCII 
C
D
11
c 
-Flt3L + Flt3L 
B 
C
F4/80 
C
D
11
c 
-Flt3L + Flt3L 
-Flt3L + Flt3L 
CD11b 
C
D
10
3 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
Mφ
0
1
2
5
15
25
*
***
** **
** + Flt3L
- Flt3L
%
 o
f L
iv
e 
C
D
45
+
D 
E 
15.2 41.7 
24.4 80.9 
61.6 12.7 
12.3 56.2 40.1 5.05 
18.2 12.9 13.5 9.98 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
Mφ
0
2
4
6
8
20
40
60
80
**
***
* *
+ Flt3L
- Flt3L
A
bs
ol
ut
e 
N
um
be
r x
10
5
124 
Figure 3.14: Role of CSF-2 in development of intestinal MPs 
A. Representative plots showing CD11c and CD64 expression on live gated CD45+CD11c+MHCII+ 
in SI LP digests from CSF-2R2b-/- and WT control mice. Numbers indicate percentage of live 
CD45+ cells. B. Representative dot plots showing CD103 and CD11b expression on 
CD11chiCD64- DCs in CSF-2R2b-/- and WT mice. C. Proportion of each MP subtype as a 
percentage of total live leukocytes in LP of  CSF-2R2b-/- and WT controls. Data are from a single 
experiment with n=3/6 per group per experiment. ***p<0.001 Student’s t test. 
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Figure 3.15: Effects of B16 melanoma-derived CSF-2 on intestinal MP populations 
Mice received 2x106 CSF-2 secreting B16 melanoma cells s.c. and SI LP DC and mφ populations 
were analysed 10 days later. A. Representative contour plots showing CD11c and MHCII 
expression by live gated CD45+ single cells in resting control and CSF-2 tumour inoculated mice. 
B. Representative plots showing CD64 and F4/80 expression on live gated CD45+B220-CD11c+ 
MHCII+ MPs in control and CSF-2 tumour bearing mice. C. Representative dot plots showing 
CD103 and CD11b expression on CD64-F4/80- DCs in control and CSF-2 tumour inoculated mice. 
D. Proportion of each MP subtype as a percentage of total live CD45+ cells in control and CSF-2 
tumour mice. E. Absolute number of each MP subset in control and CSF-2 tumour inoculated 
mice. Data are from a single experiment with n=4-7. *p,0.05, **p<0.005, ***p<0.001 Student’s t 
test. 
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Figure 3.16: Differential Kinetics of DC and mφ populations in the SI LP and MLN 
Mice were given a single i.p. injection of 1mg BrdU and fed 0.8mg/ml BrdU in the drinking water 
for 3 days. A. Representative contour plots showing CD45 and BrdU staining on single live CD45+ 
CD11c+MHCII+CD64- DCs from SI LP gated as shown in Fig. 3.3 in the presence or absence of 
DNase to expose incorporated BrdU. B.  Percentage of BrdU+ cells amongst DC and mφ 
populations at day 3 after feeding and again 3, 6 and 9 days after withdrawal of BrdU. C. 
Percentage of BrdU+ cells amongst MLN migratory DC populations gated as in Fig. 3.6 at day 3 
after feeding and again 3, 6 and 9 days thereafter. Data are from 2 independent experiments with 
n=3/4 per time point per experiment. *p<0.05, **p<0.01 and ***p<0.005. Colour of * indicates 
which DC populations are significantly different compared with listed populations. Two-way 
ANOVA with Bonferroni post-test. 
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4.1 Introduction 
In the previous chapter I identified four distinct subsets of CD64- intestinal 
DCs based on CD103 and CD11b expression (CD103+CD11b+, CD103+CD11b-, 
CD103-CD11b+ and CD103-CD11b-), which were clearly distinct from CD64+ 
intestinal mφs. While the two CD103+ DC populations were expected (Bogunovic 
et al., 2009; Varol et al., 2009) genuine CD103- DCs of this kind had not been 
identified previously, as earlier studies had used phenotyping strategies that could 
not distinguish CD103- DCs from mφs. In these earlier reports, it was also 
suggested that the CD103- “DCs” were derived from Ly6Chi monocytes rather than 
DC-committed precursors that give rise to DCs in other tissues (Geissmann et al., 
2010; Liu et al., 2009; Naik et al., 2006; 2007) and the CD103+ genuine DC 
populations in the intestine (Bogunovic et al., 2009; Varol et al., 2009). However, 
as the results in my previous chapter emphasised that intestinal CD103- MPs are 
in fact a heterogeneous population consisting of both DCs and mφs, it became 
clear that the findings of these previous studies clearly required re-examination. 
Therefore, in this chapter I set out to determine the nature of the precursors of the 
various MP populations I had identified. 
4.2 DC progenitors in the BM 
4.2.1 Defining pre-DCs in the BM 
The current theory of DC development is that common DC progenitors 
(CDPs or pro-DCs) first differentiate into either precursors of DCs (pre-DCs) or 
fully differentiated pDCs in the BM which then home to the tissues (Liu et al., 2009; 
Naik et al., 2006; 2007; Onai et al., 2007a). In order to determine if the novel 
CD103- DCs I had described in Chapter 3 are derived from a DC committed 
precursor, I set out to examine the fate of adoptively transferred pre-DCs in vivo. 
First, I had to establish methods for identifying and isolating these precursors from 
the BM, basing this on previous studies. Therefore after excluding cell aggregates 
and lineage-bearing cells (CD3, CD19, CD49b, CD11b and MHCII), I examined 
the remaining CD11c+ cells for their expression of CCR9 and B220, with pre-DCs 
being identified as CCR9-B220-CD135+SIRPαint and pDCs as CCR9+B220+ cells 
(Fig. 4.1A). Consistent with previous reports (Liu et al., 2009), these pre-DCs 
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expressed intermediate levels of CX3CR1-GFP and lacked CD8α (Fig. 4.1B,C). I 
also examined the expression of β7 integrin, which has been shown to mark a 
population of DC progenitors which home preferentially to the intestine (Zeng et 
al., 2013). A small proportion (~15%) of pre-DCs expressed this marker (Fig. 4.1D).  
4.2.2 Expansion of pre-DCs in the BM with Flt3L 
As pre-DCs constitute a very minor population (<0.1%) of cells in the BM, it 
was necessary to expand their numbers to generate sufficient numbers for 
adoptive transfer experiments. To do this, I employed a frequently used approach, 
in which WT mice were inoculated subcutaneously with B16 melanoma cells 
secreting Flt3L, the principal growth factor for DC in vivo (Karsunky et al., 2003; 
Merad and Manz, 2009; Viney et al., 1998). 10 days later, Flt3L secreting tumours 
had formed and this resulted in a dramatic increase in both the proportion and 
absolute number of pre-DCs in the BM (Fig. 4.2).  
4.3 Adoptive transfer of DC progenitors 
I next set about developing a protocol for tracking pre-DC migration and fate 
in recipient mice. As previous studies involving adoptive transfer of pre-DCs used 
recipient mice that had either been irradiated or depleted of all CD11c+ cells using 
CD11c-DTR mice, so that donor cells could be visualised more easily, this was the 
first approach I considered. Although the four populations of DCs identified in the 
previous chapter were depleted by administration of DT to CD11c-DTR mice, there 
was actually a much more intense depletion of CD11cint mφs (Fig. 4.3). As this 
result raised issues over the suitability of this approach, I decided to try to transfer 
pre-DCs into unmanipulated steady state recipients. Although I could not find 
previous reports of this, I reasoned it would be the most physiological way of 
exploring DC development without the artefacts produced by severe population 
depletion or irradiation. To this end, FACS-purified pre-DCs isolated from CD45.2 
WT donors that had been inoculated with Flt3L secreting B16 melanoma cells 10 
days prior to harvest were transferred into resting CD45.1 congenic WT recipient 
mice (Fig. 4.4A,B). To aid the identification of donor cells in recipient mice, pre-
DCs were also labelled with a CellTrace violet dye prior to transfer (Fig. 4.4B). 
Importantly, the transferred pre-DCs lacked expression of CD11b, MHCII and 
CD103 markers found at high levels on live leukocytes in the SI LP (Fig. 4.4C). 
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4.3.1 Identification and fate of donor-derived cells in the blood 
24 hours after transfer, CD45.2+violet+ donor cells could be identified in the 
bloodstream of recipient mice (Fig. 4.5A). At this time, these donor cells retained 
the CD11cintMHCII- phenotype of the pre-DCs, in contrast to the CD11chiMHCII+ 
phenotype of endogenous tissue DCs (Fig. 4.5B). Very few CD45.2+violet+ donor 
cells could be seen in the bloodstream 3, 5 or 7 days after transfer (Fig. 4.5C) 
suggesting that most surviving pre-DCs had left the bloodstream by this time.  
4.3.2 Identification and fate of donor-derived cells in the spleen 
Donor-derived cells could be detected in the spleen by 24 hours after 
transfer and were most numerous between 1 and 5 days after transfer, before 
decreasing dramatically by day 7 (Fig. 4.6A). Over this time period the donor-
derived cells showed progressively lower levels of violet dye (Fig. 4.6B) 
suggesting these cells might be proliferating, as this label halves in intensity with 
each cell division. In parallel, donor-derived cells in the spleen showed progressive 
upregulation of CD11c and MHCII to levels comparable with the endogenous 
splenic DCs. This could be seen as soon as 24 hours after transfer, although a 
true population of cells with the phenotype of mature DCs was not observed until 3 
days after transfer (Fig. 4.7). At all time points, a population of CD11c+MHCII- 
donor-derived cells remained detectable, suggesting that not all transferred pre-
DCs could differentiate into mature DCs even after 7 days (Fig. 4.7). I then 
analysed the phenotype of the mature progeny of the pre-DCs, using the 
expression of CD103 and CD8α as markers. As described previously, this 
revealed two distinct DC populations amongst endogenous DCs (CD103-CD8α- 
DCs and CD103-/intCD8α+ DCs) (Fig. 4.8A). Although CD4 and CD11b are often 
used to define DC subsets in the spleen, I found that the combination of CD103 
and CD8α gave better separation in FACS analysis than CD103 and CD11b, while 
my staining panel did not allow for incorporation of an appropriate CD4 antibody. 
Analysis of the donor-derived CD11c+MHCII+ DCs showed that these also 
acquired CD103 and CD8α expression, with CD8α+ DCs appearing 24-72 hours 
after transfer and CD103 being first detectable by 72 hours and becoming more 
apparent on days 5 and 7 (Fig. 4.8). As with the endogenous subsets, the CD103+ 
donor-derived DCs were also CD8α+ (Fig. 4.8A) and the transferred pre-DCs 
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could also generate the CD103-CD8α- DC subset normally seen in the spleen (Fig. 
4.8).  
4.3.3 Identification and fate of donor-derived cells in the SI LP 
CD45.2+violet+ donor-derived cells could also be identified in the SI LP as 
soon as 24 hours after transfer and clear populations were seen from 3-7 days 
after transfer (Fig. 4.9A). As in the spleen, there was a progressive decrease in the 
intensity of the violet dye over the time course, suggesting that donor-derived cells 
in the SILP may be proliferating in situ. The donor-derived cells began to 
upregulate CD11c and MHCII expression as soon as 24 hours after transfer and 
by day 3, approximately 30% expressed CD11c and MHCII at levels comparable 
to endogenous SI LP DCs. This population then increased steadily from day 3 to 
day 7 (Fig. 4.10). In parallel with their acquisition of the mature DC phenotype, the 
donor-derived DCs acquired expression of CD103 and CD11b, with both markers 
appearing by day 3 after transfer and by day 7, all four subsets of DCs normally 
seen amongst endogenous cells in the LP could be seen at similar proportions to 
those seen in the resting LP (Fig. 4.11). Notably, this included the CD103+CD11b+ 
DCs, in contrast to what was observed when the transferred pre-DCs differentiated 
in the spleen. Interestingly, the CD103+CD11b+ DCs appeared to take longer to 
accumulate in the LP than the other DC subsets, potentially suggesting these 
develop through a CD11b+CD103- intermediary, although this remains to be 
directly investigated. 
Similar to the spleen, a population of CD11cintMHCII- donor-derived cells 
remained in the SI LP throughout the duration of the analysis (Fig. 4.10) thus I 
next set out to investigate what these cells might be. First I examined the 
possibility that the transferred pre-DCs were contaminated with other precursor 
cells. To do this I examined the expression of CD115 which is expressed by more 
primitive progenitors (Liu et al., 2009). This revealed that a minority of these cells 
(<0.2%) expressed low levels of CD115 (Fig. 4.12A). To rule out the possibility 
that the pre-DCs were contaminated with cells not committed to the DC lineage, 
which also express CD115, although usually at higher levels, I examined the ability 
of the transferred cells to give rise to mφs. As none of the donor cells generated 
F4/80+ mφs (Fig. 4.12B), no cells of the monocyte/mφ lineage or with the potential 
to generate monocytes/mφs such as CMPs or MDPs could be present amongst 
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the transferred cells. Thus we reasoned that these contaminating cells were due to 
the presence of a minor population of contaminating CD115+ CDPs. To test this 
hypothesis, I next examined if the donor-derived CD11cintMHCII- cells in the LP 
were pDCs. As pDCs express Ly6C and B220, I examined the expression of these 
markers on all on all donor-derived cells at day 7 and compared levels to those 
seen on endogenous live SI LP cells. Unfortunately due to constraints of antibody 
and fluorochrome combinations, it was not possible to co-stain for MHCII for this 
analysis. Despite this shortcoming, this analysis demonstrated that the donor-
derived cells, which had upregulated CD11c expression and hence became DCs 
lacked expression of both Ly6C and B220. Contrary to this the donor cells, which 
remained CD11cint did express these markers suggesting that these cells were 
likely to be pDCs (Fig. 4.12C,D). Interestingly, those cells that did not acquire high 
levels of MHCII did not dilute the cell-trace dye to the same extent as the MHCII+ 
donor-derived cells (Fig. 4.12E), suggesting that pDCs do not share the ability of 
mature DCs to proliferate in situ.  
4.3.4 Identification and fate of adoptively transferred pre-DCs in the 
colonic LP 
Pre-DC derived cells were also found in the colonic LP from day 1 until day 
7 after transfer and there was a similar progressive dilution of the violet dye (Fig. 
4.13A,B). The time course of acquisition of CD11c and MHCII by donor-derived 
cells was also similar in the colonic LP, first being seen on day 3 (Fig. 4.14). As in 
the SI, CD103 and CD11b expression increased progressively on donor-derived 
DCs in the colon, again generating all four DC populations (Fig. 4.15). However, 
the relative proportions of the different DC subsets amongst donor-derived cells 
differed to those observed in the SI LP (compare Fig. 4.11B-E with Fig. 4.15B-E), 
but were similar to those found among endogenous DCs in the colonic LP, with 
CD103+CD11b- DCs predominating. Similar to the SI LP the development of the 
CD103+CD11b+ DCs was slower than that of the other subsets (Fig. 4.15B). Fewer 
donor-derived pDCs appeared to be present in the colon compared with the SI, 
which may reflect of the number of pDCs in the colonic LP versus the SI LP, which 
I have not examined in this thesis. Alternatively, this may be a technical issue as I 
identified donor cells in the colon based on co-expression of CD11c and CD45.2, 
rather than violet dye, and as such CD11clo cells may be missed using this 
approach. 
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4.3.5 Identification and fate of adoptively transferred pre-DCs in the MLN 
I next investigated the fate of donor-derived pre-DCs in the MLNs, with the 
aim of exploring whether resident and migratory DCs could be identified amongst 
the progeny. As in the other tissues, donor-derived cells were present in the MLN 
from 24 hours after transfer and could still be identified 7 days later (Fig. 4.16A). 
By day 7 there was a considerable reduction in the levels of violet dye on the 
donor-derived cells suggesting that these cells had proliferated (Fig. 4.16B). Unlike 
other tissues, MHCII expression was not acquired until day 3, but similar to the LP 
this increased progressively from day 3 to day 7 after transfer (Fig. 4.17A). 
Interestingly, however, virtually all donor-derived cells expressing MHCII remained 
in the CD11c+MHCIIint resident DC population at early time points (day 3), with 
donor-derived cells only appearing in the CD11c+MHCIIhi migratory gate by day 5. 
By day 7 after transfer the majority of donor-derived DCs were present in the 
migratory DC gate (Fig. 4.17). This relative delay in the appearance of pre-DC 
progeny within the migratory DC gate in the MLN would be consistent with them 
having matured in the LP for a few days before migrating to the MLN. This is 
supported by the fact that few cells expressing CD103 and/or CD11b could be 
seen amongst the migratory gate in the MLN 5 days after transfer, when they are 
at a peak in the LP, but became abundant by day 7 (Fig. 4.18). As in other tissues, 
the donor-derived cells in the migratory DC gate adopted the subsets in similar 
proportions as found for the endogenous migratory DC populations (Fig. 4.18B-E). 
In contrast and consistent with their designation as lymph node resident DCs, the 
CD11c+MHCIIint donor-derived DC population contained only CD103+CD11b-, 
CD103-CD11b+ and CD103-CD11b- DCs at similar proportions to the endogenous 
resident DCs (Fig. 4.19).  
4.4 Fate of Ly6Chi monocytes in vivo 
The results of these transfer studies indicate that all intestinal subsets 
including the novel CD103- DCs I had identified could be generated by precursors 
committed to the DC lineage. However, I thought it important to examine directly 
whether Ly6Chi monocytes could give rise to any of the DC subsets I had identified, 
as had been suggested by the previous studies using less rigorously characterised 
CD103- MPs (Bogunovic et al., 2009; Varol et al., 2007; 2009). To do this, Ly6Chi 
monocytes were FACS-purified from the BM of unmanipulated CX3CR1+/GFP mice 
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as CD11b+ Ly6G- Ly6Chi CD117- and CX3CR1-GFPint (Fig. 4.20) and transferred 
into CD45.2 monocytopenic CCR2-/- recipients (Fig. 4.21 A,B) (Kurihara et al., 
1997; Serbina and Pamer, 2006). These recipients were chosen as they have 
considerably fewer circulating blood monocytes and as a result have fewer 
monocytes and mφs in the intestine (Bain et al., 2013). Thus, they represent a 
model in which some space has been created in the myeloid compartment without 
the need for depletion or irradiation and this model had been used successfully in 
our lab to track intestinal mφ development in vivo. Importantly the transferred 
monocytes did not express CD11c, MHCII or CD103 (Fig. 4.21C).  
To identify the progeny of the transferred monocytes in the SI LP, I used the 
gating strategy I described in Chapter 3, in which DCs and mφs, were 
discriminated on the basis of their expression of CD11c, MHCII and F4/80. Donor 
cells were then identified amongst the DC or mφ populations by their expression of 
CX3CR1-GFP and CD45.1 This showed that donor monocytes could give rise to 
CD11cint MHCII+ F4/80+ mφs, but not to CD11chi MHCII+ F4/80- DCs (Fig. 4.22). 
These results indicate bona fide intestinal DCs, including the CD103- DCs, are the 
progeny of pre-DC precursors and not Ly6Chi monocytes as previously suggested. 
Conversely, intestinal mφs are derived exclusively from Ly6Chi monocytes.  
4.5 SI LP DCs proliferate in situ 
As described above, the dilution of the violet dye in the mature progeny of 
transferred pre-DCs suggested that these cells were dividing in situ. Although this 
had been shown previously in a number of other non-lymphoid tissues including 
the dermis, lung and kidney (Ginhoux et al., 2009), to my knowledge this had not 
been shown for DCs in the intestine. Therefore, I next to set out to confirm whether 
SI LP DCs were dividing using a pulse-chase BrdU protocol, in which mice 
received a single i.p. injection of BrdU and were sacrificed 3 hours later. BrdU 
labelling was then assessed in conjunction with Ki67 expression as a marker of 
cells in active division. This approach was validated by the fact that a considerable 
proportion (~40%) of pre-DCs in the BM were BrdU+Ki67+ 3 hours after injection of 
BrdU (Fig. 4.23). No BrdU+Ki67+ pre-DCs could be found in the blood at this time 
(Fig. 4.23) and the small number of cells phenotypically resembling pre-DCs in the 
LP (Fig. 4.24) were also BrdU-Ki-67- (Fig. 4.23). In contrast, small numbers of 
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BrdU+Ki-67+ cells were clearly detectable amongst the CD103+CD11b+, 
CD103+CD11b- and CD103-CD11b+ DC subsets in the SI LP confirming their cell 
division in situ (Fig. 4.23). Notably neither the CD103-CD11b- DCs nor the 
F4/80+CD64+ mφ population contained any BrdU+Ki67+ cells above background 
staining, demonstrating these to be non-proliferative (Fig. 4.23). Although some 
BrdU-Ki-67+ cells were detected amongst intestinal mφs, similar Ki-67 staining was 
seen in the isotype control suggesting this to be an artefact of staining protocol. 
4.6 Development of intestinal DCs in neonatal mice 
Having examined the development of the intestinal DC populations from their 
precursors in adult mice, I next investigated how this might relate to their 
appearance in the SI LP after birth. Using the gating strategies I employed for 
adult mice, all four subsets of DCs could already be identified in the SI LP of 
newborn mice, although there were very few CD103+CD11b+ DCs at this time 
(Figs. 4.25-4.27). There were also fewer CD103-CD11b- DCs in the newborn 
intestine, while the proportions of the CD103+CD11b- and CD103-CD11b- DC 
populations were increased compared with adult mice (Figs. 4.25-4.26). The 
proportion of CD103+CD11b+ DCs had increased markedly by 7 days of age and 
from 11 days onwards, they attained adult levels. The proportions of 
CD103+CD11b- DCs fell markedly from birth to 7 days of age, perhaps reflecting 
the increased numbers of CD103+CD11b+ DC, but then rose again on days 11 and 
14 before falling towards adult levels by day 21. The proportions of CD103-CD11b+ 
DCs fell slightly from day 0 to day 7, before falling more dramatically by day 11 to 
mirror the proportions seen in adulthood. The proportions of CD103-CD11b- DCs 
rose after birth to above adult levels, where they remained until 21 days of age 
(Figs. 4.25-4.26). As expected, the absolute numbers of each DC population 
increased incrementally with age (Fig. 4.27A-D), which mirrored the accumulation 
of other leukocytes in the mucosa (Fig. 4.27E). 
4.7 Intestinal DC populations in antibiotic treated mice 
One possible explanation for the low numbers of CD103+CD11b+ DCs in the 
neonatal intestine could be the lack of microbiota, which only begins to colonise 
the intestine after birth. To investigate whether this might also influence DC 
populations in adult mice, I analysed the SI LP and MLN after 2 weeks of 
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administering a well-established broad-spectrum antibiotic cocktail (Abt et al., 
2012). In contrast to what was seen in newborn mice, antibiotic treatment 
increased both the proportion and absolute number of CD103+CD11b+ DCs in the 
SI LP (Fig. 4.28). In parallel, the proportions of the CD103-CD11b+ DCs were 
reduced, although the absolute number of these DCs was not altered (Fig. 4.28). 
There were also no effects of the antibiotics on the numbers or proportions of 
either the CD103+CD11b- or CD103-CD11b- DCs in the LP (Fig. 4.28).  
The increased number of CD103+CD11b+ DCs in the SI LP of antibiotic 
treated mice was paralleled by a significant increase in the proportion of this 
subset amongst migratory DCs in the MLNs, together with a trend towards an 
increase in their absolute numbers (Fig. 4.29). As in the LP, this was accompanied 
by a decrease in the proportion of CD103+CD11b- DCs, with no change in the 
proportions or numbers of the other subsets of migratory DC apart from a small 
but significant decrease in the proportion of CD103-CD11b- DCs (Fig. 4.29). 
Together these results provide evidence that the development of CD103+CD11b+ 
intestinal DC may be regulated by the microbiota, but that treatment of adult mice 
with antibiotics may not recapitulate the state of the newborn intestine. 
4.8 Summary 
In this chapter I set out to explore directly the origin of the DC subsets I had 
identified in the previous chapter. By developing protocols which allowed me to 
track the fate of adoptively transferred DC-committed precursors in tissues of 
unmanipulated recipients, I showed that these gave rise to all four populations of 
intestinal DCs defined on the basis of CD103 and CD11b expression and obtained 
evidence that these migrated from the LP to the MLNs after maturation. Following 
their arrival in the LP, the transferred precursors first acquired MHCII and 
upregulated CD11c expression, before acquiring CD103 and/or CD11b expression. 
Approximately 5 days after transfer, the precursors had given rise to the various 
DC subsets in similar proportions to the endogenous populations. Although donor-
derived cells could also be found in the spleen, they acquired the phenotypes 
characteristic of endogenous splenic DC populations with CD103+CD11b+ DCs 
being absent from this location. A similar phenomenon was seen in the colonic LP, 
where the CD103+CD11b- DC phenotype predominated amongst donor-derived 
cells. Together these results suggest that local conditioning by the environment 
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may determine the fate of pre-DCs in tissue, although the possibility of distinct 
populations of precursors cannot be ruled out. In contrast to previous reports, 
using less rigorously characterised MPs, transferred Ly6Chi monocytes could not 
generate any of the bona fide subsets of mucosal DC including the CD103- DC 
populations I had defined, indicating that these are all derived exclusively from DC 
committed precursors. This was in direct contrast with mφs, which could only be 
generated from Ly6Chi monocytes and not pre-DCs. Taken together these studies 
confirm and extend my findings from Chapter 3, by showing that the identification 
of mucosal MPs on the basis of CD64 expression defines distinct lineages of cells.  
By using pre-DCs labelled with a violet dye which dilutes following cell 
division and a short-term BrdU pulse in combination with Ki67 staining, I was also 
able to demonstrate that most subsets of mature DCs in the SI LP proliferate in 
situ. In contrast, the rare putative pre-DCs in the LP did not divide in situ and nor 
did mφs. Interestingly, the CD103-CD11b- DCs also did not proliferate in situ, 
perhaps reflecting their derivation from isolated lymphoid follicles rather than the 
LP (Cerovic et al., 2013) or because they comprise more primitive cells as these 
are the first subset to appear in the LP after pre-DC transfer. Together, these 
findings allowed me to track the fate of LP DCs from their arrival as pre-DCs, 
through their progressive acquisition of the different subset markers and a number 
of cell divisions, before their emigration to the MLN. Overall, these processes 
appear to take place within 7 days, emphasising the short lifespan of these cells. 
 Having established that all four intestinal DC populations were derived from 
pre-DCs, I next investigated how these developed after birth. This showed that the 
CD103+CD11b+ DC subset was much reduced at birth and only gradually 
increased to adult levels over the first 2-3 weeks of life. This lag in CD103+CD11b+ 
DC development could be consistent with the fact that this population took the 
longest to appear after the transfer of pre-DCs. This progressive increase in this 
population after birth correlated with a progressive decrease in CD103-CD11b+ 
DCs, while the proportion of CD103+CD11b- DCs varied throughout the first 3 
weeks of life until reaching levels seen in the adult LP thereafter. The proportions 
of the CD103-CD11b- DCs increased dramatically between day 0 and 7 and then 
fell progressively to the levels observed in adulthood 21 days after birth. To 
determine if these changes in the proportions of each DC population were driven 
by the microbiota, I administered a cocktail of broad-spectrum antibiotics for 2 
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weeks before examining the DC populations in the SI LP and MLNs. This caused 
an increase in the proportions and numbers of CD103+CD11b+ DCs, suggesting 
that these CD103+CD11b+ DCs might be regulated by the microbiota. The 
increase in CD103+CD11b+ DCs correlated with a decrease in the population of 
CD103-CD11b+ DCs perhaps suggesting a developmental relationship between 
these DC subsets.  
Having defined four distinct DC subsets originating from DC committed 
precursors in the steady state intestine, in the next chapter I went on to 
characterise these DC populations during inflammation and infection. 
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Figure 4.1: Identification of pre-DCs in the BM 
A. Lineage- cells (CD3, CD19, CD49b, CD11b and MHCII) were identified amongst single cells in 
BM isolates and CDPs were identified as CD11c+ cells. Pre-DCs were then identified amongst 
these as CCR9-B220-/int cells. Pre-DCs uniformly expressed CD135 (black line) compared with 
isotype control (shaded grey) and were SIRPαint (black line) compared with Ly6Chi monocytes 
(dotted line) and Lineage+ cells (shaded grey). B-D. Representative dot plots showing expression 
of CX3CR1-GFP (B), CD8α  (C) and β7 (D) by pre-DCs in BM. Data are representative of at least 
10 independent experiments. 
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Figure 4.2: Expansion of pre-DCs by Flt3L in vivo 
Mice were inoculated with 2x106 B16 Flt3L secreting tumour cells subcutaneously and 10 days 
later BM was analysed to determine expansion of pre-DCs. A. Representative dot plots showing 
the proportions of pre-DCs in BM from mice with Flt3L secreting B16 tumours, compared with 
resting controls. Number indicates percentage of pre-DCs amongst single, live, lineage- (CD3, 
CD19, CD49b, MHCII, CD11b), CD11c+ CDPs. B. Proportion of pre-DCs as a percentage of total 
BM cells in the presence (+) or absence (-) of Flt3L secreting B16 tumours. C. Absolute number of 
pre-DCs/femur in the presence (+) or absence (-) of Flt3L secreting B16 tumours. Data are from a 
single experiment with n=4. **p<0.01 Student’s t test. 
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Figure 4.3: Depletion of CD11c+ cells in CD11c-DTR mice 
CD11c-DTR mice were given a single injection of 4ng/g bodyweight DT and 24 hours later, SI LP 
mononuclear phagocyte populations were examined. A. Representative dot plots showing 
expression of CD11c and F4/80 on single live CD45+CD11c+MHCII+ cells in DT-treated (+DT) or 
PBS-treated (-DT) mice. Numbers indicate percentage of each population amongst total MPs. B.  
Absolute number of  DC subsets and mφs in the SI LP of mice receiving DT or PBS. Data are from 
a single experiment with n=3 per group. *p<005, ***p<0.001 Student’s t test. 
A 
F4/80 
C
D
11
c 
-DT +DT  
39.8 
10.3 
B 
Pre-gated on single, live 
CD11c+ MHCII+ cells 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
Mφ
0.0
0.5
1.0
1.5
2.0
10
15
20
-DT
+DT
*
A
bs
ol
ut
e 
C
el
l N
um
be
r x
10
5
* *
***
10.4 15.5 
142 
Figure 4.4: Purification of pre-DCs for adoptive transfer 
A. CD45.2+ WT mice were injected with 2x106 B16 Flt3L secreting tumour cells and 10 days later 
BM was harvested and 7x105 FACS-purified pre-DCs were transferred into CD45.1+ WT mice. B 
Pre-DCs were identified as shown in Fig 4.1 and sorted to high purity. Numbers indicate the 
proportions of pre-DCs as a percentage of total BM cells before and after FACS-purification. C. 
Levels of CellTrace Violet dye on the sorted pre-DCs prior to transfer. D.  Expression of MHCII, 
CD11b and CD103 on sorted pre-cDCs (black line) compared with levels on live CD45+ SI LP cells 
(shaded grey). Data are representative of at least 4 independent experiments.  
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Figure 4.5: Identification of donor-derived cells in the bloodstream of recipients 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, recipient mice were examined for the presence of donor-derived cells. A. 
Representative contour plots of CD45.2 expression and Violet dye labelling on live-gated cells in 
the blood of mice receiving pre-DCs or PBS 1 day after transfer. Numbers indicate the proportion 
of donor-derived cells as a percentage of total live cells. B. Expression of CD11c and MHCII on 
live-gated host blood DCs or donor-derived cells 1 day after transfer. Number indicates the 
frequency of CD11c+MHCII+ as a percentage of CD45.2+Violet+ donor-derived cells. C. 
Identification of CD45.2+Violet+ donor-derived cells amongst live-gated cells 3, 5 and 7 days after 
transfer. Numbers indicate the frequency of CD45.2+Violet+ donor-derived cells as a percentage of 
total live cells. Data are representative of either a single experiment (1 & 3 days) or 3 independent 
experiments (5 & 7 days) with 2-4 recipient mice per time point per experiment.  
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Figure 4.6: Identification of donor-derived cells in the spleen 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, recipient mice were examined for the presence of donor-derived cells. A. 
Representative contour plots of CD45.2 expression and Violet dye labelling on live-gated CD3-
CD19- cells in the spleen of mice receiving pre-DCs or PBS 1, 3, 5 and 7 days after transfer. 
Numbers indicate the proportion of donor-derived cells as a percentage of live-gated CD3-CD19- 
cells. B. Levels of Violet dye were assessed on donor-derived cells 1, 3, 5 and 7 days after 
transfer.  Data are representative of either a single experiment (1 & 3 days) or 3 independent 
experiments (5 & 7 days) with 2-4 recipient mice per time point per experiment. 
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Figure 4.7:  Acquisition of CD11c and MHCII on progeny of transferred pre-DCs in 
the spleen 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, recipient mice were examined for the presence of donor-derived cells. Representative 
contour and dot plots of CD11c and MHCII expression on live-gated CD3- CD19- host cells or 
CD45.2+Violet+ donor-derived cells (gated as shown in Fig. 4.6), 1, 3, 5 and 7 days after transfer. 
Numbers indicate the frequencies of CD11c+MHCII+ cells as a percentage of total donor-derived 
cells. Data are representative of either a single experiment (1 & 3 days) or 3 independent 
experiments (5 & 7 days) with 2-4 recipient mice per time point per experiment. 
MHCII 
C
D
11
c 
Host Cells Day 1 
Day 5 Day 7 
MHCII 
C
D
11
c 
Day 3 
34.6 
33.8 13.3 
56.3 
Donor Cells 
146 
Figure 4.8: Development of DC subsets in spleen after transfer of pre-DCs 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, spleens of recipient mice were examined for the presence of donor-derived cells. A. 
Representative contour and dot plots of CD103 and CD8α expression on live-gated host DCs or 
CD11c+ MHCII+ donor-derived DCs (gated as shown in Fig. 4.7), 1, 3, 5 and 7 days after transfer. 
B,C. Frequencies of donor-derived and endogenous DCs 1, 3, 5 and 7 days after transfer 
amongst CD103-/intCD8α+ DCs (B) and CD103-CD8α- DCs (C). Data are shown as means (±1SD) 
of either a single experiment (1 & 3 days) or 3 independent experiments (5 & 7 days) with 2-4 
recipient mice per time point per experiment. 
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Figure 4.9: Identification of donor-derived cells in the SI LP 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, the SI LP of recipient mice was examined for the presence of donor-derived cells. A. 
Representative contour plots of CD45.2 expression and Violet dye labelling on live-gated cells in 
mice receiving pre-DCs or PBS, 1, 3, 5 and 7 days after transfer. Numbers indicate the proportion 
of donor-derived cells as a percentage of live-gated cells. B. Levels of Violet dye were assessed 
on donor-derived cells 1, 3, 5 and 7 days after transfer.  Data are representative of either a single 
experiment (1 & 3 days) or 3 independent experiments (5 & 7 days) with 2-4 recipient mice per 
time point per experiment. 
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Figure 4.10: Acquisition of CD11c and MHCII by donor-derived cells in the SI LP 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, the SI LP of recipient mice was examined for the presence of donor-derived cells. 
Representative contour and dot plots of CD11c and MHCII expression on live-gated host cells or 
donor-derived cells (gated as shown in Fig. 4.9), 1, 3, 5 and 7 days after transfer. Numbers 
indicate the frequencies of CD11c+MHCII+ cells as a percentage of total donor-derived cells (as 
gated in Fig. 4.9A). Data are representative of either a single experiment (1 & 3 days) or 3 
independent experiments (5 & 7 days) with 2-4 recipient mice per time point per experiment. 
MHCII 
C
D
11
c 
Host Cells Day 1 
Day 5 Day 7 
MHCII 
C
D
11
c 
Day 3 
45.9 
30.8 4.76 
57.9 
Donor Cells 
149 
Figure 4.11: Development of DC subsets in SI LP after transfer of pre-DCs 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, the SI LP of recipient mice was examined for the presence of donor-derived cells. A. 
Representative dot plots of CD103 and CD11b expression by live-gated host DCs or CD11c+ 
MHCII+ donor-derived DCs. B-E. Frequencies of donor-derived and endogenous DCs on days 3 ,5 
and 7 after transfer in each DC population defined by CD103 and CD11b expression, 
CD103+CD11b+ DCs (B), CD103+CD11b- DCs (C), CD103-CD11b+ DCs (D) or CD103-CD11b- DCs 
(E). Data are shown as means (±1SD) of either a single experiment (3 days) or 3 independent 
experiments (5 & 7 days) with 2-4 recipient mice per time point per experiment.  
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Figure 4.12 Transferred cells also give rise to pDCs but not mφs in LP 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice. A. Representative 
contour plot showing expression of CD115 by pre-DCs in BM isolates from WT mice with Flt3L 
secreting B16 tumours. Number indicates percentage of CD115+ pre-DCs. B-D. Live-gated host 
cells and total CD45.2+Violet+ donor-derived cells were examined for expression of  F4/80 (B), 
Ly6C (C) and B220 (D) 7 days after transfer. E. Total donor-derived cells were examined for 
MHCII expression and violet dye levels were assessed on MHCII+ (black line) and MHCII- (shaded 
grey) cells. Data are representative of 3 independent experiments with 2-4 recipient mice per 
experiment.  
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Figure 4.13: Identification of donor-derived cells in the colonic LP 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, the colonic LP of recipient mice was examined for the presence of donor-derived cells. 
A. Representative contour plots of CD45.2 and CD11c expression on live-gated CD45.1- cells in 
mice receiving pre-DCs or PBS 1, 3, 5 and 7 days after transfer. Numbers indicate the proportion 
of donor-derived cells as a percentage of live-gated CD45.1- cells. B. Violet dye levels on donor-
derived cells at day 1, 3, 5 and 7 after transfer. Data are representative of either a single 
experiment (1 & 3 days) or 3 independent experiments (5 & 7 days) with 2-4 recipient mice per 
time point per experiment.  
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Figure 4.14: Acquisition of MHCII by donor-derived cells in the colonic LP 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, the colonic LP of recipient mice was examined for the presence of donor-derived cells. 
Representative contour and dot plots of CD11c and MHCII expression by live-gated host cells or 
donor-derived cells (gated as shown in Fig. 4.13), 1, 3, 5 and 7 days after transfer. Numbers 
indicate proportions of MHCII+ cells as a percentage of total donor-derived DCs. Data are 
representative of either a single experiment (1 & 3 days) or 3 independent experiments (5 & 7 
days) with 2-4 recipient mice per time point per experiment.  
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Figure 4.15: Development of DC subsets in colonic LP after transfer of pre-DCs 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, recipient mice were examined for the presence of donor-derived cells. A. 
Representative dot plots of CD103 and CD11b expression by live-gated host DCs or CD11c
+MHCII+ donor-derived DCs. B-E. Frequencies of donor-derived and endogenous DCs on days 3 ,
5 and 7 after transfer in each DC population defined by CD103 and CD11b expression, 
CD103+CD11b+ DCs (B), CD103+CD11b- DCs (C), CD103-CD11b+ DCs (D) or CD103-CD11b- DCs 
(E). Data are shown as means (±1SD) of either a single experiment (3 days) or 3 independent 
experiments (5 & 7 days) with 2-4 recipient mice per time point per experiment.  
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Figure 4.16: Identification of donor-derived cells in the MLNs 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, recipient mice were examined for the presence of donor-derived cells. A. 
Representative contour plots of CD45.2 expression and Violet dye labelling on live-gated CD3-
CD19- cells in the MLNs of mice receiving pre-DCs or PBS 1, 3, 5 and 7 days after transfer. 
Numbers indicate the proportion of donor-derived cells as a percentage of live-gated CD3-CD19- 
cells. B. Dilution of Violet dye on donor-derived cells 1, 3, 5 and 7 days after transfer. Data are 
representative of either a single experiment (1 & 3 days) or 3 independent experiments (5 & 7 
days) with 2-4 recipient mice per time point per experiment.  
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Figure 4.17: Acquisition of MHCII donor-derived cells in the MLNs 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and 1, 3, 5 or 7 
days later, MLNs of recipient mice were examined for the presence of donor-derived cells. A. 
Representative contour and dot plots of CD11c and MHCII expression by live-gated host cells or 
donor-derived cells (gated as shown in Fig. 4.16), 1, 3, 5 or 7 days after transfer  B. Proportions of 
donor-derived DC adopting the phenotype of migratory (CD11c+MHCIIhi) or LN resident (CD11c+ 
MHCIIint) DCs 3, 5 and 7 days after transfer as a percentage of total donor-derived DCs. Data are 
shown as the mean (+1SD) of either a single experiment (3 days) or 3 independent experiments 
(5 & 7 days) with 2-4 recipient mice per time point per experiment. 
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Figure 4.18: Phenotypes of donor-derived cells amongst migratory DCs in MLN 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and the MLNs of 
recipient mice were examined for the presence of donor-derived cells 5 or 7 days later. A. 
Representative contour plots of CD103 and CD11b expression by live-gated migratory host DCs 
or CD11c+MHCIIhi donor-derived DCs. B-E. Frequencies of donor-derived DCs in each DC 
population as defined by CD103 and CD11b expression compared with endogenous DCs 5 and 7 
days after transfer, CD103+CD11b+ (B), CD103+CD11b- (C), CD103-CD11b+ (D) or CD103-CD11b- 
(E). Data are shown as mean ±1SD of 2 independent experiments with 2-4 recipient mice per time 
point per experiment. 
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Figure 4.19: Phenotypes of donor-derived cells amongst resident DCs in MLN 
7x105 CD45.2+Violet+ pre-DCs were transferred into resting WT CD45.1+ mice and the MLNs of 
recipient mice were examined for the presence of donor-derived cells 5 or 7 days later. A. 
Representative dot plots of CD103 and CD11b expression by live-gated migratory host DCs or 
CD11c+MHCIIint donor-derived DCs. B-D. Frequencies of donor-derived DCs in each DC 
population as defined by CD103 and CD11b expression compared with endogenous DCs 5 and 7 
days after transfer, CD103+CD11b- (B), CD103-CD11b+ (C) or CD103-CD11b- (D). Data are shown 
as mean (±1SD) of either a single experiment (3 days) or 2 independent experiments (5 days) with 
2-4 recipient mice per time point per experiment. 
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Figure 4.20: Identification of Ly6Chi monocytes in the BM 
Doublets were excluded from BM from CX3CR1+/GFP mice and Ly6Chi monocytes were identified 
amongst remaining cells as CD11b+ Ly6G- Ly6Chi CX3CR1-GFPint and CD117- cells. Data are 
representative of at least 5 independent experiments. 
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Figure 4.21: Purification of Ly6Chi monocytes for adoptive transfer 
A. BM was harvested from CD45.1+/CD45.2+ CX3CR1+/GFP mice, Ly6Chi monocytes were FACS-
purified and 1x106 were transferred into CD45.2+ CCR2-/- mice. B. Ly6Chi monocytes were 
identified as in Fig. 4.20 and sorted to high purity. Numbers indicate proportion of Ly6Chi 
monocytes a percentage of total BM cells. C. Expression of MHCII, CD11b and CD103 on Ly6Chi 
monocytes (black line) compared with levels on endogenous SI LP live CD45+ cells (shaded grey). 
Data are from a single experiment in which Ly6Chi monocytes were sorted from 6 pooled mice. 
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Figure 4.22: Progeny of adoptively transferred Ly6Chi donor monocytes in SI LP 
1x106 Ly6Chi monocytes from CD45.1/CD45.2+ CX3CR1+/GFP mice were FACS-purified and 
adoptively transferred into CD45.2+ CCR2-/- recipients. Recipient mice were analysed for the 
presence of donor cells in the SI LP 5 days after transfer. A. CD11c+MHCII+ MPs were identified in 
recipient mice amongst single, live CD45+ cells and DCs and mφs were identified based on CD11c 
and F4/80 expression respectively. B. Donor-derived CD11chiF4/80- DCs and CD11cintF4/80+ mφs 
were identified by their expression of CX3CR1-GFP and CD45.1 expression. Data are from a 
single experiment with 3 recipient mice. 
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Figure 4.23: Mature DCs but not pre-DCs or mφs proliferate in situ in SI LP  
Mice received a single i.p. injection of 1mg BrdU and 3 hours later BrdU incorporation and Ki67 
expression was assessed in BM, blood and SI LP. A,B. Representative contour plots showing 
BrdU and Ki67 staining on CD11c+F4/80- DCs (A) and CD11c+F4/80+ mφs (B) in the SI LP of BrdU 
injected mice compared with non-injected (NI) BrdU and Ki67 isotype controls. C. Proportion of 
BrdU+Ki67+ cells amongst pre-DCs in BM, blood and SILP and amongst SI LP DC subsets and 
mφs. Data are representative of 3 independent experiments with n=3/4 per experiment, **p<0.01, 
***p<0.001 Asterisks denote significant differences between each SI LP DC population and mφs, 
unless otherwise marked. One way ANOVA with Bonferroni post test.  
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Figure 4.24: Identification of putative pre-DCs in the SI LP 
Putative pre-DCs were identified as single live, CD45+, lineage- (CD3, CD19, CD49b) MHCII- 
CD11b- CD11c+ B220- and CCR9- cells. Data are representative of at least 5 independent 
experiments. 
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Figure 4.25: Development of DC subsets in SI LP after birth 
CD11c+MHCII+CD64- DCs in SI LP digests were examined for their expression of CD103 and 
CD11b. Representative dot plots showing CD103 and CD11b expression by total DCs in SI LP of 
newborn, 7 day old, 11 day old, 14 day old, 21 day old or 7 week old adult mice. Numbers indicate 
the frequencies of each DC population as a percentage of total DCs. Data are representative from 
1 or 2 experiments with n =3/4 per time point per experiment. 
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Figure 4.26: Development of DC subsets in SI LP after birth 
CD11c+MHCII+CD64- DCs in SI LP digests were examined for their expression of CD103 and 
CD11b. A-D. Proportions of CD103+CD11b+ (A), CD103+CD11b- (B), CD103-CD11b+ (C) and 
CD103-CD11b- (D) DCs as a percentage of total DCs in newborn, 7 day old, 11 day old, 14 day 
old, 21 day old and 7 week old adult mice. Data are pooled from 1 or 2 experiments with n =3/4 
per time point per experiment. 
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Figure 4.27: Development of DC subsets in SI LP after birth 
CD11c+MHCII+CD64- DCs in SI LP digests were examined for their expression of CD103 and 
CD11b. A-D. Absolute numbers of CD103+CD11b+ (A), CD103+CD11b- (B), CD103-CD11b+ (C) 
and CD103-CD11b- (D) DCs in newborn, 7 day old, 11 day old, 14 day old, 21 day old and 7 week 
old adult SI LP. E. Absolute number of total cells isolated from SI LP of newborn, 7 day old, 11 day 
old, 14 day old, 21 day old and 7 week old adult mice. Data are pooled from 1 or 2 experiments 
with n =3/4 per time point per experiment. 
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Figure 4.28: Effects of antibiotic treatment on intestinal DC subsets 
Mice received vancomycin, metronidazole, ampicillin, neomycin and gentamycin in their drinking 
water for 2 weeks. A. Representative dot plots showing CD103 and CD11b expression by CD11c+ 
MHCII+CD64- DCs in antibiotic treated mice compared with mice receiving water alone. Numbers 
represent proportion of each DC subset as a percentage of total DCs. B. Proportion of each DC 
subset as a percentage of total DCs in antibiotic treated and control mice. C. Absolute number of 
each DC subset in antibiotic treated and control mice. Data are from a single experiment with n 
=3-6 per group per experiment. *p<0.05 Student’s t test. 
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Figure 4.29: Effects of antibiotics on migratory DC subsets in MLN 
Mice received vancomycin, metronidazole, ampicillin, neomycin and gentamycin in their drinking 
water for 2 weeks. A. Representative dot plots showing CD103 and CD11b staining amongst 
CD11c+MHCIIhiB220- migratory DC in antibiotic treated and control mice. Numbers represent 
proportion of each DC subset as a percentage of total migratory DCs. B. Proportion of each DC 
subset as a percentage of total migratory DCs in antibiotic treated and control mice. C. Absolute 
numbers of each DC subset in antibiotic treated and control mice. Data are from a single 
experiment with n =3-6 per group per experiment. *p<0.05, **p<0.01 Student’s t test. 
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 Chapter 5 Characterisation of intestinal DC 
populations during inflammation and infection 
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5.1 Introduction 
In the previous two chapters, I characterised the DC populations present in 
the steady state intestinal LP and examined their development from committed DC 
precursors. I identified four distinct subsets of DCs, two of which did not express 
the prototypical gut DC marker CD103 and which had not been investigated 
thoroughly in the past due to their phenotypic overlap with intestinal mφs. As 
previous studies using less rigorous identification strategies had suggested that 
CD103- MPs were associated with intestinal inflammation, in this chapter, I set out 
to examine the DC populations during non-steady state conditions. To do this I 
used two models of sterile inflammation; dextran-sodium sulphate induced colitis 
(DSS colitis) and post-operative ileus (POI), while Citrobacter rodentium infection 
was used as a model of protective immunity similar to that seen in 
enteropathogenic (EPEC) Escherichia coli infection. 
5.2 Dextran sodium sulphate induced colitis 
DSS colitis is a model of acute intestinal inflammation and had been 
characterised extensively by previous work in the lab. Within 3 days of 
administering 2% DSS ad libitum in the drinking water, there is a rapid infiltration 
of the colonic LP by neutrophils and monocytes. This precedes clinical signs of 
disease such as rectal bleeding, diarrhoea and weight loss, which typically appear 
after 4-6 days of DSS administration. Although the previous studies in the lab had 
investigated the myeloid compartment of the colonic LP (Bain et al., 2013), these 
analyses had been carried out before I had established the methods for 
characterising DCs properly. Therefore this well-defined model of intestinal 
inflammation was the first I decided to utilise.   
5.2.1 Characterisation of DC populations during DSS colitis 
I first examined the DC populations present in the colonic LP after 4 days of 
2% DSS administration. I chose this time because there are few clinical symptoms 
at this stage, allowing me to examine the behaviour of the DC populations during 
the initiation of the disease and before mucosal destruction occurred. To ensure 
that the LP was inflamed at this time, I assessed the numbers of inflammatory 
Ly6Chi monocytes and their mφ progeny using the phenotyping scheme that had 
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been developed in the lab (Bain et al., 2013). This revealed a trend towards 
increased total cellularity in the colitic LP compared with resting controls (Fig. 
5.1A), consistent with the presence of inflammation. To investigate this further, I 
examined total myeloid (CD45+CD11b+) cells for their expression of Ly6C and 
MHCII. This revealed there to be significant increases in both the proportions and 
numbers of Ly6ChiMHCII- (P1) and Ly6ChiMHCII+ (P2) inflammatory monocytes in 
the colitic mice, clearly demonstrating that the colons were inflamed (Fig. 5.1B-E). 
Based on these results, I next set out to examine the DC populations. However as 
my DC identification strategy relies upon CD64 and/or F4/80 expression being 
restricted to mφs, it was first necessary to examine if CD64 discriminated between 
DCs and mφs in this inflammatory setting.  Analysis of total CD11c+MHCII+ MPs at 
this time point demonstrated that CD64 expression continued to define two distinct 
populations of intestinal MPs (Fig. 5.2A), suggesting it was an appropriate marker 
for distinguishing DCs and mφs in this model. While this gating strategy remains to 
be definitively demonstrated by examining the ability of these populations to 
migrate in lymph and to function as APCs, this analysis found the proportion of 
CD64+ mφs to be slightly but significantly reduced in colitic mice compared with 
controls, which correlated with a slight but non-significant increase in the 
proportion of total DCs (Fig. 5.2A). Further analysis of the CD11chiCD64- DCs for 
CD103 and CD11b expression revealed that all four populations of DCs found in 
the steady state colonic LP were also present during inflammation (Fig. 5.2B). 
Interestingly, despite previous studies suggesting the CD103- ‘DCs’ to be 
preferentially involved in inflammation (Siddiqui et al., 2010), the proportions of 
CD64- genuine DCs were not altered in this model of inflammation. In contrast, the 
proportion of CD103+CD11b+ DCs was significantly reduced in the colitic LP 
compared with controls, whereas the proportion of CD103+CD11b- DCs was 
slightly increased (Fig. 5.2C). There was a significant increase in the absolute 
numbers of all DC populations during colitis (Fig. 5.2D).  
5.2.2  DC development during inflammation  
Previous studies had suggested that the CD103- MPs that were associated 
with inflammation were derived from Ly6Chi monocytes (Bogunovic et al., 2009; 
Rivollier et al., 2012; Varol et al., 2009), which form a substantial part of the 
infiltrate in colitis, as I showed above. However, as this work did not identify 
CD103- DCs precisely, I thought it important to exploit my adoptive transfer 
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protocol to examine whether the genuine DCs I found in inflamed mucosa were 
derived from pre-DCs as they were in steady state. To do this, I had to modify the 
DSS protocol to give sufficient time for pre-DCs to mature into all subsets after 
transfer, which I found previously to be five days. As the use of 2% DSS for the 
length of time required by this protocol would result in fatal disease, I reduced the 
concentration of DSS to 1.2% and planned to transfer pre-DCs after 3 days of 
DSS administration, before continuing DSS for an additional 5 days. Before doing 
this, I examined if 3 days of feeding 1.2% DSS was sufficient to induce intestinal 
inflammation. 3 days administration of 1.2% DSS was indeed sufficient to induce 
inflammation, as there was considerable expansion of the Ly6ChiMHCII- (P1) and 
Ly6ChiMHCII+ (P2) populations of monocytes compared with control colon, 
although this was not always statistically significant (Fig. 5.3).  I next examined if 
this model of disease could be maintained for 8 days without requiring these mice 
to be culled. Using this protocol, mice progressively lost weight up to 8 days, but 
remained above 80% of their starting weight, which is the limit permissible under 
the UK Home Office guidelines (Fig. 5.4A). In parallel, mice showed increasing 
signs of disease including diarrhoea and rectal bleeding, and again, the total 
clinical score remained within the prescribed limit of 10 (Fig. 5.4B).  
Having established that this prolonged regime was effective for generating 
inflammation, I next transferred CD45.1/CD45.2+ pre-DCs into mice that had been 
receiving 1.2% DSS for 3 days. I then continued to administer 1.2% DSS for a 
further 5 days before examining the fate of the transferred cells. As described in 
the previous chapter, pre-DCs were FACS-purified from the BM of WT mice 
inoculated with Flt3L secreting melanoma cells 10 days earlier and donor-derived 
DCs were identified in the colonic LP as CD45.2+violet+CD11c+MHCII+ cells (Fig. 
5.5A). Analysis of these cells demonstrated that all four populations of intestinal 
DCs developed from pre-DCs under conditions of inflammation in the same way 
as they did in the steady state colon (Fig. 5.5B,C). However it appeared that 
donor-derived DCs contained fewer CD103+CD11b- DCs and slightly more 
CD103+CD11b+ DCs than the equivalent populations present amongst 
endogenous DCs in the inflamed colon. The significance of this finding is unclear, 
but these results, together with earlier work in the lab showing that Ly6Chi 
monocytes do not give rise to bona fide DCs in DSS colitis (Bain et al., 2013), 
indicate that pre-DCs are the only source of DCs regardless of the presence or 
absence of inflammation.  
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5.3 Characterisation of DCs during post-operative ileus 
As DSS colitis affects the colonic LP exclusively, I next wanted to 
characterise the DC populations in the small intestine during inflammation. There 
are few experimental models of inflammation in this tissue, but one such model is 
post-operative ileus (POI), in which transient inflammation occurs after mechanical 
manipulation of the gut during surgery. To induce POI, the gut was exposed by 
laparotomy and the length of the SI was rubbed with a cotton bud (Wehner et al., 
2007). Due to the rapid and transient nature of this model, it allowed me to 
examine DC populations in the SI during the early stages of inflammation, which I 
did 24 hours after surgery. The presence of inflammation was verified by a 
significant increase in both the proportion and number of Ly6ChiMHCII+ monocytes 
(P2) in mice having undergone surgery compared with resting controls (Fig. 5.6). 
There was also a trend towards increased proportions and numbers of 
Ly6ChiMHCII- monocytes (P1) (Fig. 5.6).  
Next I confirmed that as in DSS colitis, CD64 expression remained a valid 
means of distinguishing two populations assumed to be DCs and mφs amongst 
total CD11c+MHCII+ MPs in POI (Fig. 5.7A), again functional analysis remains to 
be performed to further demonstrate this. Using the gating strategy I had 
developed in my earlier analysis, I found significant reductions in the proportions of 
both CD103- DC subsets in the SI LP of mice with POI compared with resting 
controls (Fig. 5.7B,C). However, these results did not translate into significant 
differences in the absolute number of any of the DC populations (Fig. 5.7D). 
Whether this procedure would have any effect on the DC populations at different 
time points remains to be determined.  
5.4 Characterisation of DCs during Citrobacter rodentium 
infection 
Having investigated the intestinal DC populations in two models of sterile 
inflammation, I next investigated these populations during infection with C. 
rodentium. This natural murine pathogen produces a self-limiting infection 
restricted to the caecum and colon and is used as a model of EPEC and EHEC 
Escherichia coli infection. Its resolution is associated with the generation of 
protective Th17 cells (Geddes et al., 2011). WT mice were infected with C. 
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rodentium and the DC populations in the colonic LP were examined 9 days later. 
As the strain of C. rodentium used is bioluminescent, infection levels were 
monitored during this time using in vivo imaging (IVIS) in conjunction with faecal 
colony counts. These analyses confirmed that the mice were infected and 
revealed the peak of infection to be around day 6, with resolution already 
beginning by day 9 (Fig. 5.8A,B). Faecal counts were not taken on day 9, as time 
did not allow this to be done at the same time as isolating colonic LP. As these 
studies clearly demonstrated that the mice were infected, I did not examine for the 
presence of monocytes and other inflammatory cells in this model.  
As with the other models of inflammation, I first confirmed that CD64 could 
be used to distinguish between DCs and mφs, with DCs being identified as CD64-
CD11c+MHCII+ (Fig. 5.9A). Further analysis revealed there to be a significant 
decrease in the proportion of total DCs amongst CD11c+MHCII+ MPs in 
Citrobacter infected mice, paralleled by a slight increase in the proportion of mφs 
(Fig. 5.9A). The decrease in total DCs was associated with significant decreases 
in the proportions of CD103+CD11b+ and CD103+CD11b- DCs, together with a 
significant increase in the proportion of CD103-CD11b- DCs; the proportion of 
CD103-CD11b+ DCs was unaffected in infected mice (Fig. 5.9B,C). Despite the 
decreased proportions of the two CD103+ DC populations in infected mice, there 
were no significant differences in their absolute numbers. In contrast, there were 
significant increases in the numbers of CD103-CD11b+ and CD103-CD11b- DCs 
(Fig. 5.9D). These discrepancies between the proportions and absolute numbers 
can be reconciled by the overall increase in the absolute number of DCs, which 
overcame the effects of the proportional decreases in individual subsets (Fig. 
5.9E).  
5.5 Summary 
Having previously characterised intestinal DC populations in the steady state 
intestine, in this chapter I set out to examine these populations during non-steady 
state conditions, specifically in two models of sterile inflammation, DSS colitis and 
post-operative ileus, and during infection with a natural pathogen C. rodentium.  
Administration of 2% DSS for four days resulted in an increase in the overall 
cellularity of the colonic LP, mostly due to inflammatory monocytes as reported 
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previously (Bain et al., 2013). Importantly, during disease it remained possible to 
distinguish between DCs and mφs amongst total CD11c+MHCII+ intestinal MPs 
using CD64 expression and thus I was able to examine the four DC populations 
using the gating strategy I had developed in the steady state. Analysis of the four 
DC populations on the basis of CD103 and CD11b expression revealed all four 
populations to be present during disease. Overall, I found the increased cellularity 
in the colonic LP to translate into an increase in the absolute number of all DC 
subsets. However, in terms of proportion, I observed a decrease in 
CD103+CD11b+ DCs with a parallel increase in the proportion of CD103+CD11b- 
DCs. Despite previous studies suggesting the CD103- MPs to be specifically 
involved in inflammation (Siddiqui et al., 2010), I did not observe any selective 
changes in the CD103- DC populations.   
It has been suggested that Ly6Chi monocytes have the potential to 
differentiate into ‘inflammatory CD103- DCs’ during conditions of inflammation 
(Bogunovic et al., 2009; Rivollier et al., 2012; Varol et al., 2009). While previous 
studies in the lab have shown that Ly6Chi monocytes remain faithful to the 
monocyte/mφ lineage during DSS (Bain et al., 2013), I thought it important to verify 
that pre-DCs continue to generate all four DC populations under these conditions. 
By altering the concentration of DSS, I was able to administer it for 8 continuous 
days thereby allowing me to assess the differentiation of pre-DCs in the inflamed 
setting. Analysis of CD103 and CD11b expression by donor cells and their 
progeny revealed that the pre-DCs remained capable of generating all DC 
populations seen in the steady state. Overall the pre-DCs seemed to generate 
fewer CD103+CD11b- DCs and more CD103+CD11b+ DCs compared with the 
endogenous populations, which could suggest differences in in situ proliferation or 
migration of these subsets during DSS colitis. However this remains to be 
investigated. 
Induction of post-operative ileus resulted in inflammation in the small 
intestinal LP, consisting mainly of Ly6ChiMHCII+ monocytes, suggesting that the 
immediate infiltration of Ly6ChiMHCII- monocytes (P1) had already ceased by the 
time I looked at 24 hours. Again CD64 expression distinguished clearly between 
DCs and mφs in this inflammatory model, revealing that all four DC populations 
were present in the SI LP 24 hours after induction POI. However, no major 
changes were observed in the absolute numbers of the four DC populations, 
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although there was a slight reduction in the proportions of both CD103- DC 
subsets, while the proportions of the CD103+ subsets were unaffected. 
Finally, having investigated the DC populations during sterile inflammation, I 
next sought to examine whether the DC populations were altered during infection 
with a natural pathogen. The infection was monitored using bioluminescence and 
IVIS in conjunction with faecal colony counts and I examined the DC populations 
in the colonic LP just after infection had begun to resolve. In this model, there were 
increases in the absolute numbers of CD103-CD11b+ and CD103-CD11b- DCs, 
while the numbers of the two CD103+ DC populations were not significantly altered. 
Despite no overall change in their absolute numbers, these CD103+ DC 
populations were both significantly reduced in terms of proportion in the C. 
rodentium infected mice. In parallel there was an increase in the proportion of 
CD103-CD11b- DCs, while the proportion of CD103-CD11b+ DCs was unaffected.  
Together these results show that the populations of bona fide DCs change in 
terms of both frequency and number during intestinal inflammation and infection. 
However the exact pattern of DC behaviour varies dependent on the model, 
perhaps reflecting the nature of the inflammatory stimulus, as well as the 
anatomical location of each DC populations and their specific roles in the immune 
response. Thus in the next chapter I set out to examine the specific functions of 
each intestinal DC subset, by examining their ability to drive T cell responses both 
in vitro and in vivo. 
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Figure 5.1: Induction of colitis by feeding 2% DSS 
Mice received 2% DSS ad libitum in the drinking water for four days or normal water as a control 
and inflammation was assessed by enumerating monocytes in the colonic LP. A. Scatter plots 
show total cellularity in colonic LP of mice receiving DSS compared with controls. B. 
Representative dot plots showing identification of CD11b+ myeloid cells amongst single live CD45+ 
cells. C. Representative dot plots showing Ly6C and MHCII staining on CD11b+ live leukocytes in 
the colonic LP of mice receiving DSS compared with controls. D. Scatter plot shows proportions of 
P1 (Ly6ChiMHCII- monocytes) and P2 (Ly6ChiMHCII+ monocytes) as a percentage of CD11b+ cells 
in mice receiving DSS compared with controls. D. Scatter plot shows absolute cell number of P1 
and P2 in mice receiving DSS compared with controls. Data are representative of 2-3 independent 
experiments with n=4-8 per group per experiment. ***p<0.001 Student’s t test. 
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Figure 5.2: DC populations in the colonic LP following administration of DSS 
Mice received 2% DSS ad libitum in the drinking water for four days or normal water as a control 
and DC populations in the colonic LP were assessed. A. Representative dot plots showing CD11c 
and CD64 expression on total CD11c+MHCII+ MPs in mice receiving DSS compared with controls. 
Scatter plots show proportion of CD64+ mφs and CD64- DCs as a percentage of total CD11c+ 
MHCII+ MPs. B. Representative dot plots showing CD103 and CD11b expression on total CD11c+ 
MHCII+CD64- DCs in the colonic LP of mice receiving DSS compared with controls. C. Scatter plot 
shows proportions of each DC population as a percentage of total DCs in mice receiving DSS 
compared with controls. D. Scatter plot shows absolute cell number of each DC population in mice 
receiving DSS compared with controls. Data are representative of 2-3 independent experiments 
with n=4-8 per group per experiment. *p<0.05, **p<0.01, ***p<0.001 Student’s t test. 
 
A 
C 
B 
CD64 
C
D
11
c 
Pre-gated on live CD45+ CD11c+MHCII+ MPs 
Control DSS 
60 57 
32 28.8 
Control DSS
0
10
20
30
40
%
 C
D
11
c+
 M
H
C
II+
Control DSS
0
20
40
60
80 *
%
 C
D
11
c+
 M
H
C
II+
CD64- DCs CD64+ mφs 
CD11b 
C
D
10
3 
34.7 
12.1 
20.5 
Pre-gated on single live CD45+ CD11c+MHCII+CD64- DCs 
Control DSS 
10.3 
31.3 
20.3 
20.4 8.52 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
10
20
30
40
***
*
%
 T
ot
al
 D
C
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
20
40
60
80
**
***
**
***
Control
DSS
A
bs
ol
ut
e 
N
um
be
r x
10
3
D 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
20
40
60
80
**
***
**
***
Control
DSS
A
bs
ol
ut
e 
N
um
be
r x
10
3
A 
178 
Figure 5.3: Induction of colitis by administration of 1.2% DSS 
Mice received 1.2% DSS ad libitum in the drinking water for three days or normal water as a 
control and inflammation was assessed by enumerating monocytes in the colonic LP. A. 
Representative dot plots showing Ly6C and MHCII staining on CD11b+ live leukocytes in the 
colonic LP of mice receiving DSS compared with controls. B. Scatter plot shows proportions of P1 
(Ly6ChiMHCII- monocytes) and P2 (Ly6ChiMHCII+ monocytes) as a percentage of CD11b+ cells in 
mice receiving DSS compared with controls. C. Scatter plot shows absolute cell number of P1 and 
P2 in mice receiving DSS compared with controls. Data are from a single experiment with n=3 per 
group. *p<0.05 Student’s t test.  
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Figure 5.4: Induction of clinical disease by administration of 1.2% DSS 
Mice received 1.2% DSS ad libitum in the drinking water for eight days and disease was 
assessed. A. Weight loss as a percentage of original starting weight in mice receiving DSS. B. 
Clinical scores of mice receiving DSS. Dashed lines represent UK Home Office prescribed limits. 
Data are from a single experiment with n=3. 
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Figure 5.5: Fate of pre-DCs in the colonic LP of mice with DSS colitis 
A. CD45.1+ mice received 1.2% DSS ad libitum in the drinking water for 8 days. On day 3 of DSS 
administration, mice received 7x105 pre-DCs i.v., FACS-purified from the BM of Flt3L treated 
CD45.1/CD45.2+ WT mice. 5 days after transfer, CD45.2+violet+CD11c+MHCII+ donor-derived DCs 
in the colonic LP were assessed for CD103 and CD11b expression. B. Representative dot plots 
showing CD103 and CD11b staining on CD11c+MHCII+ live leukocytes in the colonic LP amongst 
donor-derived CD45.2+violet+ cells compared with host CD11c+MHCII+F4/80- cells. C. Scatter plot 
shows proportion of each DC population as a percentage of total donor-derived or host DCs. Data 
are from a single experiment with 3 recipients.  
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Figure 5.6: Inflammation induced by post-operative ileus 
POI was induced by exposing intestines by laparotomy and rubbing the length of the SI with a 
cotton bud. Control animals were not subjected to surgery. 24 hours later inflammatory infiltrates 
in the SI LP was characterised by flow cytometry. A. Representative dot plots showing Ly6C and 
MHCII staining on CD11b+ live leukocytes in the colonic LP of mice with POI compared with 
controls. B. Scatter plot shows proportions of P1 (Ly6ChiMHCII- monocytes) and P2 (Ly6ChiMHCII+ 
monocytes) as a percentage of CD11b+ cells in mice with POI compared with controls. C. Scatter 
plot shows absolute cell number of P1 and P2 in mice with POI compared with controls. Data are 
from a single experiment with n=6-8 per group per experiment. ***p<0.001 Student’s t test. 
A 
C 
MHCII 
Ly
6C
 
P1 
P2 
P1 
P2 
Control POI 
B 
Pre-gated on single live CD45+ CD11b+ cells 
P1 P2
0
50
100
150
Control
POI
***
A
bs
ol
ut
e 
C
el
l N
um
be
r x
10
3
182 
A 
C 
B 
CD64 
C
D
11
c 
Pre-gated on live CD45+ CD11c+MHCII+ MPs 
Control POI 
68.8 59.1 
21.6 21.2 
CD64- DCs CD64+ mφs 
CD11b 
C
D
10
3 
Pre-gated on single live CD45+ CD11c+MHCII+CD64- DCs 
Control POI 
D 
Control POI
0
10
20
30
40
%
 C
D
11
c+
 M
H
C
II+
Control POI
50
60
70
80
90
100
%
 C
D
11
c+
 M
H
C
II+
12.7 46.8 
13.9 9.75 
11.9 46.1 
11.8 9.08 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
5
10
15
20
30
40
50
60
***
%
 T
ot
al
 D
C
*
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
50
100
150
Control
POI
A
bs
ol
ut
e 
N
um
be
r x
10
3
CD
10
3+
11
b+
10
3+
11
b-
10
3-
11
b+
10
3-
11
b-
5
100
15
Control
POI
A
bs
ol
ut
e 
N
um
be
r x
10
3
Figure 5.7: DC populations in colonic LP during post operative ileus 
POI was induced by exposing intestines by laparotomy and rubbing the length of the SI with a 
cotton bud. Controls animals were not subjected to surgery. 24 hours later DC populations in the 
SI LP were characterised by flow cytometry. A. Representative dot plots showing CD11c and 
CD64 expression on total CD11c+MHCII+ MPs in the SI LP of mice with POI compared with 
controls. Scatter plots show proportion of CD64+ mφs and CD64- DCs as a percentage of total 
CD11c+MHCII+ MPs. B. Representative dot plots showing CD103 and CD11b expression on total 
CD11c+ MHCII+CD64- DCs in the SI LP of mice with POI compared with controls. C. Scatter plot 
shows proportions of each DC population as a percentage of total DCs in mice with POI compared 
with controls. D. Scatter plot shows absolute cell number of each DC population in mice with POI 
compared with controls. Data are from a single experiment with n=6-8. *p<0.05, ***p<0.001 
Student’s t test. 
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Figure 5.8: Infection with Citrobacter rodentium 
Mice were gavaged with 1x109 Citrobacter rodentium organisms and infection levels were 
monitored over a 9 day period. A. Infected mice were anaesthetised and the bioluminescence 
activity of the C. rodentium was assessed by IVIS on day 2, 4, 6 and 9 of infection. Representative 
images from one group of infected mice. B. Bar chart shows average radiance in photons/ 
second/cm2 in infected mice as measured by IVIS on days 2, 4, 6 and 9 post infection. C.  Bar 
chart shows CFU per gram of faeces on days 2, 4 and 6 post infection with C. rodentium as 
measured by bacterial growth on erythromycin supplemented LB agar plates. Data are from a 
single experiment with n=6-10 per group. 
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Figure 5.9: DC populations in colonic LP during Citrobacter rodentium infection 
Mice were gavaged with 1x109 C. rodentium and colonic LP DC populations were examined on 
day 9 of infection by flow cytometry. A. Representative dot plots showing CD11c and CD64 
expression on total CD11c+MHCII+ MPs in the colonic LP of infected mice compared with controls. 
Scatter plots show the proportions of CD64+ mφs and CD64- DCs as percentages of total CD11c
+MHCII+ MPs. B. Representative dot plots showing CD103 and CD11b expression on total CD11c+ 
MHCII+CD64- DCs in the colonic LP of infected mice compared with controls. C. Scatter plot 
shows proportions of each DC population as a percentage of total DCs in infected mice compared 
with controls. D. Scatter plot shows absolute cell number of each DC population in infected mice 
compared with controls. Data are from a single experiment with n=6-10. *p<0.05, **p<0.01, 
***p<0.001, Student’s t test.  
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 Chapter 6 Functions of Intestinal Dendritic Cells 
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6.1 Introduction 
Having established that there are four distinct subsets of CD64- intestinal 
dendritic cells and that their proportions change during inflammation and infection, 
I next wanted to investigate their specific roles in the induction of adaptive immune 
responses. Although previous studies have shown distinct functions for the two 
subsets of CD103+ DCs (Denning et al., 2011; Fujimoto et al., 2011; Uematsu et 
al., 2008), the novel CD103- DCs I identified in Chapter 3 have usually been 
included with mφs for functional analyses and thus their roles in initiating adaptive 
immunity remain uncertain. Now able to accurately distinguish CD103- DCs from 
mφs, in this chapter I set out to examine the specific functions of each DC subset. 
6.2 Co-stimulatory Molecule Expression 
I first used flow cytometry to assess expression of the co-stimulatory 
molecules CD80 and CD86 on the four intestinal DC subsets. This revealed that 
none of the DCs expressed CD80 (Fig. 6.1A), while all DCs expressed CD86 at 
low levels and this was slightly higher on CD103+CD11b- DCs (Fig. 6.1B,C). The 
exact relevance of these findings is unclear but it is interesting to note that in 
lymph all DC subsets express CD80 and CD86, with the CD103+CD11b- DCs 
expressing slightly elevated levels compared with the other DC subsets (Cerovic 
et al., 2013).   
6.3 SI LP DCs are Functional Antigen Presenting Cells 
As the ability to present antigen to naïve T cells is a defining characteristic of 
DCs, I first determined if all four intestinal DC populations I had identified were 
functional antigen presenting cells (APCs). To this end, DCs were FACS-purified 
from the SI LP, pulsed with 2mg/ml ovalbumin protein and co-cultured with naïve 
OVA-specific TcR transgenic CD4+ (OTII) or CD8+ (OTI) T cells. Ovalbumin 
protein was used in these studies rather than peptide to ensure the DCs were able 
to both take up and process the antigen, as well as present it to T cells. 
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6.3.1 Antigen Presentation to CD4+ T Cells 
Naïve CD4+ T cells were FACS-purified from pooled LNs from OTII 
transgenic mice as live CD4+ CD62L+ CD25- cells (Fig. 6.2). To assess T cell 
proliferation, they were labelled with CFSE and cultured with FACS-purified 
antigen-loaded DCs. To determine how efficient each SI LP DC subset was at 
antigen presentation, co-cultures were set up at a number of DC:T cell ratios 
ranging from 1:2 to 1:80. At a ratio of 1:2, all DC subsets were able to induce the 
proliferation of naïve CD4+ T cells equally. As expected, the amount of proliferation 
decreased progressively with decreasing DC to T cell ratios and this occurred with 
all the DC subsets (Fig. 6.3). However as the numbers of DCs were decreased, 
the CD103+CD11b- and CD103-CD11b+ DC subsets appeared to be slightly less 
efficient than the other subsets (Fig. 6.3). 
6.3.2 Cross-presentation to CD8+ T Cells 
I next investigated the ability of the DC subsets to cross-present antigen to 
naïve CD8+ T cells. When high numbers of DCs were used, all four DC subsets 
were able to induce CD8+ T cell proliferation as assessed by CFSE dilution (Fig. 
6.4A,B). However, when the number of DCs in the co-cultures was titrated down, 
the CD103+CD11b- DCs were clearly the most efficient at cross-presenting antigen 
(Fig. 6.4A,B). In addition only these DCs were able to induce IFNγ production by 
CD8+ T cells as assessed by cytokine bead array (CBA) analysis of the co-culture 
supernatants. Recently XCR1 expression has been suggested to identify cross-
presenting DCs in different species (Bachem et al., 2010; 2012; Crozat et al., 
2011) and in agreement with both these studies and my findings from the co-
cultures, only the CD103+CD11b- DCs from SI LP expressed XCR1 (Fig. 6.4D). 
6.4 CD4+ T Cell Polarisation 
These findings confirmed that all the DC subsets I had identified in the SI LP 
could act as APCs and I next examined their ability to induce functional 
polarisation of the proliferating CD4+ T cells. First I attempted to gain some idea of 
how this might be operating in situ, by examining the nature of the CD4+ T cells 
present in the steady state LP, by assessing the intracellular expression of FoxP3, 
IL17 and IFNγ. CD4+ T cells were identified amongst whole SI LP digests as live 
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CD45+ CD3+ CD4+ single cells (Fig. 6.5A). Analysis of IL17, FoxP3 and IFNγ 
expression revealed the majority of CD4+ T cells in the SI LP to be either IL17a+ 
Th17 or FoxP3+ TReg cells, with a smaller population of IFNγ+ Th1 cells (Fig. 
6.5B,C). 
6.4.1 Induction of FoxP3 Expression in Naïve CD4+ T Cells by LP DC 
Subsets 
I next examined the ability of the DC subsets to induce the polarisation of 
these phenotypes from naïve CD4+ T cells in vivo. Although all subsets were able 
to induce FoxP3 expression by a proportion of proliferating T cells as assessed by 
intracellular staining, the two subsets of CD103+ DCs were generally more 
effective at this than the other subsets. However, although this pattern was seen in 
repeat experiments, the differences were not statistically significant when the data 
were pooled (Fig. 6.6A,B).  To try to assess the mechanisms that might be used 
by the DC subsets, I examined the expression of factors implicated in the 
generation of TReg cells by DCs, including the production of TGFβ (Coombes et al., 
2007; Sun et al., 2007; Worthington et al., 2011), the expression of the TGFβ 
activating integrin αvβ8 (Travis et al., 2007) and the production of retinoic acid 
(Elias et al., 2008; Mucida et al., 2007). All four DC populations expressed equal 
levels of mRNA for TGFβ, but only the CD103+CD11b- DCs expressed mRNA for 
the β8 integrin (Fig. 6.6C,D). Using the commercially available ALDEFLUOR 
assay to examine the DC subsets aldehyde dehydrogenase (ALDH) activity, I 
found that the two CD103+ DC subsets and CD103-CD11b+ DCs had high levels of 
ALDEFLUOR activity, while the CD103-CD11b- showed little expression of 
ALDEFLUOR (Fig. 6.7). Interestingly, the CD103+CD11b- DCs had significantly 
higher ALDEFLUOR activity than the other subsets. Together with their unique 
expression of the β8 integrin, this result may explain the trend towards these DC 
being particularly efficient at driving the generation of FoxP3+ TReg cells 
6.4.2 Induction of IL17 Expression by Naïve CD4+ T Cells by LP DC 
Subsets 
I next examined the ability of the FACS-purified DC populations to induce 
IL17a production by proliferating CD4+ T cells. In contrast to their ability to induce 
FoxP3+ TReg cells, the CD103+CD11b- DCs failed to induce IL17 production from 
 189 
the T cells, whereas the other three populations could all induce Th17 priming, with 
the CD103-CD11b+ population appearing more effective than the others, including 
CD103+CD11b+ DCs (Fig. 6.8A,B). I next assessed the production of the Th17 
polarising cytokines, IL6, IL1β and IL23p19, by the DC subsets. All subsets except 
for the CD103+CD11b- DCs expressed similar levels of IL1β mRNA, paralleling 
their relative abilities to drive Th17 cell differentiation (Fig. 6.8C). Analysis of IL6 
mRNA expression suggested that there was a trend towards increased expression 
by the CD103- DC subsets compared with the CD103+ DCs (Fig. 6.8D), although 
these differences need to be confirmed by further experiments. I was unable to 
detect IL23p19 mRNA in any of the DC subsets sorted from steady state WT mice.  
6.4.3 Induction of IFNγ  Expression by Naïve CD4+ T Cells by LP DC 
Subsets 
I next investigated the generation of Th1 cells. While the CD103+CD11b-, 
CD103-CD11b+ and CD103-CD11b- DCs could all drive IFNγ production in 
proliferating CD4+ T cells, the CD103+CD11b+ DCs did not induce any IFNγ 
production (Fig. 6.9). IL12 is the main cytokine thought to be involved in the 
differentiation of TH1 cells, however I was unable to detect any mRNA for IL12p35 
or IL12p40 in any of the SI LP DCs when FACS-purified from the steady state gut. 
6.5 Intestinal DCs are Non-phagocytic 
I next investigated the phagocytic potential of the individual intestinal DC 
subsets and compared this with CD64+ mφ as a positive control. Total cells 
isolated from SI LP digests were incubated with pHrodo E. coli bioparticles which 
fluoresce when taken into acidified vesicles, allowing phagocytosis to be assessed 
by flow cytometry. As shown in Figure 6.10 and consistent with their definition as 
DCs (Steinman, 1973), all four DC populations were poorly phagocytic compared 
with the CD64+ mφs.  
6.6 TLR Expression by Intestinal DC Subsets 
To further investigate functional differences between the four intestinal DC 
populations, I next examined if they might respond differently to distinct microbial 
signals, by exploring their expression of different TLRs. Although most subsets 
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expressed mRNA for most TLRs, there were some differences in the expression 
levels of the individual TLRs (Fig. 6.11). For instance, the CD103-CD11b+ DCs 
expressed 2-fold less TLR2 compared with the CD103+CD11b+ DCs and ~10-fold 
lower TLR2 than the CD103+CD11b- DCs. The inverse pattern was observed for 
TLR3, where the CD103-CD11b+ DCs expressed the lowest levels, while the 
CD103+CD11b- DCs expressed ~50-fold more mRNA for TLR3 compared with the 
CD103+CD11b+ and CD103-CD11b- DCs. TLR4 mRNA was expressed by all DC 
subsets, but was lowest in CD103+CD11b+ DCs. TLR5 was expressed at the 
highest levels by the CD103-CD11b- DCs, which were ~5-fold higher than those 
seen in CD103+CD11b+ and CD103-CD11b+ DCs; the CD103+CD11b- DCs 
expressed very little mRNA for TLR5. CD103+CD11b+ DCs were the main DC 
population found to express mRNA for TLR6, at levels ~5-fold higher than the 
CD103+CD11b- and CD103-CD11b+ DCs, and no mRNA for TLR6 was detected in 
the CD103-CD11b- DCs. Consistent with a report that was published during my 
PhD (Fujimoto et al., 2011), the CD103+CD11b- DCs expressed higher levels of 
TLR7 and TLR9 than the CD103+CD11b+ DCs. Interestingly however, the CD103- 
DC populations, which had not been investigated previously, both expressed 
similar levels of mRNA for TLR7 to the CD103+CD11b- DCs, and equivalent levels 
of TLR9 mRNA to the CD103+CD11b+ DCs. Finally, TLR1 mRNA expression was 
comparable amongst all the DC populations (Fig. 6.11).  
6.7 Effects of Antibiotic Treatment on SI LP T Cells 
To further explore the potential of the DC subsets to react to microbial 
stimuli, I next examined how the antibiotic regime that had increased the number 
of CD103+CD11b+ DCs in Chapter 4 might affect the populations of CD4+ T cells in 
steady state mucosa.  Mice receiving the antibiotic cocktail for 2 weeks showed a 
significant reduction in the proportion and number of Th17 cells in the SI LP, but 
this had no effect on the TReg cell population (Fig. 6.12). Due to antibody 
constraints at the time of this experiment, I was unable to examine Th1 cells on 
this occasion, but these will be examined in the future.  
6.8 Summary 
In this chapter, I set out to investigate the functions of each of the DC 
subsets in the initiation of adaptive immunity. First I found that all the subsets 
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expressed the CD86 co-stimulatory molecule, although this was highest on 
CD103+CD11b- DCs. In contrast, none of the DCs were found to express CD80. 
This is in contrast with DCs in intestinal lymph, suggesting that acquisition of CD80 
may correlate with their decision to migrate to the MLN. However all DC subsets 
were capable of functioning as APCs, priming and cross-priming proliferation by 
CD4 and CD8 T cells respectively, especially when high numbers of DCs were 
used. Although all DCs were able to induce CD4+ T cell proliferation to similar 
extents, the CD103+CD11b- DCs excelled at cross-presentation to CD8+ T cells, a 
finding that correlated with their expression of XCR1.  
As TReg, Th17 and to a lesser extent, Th1 cells were all present in steady 
state LP, I examined the ability of each SI LP DC subset to drive the differentiation 
of these populations from naïve CD4+ T cells in vitro. The CD103+CD11b- DCs 
were the most efficient at inducing TReg cell differentiation and this was associated 
with enhanced ALDEFLUOR activity and unique expression of the TGFβ activating 
β8 integrin. These DCs also were the main inducers of Th1 cells, although the two 
CD103- DC populations were also capable of inducing some IFNγ production from 
CD4+ T cells. In contrast, the CD103+CD11b- DCs did not induce IL17a production, 
which was found to be particularly a property of CD103-CD11b+ DCs. 
CD103+CD11b+ DCs also induced some Th17 cells, however following antibiotic 
treatment mice displayed an inverse correlation between the proportion of Th17 
cells and CD103+CD11b+ DCs, suggesting these DCs may not be the main Th17 
cell inducers. The ability to induce Th17 cells correlated with the production of IL1β, 
although most subsets also produced the IL17-inducing cytokine IL6. I was unable 
to determine whether differential production of IL12 or IL23 might explain the 
induction of Th17 or Th1 cells. 
Consistent with their classical definition, none of the DC subsets were highly 
phagocytic, but they all expressed most TLRs. However there were differences in 
the pattern of TLR expression, with the CD103+CD11b- DCs expressing 
considerable amounts of TLR3, 4, 7 and 9, while the CD103+CD11b+ DCs 
expressed the most TLR4 and TLR7, and the CD103-CD11b- DCs expressed the 
most TLR5. In general, the CD103+CD11b+ DCs expressed the lowest levels of 
TLRs, with particularly low amounts of TLR4, 7 and 9, suggesting these may have 
very distinct abilities to respond to microbial stimuli.  
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Taken together these studies suggested that the distinct DC subsets I had 
identified are likely to play distinct roles in the induction of specific immune 
responses. In the next chapter, I went on to try to understand the mechanisms 
regulating DC behaviour, focusing on the potential role of the CD47-SIRPα 
regulatory axis. 
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Figure 6.1: Costimulatory molecule expression by SI LP DCs 
SI LP DCs were examined for expression of costimulatory molecules (A) CD80 and (B) CD86 by 
flow cytometry. C. ΔMFI (MFI of DC subset minus the MFI for the isotype control) for CD86 
expression by the DC subsets. ***p<0.001 One way ANOVA with Bonferroni post-test. Data are 
from a single experiment with n=6.  
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Figure 6.2: FACS-purification of naïve CD4+ T cells 
CD4+ naïve T cells were FACS-purified from pooled LNs from OTII TcR mice. A. Representative 
dot plots showing gating strategy to sort naïve CD4+ T cells as single, live, CD4+ CD62L+ CD25- 
cells. Number represents pre-sort purity of naïve CD4+ T cells as a percentage of total cells. B. 
Representative dot plots showing post-sort purity of naïve CD4+ T cells as a percentage of total 
cells.  
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Figure 6.3: SI LP DCs prime proliferation of naïve antigen-specific CD4+ T cells in 
vitro 
SI LP DCs were FACS-purified from whole digests as shown in Fig. 3.9, pulsed with 2mg/ml 
ovalbumin protein and co-cultured with FACS-purified naïve CFSE-labelled CD4+ (OTII) T cells for 
4 days. A. Representative histograms showing dilution of CFSE dye in T cells following 4 days of 
culture of 50,000 DCs with 100,000 T cells. B. Percentage of naïve CD4+ T cells that have 
undergone at least one round of cell division after co-culture of 100,000 T cells with decreasing 
numbers of each DC subset. Data are shown as the mean of two independent experiments with 
n=1 per experiment, using DC subsets pooled from 9-12 mice per experiment. Naïve CD4+ T cells 
were pooled from LNs of 2-3 mice per experiment. 
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Figure 6.4: Priming of naïve antigen-specific CD8+ T cells by SI LP DCs in vitro 
SI LP DCs were FACS-purified from whole digests as shown in Fig. 3.9, pulsed with 2mg/ml 
ovalbumin protein and co-cultured with FACS-purified CFSE-labelled naive CD8+ (OTI) T cells for 
3 days. A. Representative histograms showing dilution of CFSE dye in T cells following 3 days of 
culture of 20,000 DCs with 100,000 T cells. B. Percentage of naïve CD8+ T cells that have 
undergone at least one round of cell division after co-culture with decreasing numbers of each DC 
subset. C. IFNγ levels in co-culture supernatants assessed by cytokine bead array. D. XCR1 
expression by SI LP DC subsets compared to isotype control (shaded grey). Data are from two 
independent experiments at each DC:T cell ratio with n=1 per experiment. DC subsets were 
sorted from 9-12 mice pooled per experiment. Naïve CD8+ T cells were sorted from LNs of 2-3 
mice pooled per experiment. 
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Figure 6.5: CD4+ T cell populations in steady state SI LP 
A. CD4+ T cells were identified in the SI LP as single live CD45+ CD3+ CD4+ cells. Numbers 
represent frequency of parent gate. B,C. SI LP whole digests were stimulated for 4.5 hours with 
PMA and ionomycin in the presence of protein transport inhibitors Brefeldin A and Monensin and 
live CD45+ CD3+ CD4+ T cells in SI LP were stained for intracellular FoxP3, IL17 and IFNγ (B) or 
appropriate isotype controls (C). Numbers represent frequency of CD4+ T Cells. Data are 
representative of at least 5 independent experiments with n =3/4 per experiment. 
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Figure 6.6: FoxP3 induction in naïve CD4+ T cells by SI LP DCs in vitro 
SI LP DCs were FACS-purified from whole digests as per Fig. 3.9, pulsed with 2mg/ml ovalbumin 
protein and co-cultured with CFSE-labelled naive CD4+ (OTII) T cells as shown in Fig. 6.1 for 4 
days. A. Representative dot plots showing dilution of CFSE dye in T cells and expression of 
FoxP3 following 4 days of culture of 50,000 DCs with 100,000 T cells or T cells alone. B.  Mean 
percentage of FoxP3+ T cells as a proportion of total live T cells ±1SD. Data are from two (CD103-
CD11b-), three (CD103-CD11b+) or four (CD103+CD11b+ & CD103+CD11b-) independent 
experiments with n=1 per experiment. NS; not significant, One way ANOVA with Bonferroni post 
test. DC subsets were sorted from 9-12 mice pooled per experiment. C,D. Naïve CD4+ T cells 
were sorted from LNs of 2-3 mice pooled per experiment. Expression of mRNA for TGFβ (C) and 
β8 (D) by FACS-purified SI LP DCs. Results shown are relative to HPRT using the 2-ΔΔct method 
with CD103+CD11b- DCs set to 1. Data shown are means from 2 independent experiment with 
cells pooled from 9-12 mice in each case. ND; not detected. 
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Figure 6.7: ALDH function in SI LP DCs 
Whole SI LP digests were incubated with the fluorescent ALDH substrate ALDEFLUOR in the 
presence or absence of the ALDH inhibitor diethylaminobenzoaldehyde (DEAB) and subsequently 
stained for flow cytometry. A. Representative histograms showing ALDEFLUOR fluorescence in 
each DC subset in the presence (grey line) or absence (black line) of DEAB B. Δ Mean 
fluorescence intensity (MFI) for ALDEFLUOR activity (MFI in absence of DEAB – MFI in presence 
of DEAB) ±1SD for each DC subset. Data are representative of two independent experiments with 
n=4 per experiment. *p<0.05, ***p<0.001. One way ANOVA with Bonferroni post-test. 
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Figure 6.8: IL17a induction in naïve CD4+ T cells by SI LP DCs in vitro 
SI LP DCs were FACS-purified from whole digests as per Fig. 3.9, pulsed with 2mg/ml ovalbumin 
protein and co-cultured with CFSE-labelled naive CD4+ (OTII) T cells as shown in Fig. 6.1 for 4 
days before being restimulated with PMA and ionomycin in the presence of Brefeldin A and 
Monensin for 4.5 hours. A. Representative dot plots showing dilution of CFSE dye in T cells and 
expression of IL17a following 4 days of culture of 50,000 DCs with 100,000 T cells or T cells 
alone. B.  Mean percentage of IL17a+ T cells as a proportion of total live T cells ±1SD. Data are 
from two (CD103-CD11b-), three (CD103-CD11b+) or four (CD103+CD11b+ & CD103+CD11b-) 
independent experiments with n=1 per experiment. *p<0.05, One way ANOVA with Bonferroni post 
test. DC subsets were sorted from 9-12 mice pooled per experiment. C,D. Naïve CD4+ T cells 
were sorted from LNs of 2-3 mice pooled per experiment. Expression of mRNA for IL1β (C) and 
IL6 (D) by FACS-purified SI LP DCs. Results shown are relative to HPRT using the 2-ΔΔct method 
with CD103+CD11b- DCs set to 1. Data are shown as mean from 2 independent experiment with 
cells pooled from 9-12 mice in each case. ND; not detected. 
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Figure 6.9: IFNγ induction in naïve CD4+ T cells by SI LP DCs in vitro 
SI LP DCs were FACS-purified from whole digests as per Fig. 3.9, pulsed with 2mg/ml ovalbumin 
protein and co-cultured with CFSE-labelled naive CD4+ (OTII) T cells as shown in Fig. 6.1 for 4 
days before being restimulated with PMA and ionomycin in the presence of Brefeldin A and 
Monensin for 4.5 hours. A. Representative dot plots showing dilution of CFSE dye in T cells and 
expression of IFNγ following 4 days of culture of 50,000 DCs with 100,000 T cells or T cells alone. 
B.  Mean percentage of IFNγ+ T cells as a proportion of total live T cells ±1SD. Data are from two 
(CD103-CD11b-), three (CD103-CD11b+) or four (CD103+CD11b+ & CD103+CD11b-) independent 
experiments with n=1 per experiment. *p<0.05, One way ANOVA with Bonferroni post test. DC 
subsets were sorted from 9-12 mice pooled per experiment. Naïve CD4+ T cells were sorted from 
LNs of 2-3 mice pooled per experiment.  
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Figure 6.10: Phagocytic activity of MPs from SI LP 
Whole SI LP digests were incubated with pHrodo E. coli bioparticles for 15 mins at 37°C (black 
line) or at 4°C as a control (grey shaded line). A. Representative histograms of pHrodo dye 
fluorescence of total CD64- DCs or CD64+ mφs. B. ΔMFI (MFI at 37°C-MFI at 4°C control) +1SD 
for mφs and each DC population. Data are representative of 2 individual experiments with n=4/5. 
***p<0.001 vs. mφs. One-way ANOVA with Bonferroni post-test. 
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Figure 6.11: TLR and costimulatory molecule expression by SI LP DCs 
SI LP DCs were FACS-purified from whole digests as described in Fig. 3.9 and analysed by qRT-
PCR for expression of TLRs. Results shown are relative to HPRT using the 2-ΔΔct method with 
CD103+CD11b+ DCs set to 1. Data are from a single experiment with cells pooled from 12 mice.  
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Figure 6.12: Effects of antibiotic treatment on SI LP CD4+ T cells 
Mice received an antibiotic cocktail containing vancomycin, metronidazole, ampicillin, neomycin 
and gentamycin in sweetened drinking water for 2 weeks.  Control mice received sweetened water 
only. Whole SI LP digests were restimulated with PMA and ionomycin in the presence of Brefeldin 
A and Monensin for 4.5 hours before analysis of IL17 and FoxP3 by intracellular staining. A. 
Proportion of CD4+ T cells expressing IL17a or FoxP3 in antibiotic treated mice compared with 
mice receiving control water. B. Absolute numbers of CD4+ T cells expressing IL17a or FoxP3 in 
antibiotic treated mice compared with mice receiving control water. Data are from a single 
experiment with n=3-4 per group.  **p<0.01. Student’s t test. 
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 Chapter 7 SIRPα  Signalling Regulates Intestinal 
CD103+CD11b+ DC Homeostasis 
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7.1 Introduction 
Signal regulatory protein α (SIRP α) is an inhibitory receptor expressed by a 
number of myeloid cells, whose function has been implicated in controlling the 
behaviour of CD11b+ DCs in the spleen and skin (Iwamura et al., 2010; Saito et 
al., 2010). When I began my PhD, we were only aware of two intestinal DC 
subsets which differentially expressed SIRPα, thus one aim of this thesis was to 
examine the role played by this signalling protein in modulating the behaviour of 
the SIRPα+CD103+CD11b+ DCs. However in Chapter 3, I showed that there were 
two additional CD103- DC subsets both of which also expressed SIRPα, therefore, 
I instead investigated the role of SIRPα on multiple intestinal DC subsets, using 
mice with a point mutation that results in a truncated, inactive form of the 
cytoplasmic signalling domain, herein referred to as SIRPα mutant (mt) mice. 
7.2 CD103+CD11b+ Intestinal DCs are Reduced in SIRPα  Mutant 
Mice 
I first examined the DC populations present in the SI LP of SIRPα mt mice 
compared with WT controls. Rather unexpectedly, given the expression pattern of 
SIRPα, there was a selective reduction of approximately 50% in CD103+CD11b+ 
DCs in SIRPα mt mice compared with WT mice, whereas the other DC 
populations, as well as SIRPα-expressing mφs were unaffected (Fig. 7.1). A defect 
of similar magnitude was seen in the proportion of CD103+CD11b+ DCs amongst 
migratory DCs in the MLNs, with compensatory increases in the proportion of the 
CD103+CD11b- and CD103-CD11b- DCs (Fig. 7.2A). As there was a reduction in 
the proportion of total migratory (CD11c+MHCIIhi) DCs as a percentage of live 
leukocytes in the MLNs of SIRPα mt mice compared with WT controls, all 
migratory DC subsets were reduced in numbers. However this was most marked 
for the CD103+CD11b+ DC subset (Fig. 7.2B). Despite the much reduced 
population of CD103+CD11b+ DCs in the colon compared with the SI LP in WT 
mice, the defect in this population was replicated in the colonic LP of SIRPα mt 
mice (Fig. 7.3A), while the other DC populations and mφs were unaffected (Fig. 
7.3A,B). Confirming the previous reports and in contrast to the intestine, I found 
that SIRPα mutant mice had a selective reduction in CD103-CD11b+ DCs in the 
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spleen and amongst resident DCs in MLN (Fig. 7.3C,D). Thus SIRPα signalling 
appears to be selectively involved in the homeostasis of CD103+CD11b+ DCs in 
the intestine. 
7.3 CD47KO Mice Phenocopy SIRPα  Mutant Mice 
As the only reported ligand for SIRPα in the gut is CD47, I next examined the 
MP populations in the SI LP of CD47KO mice. As in SIRPα mt mice, CD47KO 
mice had reduced proportions and numbers of CD103+CD11b+ DCs in the SI LP. 
This was associated with increases in the proportions of the CD103+CD11b- and 
CD103-CD11b- DCs and a small but significant decrease in the numbers of 
CD103-CD11b+ DCs (Fig. 7.4A,). However, these latter features were not 
consistent between experiments and indeed I often had problems with cells dying 
when isolating cells from CD47KO intestine, leading to lower yields of viable cells. 
This appeared to be a consequence of increased mucus levels in the CD47KO 
small intestine, although this is merely an observation that requires further 
examination. No significant differences in the proportions or numbers of CD64+ 
intestinal mφs were found in the SI LP of CD47KO mice compared with WT 
controls (Fig. 7.4B). As in SIRPα mt mice, there was a reduced proportion of 
CD103+CD11b+ DCs amongst migratory DCs in the MLNs of CD47KO mice and 
again, all migratory DC populations were reduced in number due to a marked 
reduction in the total cell numbers in CD47KO MLNs (Fig. 7.4C,D).  
7.4 T Cell Responses in SIRPα  Mutant Mice 
Given the role of DCs in priming the adaptive immune response and previous 
reports that SIRPα mt mice had defective Th17 cell responses in experimental 
autoimmune encephalomyelitis, contact hypersensitivity and collagen-induced 
arthritis (Motegi et al., 2008; Okuzawa et al., 2008; Tomizawa et al., 2007), I next 
investigated CD4+ T cell populations in steady state mucosa. As shown in Chapter 
6, the normal SI LP CD4+ T cell pool comprises FoxP3+ TReg cells, IFNγ-producing 
Th1 cells and IL17a-producing Th17 cells, and I first studied these populations in 
the SI LP of SIRPα mt mice. This revealed a marked reduction in both the 
proportion and number of IL17a-producing Th17 cells in SIRPα mt mice compared 
with WT controls, whereas the populations of Th1 and TReg cells were unaffected 
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(Fig. 7.5A). To verify these findings, I FACS-purified total CD4+ T cells from the SI 
LP of WT and SIRPα mt mice and assessed mRNA expression of two Th17 cell 
associated cytokines, IL17a and IL22. This revealed a slight reduction in the levels 
of IL17 and approximately a 2-fold reduction in IL22 mRNA expression in CD4+ T 
cells from SIRPα mt mice compared with WT SI LP (Fig. 7.5B). A similar trend 
towards fewer Th17 cells was also shown by intracellular cytokine analysis of 
colonic LP CD4+ T cells, although this did not reach statistical significance, 
possibly because of the low numbers of IL17-producing T cells in the steady state 
colon (Fig. 7.5C). CD47KO mice also had reduced proportions and numbers of 
Th17 cells in SI LP, but normal populations of TReg and Th1 cells (Fig. 7.6). 
Together these results suggest that the SIRPα-CD47 axis is involved in the 
homeostasis of the CD103+CD11b+ DCs and that these DCs play a role in the 
generation of Th17 cells in vivo. 
To explore further the defect in Th17 cells in SIRPα mt mice, I next 
examined the priming of antigen-specific CD4+ T cells in vivo. First I used a model 
in which no T cell polarising conditions were used. WT and SIRPα mt mice 
received CSFE-labelled total CD45.1+/CD45.2+ OTII LN cells isolated 1 day before 
feeding 10mg ovalbumin and T cell clonal expansion and differentiation was 
assessed in MLNs four days later (Fig. 7.7). Similar numbers of donor CD4+ T 
cells could be found in MLNs in WT and SIRPα mt mice at this time point (Fig. 
7.7B), but analysis of CSFE levels showed that these had proliferated less in the 
SIRPα mt MLNs compared with that in WT MLNs (Fig. 7.7C). In both cases, donor 
cells in the MLNs differentiated into Th1, Th17 and TReg cells, as shown by 
intracellular expression of IFNγ, IL17a and FoxP3 respectively. Although there was 
a trend towards a decrease in the proportion of donor cells expressing IL17a in 
SIRPα mt MLNs compared with WT MLNs, this did not attain statistical 
significance. As in the endogenous LP T cell populations, there were no 
differences in the generation of antigen specific Th1 and TReg cells in response to 
OVA feeding in SIRPα mt MLNs (Fig. 7.7D-F).  
Next I examined a model of antigen-specific immunisation which is known 
to favour the polarisation of Th17 cells in MLNs (Persson et al., 2013b). In addition, 
I included a step which prevents these cells emigrating from the MLNs as a means 
of ensuring I could detect maximal polarisation of antigen specific CD4+ T cells. To 
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do this, I immunised SIRPα mt and WT mice with OVA i.p., together with α-CD40 
and LPS as adjuvants and administered the S1P inhibitor FTY720, to block T cell 
migration from the MLNs (Fig. 7.8). Under these conditions, there was a significant 
reduction in the proportion of donor CD4+ T cells in the MLNs of SIRPα mt mice 
compared with WT MLNs (Fig. 7.8B), although similar proportions of these cells 
had undergone at least one division as assessed by CFSE dilution in both cases 
(Fig. 7.8C). Furthermore, while the proportion of IL17a+ cells amongst donor cells 
was the same in the two strains (Fig. 7.8D), the absolute number of Th17 cells was 
significantly reduced in the MLNs of SIRPα mt mice compared with WT (Fig. 7.8E). 
Interestingly, despite the reduced population of donor cells, there was an increase 
in the number of Th1 and TReg cells induced in the MLNs of SIRPα mt mice (Fig. 
7.8F,G). To rule out the possibility that there was an intrinsic defect in the ability of 
SIRPα mt T cells to generate Th17 cells, I cultured FACS-purified naïve CD4+ T 
cells from the MLNs of WT and SIRPα mt mice in vitro with TGFβ, IL6, IL1β, IL23, 
anti-IL2, anti-IL4 and anti-IFNγ, a protocol used routinely within the department to 
induce Th17 cell polarisation in vitro. Using this approach, SIRPα mt T cells 
generated entirely normal proportions and numbers of CD4+ T cells expressing 
IL17a and the Th17 cell transcription factor RORγt (Fig. 7.9). Together these 
experiments are further evidence that the defect in CD103+CD11b+ DCs in SIRPα 
mt mice leads to a selective defect in Th17 priming. 
7.5 DC Function in SIRPα  Mutant Mice 
I next thought it important to examine whether the reduced population of 
Th17 cells in the SI LP of SIRPα mt mice could reflect abnormalities in the function 
of the DCs remaining in these mice.  Examination of mRNA expression of the Th17 
inducing cytokines IL6, IL1β and IL23p19 by total SI LP DCs revealed a ~2-fold 
reduction in the levels of Il6 and a slight reduction in Il1b expression compared 
with WT controls (Fig. 7.10A). As in previous experiments, I could not detect 
mRNA for IL23p19 in either WT or SIRPα mt SI LP DCs. To determine if this 
reduced cytokine expression by total DCs was due to the CD103+CD11b+ DC 
defect, I next examined mRNA expression of IL6 and IL1β by FACS-purified 
CD103+CD11b+ DCs. This demonstrated the remaining DCs in the SIRPα mt mice 
expressed slightly more Il6 and slightly less Il1β than WT controls (Fig. 7.10B). 
Although I was unable to obtain sufficient mice to repeat these experiments, these 
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results support the idea that the apparent defect in IL6 production amongst total 
DCs from SIRPα mt mice may be explained by the reduced number of 
CD103+CD11b+ DCs in these mice. 
To extend the analysis of DC function, I performed a preliminary experiment 
in which FACS-purified CD103+CD11b+ and CD103-CD11b+ DCs from WT and 
SIRPα mt mice were pulsed with OVA and used to prime naïve CD4+ T cells in 
vitro. To avoid any potential bias, in terms of cell viability due to the time required 
to sort each strain individually, I mixed CD45.1+ WT and CD45.2+ SIRPα mt SI LP 
isolates prior sorting to ensure WT and SIRPα mt DCs were treated in the same 
manner before co-culture. Because I could only sort four ways using the FACSAria 
cell sorter, I could only examine two DC populations from each strain. In addition 
to the CD103+CD11b+ DCs, I chose to examine CD103-CD11b+ DCs, as my 
experiments in Chapter 6 had shown this subset to be proficient at inducing Th17 
cell polarisation. As I found before, these two subsets induced identical levels of 
proliferation by naïve CD4+ T cells and there were no differences between DCs 
from WT and SIRPα mt SI LP (Fig. 7.11A). Furthermore, CD103+CD11b+ DCs 
from WT and SIRPα mt mice induced equivalent levels of Th17, Th1 and TReg cell 
differentiation (Fig. 7.11B). Interestingly however, the CD103-CD11b+ DCs from 
SIRPα mt mice appeared to induce fewer Th17 cells, more Th1 cells and equal 
proportions of TReg cells compared with WT controls (Fig. 7.11C). As I was only 
able to perform this experiment once, more studies are required to assess the 
significance of these findings.  
7.5.1 Effects of SIRPα Mutation on Immune Function in vivo 
7.5.1.1 C. rodentium Infection 
Having established that SIRPα mt mice have reduced numbers of Th17 
cells, I next wanted to investigate the consequences of this defect and to do this, I 
first used the mouse model of C. rodentium infection, in which Th17 cells play an 
important protective role (Ishigame et al., 2009; Ivanov et al., 2009; Mangan et al., 
2006). SIRPα mt and WT mice were infected with C. rodentium and infection was 
monitored by faecal colony forming units (CFU) counts. This revealed that while 
the initial colonisation of C. rodentium was similar in both strains, by day 11 of 
infection the WT mice had begun to clear the infection, whereas the SIRPα mt 
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mice did not do so until day 14 (Fig. 7.12A). To investigate if this reduced 
clearance was due to an impaired ability to induce Th17 cells, I examined Th17 
cells in the MLNs and colonic LP at day 8 of infection, a time point where both 
strains had similar levels of colonisation (Fig. 7.12B). This revealed a marked 
reduction in the number of IL17a producing CD4+ T cells in the MLNs of SIRPα mt 
mice compared with WT controls. In contrast, the proportions of Th17 cells in the 
colonic LP at this time point were similar in the two strains, perhaps because this 
was too early to see maximal localisation of effector T cells in this site (Fig. 7.12C).  
7.5.1.2 DSS-Induced Colitis 
As discussed in Chapter 5, DSS-colitis is a model of IBD routinely used in 
the lab. As our previous studies have demonstrated this model of IBD to be 
dependent on myeloid innate cells (Bain et al., 2013; Bain and Mowat, 2012; Platt 
et al., 2010), the majority of which express SIRPα, I next examined the 
susceptibility of the SIRPα mt mice to DSS colitis. Both WT and SIRPα mt mice 
developed clinical signs of disease after 5 days of receiving 2% DSS ad libitum in 
their drinking water and no significant differences were observed between the two 
groups in terms of weight loss or total clinical score during the 8 days of DSS 
administration (Fig. 7.13).  
7.5.1.3 Induction of Oral Tolerance 
Although my results from SIRPα mt mice had emphasised a role for 
CD103+CD11b+ DCs in driving Th17 cells, I had also shown earlier that this DC 
subset could also induce FoxP3+ TReg cells in vitro. Furthermore, CD103+ DCs 
have often been assumed to be crucial for tolerance induction in vivo. Therefore, I 
decided to examine whether oral tolerance could be induced normally by feeding 
antigen to SIRPα mt mice. Mice were gavaged with a single dose of 25mg OVA or 
PBS as a control and 7 days later were immunised with OVA/CFA subcutaneously. 
The induction of tolerance was assessed by measuring the DTH response to a 
challenge injection of heat aggregated OVA (HAO). Although PBS fed SIRPα 
controls showed a trend towards increased DTH responses compared with WT 
controls, both strains showed similar levels of suppression of DTH responses after 
feeding OVA compared with PBS controls (Fig. 7.14). Thus tolerance can be 
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induced normally in the absence of SIRPα signalling and despite the defect in 
CD103+CD11b+ DCs. 
7.6 Lack of Spontaneous Disease and Restoration of DC Defect 
in Ageing SIRPα  Mutant Mice 
In view of the defects in DCs and T cells I found in young adult SIRPα mt 
mice, I thought it important to monitor if these animals developed overt disease 
such as increased susceptibility to infection or IBD as they aged. No difference in 
weight loss or any other clinical signs of disease were seen in either WT or SIRPα 
mt mice left to age for 11 months. Interestingly however, the CD103+CD11b+ DC 
defect in the SI LP was absent in the aged SIRPα mt mice, which showed an 
increased proportion of these DCs compared with young mice (Fig. 7.15). In 
addition there was now a significant decrease in the proportions of CD103-CD11b+ 
and CD103-CD11b- DCs in the aged SIRPα mt compared with aged matched WT 
controls (Fig. 7.15), although this seemed to be due to a trend towards increased 
proportions of these subsets in ageing WT mice compared with their younger 
counterparts. A similar restoration of Th17 cells was also seen in the SI LP of aged 
SIRPα mt mice and these cells were now present in identical proportions to aged 
matched WT controls and at significantly higher levels than in young SIRPα mt 
mice (Fig. 7.16). In contrast, there were no effects of ageing on the DC defect in 
the spleen of SIRPα mt mice, where a severe reduction in CD4+ DCs was seen in 
both young and old mice, even though this population also decreased in aged WT 
mice compared with their young controls. There was no effect of SIRPα mutation 
on CD4- DCs in the spleen at any age (Fig. 7.17).   
7.7 Summary 
In this chapter, I set out to investigate the role of the inhibitory receptor 
SIRPα on intestinal DC function. Despite the fact that SIRPα is expressed by most 
intestinal DC subsets, as well as resident macrophages, I found SIRPα mt mice to 
have a selective reduction in the proportions and numbers of CD103+CD11b+ DCs 
in LP and amongst migratory DCs in the MLNs. Consistent with previous reports, I 
also found a reduction in the proportion and numbers of CD4+/CD11b+ splenic and 
LN resident DCs in these mice (Saito et al., 2010). The requirement for a 
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functional SIRPα signal in the homeostasis of these DCs was confirmed using 
mice in which the only known ligand for SIRPα in the gut, CD47, was knocked out, 
as these CD47KO mice phenocopied the DC defects observed in the SIRPα mt 
mice.   
This intestinal CD103+CD11b+ DC defect correlated with a selective 
reduction in the local population of Th17 cells in the LP, while Th1 and TReg cells 
were present in normal numbers. The normal populations of FoxP3+ TReg cells 
correlated with the normal induction of oral tolerance to fed antigen by the SIRPα 
mt mice. Antigen specific CD4+ T cells transferred into SIRPα mt mice also 
showed defective proliferation and generation of Th17 cells in the MLNs following 
oral and systemic administration of antigen, particularly when LPS and anti-CD40 
were used as adjuvants. SIRPα mt mice exhibited delayed clearance of C. 
rodentium and this was associated with defective priming of Th17 cells in MLNs. 
The defects in Th17 cells were not due to an intrinsic inability to generate these 
cells, as Th17 cells could be generated from naïve SIRPα mt CD4+ T cells 
normally under polarising conditions in vitro. Moreover, the lack of SIRPα 
signalling on the remaining CD103+CD11b+ DCs in the LP, did not appear to be 
responsible for the Th17 defect, as the remaining DCs expressed the cytokines 
required to generate Th17 cells and could drive Th17 polarisation in vitro. Thus the 
defect in Th17 cells in SIRPα mt mice appears to be a consequence of the SIRPα 
mt mice having fewer CD103+CD11b+ DCs. This hypothesis was supported by the 
correlation I and others have found between this DC population and Th17 cells in 
the SI compared with the colon (Denning et al., 2011). Interestingly however, I 
obtained preliminary evidence that despite being present in normal numbers, 
CD103-CD11b+ DCs from SIRPα mt mice may have a may have a reduced ability 
to drive Th17 cell generation in vitro. As this could be consistent with my earlier 
findings that this subset is efficient at inducing Th17 cells, the contribution of 
CD103-CD11b+ DCs to the T cell phenotype in SIRPα mt mice requires further 
investigation.  
Despite being expressed by most myeloid innate cells, the lack of SIRPα 
signalling in SIRPα mt mice did not affect disease progression in animals receiving 
DSS. I found weight loss and colitis scores to be consistent between WT and 
SIRPα mt animals. Furthermore, despite their proposed involvement in IBD, the 
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reduced population of Th17 cells did not alter the susceptibility of SIRPα mt mice 
to chemically-induced colitis, although this may not be the best model to evaluate 
the deficit in Th17 cells as DSS colitis has been shown to develop normally in 
SCID animals, suggesting a minimal involvement for T cells in this IBD model 
(Axelsson et al., 1996). Moreover, the defect in Th17 cells was less pronounced in 
the colon compared with the SI LP.   
Finally, examination of aged SIRPα mt mice revealed that these mice appear 
to overcome the selective reduction in intestinal CD103+CD11b+ DCs and Th17 
cells with time, again underlining the association between these cells in vivo, but in 
direct contrast with the splenic CD4+ DC defect, which did not recover with age. 
Together these results show that the abrogation of the SIRPα-CD47 axis has 
a transient, yet selective effect on the homeostasis intestinal CD103+CD11b+ DCs 
and in the next chapter, I set out to explore the possible mechanisms governing 
this.  
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Figure 7.1: Effects of SIRPα mutation on MPs in SI LP 
A. Representative dot plots showing identification of total DCs as CD64-CD11chiB220- cells and 
mφs as CD11c+CD64+ cells amongst single live CD45+CD11c+MHCII+ MPs in SI LP digests from 
SIRPα mt or control WT mice. Total DCs were divided into four subsets on the basis of their 
expression of CD103 and CD11b. B. Proportion of each DC subset as a percentage of total DCs  
in SIRPα mt and control mice as gated in A. C. Absolute number of of each DC population in 
SIRPα mt mice compared with WT controls. D. Proportion of CD64+ mφs as a percentage of live 
CD45+ cells in SIRPα mt and control mice. E. Absolute number of CD64+ mφs in SIRPα mt mice 
compared with controls. Data are representative of at least 10 independent experiments with n 
=3/4 per experiment. **p<0.01. Student’s t test. 
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Figure 7.2: Effects of SIRPα mutation on migratory DCs in MLNs 
A. Representative dot plots showing CD103 and CD11b expression on CD11c+MHCIIhi migratory 
MLN DCs in SIRPα mt mice compared with WT controls. B. Proportion of CD11c+MHCIIhi 
migratory DCs as a percentage of total DCs in MLNs of SIRPα mt and control mice. C. Proportion 
of each DC subset as a percentage of total migratory DCs as gated in A in MLNs of SIRPα mt and 
control mice. D. Absolute number of of each DC population in MLNs of SIRPα mt mice compared 
with WT controls. Data are representative of at least 10 independent experiments with n =3/4 per 
experiment. *p<0.05, **p<0.01, ***p<0.001. Student’s t test. 
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Figure 7.3: Effects of SIRPα mutation on colonic LP MPs and lymphoid tissue DCs 
A. Proportion of each DC subset as a percentage of total DCs in colonic LP of SIRPα mt and 
control mice. B. Proportion of mφs as a percentage of live CD45+ cells in colonic LP of SIRPα mt 
mice compared with controls. C. Proportion of each DC subset as a percentage of total resident 
DCs in MLNs of SIRPα mt mice compared with WT controls. D. Proportion of each DC subset as 
a percentage of total splenic DCs in SIRPα mt mice compared with WT controls. Data are 
representative of at least 3 independent experiments with n =3/4 per experiment. **p<0.01, 
***p<0.001, Student’s t test. 
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Figure 7.4: Effects of loss of CD47 on SI LP MPs and migratory MLN DCs 
A. Proportion and absolute number of each DC subset as a percentage of total DCs in the SI LP 
of CD47KO and control WT mice. B. Proportion and absolute number of CD64+ mφs as a 
percentage of live CD45+ cells in the SI LP of CD47KO and control mice. C. Proportion and 
absolute number of each DC subset as a percentage of total migratory DCs in MLNs of CD47KO 
and control mice. D. Absolute number of cells in MLNs of CD47KO mice compared with WT 
controls. Data are representative of at least 5 independent experiments with n =3/4 per 
experiment. *p<0.05, **p<0.01, ***p<0.001. Student’s t test.  
A 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
10
20
30
40 **
**
*
%
 o
f T
ot
al
 D
C
s
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
50
100
150
200 ***
**
A
bs
ol
ut
e 
C
el
l N
um
be
r x
10
3
C 
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
20
40
60
80
**
*
%
 o
f T
ot
al
 D
C
s
CD
10
3+
CD
11
b+
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
10
20
30
40 ***
**
A
bs
ol
ut
e 
C
el
l N
um
be
r x
10
3
***
*
D 
WT CD47KO
0
5
10
15
A
bs
ol
ut
e 
C
el
l N
um
be
r x
10
6
**
WT CD47KO
0
5
10
15
20
%
 o
f C
D
45
+
WT CD47KO
0
500
1000
1500
2000
A
bs
ol
ut
e 
C
el
l N
um
be
r x
10
3
B 
WT
CD47KO
WT
CD47KO
Small Intestine LP DCs 
Small Intestine LP Mφs 
MLN mig. DCs MLN cells 
219 
Figure 7.5: Effects of SIRPα mutation on CD4+ T cells in steady state intestine 
A. Whole SI LP digests were restimulated with PMA and ionomycin in the presence of brefeldin A 
and monensin for 4.5 hours and CD4+ T cells were assessed for expression of IL17a, IFNγ and 
FoxP3 by intracellular staining. Frequencies and absolute numbers of Th17, Th1 and TRegs 
amongst total live CD4+ T cells in the SI LP of SIRPα mt mice compared with WT controls. Data 
are representative of 2 independent experiments with n=4 per experiment.  **p<0.01. Student’s t 
test. B. Total CD4+ T cells were FACS-purified from SI LP of SIRPα mt mice and analysed by qRT-
PCR for mRNA expression of Il17 and Il22. Results shown are relative to HPRT using the 2-ΔΔct 
method with WT T cells set to 1. Data are pooled from 2 independent experiments with 9 mice per 
experiment. C. Whole colonic LP digests were restimulated with PMA and ionomycin in the 
presence of brefeldin A and monensin for 4.5 hours and CD4+ T cells were assessed for 
expression of IL17a by intracellular staining. Frequencies of Th17 cells amongst total live CD4+ T 
cells in the colonic LP of SIRPα mt mice compared with WT controls. Data are representative of 2 
independent experiments with n=4 per experiment.  
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Figure 7.6: Effects of loss of CD47 on CD4+ T cell populations in steady state SI LP 
Whole SI LP digests were restimulated with PMA and ionomycin in the presence of brefeldin A and 
monensin for 4.5 hours and CD4+ T cells were assessed for expression of IL17a, IFNγ and FoxP3 
by intracellular staining. Frequencies and absolute numbers of Th17, Th1 and TRegs amongst total 
live CD4+ T cells in the SI LP of CD47KO mice compared with WT controls. Data are 
representative of 2 independent experiments with n=4 per experiment.  *p<0.05, **p<0.01. 
Student’s t test. 
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Figure 7.7: Priming of antigen-specific CD4+ T cells in SIRPα mt mice by oral 
administration of OVA 
A. 5x106 cells from the LNs of CD45.1/CD45.2 OTII mice were adoptively transferred into CD45.1+ 
WT or CD45.2+ SIRPα mt mice. 24 hours later mice received a single gavage of 10mg ovalbumin 
and 3 days later donor T cells were identified as CD45.2+ or CD45.1+ in the MLNs of WT or SIRPα 
mt mice respectively. B. Absolute number of OTII CD4+ T cells in MLNs of WT and SIRPα mt 
mice. C. Proliferation of OTII cells in the MLNs of WT and SIRPα mt mice as assessed by CFSE 
dilution. Results show the proportion of donor cells that had gone through at least one round of 
division as a percentage of total donor cells. D-F. Percentage of donor cells in MLN polarized to 
express (D) IL17a, (E) IFNγ or (F) FoxP3. Data are representative of 2 independent experiments 
with n=4 per experiment.  
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Figure 7.8: Priming of antigen-specific CD4+ T cells in SIRPα mt mice by i.p. 
administration of OVA, LPS and α-CD40 
A. 5x106 cells from LNs of CD45.1/CD45.2 OTII mice were adoptively transferred into CD45.1+ 
WT or CD45.2+ SIRPα mt mice. 24 hours later mice received an i.p. injection of 0.5mg OVA 
together with 25µg α-CD40 and 15µg LPS, and 1 and 3 days later, mice were received 1mg/kg 
FTY720 i.p. On day 6 donor T cell proliferation was assessed in the MLNs. B. Proportion of OTII 
CD4+ T cells in the MLNs of WT and SIRPα mt mice shown as a percentage of live cells. C. 
Proliferation of OTII cells in the MLNs of WT and SIRPα mt mice as assessed by CFSE dilution. 
Results show the proportion of donor cells that had gone through at least one round of division as 
a percentage of total donor cells. D. Percentage of donor cells in MLN polarized to express IL17a. 
E-G. Absolute number of donor cells in MLN polarized to induce (E) Th17, (F) Th1 or (G) TReg cells. 
Data are from a single experiment with n=8-10. *p<0.05, **p<0.01, ***p<0.001 Student’s t test or 
Mann Whitney. 
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Figure 7.9: SIRPα mt mice have no intrinsic defect in ability to generate Th17 cells 
Naïve CD4+ T cells were FACS-purified from MLNs of WT or SIRPα mt mice and cultured in vitro 
for 4 days with a Th17 inducing cytokine cocktail, containing IL6, IL1β, IL23, TGFβ, anti-IL2, anti-
IL4 and anti-IFNγ restimulated with PMA and ionomycin in the presence of brefeldin A and 
monensin for 4.5 hours and examined for expression of IL17a and RORγt by intracellular staining. 
A. Representative dot plots showing IL17a and RORγt isotype controls on cultured T cells from 
WT mice. Numbers indicate percentage of live cells. B. Representative dot plots showing IL17a 
and RORγt staining in WT and SIRPα mt cultures. Numbers indicate percentage of live cells. C,D. 
Mean frequencies (C) and absolute numbers (D) of RORγt+ IL17a+ Th17 cells ±1SD amongst total 
live cells. Data are from a single experiment with n=3. 
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Figure 7.10: IL6 and IL1β expression by total and sorted CD103+CD11b+ DCs from SI 
LP from SIRPα mt mice 
A-B. Total CD64- CD11c+MHCII+ DCs were FACS-purified from the SI LP of WT or SIRPα mt mice 
and analysed by qRT-PCR for expression of mRNA for (C) Il6 and (D) Il1β. C-D. CD103+CD11b+ 
were FACS-purified from the SI LP of WT or SIRPα mt mice and analysed by qRT-PCR for 
expression of mRNA for (A) Il6 and (B) Il1β. Results shown are relative to HPRT using the 2-ΔΔct 
method with WT DCs set to 1. Data are pooled from 2 independent experiments with cells pooled 
from 9-12 mice per experiment.  
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Figure 7.11: Th17 polarising ability of CD103+CD11b+ and CD103-CD11b+ DCs from 
WT and SIRPα mt mice 
3x104 SI LP CD103+CD11b+ and CD103-CD11b+ DCs from SIRPα mt or WT mice were pulsed 
with 2mg/ml OVA and co-cultured with 1x105 naïve CD4+ T cells for 4 days. A. Proliferation of total 
live OTII cells co-cultured with WT (black line) or SIRPα mt (shaded grey) DCs as assessed by 
CFSE dilution. B. Percentage of IL17a+, IFNγ+ and FoxP3+ T cells as a proportion of total live T 
cells from co-cultures of naïve CD4+ T cells with CD103+CD11b+ DCs from WT and SIRPα mt 
mice. B. Percentage of IL17a+, IFNγ+ and FoxP3+ T cells as a proportion of total live T cells from 
co-cultures of naïve CD4+ T cells with CD103-CD11b+ DCs from WT and SIRPα mt mice. Data are 
from a single experiment. 
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Figure 7.12: Citrobacter rodentium infection in SIRPα mt mice 
WT and SIRPα mt mice were gavaged with 1x109 C. rodentium and infection was monitored by 
faecal CFU counts. A. Bacterial counts in faceces enumerated as CFU/gram of faeces. Data are 
from a single experiment with 10 WT and 8 SIRPα mt mice. B. CFU counts of C. rodentium per 
gram of faeces in SIRPα mt mice compared with WT controls on day 8 of infection. C. Following 
restimulation with PMA and ionomycin in the presence of brefeldin A and monensin, MLN and 
colonic LP isolates were examined for IL17a producing CD4+ T cells by intracellular cytokine 
staining. Results show proportion of Th17 cells as a percentage of total CD4+ T cells in the MLN 
and colonic LP of SIRPα mt mice compared with WT controls on day 8 of infection. Data are from 
a single experiment with 6 WT and 3 SIRPα mt mice. *p<0.05, **p<0.01, Student’s t test. 
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Figure 7.13: DSS colitis in SIRPα mt mice 
WT or SIRPα mt mice received 2% DSS ad libitum in the drinking water for eight days. A. Weight 
loss was assessed daily and expressed as percentage of starting weight +1SD. B. Clinical scores 
+1SD calculated as described in Materials and Methods. Data are representative of 2 independent 
experiment with n=4-8 per experiment.  
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Figure 7.14: Induction of oral tolerance in SIRPα mt mice 
A. WT or SIRPα mt mice were fed a single dose of 25mg OVA or PBS and immunized in the right 
hind footpad with OVA emulsified in CFA 7 days later. 21 days later, mice were challenged in the 
contralateral footpad with HAO and 24 hours later, OVA specific DTH responses were assessed 
by measuring the increase in footpad size. A. Schematic of oral tolerance protocol. B. OVA 
specific DTH responses are shown as the mean increase in footpad measurement of 4-5 mice per 
group and are representative of two independent experiments. *p<0.05, **p<0.01. One Way 
ANOVA with Bonferroni post-test. 
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Figure 7.15: Effects of ageing on DC populations in SI LP of SIRPα mt mice 
LP cells were isolated from the SI of 11 month old (aged) and 6-8 week old (young) WT and 
SIRPα mt mice and total DCs amongst live CD45+ CD11c+ MHCII+ CD64- cells were divided into 
four subsets on the basis of their expression of CD103 and CD11b, by flow cytometry as shown in 
Fig. 7.1. Proportion of each DC subset as a percentage of live CD45+ cells in young and aged WT 
and SIRPα mt mice. Data are from a single experiment with n=4-6 per group. *p<0.05, **p<0.01, 
two way ANOVA with Bonferroni post-test.  
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Figure 7.16: Effects of ageing on Th17 cells in SI LP of SIRPα mt mice 
LP cells were isolated from the SI of 11 month old (aged) and 6-8week old (young) WT and SIRPα 
mt mice, restimulated for 4.5hours with PMA and ionomycin in the presence of brefeldin A and 
monensin and IL17a-producing CD4+ T cells were assessed by intracellular cytokine staining. A. 
Representative contour plots showing CD4 and IL17a staining on CD4+ T cells in SI LP of young 
and aged WT and SIRPα mt mice. B. Proportion of IL17+ CD4+ T cells as a percentage of total 
CD4+ T cells. Data are from a single experiment with n=4-6 per group. *p<0.05, **p<0.01, two way 
ANOVA with Bonferroni post-test.  
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Figure 7.17: Effects of ageing on splenic DC populations in SIRPα mt mice 
Splenocytes were isolated from resting 11 month old (aged) and 6-8week old (young) WT and 
SIRPα mt mice and DC populations were assessed by flow cytometry. A. DCs were identified as 
CD11c+MHCII+ cells amongst live CD45+ cells and analysed for expression of CD4. B. Proportion 
of each DC subset as a percentage of total live CD45+ cells. Data are from a single experiment 
with n=4-6 per group. ***p<0.001, two way ANOVA with Bonferroni post-test.  
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8.1 Introduction 
In the previous chapter I identified a selective defect in the proportion and 
number of CD103+CD11b+ DCs in the LP and MLNs of SIRPα mt and CD47KO 
mice. In this chapter, I set out to explore the basis of this defect by investigating 
the development, in situ proliferation, migration and survival of CD103+CD11b+ 
DCs in SIRPα mt mice compared with WT controls. In addition, I examined 
whether the SIRPα-dependent DC defect was cell intrinsic by generating 
WT:SIRPα mt mixed BM chimeras and tried to identify the CD47+ cells in the LP 
which could be interacting with the SIRPα+CD103+CD11b+ DCs. 
8.2 Expression of CD47 in the Intestinal Mucosa  
Although CD47 is reported to be expressed ubiquitously (Barclay and Brown, 
2006; Brown and Frazier, 2001), there is little information available regarding 
exactly which cells in which tissues express this receptor and to the best of my 
knowledge this has not been rigorously explored in the intestine. Therefore I 
decided to investigate which cells may be interacting with the 
SIRPα+CD103+CD11b+ DCs in the intestine, by identifying CD47+ cells in the LP. 
Flow cytometric analysis of isolated cells revealed that both haematopoietic and 
non-haematopoietic cells expressed CD47, although at variable levels (Fig. 8.1A). 
Examination of the intestinal MP populations identified in Chapter 3 showed that 
most of the DC subsets expressed CD47 at similar levels, with the CD103+CD11b+ 
DCs perhaps expressing slightly lower levels that the other populations (Fig. 8.1B). 
CD11c+MHCII+ F4/80+ mφs also expressed similar levels of CD47 (Fig. 8.1C). This 
widespread expression of CD47 made it unlikely that I would be able to determine 
which specific cell types were interacting with SIRPα+CD103+CD11b+ DCs on the 
basis of CD47 expression alone. As multi-colour microscopy techniques that might 
allow interacting CD47+ cells to be identified precisely were not yet established in 
our lab, I did not take this analysis any further. Instead this will be a focus for a 
new PhD student in the lab. 
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8.3 DC Development in the Absence of SIRPα  Signalling 
I hypothesised that SIRPα might affect the homeostasis of CD103+CD11b+ 
DCs at one or more of the different phases of DC lifespan: generation or migration 
of precursors to the intestinal mucosa, subsequent differentiation and/or 
proliferation in the mucosa, survival of mature DC, or their migration out of the LP 
into the MLN. First I examined the role of SIRPα in the development of 
CD103+CD11b+ DCs from their precursors. SIRPα mt and WT mice had similar 
proportions and numbers of pre-DCs in the BM (Fig. 8.2A). Similar results were 
obtained when pre-DCs when examined in blood (Fig. 8.2B). Next, I performed 
competitive adoptive transfers in which a 50:50 mix of pre-DCs from CD45.1+ WT 
and CD45.2+ SIRPα mt BM was transferred into unmanipulated CD45.1/CD45.2 
WT recipients (Fig. 8.3A). Because of difficulties in obtaining sufficient cells from 
both strains simultaneously, I had to use separate adoptive transfer experiments to 
examine pre-DC development at each time point after transfer.  
As I showed in Chapter 4, 3 days after transfer all four DC populations could 
be seen amongst the progeny of transferred pre-DCs in the SI LP, although there 
were few donor-derived CD103+CD11b+ DCs at this time (Fig. 8.3B). Interestingly, 
approximately 80% of donor-derived CD103+CD11b+ DCs were from the SIRPα 
mt pre-DCs at this time (Fig. 8.3C), whereas the other DC populations retained the 
approximately 50:50 ratio of WT:SIRPα mt found in the original transfer mix (Fig. 
8.3D). A similar pattern was observed 5 days after transfer, where although all DC 
populations were present amongst donor-derived cells (Fig. 8.4B), the majority 
(~70%) of CD103+CD11b+ DCs was derived from SIRPα mt pre-DCs (Fig. 8.4C). 
At this time, there was also a slight bias towards CD103+CD11b- DCs being 
derived from SIRPα mt pre-DCs, whereas both CD103− DC populations were 
derived from WT and SIRPα mt pre-DCs in equal ratios (Fig.8.4D). By day 7, the 
SIRPα mt pre-DCs no longer had an advantage over the WT pre-DCs in terms of 
generating CD103+CD11b+ DCs, with the proportions of each now being almost 
identical to the transferred population (Fig. 8.5B,D). The other DC populations also 
showed no preference towards WT or SIRPα mt origin at this time (Fig. 8.5D).   
Having established that SIRPα mt pre-DCs appear to generate 
CD103+CD11b+ DCs in the LP more rapidly than their WT counterparts, I 
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hypothesised that these should then be detected sooner in the MLNs of recipient 
mice. As my previous adoptive transfer using WT pre-DCs and BrdU incorporation 
studies had indicated that DCs take approximately 48 hours to transit from the SI 
LP to the MLNs, I examined the fate of the mixed pre-DCs in the MLNs 5 and 7 
days after transfer. Due to the fact that only small numbers of donor cells could be 
found in the recipient MLNs, I could only analyse total CD11c+MHCII+ DCs rather 
than defining resident and migratory DCs separately. However this should not 
affect the identification of LP-derived CD103+CD11b+ DCs, as these can only be 
found within the migratory DC population of the MLNs (Fig. 3.6). 5 days after 
transfer, I found the same bias towards the CD103+CD11b+ DCs in MLN being 
derived from CD45.2+ SIRPα mt pre-DCs as I had seen in the LP (Fig. 8.6B). This 
was paralleled by a decrease in the proportion of CD103+CD11b- derived from 
SIRPα mt pre-DCs, while all CD103- DCs showed same ratio as in injected 
mixture (Fig. 8.6B). These differences were not seen 7 days after transfer, when 
all DC subsets showed same ratio of WT:SIRPα derived cells as in the transferred 
pre-DCs (Fig. 8.6C). Together these results suggest SIRPα mt pre-DCs may 
generate CD103+CD11b+ DCs more efficiently than WT pre-DCs in LP and as a 
result of this increased maturation, these migrate to the MLN more quickly than 
WT DCs. As these experiments were done with small numbers of mice, repeat 
studies are required to verify these results. However it is clear that these results 
cannot explain the selective CD103+CD11b+ DC defect observed in the LP and 
MLNs of SIRPα mt mice. Indeed they indicate that an increased ability to generate 
CD103+CD11b+ DCs in these mice must be counteracted by even more potent 
mechanism which depletes these cells.  
8.4 In Situ Proliferation of DCs in SIRPα  Mt Mice 
To explore this, I first examined if the lower numbers of CD103+CD11b+ DCs 
in SIRPα mt LP might reflect reduced proliferation of this DC population in situ. To 
investigate this, WT and SIRPα mt mice were given a single i.p. injection of BrdU 
and DCs in the SI LP were assessed for BrdU incorporation 3 hours later. This 
time was chosen on the basis of my results in Chapter 4, which had shown that no 
BrdU+ pre-DCs were present in the blood at this time point and hence any BrdU+ 
cells in the LP would be the result of in situ proliferation. Approximately 2% of 
CD103+CD11b+ DCs in both SIRPα mt and WT LP were BrdU+ at this time and 
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there were also no differences in the levels of BrdU incorporation by the other DC 
subsets in SIRPα mt SI LP compared with WT controls (Fig. 8.7). Thus in situ 
proliferation does not appear to account for the differences in the number of 
CD103+CD11b+ DCs in SIRPα mt mice.  
8.5 Activation Status of DCs in SIRPα  Mt Mice 
As SIRPα is primarily thought to be an inhibitory receptor, I next investigated 
if the lack of functional SIRPα signalling increased the activation status of 
CD103+CD11b+ DCs, with the hypothesis that over-activation of the DCs may be 
detrimental to the viability of CD103+CD11b+ DCs and thus contribute potentially 
explain the defect observed in these DCs in SIRPα mt mice. Therefore I assessed 
the expression of the co-stimulatory molecules, CD40, CD80 and CD86 on SI LP 
DCs from WT and SIRPα mt mice. This showed that CD103+CD11b+ DCs from 
SIRPα mt mice expressed similar levels of CD40 and CD80 as WT controls, but 
expressed significantly more CD86 (Fig. 8.8A,B). This increase in CD86 
expression was not seen with the other subsets of DCs in SIRPα mt LP, although 
SIRPα mt CD103-CD11b- DCs had decreased expression of CD80 and SIRPα mt 
CD103+CD11b- DCs had decreased CD40 expression compared with WT controls 
(Fig. 8.8C). However, it should be noted that these differences in co-stimulatory 
molecule expression were all minor compared with the ~50% increase in CD86 
expression seen with SIRPα mt CD103+CD11b+ DCs. All other co-stimulatory 
molecule expression patterns were identical in WT and SIRPα mt LP DCs. 
8.6 Migration of DCs to MLNs 
As my competitive adoptive transfer studies suggested that SIRPα mt 
CD103+CD11b+ SI LP DCs might transit to the MLNs more quickly than WT 
counterparts, I next examined this directly. To do this, I collaborated with Dr. 
Simon Milling’s lab to investigate DC subsets in pseudo-afferent intestinal lymph. 
For this, WT and SIRPα mt mice underwent mesenteric lymphadenectomy (MLNx) 
and were left for 6 weeks to allow reanastomosis of the lymphatics before lymph 
was collected by cannulation of the thoracic duct. The collected lymph thus 
consists mostly of lymph that drains the intestine, containing the DCs that would 
have previously drained to the MLNs (Cerovic et al., 2013). DCs were identified in 
 237 
lymph as single, live CD45+, B220-, CD64-, CD11c+ and MHCII+ cells (Fig. 8.9A) 
and as with both SI LP and migratory DCs in the MLNs, lymph DCs could be 
divided into four distinct subsets based on CD103 and CD11b expression (Fig. 
8.9B). Consistent with recent work from the Milling lab (Cerovic et al., 2013), the 
proportions of DCs in lymph mirrored those found amongst migratory MLN DCs, 
with the CD103+CD11b+ DCs dominating, followed by the CD103+CD11b- and 
finally the two smaller populations of CD103- DCs, the majority of these being 
CD11b+. Somewhat unexpectedly, all these subsets were found in similar 
proportions in SIRPα mt and WT lymph, apart from CD103+CD11b- DCs, which 
were increased in proportion in SIRPα mt lymph compared with WT lymph (Fig. 
8.9C). Unfortunately this technique does not allow quantitation of DC numbers in 
lymph, but the apparently normal proportions of CD103+CD11b+ DCs in SIRPα mt 
lymph could reflect the increased efficiency of migration to the MLNs, 
counterbalancing the reduced numbers of these cells in the LP. Alternatively, it 
may be because the mice used in this experiment had to be relatively old due to 
the need to wait for lymphatic re-anastomosis and as I showed earlier, the DC 
defect in SIRPα mt may be reduced with age. Further investigation is required to 
determine if the SIRPα mt CD103+CD11b+ DCs do indeed migrate more efficiently 
than WT counterparts. 
8.7 DC Survival in SIRPα  Mt Mice 
Next I investigated if survival of the CD103+CD11b+ DCs was impaired in 
SIRPα mt mice. For this, I started by examining MLNs, reasoning that as the 
digestion process used to isolate the DCs from this tissue was less extensive, the 
isolated DCs would be in better condition for analysis. Total cell isolates were 
stained with Annexin V and 7-AAD to identify apoptotic (Annexin V+ 7-AAD-) and 
dead (Annexin V+ 7-AAD+) cells. Although there was considerable variability, this 
showed significantly more apoptotic cells amongst the CD103+CD11b+ subset of 
migratory DCs in SIRPα mt MLNs compared with WT controls (Fig. 8.10). There 
were no differences in apoptosis amongst the other migratory DC populations in 
SIRPα mt and WT MLNs (Fig. 8.10). I next attempted to study apoptosis amongst 
freshly isolated SI LP DCs, but no differences could be detected in any of the DC 
populations between WT and SIRPα mt mice (Fig. 8.11A). However the overall 
levels of apoptosis were much lower in this experiment than I had observed in the 
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MLNs and I reasoned that many cells that might have been undergoing apoptosis 
in situ may have been killed during the lengthy digestion process needed to obtain 
LP cells. In an attempt to overcome this, I isolated cells from the SI LP of WT and 
SIRPα mt mice and cultured them for 3 hours at 37oC ex vivo before examining 
Annexin V and 7-AAD staining on the DC populations. Again, no differences were 
observed between any of the DC subsets in WT and SIRPα mt mice (Fig. 8.11B) 
and the proportions of apoptotic cells remained low, except for CD103+CD11b- 
DCs from both strains.  
With the ongoing difficulties with the Annexin V assay, I sought to find 
another method for examining apoptosis in intestinal DCs. Tunel staining in situ 
was not feasible as it would not allow the identification of CD103+CD11b+ DCs. 
Therefore I decided to examine the expression of the pro-apoptotic gene Caspase 
3 in CD103+CD11b+ DCs FACS-purified from the SI LP of WT and SIRPα mt mice. 
This showed a 2-fold increase in the expression of Caspase 3 in CD103+CD11b+ 
DCs isolated from SIRPα mt mice compared with the WT subset (Fig. 8.12). 
However SIRPα mt CD103+CD11b+ DCs also showed a similar increase in the 
anti-apoptotic Bcl2 gene (Fig. 8.12,) making it difficult to assess the significance of 
the Caspase 3 results and thus further experiments are required to clarify the 
relative expression of pro- and anti-apoptotic genes. Furthermore, as I did not 
have RNA from the other DC subsets, it is not clear if these changes in gene 
expression are specific to the CD103+CD11b+ DC subset. In the future, protein 
levels will be also be investigated, as this may be more relevant, especially given 
the presence of inactive pro-caspase 3. 
At the time I was carrying out these studies, our collaborators in Lund found 
a similar survival defect in CD103+CD11b+ DCs in mice with a DC-specific deletion 
of the transcription factor IRF4 (Persson et al., 2013b). Therefore, I decided to 
examine if the SIRPα mutation might be acting by downregulating this pathway by 
assessing the expression of Irf4 in the CD103+CD11b+ DCs FACS-purified from 
the SI LP of WT and SIRPα mt mice. However, this revealed a 5-fold increase in 
expression of Irf4 in the CD103+CD11b+ DCs isolated from the SIRPα mt mice 
compared with their WT counterparts (Fig. 8.12), indicating that the reduction in 
CD103+CD11b+ DCs in SIRPα mutant mice is not due to defective IRF4 
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expression and suggesting that IRF4 may actually be upregulated to compensate 
for the lack of SIRPα signalling.  
In a further attempt to examine the survival of CD103+CD11b+ DCs in the SI 
LP of SIRPα mt mice, I next FACS-purified these DCs from the SI LP of CD45.1+ 
WT and CD45.2+ SIRPα mt mice, mixed them in a 50:50 ratio and cultured them 
for 16 hours before analysing cell death by 7-AAD staining. In this study I digested 
the SI from the two strains in the same tube, thus avoiding any bias at the 
digestion stage. The pooled CD103+CD11b+ DCs were then separated by FACS-
purification on the basis of CD45.1 and CD45.2 expression, before being mixed 
back together at a 50:50 ratio for culture. After 16 hours of culture, there were 
more dead cells amongst the SIRPα mt DCs, with only ~30% being alive, while 
36% of the WT CD103+CD11b+ DCs were alive at this time (Fig. 8.13A). As 
mentioned previously, due to the set up of our FACS-Aria, I could only sort one 
other population of DCs from WT and SIRPα mt SI LP isolates simultaneously. I 
chose to use the CD103-CD11b+ DCs as a control population, as they also 
express SIRPα, but are unaffected in the SIRPα mt mice. In this case the 
proportion of live DCs after culture was similar amongst the WT and SIRPα cells 
and I also noted that this subset showed better overall viability after culture than 
the CD103+CD11b+ DCs (Fig. 8.13B). Taken together these results suggest that 
CD103+CD11b+ DCs might be generally more prone to dying and that this is 
enhanced in SIRPα mt mice. However, as I was only able to do the experiment 
once with a single replicate, these results need to be repeated. 
8.8 Is the CD103+CD11b+ DC Defect Cell Intrinsic? 
Finally, I examined if the selective defect in CD103+CD11b+ DCs was cell 
intrinsic or could be overcome in an environment where functional SIRPα was 
expressed normally by stromal and haematopoietic cells. To investigate this, I 
generated mixed bone marrow chimeras, in which CD45.1/CD45.2 WT recipients 
were reconstituted with a 50:50 mix of CD45.1+ WT and CD45.2+ SIRPα mt BM 
(Fig. 8.14A,B). Importantly, all subsets of intestinal DC were present at the 
expected frequencies 8 weeks after reconstitution (Fig. 8.14D). However it should 
be noted that only ~40% of non-host cells derived from SIRPα mt BM, suggesting 
that SIRPα mt BM was slightly defective in its ability to repopulate CD45+ 
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leukocytes in general (Fig. 8.14C-E). CD103+CD11b+ DCs were not affected to 
any greater extent than the other subsets in LP and similar results were seen for 
all subsets of migratory DCs in recipient MLNs, although in this case, the CD103+ 
DC subsets showed slightly lower reconstitution by SIRPα mt BM (~30%) (Fig. 
8.14F). A different pattern was seen in the spleen, where CD11b+ DCs were 
clearly skewed towards WT reconstitution, with only 20% of these being of SIRPα 
mt origin (Fig. 8.15). In contrast, the CD11b- DCs mirrored the reconstitution ratio 
seen amongst the total leukocyte populations. Together these results indicate a 
slight cell intrinsic defect in the ability of SIRPα mt BM to generate DCs and other 
leukocytes, but that this is not different for the CD103+CD11b+ DCs in LP and so 
does not seem to account for the selective defect in this subset in the intact SIRPα 
mt mouse. However, this may be different for the splenic CD11b+ population. 
Again it is important to note that because these BM chimeric mice were older than 
the mice I normally used, it will be important to ensure that this does not account 
for any apparent differences between the steady state and chimeric SIRPα mt 
animals. 
8.9  Summary 
In this chapter I set out to examine the cause of the SIRPα-mediated 
reduction in intestinal CD103+CD11b+ DCs in SIRPα mt mice that I had identified 
in Chapter 7. Initially I examined the cellular distribution of the SIRPα ligand CD47 
in the intestine, as I hoped this would aid the identification of which CD47+ cells 
might be interacting with SIRPα+CD103+CD11b+ DCs in situ. However, this 
showed that many different intestinal cells expressed CD47, including the DCs 
themselves, meaning it was going to be difficult to identify interacting cells by 
CD47 expression alone.  
I next examined the ability of SIRPα mt mice to generate pre-DCs. As their 
proportions were normal in both the BM and blood, I went on to compare the ability 
of SIRPα mt and WT pre-DCs to give rise to CD103+CD11b+ DCs. When 
transferred into resting WT recipients, SIRPα mt pre-DCs generated 
CD103+CD11b+ SI LP DCs more efficiently than their WT counterparts and this did 
not affect the other DC subsets. This was mirrored by a more rapid appearance of 
SIRPα mt-derived CD103+CD11b+ DCs in MLNs. No differences were seen in the 
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levels of in situ proliferation by any of the mature DC subsets in SIRPα mt and WT 
LP, but CD103+CD11b+ DCs from SIRPα mt LP showed increased expression of 
CD86 compared with WT counterparts, and this was not seen with other DC 
subsets. These results could suggest that the absence of SIRPα signalling leads 
to more efficient differentiation and/or activation of CD103+CD11b+ DCs in the gut 
environment. To determine if this might be reflected in more rapid emigration from 
the LP, I next examined DCs in pseudo-afferent lymph from MLNx mice. This 
showed no differences in the proportions of the DC subsets between WT and 
SIRPα mt lymph, with the exception of CD103+CD11b- DCs being slightly 
increased in SIRPα mt mice. This finding was surprising given the absence of 
SIRPα expression by these DCs and could indicate the secondary effects of subtle 
changes in the other, SIRPα expressing DCs which were not evident in the 
original analysis. The equal proportions of CD103+CD11b+ DCs in lymph contrasts 
with their decreased numbers in the LP and could indicate these cells have an 
increased ability to migrate out of the LP. However, as these mice were quite old 
by the time they were cannulated and I found earlier that the DC defect in SIRPα 
mt mice reduces with age, these results need more detailed follow up.  
Studies comparing DC survival between WT and SIRPα mt mice were 
inconclusive. Although Annexin V staining suggested enhanced and selective cell 
death amongst CD103+CD11b+ DCs in SIRPα mt MLNs, this was not seen in the 
LP, possibly as a consequence of the extensive enzymatic digestion used to 
isolate the DCs. Furthermore, although the CD103+CD11b+ DCs from SIRPα mt SI 
LP expressed approximately 2-fold more mRNA for the pro-apoptotic gene 
Caspase 3, a similar increase was seen for the anti-apoptotic gene Bcl2. However, 
studies using CD103+CD11b+ DCs that had been isolated and sorted together 
from WT and SIRPα mt mice did suggest that the SIRPα mt CD103+CD11b+ SI LP 
DCs were slightly more susceptible to death following culture overnight, although 
these differences were minor. Interestingly all my studies suggested that the 
CD103-CD11b+ DCs survive better than the CD103+CD11b+ DCs. CD103+CD11b+ 
DCs from SIRPα mt mice SI LP had increased expression of IRF4, whose deletion 
in DCs leads to a similar selective reduction in CD103+CD11b+ intestinal DCs in 
vivo. Thus, while impaired survival may account for the selective defect in 
CD103+CD11b+ DCs in SIRPα mt MLNs, more work is required to assess whether 
 242 
this accounts for the effects of the lack of SIRPα signalling on CD103+CD11b+ DC 
homeostasis in the LP.  
Finally, mixed WT:SIRPα mt BM chimeras showed there was a slight cell 
intrinsic defect in the ability of SIRPα mt BM to generate DCs and other leukocytes 
in the intestine and elsewhere. However there was no additional defect in the 
generation of CD103+CD11b+ intestinal DCs by SIRPα mt BM, although 
CD4+CD11b+ splenic DCs did appear to show a cell intrinsic defect of greater 
magnitude.  
Overall my studies suggest that a lack of SIRPα signalling on pre-DCs 
causes them to differentiate locally into CD103+CD11b+ DCs more efficiently. In 
turn, these DCs express higher levels of the co-stimulatory molecule CD86 
compared with WT controls suggesting they may be more activated. Possibly as a 
consequence of this increased activation, the SIRPα mt CD103+CD11b+ DCs 
appear to exit the LP more rapidly and at least in the MLN, appear more prone to 
apoptosis. Together these effects may account for the defect in these DCs in the 
LP and MLNs of SIRPα mt mice. However, the lack of a selective inability of 
SIRPα mt BM to reconstitute irradiated mice compared with WT BM suggests the 
role of this signalling molecule may be more complex. Alternatively, this apparent 
lack of a cell intrinsic defect may also be due to the age of the animals and this 
remains to be examined directly. 
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Figure 8.1: Expression of CD47 by intestinal cells 
Whole SI LP digests from WT (coloured histograms) and CD47KO mice (black histograms) were 
assessed for CD47 expression and compared with isotype controls (shaded grey histograms). A. 
Representative plots showing CD45 expression and 7-AAD staining on single cells (left panel) and 
histograms showing CD47 expression on live CD45- and CD45+ cells. B. Representative plots 
showing CD103 and CD11b expression on total CD11c+MHCII+F4/80- DCs showing CD47 
expression on each DC population. C. Representative plots showing CD11c and F4/80  
expression on total CD11c+MHCII+ MPs and histogram showing CD47 expression on CD11c
+F4/80+ mφs. Data are representative of 2-5 independent experiments with n =3/4 per experiment.  
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Figure 8.2: Pre-DCs in BM and blood of SIRPα mt mice. 
Pre-DCs were identified in BM and blood amongst total donor cells as live lin-, CD11c+, B220-, 
CCR9-, CD135+ cells as described in Fig. 4.1 in WT and SIRPa mt mice. Data are shown as mean 
proportion of pre-DCs as a percentage of total cells ±1SD. Data are representative of 2-5 
independent experiments with n =3/4 per experiment.  
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Figure 8.3: Generation of DC subsets in LP 3 days after competitive transfer of WT 
and SIRPα mt pre-DCs 
A. CD45.1+ WT and CD45.2+ SIRPα mt mice were injected with 2x106 B16 melanoma cells 
secreting Flt3L. 10 days later BM was harvested, pre-DCs sorted as described in Fig. 4.4, mixed 
in a 50:50 ratio and 7x105 total pre-DCs were transferred into resting CD45.1/CD45.2 WT 
recipients. 3 days later recipient mice were examined for the presence of donor cells. B. 
Representative plot showing CD103 and CD11b expression by donor-derived CD11c+MHCII+ DCs 
in the SI LP. C. Proportion of CD45.1 WT and CD45.2 SIRPα mt pre-DCs amongst total 
transferred cells in SI LP. D. Percentages of CD45.1+ and CD45.2+ cells amongst CD103+CD11b+, 
CD103+CD11b-, CD103-CD11b+ and CD103-CD11b- donor-derived DCs. Data are shown as 
means from a single experiment with n=2. 
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Figure 8.4:  Generation of DC subsets in LP 5 days after competitive transfer of WT 
and SIRPα mt pre-DCs 
A. CD45.1+ WT and CD45.2+ SIRPα mt mice were injected with 2x106 B16 melanoma cells 
secreting Flt3L. 10 days later BM was harvested, pre-DCs sorted as described in Fig. 4.4, mixed 
in a 50:50 ratio and 7x105 total pre-DCs were transferred into resting CD45.1/CD45.2 WT 
recipients. 5 days later recipient mice were examined for the presence of donor cells. B. 
Representative plot showing CD103 and CD11b expression by donor-derived CD11c+MHCII+ DCs 
in the SI LP. C. Proportion of CD45.1 WT and CD45.2 SIRPα mt pre-DCs amongst total 
transferred cells in SI LP. D. Percentages of CD45.1+ and CD45.2+ cells amongst CD103+CD11b+, 
CD103+CD11b-, CD103-CD11b+ and CD103-CD11b- donor-derived DCs. Data are shown as mean 
±1SD from 2 independent experiments pooled with n=4. *p<0.05, **p<0.01. 
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Figure 8.5: Generation of DC subsets in LP 7 days after competitive transfer of WT 
and SIRPα mt pre-DCs 
A. CD45.1+ WT and CD45.2+ SIRPα mt mice were injected with 2x106 B16 melanoma cells 
secreting Flt3L. 10 days later BM was harvested, pre-DCs sorted as described in Fig. 4.4, mixed 
in a 50:50 ratio and 7x105 total pre-DCs were transferred into resting CD45.1/CD45.2 WT 
recipients. 7 days later recipient mice were examined for the presence of donor cells. B. 
Representative plot showing CD103 and CD11b expression by donor-derived CD11c+MHCII+ DCs 
in the SI LP. C. Proportion of CD45.1 WT and CD45.2 SIRPα mt pre-DCs amongst total 
transferred cells in SI LP. D. Percentages of CD45.1+ and CD45.2+ cells amongst CD103+CD11b+, 
CD103+CD11b-, CD103-CD11b+ and CD103-CD11b- donor-derived DCs. Data are shown as 
means from a single experiment with n=2. 
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Figure 8.6: Generation of DC subsets in MLN after competitive transfer of WT and 
SIRPα mt pre-DCs 
A. CD45.1+ WT and CD45.2+ SIRPα mt mice were injected with 2x106 B16 melanoma cells 
secreting Flt3L. 10 days later BM was harvested, pre-DCs sorted as described in Fig. 4.4, mixed 
in a 50:50 ratio and 7x105 total pre-DCs were transferred into resting CD45.1/CD45.2 WT 
recipients. 5 and 7 days later recipient mice MLNs were examined for the presence of donor cells. 
B. Percentages of CD45.1+ and CD45.2+ cells amongst CD103+CD11b+, CD103+CD11b-, CD103-
CD11b+ and CD103-CD11b- donor-derived DCs 5 days after transfer. Data are pooled from 2 
independent experiments with n=2 per experiment and results shown as means ±1SD. C. 
Percentages of CD45.1+ and CD45.2+ cells amongst CD103+CD11b+, CD103+CD11b-, CD103-
CD11b+ and CD103-CD11b- CD11c+MHCII+ donor-derived DCs 7 days after transfer. Data are 
shown as mean from a single experiment with n=2. *p<0.05 Student’s t test. 
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Figure 8.7: In situ proliferation of DC subsets in LP of SIRPα mt mice 
WT and SIRPα mt mice received 1mg BrdU i.p. and BrdU+ cells amongst SI LP DCs were 
assessed 3 hours later. A. Representative plots showing BrdU staining in each DC population in 
WT (top panel) and SIRPα mt mice (lower panel). Number represents percentage of BrdU+ cells. 
B. Representative plot showing BrdU staining amongst total CD11c+ MHCII+CD64- DCs from a 
non-BrdU injected control (NI). C. Proportions of BrdU+ cells as a percentage of each DC 
population in SI LP of WT and SIRPα mt mice. Data are from a single experiment with n=4 per 
group.  
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Figure 8.8: Expression of co-stimulatory molecules by SI LP DCs from SIRPα mt mice 
LP DC subsets from WT and SIRPα mt mice were examined for their expression of the co-
stimulatory molecules CD40, CD80 and CD86. A. Representative histograms showing CD40, 
CD80 and CD86 expression CD103+CD11b+ DCs from SIRPα mt mice (black line) compared with 
WT controls (shaded grey histogram). B. Mean fluorescence intensity (MFI) for CD40, CD80 and 
CD86 expression by SIRPα mt and WT CD103+CD11b+ SI LP DCs. C. Mean fluorescence 
intensity (MFI) for CD40, CD80 and CD86 expression by CD103+CD11b-, CD103-CD11b+ and 
CD103-CD11b- DCs from WT and SIRPα mt SI LP. Data are from a single experiment with n=3 per 
group. *p<0.05, **p<0.01, Student’s t test. 
A 
B 
CD40 
%
 o
f m
ax
. 
CD80 
%
 o
f m
ax
. 
CD86 
%
 o
f m
ax
. 
CD40 CD80 CD86 
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
200
400
600
800
1000
M
FI
*
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
200
400
600
800
1000
WT
SIRPα Mt
M
FI
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
200
400
600
800
1000
WT
SIRPα Mt
M
FI
C 
CD40 CD80 CD86 
WT SIRPα Mt 
0
200
400
600
800
1000
M
FI
WT SIRPα Mt 
0
200
400
600
800
1000
M
FI
WT SIRPα Mt 
0
200
400
600
800
1000
**
M
FI
251 
Figure 8.9: DC subsets in pseudo-afferent intestinal lymph of SIRPα mt mice 
MLNs of WT and SIRPα mt mice were removed and lymphatics allowed to reanastamose. 6 
weeks later the thoracic ducts were cannulated and lymph collected overnight. A. DCs were 
identified in lymph as single, live CD45+ B220- CD11c+ MHCII+ cells. B. Representative dot plots 
showing CD103 and CD11b expression on lymph DCs and DC subsets in the lymph of WT and 
SIRPα mt mice. Numbers represent proportion of total DCs. C. Proportions of each DC subset as 
a percentage of total DCs in lymph of WT and SIRPα mt mice. Data are from a single experiment 
with n=3-6 per group. *p<0.05 Student’s t test. 
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Figure 8.10: Apoptosis of CD103+CD11b+ DCs from MLNs of SIRPα mt mice 
DC subsets were identified amongst migratory DCs in whole MLN isolates from WT and SIRPα mt 
mice and stained for Annexin V and 7-AAD. A. Representative plots showing Annexin V and 7-
AAD staining in each DC population in WT (top panel) and SIRPα mt mice (lower panel). Numbers 
represent proportions of apoptotic (Annexin V+ 7-AAD-) cells. B. Representative plot showing 
Annexin V and 7-AAD staining in fluorescence minus one (FMO) controls used to set gates 
amongst total migratory (CD11c+ MHCIIhi) DCs. C. Proportions of apoptotic (Annexin V+ 7-AAD-) 
cells as a percentage of each DC subset in WT and SIRPα mt MLNs. Data are pooled from four 
independent experiments with n=3-4 per group per experiment. **p<0.01 Student’s t test. 
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Figure 8.11: Apoptosis of SI LP DCs from SIRPα mt mice 
DC subsets were identified amongst DCs in SI LP isolates from WT and SIRPα mt mice and 
stained for Annexin V and 7-AAD. A. Proportions of apoptotic (Annexin V+ 7-AAD-) cells as a 
percentage of each DC subset in WT and SIRPα mt SI LP. B. Proportions of apoptotic (Annexin V
+ 7-AAD-) cells as a percentage of each DC subset in WT and SIRPα mt SI LP following 3 hours of 
culture at 37oC. Data are from a single experiment with n=3/4 per group.  
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Figure 8.12: Expression of apoptosis associated genes by CD103+CD11b+ SI LP DCs 
from SIRPα mt mice 
CD103+CD11b+ DCs were FACS-purified from SI LP of WT and SIRPα mt mice as described in 
Fig. 3.10 and analysed by qRT-PCR for expression of mRNA for Caspase 3, Bcl2 and Irf4. Results 
shown are relative to HPRT using the 2-ΔΔct method with WT set to 1. Data are from two (Caspase 
3 and Bcl2) or three (Irf4) independent experiments and are shown as means ±1SD. Cells were 
pooled from 6-9 mice per group per experiment. 
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Figure 8.13: Survival of SI LP DCs in SIRPα mt mice 
SI from CD45.1+ WT and CD45.2+ SIRPα mt mice were pooled, digested together and 
CD103+CD11b+ and CD103-CD11b+ DCs FACS-purified as described in Fig. 3.1. After sorting, 
30,000 CD45.1+ and CD45.2+ cells were mixed together in a 50:50 ratio and cultured for 16 hours 
before their viability was assessed. A. Representative plots showing CD45.1 and CD45.2 staining 
on CD103+CD11b+ DCs after culture and 7-AAD staining and FSC-A profiles of CD45.1+ WT and 
CD45.2+ SIRPα mt DCs. Numbers represent proportions of parent population. B. Representative 
plots showing CD45.1 and CD45.2 staining on CD103-CD11b+ DCs after culture and 7-AAD 
staining and FSC-A profiles of CD45.1 WT and CD45.2 SIRPα mt DCs. Numbers represent 
proportions of parent population. Data are from a single experiment with n=1. Cells were pooled 
from 6 mice per group. 
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Figure 8.14: DCs in SI LP and MLNs of mixed WT:SIRPα mt BM chimeras 
A. Mixed BM chimeras were generated by lethally irradiating CD45.1/CD45.2 WT mice and 
reconstituting with a 50:50 mix of CD45.1+ WT and CD45.2+ SIRPα mt BM. Mice were left for 8 
weeks to allow reconstitution of all populations. B. Proportions of CD45.1+ WT and CD45.2+ 
SIRPα mt BM used for reconstitution. C. Representative dot plot showing expression of CD45.1 
and CD45.2 by total live SI LP cells 8 weeks after reconstitution. Numbers represent proportions 
of live cells. D. Representative plot showing CD103 and CD11b expression by CD11c+MHCII
+CD64- DCs in the SI LP 8 weeks after reconstitution. E. Proportions of CD45.2+ SIRPα mt BM-
derived cells shown as a percentage of each DC population in the SI LP 8 weeks after 
reconstitution. F. Proportions of CD45.2+ SIRPα mt BM-derived cells shown as a percentage of 
CD11c+MHCIIhi migratory DCs in the MLNs 8 weeks after reconstitution. Data are shown as mean 
±1SD from 2 independent experiments pooled with n=8. ***p<0.001 Student’s t test. 
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Figure 8.15: DCs in spleen of mixed WT:SIRPα mt BM chimeras 
A. Mixed BM chimeras were generated by lethally irradiating CD45.1/CD45.2 WT mice and 
reconstituting with a 50:50 mix of CD45.1+ WT and CD45.2+ SIRPα mt BM. Mice were left for 8 
weeks to allow reconstitution of all populations. B. Proportions of CD45.2+ SIRPα mt BM-derived 
cells shown as a percentage of each DC population in the spleen 8 weeks after reconstitution. C. 
Representative dot plot showing expression of CD45.1 and CD45.2 by total live splenocytes 8 
weeks after reconstitution. Numbers represent proportions of live cells. Data are shown as mean 
±1SD of 2 independent experiments, n=8. ***p<0.001, Student’s t test. 
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 Chapter 9 CCR2+ Intestinal Dendritic Cells 
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9.1 Introduction 
In the previous chapters I demonstrated that CD103-CD11b+CD64- intestinal 
MPs were genuine DCs derived from committed DC precursors (pre-DCs). 
However towards the end of my PhD, a CCR2-dependent Zbtb46+ Ly6Clo MP 
population was identified that was proposed to comprise monocyte-derived DCs 
(mo-DCs) (Zigmond et al., 2012) based on the known dependence of monocytes 
on CCR2 for BM egress (Kurihara et al., 1997; Serbina and Pamer, 2006). As I 
could find no evidence of a population of mo-DCs in my previous adoptive transfer 
studies, in this chapter I set out to investigate if I had overlooked this mo-DC 
population in my previous analyses. 
9.2 CD103-CD11b+ DCs are Reduced in CCR2- /- Intestine 
I first examined whether deletion of CCR2 affected the abundance of DCs in 
the steady state mucosa by comparing the four populations of intestinal DCs in 
CCR2-/- mice and WT controls. This revealed a partial reduction in both the 
proportion and number of CD103-CD11b+ DCs in the SI LP of CCR2-/- mice 
compared with WT controls (Fig. 9.1). In parallel there was a slight increase in 
CD103+CD11b+ DCs in terms of proportion, but this did not translate into a change 
in their absolute number (Fig. 9.1B,C). There was also a slight but significant 
reduction in the absolute number of CD103-CD11b- DCs in the CCR2-/- LP (Fig. 
9.1C). Consistent with our previous report in the colonic LP (Bain et al., 2013), the 
absolute number of mφs in the SI LP was also reduced in CCR2-/- mice compared 
with WT controls (Fig. 9.1D) consistent with these being monocyte-derived cells. 
There was an even more profound reduction in the proportion and absolute 
number of CD103-CD11b+ DCs amongst migratory DCs in CCR2-/- MLNs, where 
there was also a slight increase in the proportion of CD103+CD11b+ DCs. Again 
there was a slight decrease in the numbers of CD103-CD11b- DCs (Fig. 9.2). 
Unlike LP, the number of CD103+CD11b- migratory DCs was also decreased in 
CCR2-/- MLNs, despite an increase in their proportion compared with WT control 
MLNs (Fig. 9.2B,C). These decreases in the numbers of the DC subsets reflected 
a significant decrease in the total number of migratory DCs in CCR2-/- MLNs (Fig. 
9.2D). In contrast the total cellularity of their MLNs was normal (Fig. 9.2E), as were 
all subsets of resident DCs, apart from a small but significant decrease in the 
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proportion of CD103-CD11b- DCs (Fig. 9.3). Together these results could suggest 
that some intestinal DCs are dependent upon CCR2 and that this chemokine 
receptor may play an additional role in DC migration to the MLNs.  
There was also a significant reduction in the numbers of both CD4+ (CD11b+) 
and CD4- (CD11b-) DC populations in the spleen of CCR2-/- mice, although their 
proportions were normal (Fig. 9.4A-C). In parallel, total DC numbers were reduced 
in the spleen compared with WT controls, while total cell numbers were normal 
(Fig. 9.4D,E). Thus although CCR2 may have more widespread effects on DCs in 
general, it appears to play a particularly important role in the homeostasis of 
CD103-CD11b+ DCs in the intestine.  
9.3 The Defect in CD103-CD11b+ DCs in CCR2- /- Mice is Cell 
Intrinsic 
To examine if this defect in CD103-CD11b+ DCs in CCR2-/- mice was cell 
intrinsic, I generated mixed BM chimeras, in which lethally irradiated 
CD45.1/CD45.2 WT mice were reconstituted with a 50:50 mix of CD45.1+ WT and 
CD45.2+ CCR2-/- BM (Fig. 9.5A). 8 weeks after reconstitution, mφs in the SI LP 
were derived almost exclusively from WT BM (Fig. 9.5B,C), confirming the known 
requirement for CCR2-dependent monocytes in replenishing this population (Bain 
et al., 2013; Tamoutounour et al., 2012). All the DC populations in chimeric SI LP 
also showed slightly skewed reconstitution in favour of WT origin, suggesting that 
CCR2 may also play a cell intrinsic role in the development and/or recruitment of 
these cells. However, a similar bias was seen when eosinophils were examined, a 
population with no known requirement for CCR2 in their development or 
recruitment, suggesting that the overall reconstitution by KO BM was less efficient. 
The only exception to this were the CD103-CD11b+ DCs, which had a WT:KO ratio 
of ~3, which was greater than the other DC subsets and eosinophils, although less 
than for mφ. This finding would be consistent with the idea that a cell intrinsic 
defect in CD103-CD11b+ DCs accounts for at least part of their selective reduction 
in CCR2-/- mice (Fig. 9.5B,C). There was a similar and significant skewing towards 
WT origin amongst CD103-CD11b+ migratory DCs in the MLNs of chimeric mice, 
with a WT:KO ratio of ~2.5 , compared with the other DC subsets which had a 
ratio of 1-1.8 (Fig. 9.6). In this case, the CD103+CD11b+ DCs had a WT:KO ratio 
approaching 1, which was significantly higher than that of the CD103+CD11b- and 
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CD103-CD11b- DC subsets (Fig. 9.6). In contrast, there was no skewing to WT 
origin amongst MLN resident or splenic DCs (Fig. 9.7 and Fig. 9.8). Together 
these findings indicate that the partial reduction of CD103-CD11b+ DCs in the 
intestine of CCR2-/- mice is cell intrinsic, whereas the effects of CCR2 deficiency 
on other DCs in the MLN and spleen are secondary to effects on other cell types. 
9.4 CD103-CD11b+ DCs in WT:CCR2- /- Parabiotic Mice 
To verify further the partial dependence of CD103-CD11b+ DCs on CCR2, I 
had the opportunity to examine WT:CCR2-/- parabiotic mice in collaboration with 
Bernard Malissen’s lab in Marseille. These were created by surgically joining 
CD45.1+ WT mice with CD45.2+ CCR2-/- mice and they were compared to 
CD45.1+ WT partnered with CD45.2+ WT controls (Fig. 9.9). The parabiotic mice 
were left for 12 weeks after the procedure to allow blood vessels to fuse and 
chimerism to be established. The level of chimerism for CD45.1+-derived DCs in 
the SI LP of the CD45.2+ WT partners in the WT:WT parabionts varied slightly 
between the subsets, but was generally in the region of 10-20% (Fig. 9.10A,C). 
Identical levels of chimerism were found for CD45.1+ WT-derived CD103+CD11b+, 
CD103+CD11b- and CD103-CD11b- DCs in the CD45.2+ CCR2-/- partners in the 
WT:CCR2-/- parabionts. However considerably more CD45.1+ WT-derived cells 
(~30%) were present amongst the CD103-CD11b+ DCs in WT:CCR2-/- parabionts 
than in the WT:WT parabionts (Fig. 9.10B,C). Unfortunately, the small group size 
meant that I could not conduct statistical analysis of these differences and we 
were also unable to obtain sufficient blood cells as a baseline control for the levels 
of chimerism for pre-DCs in the parabionts. Therefore these findings need to be 
verified with larger sample numbers and appropriate blood controls. 
Analysis of the opposite (CD45.1+) partners suggested that CD45.2+ blood-
derived cells were generally more efficient at reconstituting the CD45.1 host, as 
15-30% of SI LP DCs were of non-host origin in these mice (Fig. 9.11A,C). Under 
these conditions, all DC subsets showed a defective chimerism when derived from 
CCR2-/- origin, with only 5-10% being of non-host (CCR2-/-) origin (Fig. 9.11B,C). 
The reasons for this discrepancy between partners is unclear, but it seems to 
confirm my findings in competitive chimeras, where all DC populations and CCR2-
independent eosinophils showed a slight bias towards WT reconstitution.  
 262 
9.5  CCR2 Expression by Intestinal DCs 
9.5.1 Anti-CCR2 Antibody Reactivity 
Having established that the CD103-CD11b+ DCs were partially dependent 
upon CCR2, I hypothesised that this may reflect heterogeneity of CCR2 
expression within this population. Therefore, I examined the levels of CCR2 on the 
various DC subsets, first using a commercially available anti-CCR2 antibody. 
Because of previous problems in the laboratory with non-specific staining using 
anti-CCR2 antibodies, I used total CD11c+MHCII+CD64- LP DCs from CCR2-/- 
mice as controls. This revealed the presence of two distinct populations of CD103-
CD11b+ DCs, the majority of which were CCR2- and 15-30% were CCR2+ (Fig. 
9.12). While some CCR2 expression was also detected amongst CD103+CD11b- 
DCs, this was considerably lower than that on CD103-CD11b+ DCs and a clear 
positive population was not observed (Fig. 9.12). CD103+CD11b+ DCs did not 
express CCR2 above background levels, but somewhat surprisingly given their 
normal levels in CCR2-/- LP, the CD103-CD11b- DCs expressed similar levels of 
CCR2 to CD103-CD11b+ DCs (Fig. 9.12). CCR2+CD103-CD11b+ DCs were also 
present amongst total migratory DCs in the MLN, whereas none of the other 
migratory DC populations expressed CCR2, including the CD103-CD11b- DCs 
which were CCR2+ in LP (Fig. 9.13).  Interestingly, similar populations of CCR2+ 
cells could be identified amongst CD103-CD11b+ DCs in the lung and amongst 
CD11b+ (CD4+) DCs in the spleen (Fig. 9.14). 
9.5.2 CCL2-AF647 Uptake Assay 
Due to the problems we and others had encountered with the anti-CCR2 
antibody, I decided to try and confirm my results using a new assay developed by 
Professor Rob Nibbs’ group in our department in which CCR2+ cells are identified 
by the uptake of fluorescently labelled CCL2. This had already been used 
successfully for analysis of spleen and lymph nodes (Ford et al., 2013; McKimmie 
et al., 2008), but not in the intestine. This approach validated the results I obtained 
in the MLN using anti-CCR2 antibody staining, with only the CD103-CD11b+ 
migratory DCs showing uptake of CCL2 (Fig. 9.15). The specificity of this assay 
was confirmed by the absence of uptake by any DCs from CCR2-/- MLNs.  
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Rather different results were obtained when DC from SI LP were examined 
using this assay, as all the populations of DCs showed significant and similar 
levels of CCL2 uptake, apart from CD103+CD11b+ DCs which were negative (Fig. 
9.16). As this assay has not yet been compared exhaustively with antibody 
staining for a wide range of cells and tissues, the reasons for these discrepancies 
are unclear and require further investigation.  
9.5.3 CCR2+/RFP Mice 
To attempt to address the discrepancies between the anti-CCR2 antibody 
and CCL2 uptake assay, I had the opportunity to examine CCR2+/RFP mice in 
collaboration with Dr. Barry McColl in Edinburgh. These mice revealed yet another 
pattern of CCR2 expression amongst DCs. Consistent with the results I had 
obtained using antibody staining, the CD103-CD11b+ LP DCs were the major 
CCR2-expressing DC population in the SI LP of CCR2+/RFP mice (Fig. 9.17). 
However ~70% of these were CCR2+ using this approach, compared with only 
~20% using antibody staining. In parallel, the CD103+CD11b+, CD103+CD11b- and 
CD103-CD11b- LP DCs also appeared to contain more CCR2+ cells using the RFP 
mice (~20%, 20% or 50% respectively), whereas antibody staining had suggested 
that these populations were largely negative for CCR2 expression (Fig. 9.17). 
Analysis of the migratory DC populations in the MLNs of these mice revealed a 
similar pattern to that seen in the LP (Fig. 9.18). It is possible that the additional 
CCR2+ cells revealed in the CCR2+/RFP mice may represent intracellular 
expression of CCR2 that was not detected by the antibody. Alternatively, it is not 
known how long RFP expression is maintained after downregulation of CCR2 
surface expression, nor at what stage(s) of development this may occur. Thus 
CCR2-RFP+ cells in these mice may have expressed CCR2 earlier in development 
but fail to maintain expression. 
Together these results appear to confirm the findings in CCR2-/- mice that 
intestinal CD103-CD11b+ DCs show a selective association with expression of this 
receptor. However further investigation is required to explore the reasons for the 
discrepant results obtained using different methods for detecting CCR2 expression. 
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9.6 Putative CCR2+CD103-CD11b+ Equivalent DCs Exist in the 
Healthy Human Colonic LP 
Around the time I had identified CCR2+ DCs in the murine intestine, Dr 
Simon Milling’s group were establishing methods for characterising DCs in human 
intestine and I decided it would be of interest to examine if CCR2 expression might 
also define heterogeneity in humans. DCs were identified in healthy human colonic 
LP as live CD45+ CD14- CD64- CD11c+ HLA-DR+ cells (Bain et al., 2013; 
Jaensson et al., 2008; Persson et al., 2013b; Schlitzer et al., 2013) and then 
divided into three populations on the basis of CD103 and SIRPα expression (Fig. 
9.19A,B). The latter was used as a surrogate marker for CD11b, which is not a 
useful marker of human DCs, but its expression in many species appears to 
identify the DC subsets homologous to CD11b+ DCs in mice (Persson et al., 
2013b; Schlitzer et al., 2013). Using this approach, clear populations of 
CD103+SIRPα+, CD103+SIRPα- and CD103-SIRPα+ DCs could be identified. 
Interestingly, a significant proportion of CD103-SIRPα+ DCs, the putative 
equivalents of murine CD103-CD11b+ DCs, expressed CCR2, indicating that this 
population may be heterogeneous in both species. However, in contrast to mice, 
humans CD103-SIRPα+ DCs contained approximately equal proportions of CCR2+ 
and CCR2- cells (Fig. 9.19C). A smaller proportion of human CD103+SIRPα+ DCs 
also expressed CCR2, while the CD103+SIRPα- DCs did not (Fig. 9.19C). 
However, it should be noted that it was more difficult to resolve clearly between 
CD103+ and CD103- DCs in humans than in mice. Thus the apparent expression 
of CCR2 by CD103+SIRPα+ DCs needs further confirmation using better-optimised 
staining methods.  
9.7 CCR2+CD103-CD11b+ MPs are genuine DCs  
As noted above, CCR2 dependency has usually been interpreted to mean 
that MPs are derived from monocytes. Therefore I thought it important to rule out 
the possibility that the CCR2+ subset of CD103-CD11b+ I had found represented a 
population of monocyte derived cells that might have had been overlooked in my 
earlier analyses in which I had assumed the CD103-CD11b+ DCs to be a 
homogenous population. First, I FACS-purified the CCR2- and CCR2+ subsets of 
CD103-CD11b+ SI LP DCs and compared their expression of mRNA for the DC-
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specific genes, Zbtb46 and Flt3 with the other LP populations of DCs and mφs. 
This showed that both the CCR2+ and CCR2- subsets of CD103-CD11b+ DCs 
expressed Zbtb46 and Flt3 at identical levels to the CD103+ DC subsets (Fig. 
9.20). In addition and consistent with their presence in the migratory population of 
DCs in the MLNs, the CCR2+CD103-CD11b+ DCs also expressed mRNA for Ccr7 
at similar levels to the CCR2-CD103-CD11b+ and CD103+ DC subsets (Fig. 9.20). 
These results contrasted markedly with the lack of expression of any of these 
genes by the CD64+ mφs which are the progeny of CCR2-dependent Ly6Chi 
monocytes (Bain et al., 2013; Tamoutounour et al., 2012).  
As these results suggested that pre-DCs were likely to give rise to CCR2+ 
DCs, I next examined this directly by investigating CCR2 expression by donor-
derived DCs in the SI LP 5 days after transfer of FACS-purified pre-DCs. Under 
these conditions, 15-20% of donor-derived CD103-CD11b+ and CD103-CD11b- 
DCs in the SI LP expressed CCR2, clearly demonstrating that CCR2+CD103- DCs 
arise from pre-DCs (Fig. 9.21). Small numbers of donor-derived CD103+CD11b+ 
and CD103+CD11b- DCs SI LP DCs also expressed CCR2, although these were 
far lower than with the CD103- subsets (Fig. 9.21).  
9.8 Development of all SI LP DC Subsets is Partially Dependent 
on CCR2 
I next investigated whether CCR2 expression by pre-DCs might account for 
the expression of and dependence on CCR2 by some LP DCs. Anti-CCR2 
antibody staining showed that a proportion of pre-DCs (~25%) in normal BM 
expressed this receptor and this was specific, as no staining was found using 
CCR2-/- BM as controls (Fig. 9.22A,B). In comparison, ~80% of Ly6Chi monocytes 
were CCR2+ in the same experiment (Fig. 9.22A,B). This expression of CCR2 did 
not appear to correlate with a dependence of pre-DCs on CCR2, as WT and 
CCR2-/- mice had identical proportions of pre-DCs in the BM and blood. In contrast 
and as expected, Ly6Chi monocytes were virtually absent from the blood of CCR2-
/- mice, confirming the requirement for this receptor in the export of these cells 
from the BM (Fig. 9.22C,D).  
As I was unable to purify enough CCR2+ pre-DCs to determine whether 
CCR2 expression defined the function of pre-DCs using an adoptive transfer 
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approach, I decided to examine this by competitively transferring pre-DCs from 
CD45.1+/CD45.2+ WT and CD45.2+ CCR2-/- BM into CD45.1 resting WT recipients. 
Interestingly, 7 days after transfer, I found that all DC subsets were derived 
preferentially from WT pre-DCs, with only 25-35% being derived from the CCR2-/- 
pre-DCs. No significant differences in CCR2 dependence were seen between the 
DC subsets under these conditions (Fig. 9.23). Thus CCR2 plays a role in the 
generation of all DC subsets, suggesting that it may be required for the recruitment 
of pre-DCs into tissues and/or their subsequent development into mature DCs. 
Further studies are required to investigate this phenomenon. 
9.9 Functions of CCR2+CD103-CD11b+ Intestinal DCs 
Having identified CCR2+ DCs in SI LP, I wanted to examine if these were 
functionally distinct from their CCR2- counterparts.  
9.9.1 In Vitro Functions 
Due to the limitations on sorting multiple populations simultaneously, I 
decided to focus on the CCR2+CD103-CD11b+ DCs, as these were the subset 
which consistently showed the highest expression of CCR2 and dependence on its 
presence. Furthermore, these were the only CCR2+ DCs found in the MLNs, the 
tissue where any immune priming activity by mucosa-derived DCs will take place.  
Thus I FACS-purified CCR2+ and CCR2- CD103-CD11b+ DCs from SI LP of WT 
mice, pulsed them with OVA-protein and examined their ability to induce 
proliferation and functional differentiation of FACS-purified, naïve, CFSE-labelled 
OTII CD4+ T cells in vitro. As controls, I compared the APC activity of sorted 
CD103+CD11b+ and CD103+CD11b- DCs from the same mice.  
These studies showed that the CCR2+CD103-CD11b+ LP DCs (herein 
referred to as CCR2+ DCs) were as capable as the other SI LP DC populations at 
inducing antigen-specific CD4+ T cell proliferation, as assessed by dilution of the 
CSFE dye (Fig. 9.24A). The CCR2+ and CCR2- subsets of CD103-CD11b+ DCs 
induced similar levels of FoxP3 expression by the CD4+ T cells, with both being 
less efficient at this than either of the CD103+ DC populations, consistent with my 
previous findings (Fig. 9.24). The CCR2+ subset also induced similar proportions 
of IFNγ production by co-cultured CD4+ T cells as the CCR2-CD103-CD11b+ and 
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CD103+CD11b+ DCs. As before, the CD103+CD11b- DCs were the most effective 
inducers of IFNγ (Fig. 9.25). In contrast, the CCR2+ DCs were the most efficient at 
driving Th17 cell polarisation, inducing 2-fold more IL17a+ CD4+ T cells than either 
their CCR2- counterparts or the CD103+CD11b+ DCs and approximately 5-fold 
more IL17a+ T cells than the CD103+CD11b- DCs (Fig. 9.26).  
As these results suggested that the CCR2+CD103-CD11b+ DCs had a 
superior ability to prime Th17 cells in vitro, I next investigated if the absence of 
CCR2 dependent DCs in CCR2-/- mice influenced the ability of LP DCs to induce T 
cell priming in vitro. To do this, I cultured naïve CD4+ T cells with OVA pulsed 
CD103-CD11b+ DCs from the SI LP of WT and CCR2-/- mice. These experiments 
showed that CD103-CD11b+ DCs from WT and CCR2-/- mice induced similar 
levels of proliferation and Th1 differentiation in vitro, but the CCR2-/- DCs were 
significantly less effective at inducing Th17 differentiation than their WT 
counterparts (Fig. 9.27). 
Together these results suggest that the CCR2 expressing/dependent subset 
of CD103-CD11b+ DCs has a preferential ability to drive the generation of Th17 
cells in vitro. 
9.9.2 In Vivo Functions 
 I next examined the in vivo consequences of these findings by comparing T 
cell priming in WT and CCR2-/- mice using a protocol known to induce Th17 
differentiation in MLNs (Persson et al., 2013b). Naïve OTII cells were transferred 
into WT and CCR2-/- mice, which were immunised i.p. 1 day later with OVA 
together with anti-CD40 and LPS as adjuvants. Immunised mice also received the 
S1P agonist FTY720 1 and 3 days after immunisation to prevent the activated T 
cells from leaving the MLNs. Four days after immunisation, intracellular cytokine 
staining revealed there were significantly fewer IL17a+ cells in the MLNs of 
immunised CCR2-/- mice compared with WT controls, whereas IFNγ+ cells were 
identical (Fig. 9.28A). 
To investigate further the role of CCR2-dependent CD103-CD11b+ DCs in 
priming Th17 cells in vivo, I next infected WT and CCR2-/- mice with Citrobacter 
rodentium. 6 days later, the two strains showed similar levels of infection as 
 268 
assessed counts of colony forming units in faeces (Fig. 9.28B). However on day 7, 
the CCR2-/- mice had significantly fewer Th17 cells in the MLNs than seen in WT 
mice, whereas Th1 cell priming was unaffected (Fig. 9.28C). Together these 
results support the idea that CCR2-dependent CD103-CD11b+ DCs play a 
selective role in the priming of Th17 cells. 
9.9.3 Enhanced Th17 Induction by CCR2+CD103-CD11b+ DCs Correlates 
with Increased IL12/IL23p40 Production 
In an attempt to understand why CCR2+CD103-CD11b+ DCs had a 
preferential ability to prime Th17 cells, I compared the CCR2- and CCR2+ CD103-
CD11b+ DCs, as well as the CD103+ DC populations for their expression of Th17 
polarising cytokines. First I examined IL6 production by the DC subsets in the 
presence and absence of exogenous TLR4 stimulation. Intracellular cytokine 
staining revealed that a slightly lower proportion of resting CCR2+CD103-CD11b+ 
DCs produced IL6 than the other subsets and a similar pattern was seen when the 
DCs were stimulated with LPS, which had no significant effects on IL6 production 
by any subset (Fig. 9.29). Thus IL6 production is unlikely to account for the 
increased propensity of CCR2+ DCs to induce Th17 cell differentiation. In contrast, 
~3-fold more CCR2+CD103-CD11b+ DCs expressed IL12/IL23p40 in the steady 
state than either the CCR2-CD103-CD11b+ or CD103+CD11b+ DC subsets (Fig. 
9.30). Interestingly the preferential ability of steady state CD103+CD11b- DCs to 
prime Th1 cells in vitro was associated with the presence of similar numbers of 
IL12/IL23p40 producing cells to those seen amongst CCR2+CD103-CD11b+ DCs, 
perhaps reflecting IL12 production by the CD103+CD11b- DCs. LPS stimulation led 
to increases in the proportion of IL12/IL23p40 producing cells amongst all the DC 
subsets except for the CD103+CD11b- DCs, but this was much more marked with 
CCR2+CD103-CD11b+ DCs, with ~30% of these now producing the cytokine (Fig. 
9.30). As I was unable to detect IL23p19 using either commercially available 
antibodies or qPCR analysis of steady state DCs, or develop a protocol in which 
LPS stimulated DCs could be analysed by qPCR, it is not possible to conclude 
definitively that these findings reflect enhanced IL23 production by the 
CCR2+CD103-CD11b+ DCs. However, their selective effect on Th17 cell 
differentiation and the lack of correlation between their ability to produce 
IL12/IL23p40 and prime Th1 cells would suggest that IL23 accounts for the 
difference in IL12/IL23p40 production by these cells.  
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9.10  Summary  
In the previous chapters, I had defined DC populations in the intestine based 
on their phenotype, kinetics, Flt3L dependence, ontogeny and function. These 
studies revealed four distinct subsets of DCs, including two novel CD103- DC 
populations, which were derived from DC-committed precursors and not from the 
Ly6Chi monocytes, which gave rise solely to CD64+F4/80+ mφs. However recent 
work from the Jung lab proposed that a genuine population of CCR2-dependent, 
Zbtb46+ monocyte-derived DC exists, albeit during inflammation (Zigmond et al., 
2012). Thus in order to align these results with my own, in this chapter I examined 
the CCR2 dependence of the DC populations I had identified earlier.  
Initially I found that CCR2-/- mice had reduced numbers of CD103-CD11b+ 
DCs in the SI LP and amongst migratory DCs in the MLNs. This partial reduction 
was cell intrinsic, as these DC populations were also reduced in WT:CCR2-/- 
mixed BM chimeras. A population of CCR2-dependent CD11b+ DCs was also 
found in lung and spleen and I hypothesised that these DCs may correspond to 
steady state equivalents of those identified by Zigmond et al. (Zigmond et al., 
2012).  
I next investigated if the partial dependence on CCR2 reflected heterogeneity 
in the CD103-CD11b+ DC subset and examined their expression of CCR2, using 
antibody staining, a CCL2 uptake assay and CCR2+/RFP reporter mice. All these 
methods showed that the intestinal CD103-CD11b+ DC population was 
consistently heterogeneous for CCR2 expression, with the majority of the 
population being CCR2- while 15-25% were CCR2+, consistent with these being 
reduced in CCR2-/- mice. However the exact levels of CCR2 and the pattern of 
CCR2 expression by the different DC subsets varied depending on the assay used 
and it appeared that CCR2 may also be expressed by other intestinal DC at least 
at some stages of their development. This requires further investigation in the 
future. 
Although I had not been able to find Ly6Chi monocytes giving rise to any of 
my original DC subsets in Chapter 4, to rule out the possibility that the newly 
discovered small subset of CCR2+CD103-CD11b+ DCs might have been 
overlooked in my previous analyses, I first showed that this subset expressed the 
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DC specific genes Zbtb46, Flt3 and CCR7 at the same levels as the other, 
previously defined subsets in SI LP. I next found that adoptively transferred pre-
DC gave rise to both CCR2+ and CCR2- CD103-CD11b+ DCs. Interestingly a small 
population of pre-DCs also expressed CCR2 and although pre-DC numbers were 
normal in CCR2-deficient mice, WT precursors outcompeted CCR2-/- pre-DCs in 
their ability to generate all DC subsets in vivo. Thus CCR2 may play a wider role in 
DC development than is suggested by the small and selective defect in the KO 
mice.  
I next determined the functional characteristics of this previously 
unrecognised population of CCR2+CD103-CD11b+ DCs. The CCR2+ DCs were 
equally capable of inducing naïve CD4+ T cells to proliferate and acquire FoxP3 
expression or IFNγ production in vitro as the CCR2-CD103-CD11b+ DC subset 
However the CCR2+ DCs were superior at inducing IL17a production by 
proliferating T cells to any other DC subset, including the CD103+CD11b+ DCs 
recently proposed to be the main inducers of mucosal Th17 responses in vivo 
(Denning et al., 2011; Lewis et al., 2011; Persson et al., 2013b; Schlitzer et al., 
2013). Importantly, total CD103-CD11b+ DCs from CCR2-/- mice were also less 
able to induce Th17 cells compared with WT CD103-CD11b+ DC ex vivo and 
CCR2-/- mice had defective induction of Th17 cells in the MLNs in vivo after 
immunisation with specific antigen plus adjuvant, and during infection with 
Citrobacter rodentium. The enhanced ability of CCR2+CD103-CD11b+ DCs to drive 
Th17 responses correlated with high levels of production of IL12/IL23 and this 
appeared to reflect IL23 rather than IL12. As I was able to identify a population of 
CCR2+CD103-SIRPα+ DCs in the healthy human colonic LP, this heterogeneity 
may be of clinical relevance. 
Overall, these studies have identified a novel population of CCR2+ CD103-
CD11b+ DCs that are derived from DC-committed precursors and that are involved 
in driving Th17 responses both in vitro and in vivo. However it has to be noted that 
this conclusion appears to contradict my earlier findings in Chapters 7 and 8, 
where I found that a lack of CD103+CD11b+ DCs was associated with decreased 
Th17 responses in vivo and these discrepant results require further exploration. 
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Figure 9.1: DC subsets in SI LP of CCR2-/- mice 
SI LP cells were isolated from WT and CCR2-/- mice and total DC (live CD45+ CD11c+ MHCII+ 
CD64-) were analysed for expression of CD103 and CD11b. A. Representative dot plots of CD103 
and CD11b expression by WT and CCR2-/- mice. B. Proportion of each SI LP DC population as a 
percentage of total DC in WT and CCR2-/- (KO) mice. C. Absolute number of each DC population 
in SI LP of WT and CCR2-/- (KO) mice. D. Absolute number of CD64+ mφs in the SI LP of CCR2-/- 
mice compared with WT controls. Data are representative of 2 independent experiments with 
n=3-4 per group per experiment. *p<0.05, **p<0.01, ***p<0.001, Student’s t test. 
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Figure 9.2: DC subsets amongst migratory DC in MLNs of CCR2-/- mice 
MLN cells were isolated from WT and CCR2-/- mice and CD11c+MHCIIhi migratory DCs were 
examined for expression of CD103 and CD11b. A. Representative CD103 and CD11b expression 
by migratory DCs in WT and CCR2-/- mice. B. Proportion of each migratory DC subset as a 
percentage of total migratory DC in the MLNs of WT and CCR2-/- (KO) mice. C. Absolute numbers 
of each migratory DC population in WT and CCR2-/- (KO) mice. D. Absolute numbers of total 
migratory DCs in WT and CCR2-/- (KO) mice. E. Total cell number in MLNs of WT and CCR2-/- 
(KO) mice. Data are from a single experiment with n=4. *p<0.05, **p<0.01, Student’s t test. 
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Figure 9.3: DC subsets amongst resident DCs in MLN of CCR2-/- mice 
MLN cells were isolated from WT and CCR2-/- mice and CD11c+MHCIIint resident DCs were 
examined for expression of CD103 and CD11b. A. Representative CD103 and CD11b expression by 
resident DCs in WT and CCR2-/- mice. B. Proportion of each resident DC subset as a percentage of 
total resident DCs in the MLN of WT and CCR2-/- (KO) mice. C. Absolute numbers of each resident 
DC population in WT and CCR2-/- (KO) mice. Data are from a single experiment  with n=4. *p<0.05, 
Student’s t test. 
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Figure 9.4: DC subsets in spleen of CCR2-/- mice 
Splenocytes were isolated from WT and CCR2-/- mice and total CD11c+MHCII+CD64- DCs were 
examined for expression of CD4. A. Representative staining of CD11c and CD4 expression by 
total DC in WT and CCR2-/- mice. B. Proportion of CD4+ and CD4- DC as a percentage of total DC 
in WT and CCR2-/- (KO) mice. C. Absolute numbers of CD4+ and CD4- DC in WT and CCR2-/- (KO) 
mice. D. Absolute numbers of total DCs in spleens of WT and CCR2-/- (KO) mice. E. Total cell 
numbers in spleens of WT and CCR2-/- (KO) mice.  Data are from a single experiment with 
n=4.**p<0.01, ***p<0.001, Student’s t test. 
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Figure 9.5: Myeloid Populations in SI LP of WT:CCR2-/- competitive BM chimeras 
Mixed WT:CCR2-/- BM chimeras were generated by lethally irradiating CD45.1/CD45.2 WT mice 
and reconstituting with a 50:50 mix of CD45.1+ WT and CD45.2+ CCR2-/- BM. The level of 
chimerism was assessed 8 weeks after reconstitution. A. CD45.1 and CD45.2 expression by the 
BM leukocyte mixture used to reconstitute irradiated recipients. B. Live CD45+ CD11c+ MHCII+ MP 
populations as defined in Fig. 3.3 and live CD45+ CD11b+ MHCII- SSChi eosinophils  in SI LP were 
analysed for CD45.1+ and CD45.2+ expression. Numbers represent percentage of CD45.1 or 
CD45.2 cells amongst each population. C. Ratio of WT:CCR2-/- derived cells amongst the 
populations of MPs and eosinophils from SI LP of chimeric mice. ***p<0.001, one way ANOVA 
with Bonferroni post-test between mφs and all other SI LP MP populations.	  Data are from a single 
experiment with n=3. 
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Figure 9.6: Migratory DCs in MLNs of WT:CCR2-/- competitive BM chimeras 
Mixed WT:CCR2-/- BM chimeras were generated by lethally irradiating CD45.1/CD45.2 WT mice 
and reconstituting with a 50:50 mix of CD45.1+ WT and CD45.2+ CCR2-/- BM. The level of 
chimerism was assessed 8 weeks after reconstitution. A. Migratory MLN CD11c+MHCIIhi DCs 
were analysed for CD45.1 and CD45.2 expression. Numbers represent percentage of CD45.1+ or 
CD45.2+ cells amongst each DC population. B. Ratio of WT:CCR2-/- derived cells amongst the 
populations of migratory DCs in MLNs of chimeric mice. *p<0.05, **p<0.01, ***p<0.001, one way 
ANOVA with Bonferroni post-test.	  Data are from a single experiment with n=3. 
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Figure 9.7: Resident DCs in MLNs of WT:CCR2-/- competitive BM chimeras 
Mixed WT:CCR2-/- BM chimeras were generated by lethally irradiating CD45.1/CD45.2 WT mice 
and reconstituting with a 50:50 mix of CD45.1+ WT and CD45.2+ CCR2-/- BM. The level of 
chimerism was assessed 8 weeks after reconstitution. A. Resident MLN CD11c+MHCIIint DCs 
were analysed for CD45.1 and CD45.2 expression. Numbers represent percentage of CD45.1+ or 
CD45.2+ cells amongst each DC population. B. Ratio of WT:CCR2-/- derived cells amongst the 
populations of resident DCs in MLNs of chimeric mice. **p<0.01, one way ANOVA with Bonferroni 
post-test.	  Data are from a single experiment with n=3. 
A 
CD45.2 
C
D
45
.1
 
59.2 
39.9 
33.6 
64.5 
CD103+CD11b- CD103-CD11b+ CD103-CD11b- 
B 
43.2 
54.9 
CD
10
3+
CD
11
b-
CD
10
3- C
D1
1b
+
CD
10
3- C
D1
1b
-
0
1
2
3
4
Input     
R
at
io
 o
f
 W
T:
K
O **
278 
Figure 9.8: Splenic DC populations in WT:CCR2-/- competitive BM chimeras 
Mixed WT:CCR2-/- BM chimeras were generated by lethally irradiating CD45.1/CD45.2 WT mice 
and reconstituting with a 50:50 mix of CD45.1+ WT and CD45.2+ CCR2-/- BM. The level of 
chimerism was assessed 8 weeks after reconstitution. A. Splenic CD11c+MHCII+CD64- DCs were 
analysed for CD45.1 and CD45.2 expression. Numbers represent percentage of CD45.1+ or 
CD45.2+ cells amongst each DC population. B. Ratio of WT:CCR2-/- derived cells amongst the 
populations of splenic DCs of chimeric mice.	  Data are from a single experiment with n=3. 
A 
CD45.2 
C
D
45
.1
 
54.3 
39.8 
55.9 
36.6 
CD11b+ CD11b- 
B 
CD11b+ CD11b-
0
1
2
3
4
Input     
R
at
io
 o
f 
W
T:
K
O
279 
Figure 9.9: Generation of WT:WT and WT:CCR2-/- parabiotic mice 
Parabiotic mice were generated in Bernard Malissen’s group in Marseille, France by Dr. Sandrine 
Henri. A,B. WT:WT parabionts (A) and WT:CCR2-/- parabionts (B) were surgically and left for 12 
weeks to allow exchange of blood leukocytes, before the SI LP was analysed for the level of 
chimerism in each partner.  
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Figure 9.10: CD45.1+ DC populations in SI LP of CD45.2+ parabiont partner 
WT:WT (CD45.1:CD45.2) and WT:CCR2-/- (CD45.1:CD45.2) parabiotic mice were generated as 
shown in Fig. 9.9 and left for 12 weeks before tissues were harvested and the level of chimerism 
examined.  A. Representative CD45.1 and CD45.2 staining amongst populations of CD11c+MHCII
+CD64- DCs in SI LP of the CD45.2+ WT partner of WT:WT parabionts. Numbers represent 
percentage of CD45.1+ or CD45.2+ cells in each DC population. B. Representative CD45.1 and 
CD45.2 staining amongst populations of CD11c+MHCII+CD64- DCs in SI LP of the CD45.2+ 
CCR2-/- partner of WT:CCR2-/- parabionts. Numbers represent percentages of CD45.1+ or CD45.2+ 
cells in each DC population. C. Percentage of non-host (CD45.1+) cells in CD45.2+ parabiotic 
partners. Data are from a single experiment with 4 WT:WT parabionts and 2 WT:CCR2-/- 
parabionts. 
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Figure 9.11: CD45.2+ DC populations in SI LP of CD45.1+ parabiotic mice 
WT:WT (CD45.1:CD45.2) and WT:CCR2-/- (CD45.1:CD45.2) parabiotic mice were generated as 
shown in Fig. 9.9 and left for 12 weeks before tissues were harvested and the level of chimerism 
examined.  A. Representative CD45.1 and CD45.2 staining amongst populations of CD11c+MHCII
+CD64- DCs in SI LP of the CD45.1+ WT partner of WT:WT parabionts. Numbers represent 
percentage of CD45.1+ or CD45.2+ cells in each DC population. B. Representative CD45.1 and 
CD45.2 staining amongst populations of CD11c+MHCII+CD64- DCs in SI LP of the CD45.1+ 
CCR2-/- partner of WT:CCR2-/- parabionts. Numbers represent percentages of CD45.1+ or CD45.2+ 
cells in each DC population. C. Percentage of non-host (CD45.2+) cells in CD45.1+ parabiotic 
partners. Data are from a single experiment with 4 WT:WT parabionts and 2 WT:CCR2-/- 
parabionts. 
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Figure 9.12: CCR2 expression by SI LP DCs 
SI LP DC populations were identified as CD11c+MHCII+CD64- and examined for expression of 
CCR2 by flow cytometry. A. Representative CCR2 expression on each SI LP DC population from 
WT mice. B. CCR2 expression by total CD11c+MHCII+CD64- DCs from CCR2-/- mice as control. 
Numbers represent percentage of CCR2+ DCs. C. Proportion of CCR2+ cells as a percentage of 
each DC population. Data are representative of at least 7 independent experiments with n=3-5 per 
experiment. 
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Figure 9.13: CCR2 expression by migratory DCs in MLN 
DC populations amongst CD11c+MHCIIhi migratory MLN DCs were identified and examined for 
expression of CCR2 by flow cytometry. A. Representative CCR2 expression on each DC 
population from WT mice. B. CCR2 expression by total migratory CD11c+MHCIIhi DCs from 
CCR2-/- mice as control. Numbers represent percentage of CCR2+ DCs. C. Proportion of CCR2+ 
cells as a percentage of each DC population. Data are representative of at least 2 independent 
experiments with n=4 per experiment. 
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Figure 9.14: CCR2 expression by DCS from lung and spleen 
A. CD103-CD11b+ DC were identified amongst live CD45+ CD11c+ MHCII+ CD64- non-
autofluorescent cells in lung digests of WT mice as and examined for expression of CCR2 and 
compared with CD103-CD11b+ DC from lungs of CCR2-/- mice. B. CD11b+ DCs were identified 
amongst live CD45+ CD11c+ MHCII+ cells in spleen digests of WT mice as and examined for 
expression of CCR2 and compared with CD11b+ DCs from spleen of CCR2-/- mice. Data are from 
a single experiment with 4 WT mice and 1 CCR2-/- mouse. 
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Figure 9.15: CCL2-AF647 uptake by migratory DCs in the MLN 
Populations of migratory CD11c+MHCIIhi DCs from WT and CCR2-/- MLNs were examined for their 
ability to bind AF647-labelled CCL2 by flow cytometry. A-D. AF647 fluorescence of (A) 
CD103+CD11b+, (B) CD103+CD11b-, (C) CD103-CD11b+ and (D) CD103-CD11b- migratory MLN 
DCs in WT mice compared with CCR2-/- controls. Numbers represent percentages of CCL2-
AF647+ DCs in each population. E. Background AF647 fluorescence by total migratory DCs in WT 
mice in the absence of AF647-CCL2 in fluorescence minus one (FMO) control. F. Proportion of 
CCR2+ DCs binding AF647-CCL2 as a percentage of each DC subset. Data are from a single 
experiment with n=4. 
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Figure 9.16: CCL2-AF647 uptake by SI LP DC. 
Populations of CD11c+MHCII+CD64- DCs from WT and CCR2-/- SI LP were examined for their 
ability to bind AF647-labelled CCL2 by flow cytometry. A-D. AF647 fluorescence of (A) 
CD103+CD11b+, (B) CD103+CD11b-, (C) CD103-CD11b+ and (D) CD103-CD11b- SI LP DCs in WT 
mice compared with CCR2-/- controls. Numbers represent percentages of CCL2-AF647+ DCs in 
each population. E. Background AF647 fluorescence by total migratory DCs in WT mice in the 
absence of AF647-CCL2 in fluorescence minus one (FMO) control. F. Proportion of CCR2+ DCs 
binding AF647-CCL2 as a percentage of each DC subset. Data are from a single experiment with 
n=4. 
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Figure 9.17: CCR2-RFP expression by SI LP DCs 
Populations of CD11c+MHCII+F4/80- DCs from CCR2+/RFP SI LP were examined for RFP 
expression by flow cytometry. A. RFP expression by each DC population. B. Background RFP 
expression in total DCs from WT SI LP. C. Proportion of CCR2-RFP+ DCs as a percentage of each 
DC subset. Data are from a single experiment with n=4. 
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Figure 9.18: CCR2-RFP expression by migratory MLN DCs 
Populations of migratory CD11c+MHCIIhi DCs from CCR2+/RFP MLNs were examined for RFP 
expression by flow cytometry. A. RFP expression by each migratory DC population. B. 
Background RFP expression in total migratory DCs from WT MLNs. C. Proportion of CCR2-RFP+ 
DCs as a percentage of each DC subset. Data are from a single experiment with n=4. 
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Figure 9.19: Putative CCR2+CD103-CD11b+ DC equivalents exist in healthy human 
 colonic lamina propria. 
A. DCs were identified in resected samples of healthy human colon as live CD45+ CD14- CD64- 
CD11c+ HLA-DR+ cells. B. Expression of CD103 and SIRPα was assessed on total human colonic 
LP DCs. C. Each DC population was assessed for CCR2 expression compared with CCR2 
isotype control by flow cytometry. Numbers represent the proportions of CCR2+ cells as a 
percentage of each DC population. Data are representative of 2 independent experiments. 
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Figure 9.20: Expression of DC related genes by CCR2+CD103-CD11b+ DCs from SI LP 
CCR2+ and CCR2- subsets of CD103-CD11b+ DC were  FACS-purified from SI LP digests of WT 
mice as shown in Fig. 9.12, together with CD103+CD11b+ DCs, CD103+CD11b- DCs and CD64+ 
mφs. A-C. qRT-PCR analysis of expression of (A) Zbtb46, (B) Flt3 and (C) Ccr7 mRNA expression 
by each subsets. Results shown are relative to HPRT using the 2-ΔΔct method with mφ set to 1. 
Data are from a single experiment with cells pooled from 9-12 mice.  
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Figure 9.21: Pre-DC are heterogeneous for CCR2 expression and give rise to CCR2+ 
CD103-CD11b+ DC 
7x105 CD45.1+/CD45.2+ pre-DCs from WT mice that had been inoculated with Flt3L secreting B16 
melanoma cells 10 days before, were FACS-purified, labelled with Cell Trace Violet dye and 
transferred i.v. into resting CD45.1+ recipients and analysed for CCR2 expression 5 days later. A. 
CD45.2+Violet+CD11c+MHCII+CD64- donor-derived SI LP DCs were examined for CCR2 
expression by flow cytometry. B. CCR2 isotype staining of endogenous host CD103+ and CD103- 
CD11c+MHCII+CD64- DCs. Numbers represent proportion of each DC population expressing 
CCR2 or binding isotype. Data are from a single experiment with 1 recipient mouse.  
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Figure 9.22: CCR2 expression and dependence by pre-DCs and Ly6Chi monocytes 
A. CCR2 expression was assessed on lin-CD11c+B220-CCR9- pre-DCs and Ly6Chi monocytes 
from WT and CCR2-/- BM by flow cytometry. Numbers represent the proportion of CCR2+ cells. B. 
Proportions of CCR2+ cells as a percentage of BM Ly6Chi monocytes or pre-DCs. C. Proportion of 
pre-DCs and Ly6Chi monocytes in WT and CCR2-/- BM as a percentage of total cells. D. 
Proportion of pre-DCs and Ly6Chi monocytes in WT and CCR2-/- blood as a percentage of total 
cells. Data are from a single experiment with n=4. **p<0.01, ***p<0.001 Student’s t test.  
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Figure 9.23: Comparative ability of WT and CCR2-/- pre-DCs to generate DCs in SI LP. 
3.5x105 CD45.2+ CCR2-/- pre-DCs and 3.5x105 CD45.1+/CD45.2+ WT pre-DCs from mice 
inoculated with Flt3L-secreting B16 melanoma cells 10 days before, were labelled with Cell Trace 
Violet dye, FACS-purified and adoptively transferred i.v. into resting CD45.1+ WT mice. 7 days 
later tissues were harvested and examined for CCR2-/- and WT derived DC. A. CD45.1 and 
CD45.2 expression by transferred pre-DCs. B. Identification of donor-derived CD45.2+Violet+ cells 
in SI LP of recipient mice compared with non-injected control. C. Representative staining showing 
CD11c and MHCII expression on donor-derived cells identified in B. D. Representative staining 
showing CD103 and CD11b expression amongst donor-derived CD11c+MHCII+ DCs identified in 
C. E. Ratio of CCR2-/- CD45.2+:WTCD45.1+/CD45.2+ derived DCs for each DC population in SI LP 
compared with the input ratio of transferred pre-DCs. F. Representative CD45.1 and CD45.2 
staining by each donor-derived DC population in SI LP. Data are from a single experiment with 3 
recipient mice. 
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Figure 9.24: Induction of FoxP3 in naïve CD4+ T cells by DC subsets from SI LP 
3x104 FACS-purified DC subsets from siLP were pulsed with 2mg/ml OVA protein and co-cultured 
for 4 days with 1x105 FACS-purified CFSE labeled naïve OVA-specific CD4+ (OTII) T cells before 
being assessed for CFSE dilution and FoxP3 expression by intracellular staining. A. 
Representative dilution of CFSE dye and FoxP3 expression by total T cells in culture with each 
DC subset. Numbers represent percentage of FoxP3+ T cells. B. Scatter plots show fold change in 
FoxP3 induction by each DC population compared with that obtained using CCR2-CD103-CD11b+ 
DCs. Data are shown as means ±1SD pooled from three independent experiments.  
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Figure 9.25: Induction of IFNγ in naïve CD4+ T cells by DC subsets from SI LP 
3x104 FACS-purified DC subsets from siLP were pulsed with 2mg/ml OVA protein and co-cultured 
for 4 days with 1x105 FACS-purified CFSE labeled naïve OVA-specific CD4+ (OTII) T cells before 
being assessed for CFSE dilution and IFNγ expression by intracellular staining. A. Representative 
dilution of CFSE dye and IFNγ expression by total T cells in culture with each DC subset. 
Numbers represent percentage of IFNγ+ T cells. B. Scatter plots show fold change in IFNγ 
induction by each DC population compared with that obtained using CCR2-CD103-CD11b+ DCs. 
Data are shown as means ±1SD pooled from three independent experiments.  
*p<0.05, one way ANOVA with Bonferroni post-test.  
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Figure 9.26: Induction of IL17a in naïve CD4+ T cells by DC subsets from SI LP 
3x104 FACS-purified DC subsets from siLP were pulsed with 2mg/ml OVA protein and co-cultured 
for 4 days with 1x105 FACS-purified CFSE labeled naïve OVA-specific CD4+ (OTII) T cells before 
being assessed for CFSE dilution and IL17a expression by intracellular staining. A. 
Representative dilution of CFSE dye and IL17a expression by total T cells in culture with each DC 
subset. Numbers represent percentage of IL17a+ T cells. B. Scatter plots show fold change in 
IL17a induction by each DC population compared with that obtained using CCR2-CD103-CD11b+ 
DCs. Data are shown as means ±1SD pooled from three independent experiments. *p<0.05, 
**p<0.01, ***p<0.001, one way ANOVA with Bonferroni post-test.  
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Figure 9.27: Role of CCR2 in generation of antigen-specific CD4+ effector T cells in 
vitro 
1.8x103 CD103‑CD11b+ DCs were FACS-purified from the SI LP of WT and CCR2-/- mice, pulsed 
with 2mg/ml OVA protein and co-cultured with naïve FACS-purified CFSE-labelled OTII cells for 
four days before IFNγ and IL17a production was assessed by intracellular cytokine staining. A 
Proportion of total T cells having gone through at least one round of proliferation as assessed by 
CFSE dilution following co-culture with WT or CCR2-/- CD103-CD11b+ DCs. B. Proportion of IFNγ+ 
and IL17a+ CD4+ T cells following co-culture with WT or CCR2-/- CD103-CD11b+ DCs as a 
percentage of total live CD4+ T cells. *p<0.05, Student’s t test. Data are pooled from three 
independent experiments with 1-2 mice per group per experiment.  
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Figure 9.28: Role of CCR2 in generation of antigen-specific CD4+ effector T cells in 
vivo 
A. WT and CCR2-/- mice received OTII cells i.v. and one day later were immunised i.p. with 0.5mg 
OVA, together with 25µg α-CD40 and 15µg LPS. One and three days later mice received 1mg/kg 
bodyweight FTY720 i.p. Mice were sacrificed four days after immunisation and IL17a+ and IFNγ+ T 
cells in the MLNs were identified by intracellular cytokine staining. Proportions of IL17a+ and IFNγ+ 
T cells in MLNs of WT and CCR2-/- mice. *p<0.05, Student’s t test. Data are from a single 
experiment with n=9-10 per group. B,C. WT and CCR2-/- mice were infected with 1x109 C. 
rodentium CFUs and on day 6 of infection, bacteria levels were examined by faecal colony counts 
(B). (C) On day 7, IL17a+ and IFNγ+ T cells in the MLNs were identified by intracellular cytokine 
staining. Proportions of IL17a+ and IFNγ+ T cells in MLNs of WT and CCR2-/- mice. *p<0.05, 
Student’s t test. Data are from a single experiment with n=5-10 per group.  
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Figure 9.29: Production of IL6 by DC subsets from SI LP 
Whole SI LP digests were incubated for 4.5hours in the presence of monensin and brefeldin A ± 
100ng/ml LPS and IL6 expression by subsets of CD11c+MHCII+CD64- DCs was assessed by 
intracellular cytokine staining. A,B. Representative staining showing IL6 expression by (A) CCR2-
CD103-CD11b+ and (B) CCR2+CD103-CD11b+ DC. C. Percentage of IL6+ cells in CCR2- and 
CCR2+ CD103-CD11b+ DC in the presence (+LPS) or absence (Unstim.) of LPS. Data are from a 
single experiment with n=4. **p<0.01 Student’s t test. D. Percentage of IL6+ cells amongst all 
populations of SI LP DCs in the presence (+LPS) or absence (Unstim.) of LPS. Data are from a 
single experiment with n=4. *p<0.05, **p<0.01, two way ANOVA with Bonferroni post-test. 
Asterisks denote different from CCR2+CD103-CD11b+ DCs. 
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Figure 9.30: Production of IL12/IL23p40 expression by DC subsets from SI LP 
Whole SI LP digests were incubated for 4.5hours in the presence of monensin and brefeldin A ± 
100ng/ml LPS and IL12/IL23p40 expression by subsets of CD11c+MHCII+CD64- DCs was 
assessed by intracellular cytokine staining. A,B. Representative staining showing IL12/IL23p40 
expression by (A) CCR2-CD103-CD11b+ and (B) CCR2+CD103-CD11b+ DC. C. Percentage of 
IL12/IL23p40+ cells in CCR2- and CCR2+ CD103-CD11b+ DC in the presence (+LPS) or absence 
(Unstim.) of LPS. Data are representative of 2 independent experiments with n=4-5 per 
experiment. ***p<0.001, Student’s t test. D. Percentage of IL12/IL23p40+ cells amongst all 
populations of SI LP DC in the presence (+LPS) or absence (Unstim.) of LPS. Data are 
representative of 2 independent experiments with n=4-5 per experiment. **p<0.01, ***p<0.001, 
two way ANOVA with Bonferroni post-test. Asterisks denote different from CCR2+CD103-CD11b+ 
DCs. 
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Chapter 10 General Discussion 
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10.1 Introduction 
The intestinal immune system is exposed continuously to a wide array of 
antigens including those from harmful pathogens, as well as harmless antigen 
deriving from commensal bacteria and dietary constituents. The immune system 
must respond appropriately by inducing active immunity against pathogens and 
tolerance to the harmless antigens. Dendritic cells (DCs), as sentinels of the 
immune system, are central to this process. However DCs in the intestine have 
been poorly characterised and often confused with other intestinal mononuclear 
phagocytes (MPs) such as mφs, resulting from the use of non-specific and 
overlapping markers. This is not simply a semantic issue, as the correct 
identification of DCs and mφs has important functional implications. Intestinal DCs 
acquire antigen and migrate to the MLNs, where they induce adaptive immune 
responses by presenting antigen to naïve T lymphocytes. In contrast intestinal 
mφs are tissue resident cells, which maintain the local environment by scavenging 
bacteria and damaged cells, as well as regulating epithelial integrity. Thus the 
main aim of this thesis was to analyse intestinal MP populations properly, so that 
the phenotype, ontogeny and function of intestinal DCs could be characterised 
precisely. To do this, I used multi-parameter flow cytometric techniques in 
combination with genetically modified mice and precursor tracking focussing 
principally on the small intestine and their draining lymph nodes.  
10.2 Identifying Dendritic Cells in the Intestine 
When I began my PhD, the prevailing dogma was that intestinal DCs could 
be identified solely on the basis of their expression of CD11c and MHCII, and that 
they consisted of three distinct populations. Two of these were CD103+ and 
derived from committed-DC precursors, while the third was CD103- and was 
thought to be monocyte-derived (Bogunovic et al., 2009; Varol et al., 2007; 2009). 
However, around the time I started, CX3CR1+/GFP mice (Jung et al., 2000) became 
widely available for the characterisation of myeloid cells and were used to identify 
a population of Flt3L-unresponsive, non-migratory CX3CR1-expressing cells which 
appeared to be the CD103- ‘DCs’ that had been found in previous studies (Schulz 
et al., 2009). This report suggested that the majority of these CD103- cells were 
mφs rather than DCs and it was proposed that mutually exclusive expression of 
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CD103 and CX3CR1 could be used to identify intestinal DCs and mφs respectively. 
Although I planned initially to employ this strategy, others in the lab had observed 
a population of CX3CR1intCD103- MPs which did not express the pan mφ marker 
F4/80 (Bain et al., 2013). Indeed, a small population of cells with this phenotype 
had been noted by Schulz and they appeared to expand in response to 
exogenous Flt3L in vivo, albeit at a greatly reduced level compared with the 
CD103+ DCs (Schulz et al., 2009). 
Together these results suggested that at least some CX3CR1-expressing 
MPs might be genuine DCs and therefore, I decided to develop a new gating 
strategy in which I made no a priori assumptions regarding the lineage restricted 
expression of CD103 and CX3CR1. Furthermore, as an important aim of my PhD 
was to determine the role of the signalling receptor SIRPα on intestinal DC 
function, using mice which lacked the CX3CR1 reporter gene and no antibody to 
CX3CR1 was available, I had to find an approach which could distinguish DCs and 
mφs without relying on CX3CR1 expression. To do this, I first identified MPs as 
total CD11c+MHCII+ live leukocytes in digests of lamina propria and examined 
them for their expression of CD103 and CD11b. This identified four populations, 
two of which were CD103+ and two of which were CD103-, with the subsets being 
distinguished by their expression of CD11b. These four subsets were then 
examined for expression of F4/80 and CD64, a marker that Bernard Malissen’s 
group at the CIML in Marseille had shown to be specific for mφs in the intestine 
(Bain et al., 2013; Tamoutounour et al., 2012). This showed that both subsets of 
CD103+ MPs were CD64-F4/80-, as were the CD103-CD11b- MPs. In contrast, the 
CD103-CD11b+ MPs were heterogeneous, consisting of a large number of 
CD64+F4/80+ cells and a smaller population of CD64-F4/80- cells. Examination of 
CD8α and SIRPα expression, two markers commonly used to subset DCs, 
showed that the CD64-CD103+CD11b- DCs expressed CD8α homogeneously and 
lacked SIRPα expression. It is important to note that although it has often been 
assumed that CD8α+ DCs found in preparations of the LP were contaminants from 
PPs or ILFs, recent work has shown they are present in LP preparations from 
RORγt-/- mice which lack these structures, demonstrating they are present in the 
LP itself (Cerovic et al., 2013). Both the CD103+CD11b+ and putative CD103-
CD11b+ DCs expressed SIRPα and lacked CD8α. Interestingly, the CD103-
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CD11b- putative DCs were heterogeneous for these markers, suggesting they 
could be a mixed population.  
Consistent with previous reports (Denning et al., 2011), I found the 
distribution of the two CD103+ DC populations to change from the SI LP to the 
colonic LP, with CD103+CD11b+ DCs predominating in the SI, whereas 
CD103+CD11b- DCs constituted the major population in the colon. The proportions 
of the two CD103- putative DC populations did not alter significantly in the two 
locations. 
This initial analysis based on F4/80 and CD64 expression therefore 
appeared to confirm the DC nature of the CD103+ MP populations, but also 
suggested that the CD103-CD11b+ MPs included both DCs and mφs. However, 
although CD64 was described to be a mφ-specific marker in the gut (Bain et al., 
2013; Tamoutounour et al., 2012), it has also been reported to be present on 
monocyte-derived ‘DCs’ in the muscle and lung (Langlet et al., 2012; Plantinga et 
al., 2013). Thus, while the definition of these CD64+ cells as ‘DCs’ is controversial 
and indeed a subsequent study has concluded that these ‘monocyte-derived DCs’ 
in the lung are in fact mφs (Schlitzer et al., 2013), I thought it necessary to confirm 
my phenotypic classifications by examining the expression of a variety of genes 
and other surface markers. Consistent with their identification as DCs, all the 
CD64-F4/80- MPs expressed mRNA for the recently described DC-specific 
transcription factor Zbtb46 (zDC) (Meredith et al., 2012a; Satpathy et al., 2012), as 
well as the surface markers CD26 and CD272, which the Immunological Genome 
Consortium had reported to be DC-specific (Miller et al., 2012). In contrast, the 
CD64+F4/80+ MPs lacked these markers but instead expressed the mφ-specific 
markers CD14 and MerTk, which were absent from the CD64- MPs (Gautier et al., 
2012). Even more importantly, the CD64- MPs all expressed CD135, the receptor 
for the DC-specific growth factor Flt3L (Karsunky et al., 2003; Merad and Manz, 
2009). In parallel, all these putative DCs were virtually absent from the LP of Flt3L-
/- mice and their numbers were greatly expanded by administration of exogenous 
Flt3L in vivo, a characteristic of genuine DCs (Maraskovsky et al., 1996). This 
finding was consistent with earlier results in our lab, demonstrating the presence of 
a Flt3L responsive CD103- MP population in the colonic LP (Bain et al., 2013) and 
with studies performed simultaneously by the Milling lab on the subsets found 
migrating in pseudo-afferent lymph (Cerovic et al., 2013). In contrast, the 
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CD64+F4/80+ MPs lacked CD135 expression, but instead expressed high levels of 
CSF-1R (CD115), the receptor for the monocyte/macrophage specific growth 
factor, CSF-1 (Witmer-Pack et al., 1993; Yoshida et al., 1990). Although the CD64-
CD103- MP populations also expressed CD115, this was at much lower levels 
than observed for the CD64+ MPs. Unlike the CD64- MPs, the CD64+ mφs also 
had high phagocytic activity indicating that the CD64 defined subsets may be 
functionally distinct. Moreover, these populations had distinct kinetics in vivo, with 
all the DC populations showing 70-80% BrdU labelling following 3 days of feeding, 
compared with only approximately 20% of the CD64+F4/80+ mφs being labelled in 
the same period. Together these findings confirm that CD64 and F4/80 are 
sufficient for discriminating DCs and mφs amongst CD11c+MHCII+ intestinal MPs. 
At the time I carried out this work, my results were the only ones to identify 
genuine intestinal SI LP CD103- DCs (C.L. Scott et al., submitted for publication) 
however while I was preparing this thesis and manuscript, the presence of CD103- 
DCs in the SI LP was confirmed by three independent studies using either CD64 
or DNGR-1 expression to discriminate between the two lineages (Schlitzer et al., 
2013; Schraml et al., 2013; Tamoutounour et al., 2012). 
In contrast to the distinct patterns of expression seen for Flt3 and CSF-1R, 
all intestinal MP populations expressed similar levels of the receptor for CSF-2 
(GM-CSF). However only the CD64- DC populations increased in response to 
exogenous CSF-2 in vivo, while the numbers of mφs were unaffected. However, 
as the distinction between CD64+ and CD64- MPs in the intestinal LP observed in 
resting mice was lost following administration of CSF-2, it became difficult to 
accurately set the CD64- versus CD64+ gates and hence it remains unclear if DC 
and mφ populations were defined accurately in these studies. Interestingly, while 
this result seemed to contradict the expression pattern of CSF-2R, it is consistent 
with the findings of Schulz and co-workers who found that exogenous CSF-2 
administration expanded CD103+ DCs and not CX3CR1+ mφs (Schulz et al., 2009). 
Thus further experiments are required to validate these results and possibly define 
new markers to pull apart DCs and mφs in non-steady state scenarios. One 
possible way to overcome this issue could be to perform these studies in Zbtb46-
reporter mice, allowing DCs and mφs to be distinguished. Interestingly, although 
all the DC populations appeared to respond to exogenous CSF-2 in vivo, I found 
that only the CD103+CD11b+ SI LP DCs were dependent upon this growth factor in 
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vivo, as CSF-2RKO mice had a reduction in this population. However, the correct 
interpretation of these results is also unclear, as I found a population of 
CD103intCD11b+ DCs in these mice that were absent from WT controls. Therefore 
these results could reflect the reported ability of CSF-2 to induce CD103 
expression (Zhan et al., 2011) rather than indicating the dependence of specific 
MP subsets on this growth factor. Others have recently reported a similar 
reduction in CD103+CD11b+ LP DCs in CSF-2RKO mice using CD24 as a 
surrogate marker for CD103 and hence suggesting that the effects are not simply 
a result of the lack of CD103 expression (Greter et al., 2012). However, while 
preparing this thesis I have examined CD24 expression by the various subsets of 
intestinal MPs and found that it is present on all subsets and may not be an 
accurate marker of CD103+ DCs, thus further investigation is warranted. 
Interestingly, despite a recent report that alveolar mφs in the lung develop through 
a CSF-2 dependent pathway (Guilliams et al., 2013b), the intestinal mφs appear to 
be CSF-2 independent as they were unaffected in the CSF-2RKO animals, 
suggesting a tissue-specific role for this growth factor. 
Consistent with previous reports (Bogunovic et al., 2009; Schulz et al., 2009; 
Varol et al., 2009), I found that CD103+ DCs lacked CX3CR1 expression, while the 
CD103-CD11b+CD64+F4/80+ mφs expressed either high or intermediate levels of 
the chemokine receptor. Interestingly, I found that the CD64-CD103-CD11b+ DCs 
also expressed intermediate levels of CX3CR1, consistent with earlier findings that 
Flt3L had some ability to expand a population of CX3CR1int MPs in vivo (Schulz et 
al., 2009). Similar findings have been made in our own laboratory, where a 
population of CX3CR1int non-mφs in the colon (Bain et al., 2013) and the presence 
of CX3CR1-expressing genuine DCs in pseudo-afferent intestinal lymph (Cerovic 
et al., 2013) were identified. It is important to note that none of these studies, 
including my own, found evidence of DCs expressing high levels of CX3CR1 in the 
steady state intestine, lymph or MLN. This is in direct contrast to a recent study 
which proposed that CX3CR1hi MPs could migrate from the LP to the MLN (Diehl 
et al., 2013). The reasons for this discrepancy are unclear, but it seems likely that 
this reflects inaccurate gating of CX3CR1-expressing cells by Diehl et al., with the 
CX3CR1int cells I found likely being misidentified as CX3CR1hi (Diehl et al., 2013). 
All other work suggests that CX3CR1hi cells in the intestine are the sessile mφs 
which comprise the majority of the phagocytic F4/80+CD64+CD11b+ MPs I 
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identified. Contrary to the other intestinal DC populations, the CD103-CD11b- DCs 
were heterogeneous for CX3CR1 expression, with some being CX3CR1- and 
others CX3CR1int. This seems to confirm my results with CD8α and SIRPα that 
these are a mixed population. 
10.3 Migratory DC Populations in the MLN 
As the primary function of DCs is to migrate to the draining lymph nodes and 
present antigen, I explored the ability of the DC populations I had discovered in the 
LP to migrate to the draining MLN. Migratory DCs in the MLN were identified as 
MHCIIhi (Henri et al., 2001; Persson et al., 2013b; Plantinga et al., 2013; Schlitzer 
et al., 2013) and all four populations of CD64- DCs were found in this gate. In 
contrast, the resident CD11c+MHCIIint gate contained only 3 populations of DCs, 
with the CD103+CD11b+ DCs being missing. As CD103+CD11b+ DCs are found 
almost exclusively in the intestinal mucosa, their absence from the CD11c+MHCIIint 
gate is consistent with these CD11c+MHCIIint cells being derived from the 
bloodstream rather than the mucosa. It should be noted that although I also 
identified a small population of CD64+F4/80+ mφs within the ‘migratory DC’ 
compartment of the MLN, cells with this phenotype cannot be found in afferent 
lymph draining to the MLN ((Cerovic et al., 2013) and C.L. Scott, C.C. Bain, V. 
Cerovic and S.A. Houston, unpublished data). This could suggest that this gated 
population may be contaminated by some LN resident cells or by blood. Indeed 
the convention that this gate represents only migratory DCs is not backed up by 
much direct evidence and thus care must be taken when using this approach to 
identify migratory cells. Once these CD64+F4/80+ cells were excluded from the 
CD11c+MHCIIhi gate in MLN, the remaining four DC populations were present in 
similar proportions to those found in intestinal lymph (Cerovic et al., 2013), 
suggesting that this additional step allows migratory DCs to be identified in the 
MLN accurately. It is worth noting that the proportions of the DC populations in 
lymph and amongst migratory DCs in the MLNs differed slightly from those in the 
SI LP. In particular, the CD103- DCs make up a smaller population of DCs in the 
MLN than in the LP, perhaps reflecting the ontogeny of these cells (see below). My 
BrdU incorporation studies, further confirmed the migratory nature of CD64-F4/80- 
cells within the CD11c+MHCIIint gate in the MLN, as they had distinct kinetics 
compared with those in both the resident DC population and in the LP. DCs in the 
LP were labelled maximally after 3 days of BrdU feeding, whereas most of the 
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migratory DC populations in the MLN did not show maximal labelling until 3 days 
after cessation of BrdU administration. The only exception to this was the 
migratory CD103-CD11b- DCs, which, were labelled maximally after 3 days of 
feeding in both the LP and MLN. This result was surprising, given that the 
presence of this subset intestinal lymph suggests they can migrate from the 
intestine (Cerovic et al., 2013). However this population is unique in that it is 
significantly reduced in the LP of RORγt-/- mice which lack PP and isolated 
lymphoid follicles (ILFs) (Cerovic et al., 2013), suggesting that these DCs may 
arrive in the MLN from a distinct anatomical location, such as the ILFs or PPs, 
possibly explaining their distinct kinetics. My BrdU incorporation results appear to 
contradict an earlier report from Jaensson and colleagues, which suggested that 
CD103- DCs in MLN shared the population kinetics of DCs derived from the 
bloodstream. However, this study did not discriminate between migratory and 
resident DCs and as the latter constitute the majority of MLN DCs, most of the 
CD103- DCs would indeed have been blood-derived (Jaensson et al., 2008). 
Taken together, my studies clearly demonstrate the presence of previously 
unappreciated bona fide CD103- DCs in the intestine that are capable of migrating 
to the MLNs. 
10.4 Ontogeny of Intestinal DC Populations 
In adult animals DCs derive from DC-committed progenitors, while mφs 
derive from monocytes (BM or foetal liver) or primitive yolk-sac macrophages and 
when I began my project, intestinal CD103+ DCs were thought to be derived from 
DC-committed progenitors, while CD103- ‘DCs’, which I have now shown includes 
both DCs and mφs, were thought be the progeny of BM-derived Ly6Chi monocytes 
(Bogunovic et al., 2009; Varol et al., 2009). Given the heterogeneity I had 
uncovered amongst the SI LP CD103-CD11b+ MPs, I thought it important to re-
examine the origin of CD103- intestinal MPs directly. To this end, I set up models 
to examine the fate of adoptively transferred precursors in vivo. My initial plan was 
to do this using recipient mice depleted of CD11c-expressing cells using the 
CD11c-DTR system, but my preliminary studies revealed that DCs were not 
depleted efficiently in these animals. Indeed, a greater proportion of CD11c+ mφs 
was ablated. Therefore I decided to attempt the transfers into WT recipients, which 
I hoped would also be a physiologically more relevant model of homeostatic DC 
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development. To the best of my knowledge this is the first study to examine the 
fate of pre-DCs in resting WT mice and therefore I decided to investigate DC 
development from pre-DCs over a time-course. However in order to perform these 
studies, a large number of progenitors was required and therefore I decided to first 
expand the numbers of pre-DCs in BM in vivo by inoculating donor mice with B16 
melanoma cells secreting Flt3L. This is a standard method for expanding DCs and 
pre-DCs and there is no evidence that it alters the functions of the expanded cells 
(Maraskovsky et al., 1996; Naik, 2010; Naik et al., 2007; Viney et al., 1998; Zeng 
et al., 2013). BM monocytes were transferred into CCR2-/- recipients as these 
monocytopenic mice provide a partially empty niche without the need for additional 
manipulation and this model had been previously established in the laboratory, 
which demonstrated that unlike other tissues, gut mφs derive from BM not foetal 
liver monocytes or primitive macrophages (Bain et al., 2013). 
These approaches showed clearly that all the populations of CD103+ and 
CD103- DCs, I had identified were derived only from DC-committed progenitors. In 
contrast, Ly6Chi monocytes could not give rise to any of the CD64-F4/80- MPs, 
despite repopulating CD64+F4/80+ mφs efficiently. By labelling the pre-DCs with 
CellTrace Violet dye and examining the time course of their appearance in the 
mucosa, I was able to obtain insights into the processes involved in the 
development of the DC subsets. 2-3 days after their arrival in the mucosa, the 
precursors acquired MHCII and upregulated CD11c before acquiring CD103 or 
CD11b. Interestingly however, CD103+CD11b+ DCs did not appear until days 5-7 
after transfer indicating that these are a terminal stage of differentiation. Following 
acquisition of MHCII, the donor cells began to undergo cell division as assessed 
by dilution of the CellTrace dye. Previous studies have shown that mature DCs 
divide in situ (Ginhoux et al., 2009) but this has never been examined previously in 
the intestine. This proliferation was confirmed by short-term BrdU uptake and Ki67 
staining which showed that up to 6% of all populations of intestinal DCs were 
dividing in situ. However putative pre-DCs in the LP were not dividing and nor 
were CD64+ mφs, underlining the different population kinetics of these cells.  
Pre-DC development could also be observed in the colonic LP and also in 
the MLN where donor-derived cells first appeared in the resident (CD11c+MHCIIint) 
gate. Importantly, donor cell progeny could not be found amongst the migratory 
(CD11c+MHCIIhi) DC gate in the MLN until day 3-5, supporting the idea that these 
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had come from the mucosa. In the MLN and colonic LP, progeny of pre-DCs 
acquired the same pattern of subset distribution as the endogenous populations, 
with CD103+CD11b- DCs for example being the predominant population in the 
colon. Transferred pre-DCs also gave rise to CD103+CD11b+ DCs only in the 
intestine, consistent with the absence of this DC population from non-intestinal 
tissues, such as the spleen, lung, liver and kidney. This ability to recapitulate the 
normal pattern of DC subset distribution in different tissues could reflect individual 
subsets of pre-DCs generating each mature DC populations as hypothesised by 
Naik and colleagues based on CD24 expression (Naik et al., 2006), tissue-specific 
subsets of pre-DCs or could also suggest the differential conditioning of the same 
progenitors by the local environment. It will be interesting to examine these 
possibilities directly in the future. Recently a population of gut-tropic DC 
progenitors has been described, suggesting that distinct precursors may be 
involved in the generation of intestinal DCs compared with those in other tissues 
(Zeng et al., 2013). However, it should be noted that these pre-mucosal DCs (pre-
µDCs) were also capable of generating splenic DCs and appeared to generate 
CD103+CD11b- DCs preferentially even in the SI (Zeng et al., 2013). These pre-
µDCs expressed the β7 integrin and B220 and thus exactly how they relate 
classical pre-DCs, which are B220- is unclear.  A proportion of the pre-DCs I used 
did express β7, suggesting there may be heterogeneity amongst the pre-DCs, I 
and others have used in transfer studies (Bogunovic et al., 2009; Liu et al., 2009; 
Naik et al., 2006; 2007) and hence there may be gut-specific precursors amongst 
them. An alternative possibility is that the DC progenitors are pre-programmed in 
the BM to become a distinct DC subset and this hypothesis is consistent with 
recent work which reported that HSCs in the BM are imprinted to become a 
specific cell type from an early stage, with clonally expanded HSCs giving rise to 
the same cell types in different mice (Naik et al., 2013). Thus the fate of DC 
progenitors needs to be examined at the single cell level, the feasibility of which is 
currently limited.  
On the other hand, the idea that environmental conditioning might determine 
the fate of DC progenitors is supported by the fact that although pre-DCs could not 
generate CD103+CD11b+ DCs in any other steady state tissue, CD103+CD11b+ 
DCs are reported to appear in the inflamed lung (Guilliams et al., 2013a). Thus the 
presence of this population in the steady state gut may reflect the state of 
‘physiological inflammation’ that characterises this tissue. That the development of 
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CD103+CD11b+ DCs in the gut requires specific signals from the local environment 
would be consistent with my finding that they were the last to appear after transfer 
of pre-DCs. In addition, they were the last subset to arrive in the intestine after 
birth, whereas CD103+CD11b- DCs and both subsets of CD103- DCs could be 
identified from birth.  
As discussed in Chapter 1, the nature of the local ‘conditioning’ factors that 
might drive the phenotype and function of intestinal DCs remains elusive, with a 
wide variety of different dietary, hormonal and cytokine-mediated processes 
having being proposed (Scott et al., 2011). Investigating this was beyond the 
scope of my project, but one factor I thought important to explore was the 
presence of the microbiota, especially as this could perhaps account for the 
changes in the neonatal period. Although previous studies have examined ‘DC’ 
populations in germ-free mice, these failed to distinguish accurately between the 
DC populations and included mφs amongst the gated DCs, as well as gating 
CD103+CD11b+ with CD103- DCs and mφs (Rivollier et al., 2012). However, I 
found that broad-spectrum antibiotics only affected CD103+CD11b+ DCs. Contrary 
to what I would have expected from my studies of neonatal mice, I found that the 
augmentation of the microbiota with antibiotics caused an increase in the numbers 
of CD103+CD11b+ DCs in the SI LP. There was also a proportional increase in this 
DC population amongst migratory DCs in the MLN. It is possible that this 
discrepancy reflects the need for specific bacterial species in the development of 
individual DC subsets and that these are differentially susceptible to the antibiotics 
I used. Additionally they may be differentially located in the small and large 
intestines explaining the differences in the number of CD103+CD11b+ DCs in 
these locations. To explore this, it will be necessary to study germ-free mice re-
colonised with specific bacterial strains.   
I also considered the possibility that CSF-2 might be involved in the 
development of CD103+CD11b+ DCs (Greter et al., 2012). Therefore, while 
preparing this thesis I tested the hypothesis that the levels of CSF-2 in different 
parts of the body and in the small versus large intestine would correlate with the 
frequency of CD103+CD11b+ DCs at each site. However, CSF-2 ELISAs showed 
that the levels of this growth factor were considerably lower in both the small and 
large intestine compared with a number of other tissues including the lung.  
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Irrespective of whether local conditioning factors or distinct precursors are 
involved, it is clear that the development of individual DC populations requires 
specific transcription factors. For example Batf3, Id2 and IRF8 are required for the 
homeostasis of CD8α+ DCs in lymphoid tissues and their CD103+CD11b- DC 
counterparts in non-lymphoid tissues, including the intestine (Aliberti, 2002; 
Edelson et al., 2010; Ginhoux et al., 2009; Hildner et al., 2008; Tailor et al., 2008). 
Despite this, I found Batf3 and Id2 to be expressed at similar levels by all intestinal 
MP populations. In addition, although CD103+CD11b- DCs expressed IRF8 at 
higher levels than the other DCs, it was also expressed by mφs. Similarly, while I 
and others have found IRF4 to be expressed by all intestinal DCs and mφs, with 
the exception of CD103+CD11b- DCs (Schlitzer et al., 2013), recent work indicates 
that IRF4 has a selective role in the homeostasis of CD103+CD11b+ DCs in the 
intestine (Persson et al., 2013b; Schlitzer et al., 2013). Although a role for IRF4 in 
CD103-CD11b+ DC development and/or homeostasis could also be argued from 
these data (Persson et al., 2013b; Schlitzer et al., 2013). However, this lack of a 
correlation between the expression of individual transcription factors and their 
requirement for homeostasis may support the idea that all DCs derive from a 
single precursor, whose subsequent fate is under the control of specific 
environmental cues. Importantly, the stage of DC development at which these 
transcription factors act is largely unknown, and indeed their role may not be in 
development at all. The effects of IRF4 on the homeostasis of CD103+CD11b+ 
DCs in the intestine appear to be due to its influence on their survival (Persson et 
al., 2013b), while IRF4 has also been implicated in regulating DC migration to the 
LNs (Bajaña et al., 2012). Further studies are thus required to examine these 
issues. 
10.4.1 Role of CCR2 in Development of Intestinal DCs 
My findings that intestinal CD103-CD11b+ DCs derive exclusively from DC-
committed progenitors directly contradict previous studies which proposed that 
these DCs were generated from monocytes both in the steady state (Bogunovic et 
al., 2009; Varol et al., 2007; 2009) and during inflammation (Rivollier et al., 2012; 
Zigmond et al., 2012). Although I proposed that this was due to the imprecise 
gating strategies used in other studies to define DCs and mφs, a recent study by 
Zigmond and colleagues, which discriminated CD103-CD11b+ DCs from mφs 
accurately on the basis of zDC expression, also concluded that CD103- DCs were 
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monocyte-derived. This conclusion was based on their loss following in vivo 
administration of an anti-CCR2 antibody (Zigmond et al., 2012), a strategy which is 
usually considered to act by depleting Ly6Chi monocytes. Therefore towards the 
end of my project, I assessed the role of CCR2 in the development and/or 
homeostasis of the intestinal DC populations I had defined in case I had missed 
some monocyte-derived DCs in my original transfer experiments. First I found 
there was a selective reduction in the proportion and number of CD103-CD11b+ 
DCs in the SI LP and amongst migratory DCs in the MLN. This finding was 
replicated in WT:CCR2-/- competitive BM chimeras where the CD103-CD11b+ DCs 
were less efficiently reconstituted by CCR2-/- cells than the other DC subsets or 
the eosinophils which were used as control myeloid cells. Notably, this defect was 
considerably less severe than that observed for the monocyte-derived mφ 
population in the same mice, suggesting these may not be completely dependent 
upon CCR2-expressing cells, presumably monocytes, as is the case for intestinal 
mφs (Bain et al., 2013; Tamoutounour et al., 2012).  Interestingly, in preliminary 
parabiosis studies CCR2-/- mice had an enhanced population of CD103-CD11b+ 
DCs in the SI LP deriving from their WT partner compared with the other DC 
subsets, further suggesting a dependence of these DCs on CCR2. Unfortunately it 
was not possible to examine the exchange between the DC-committed progenitors 
in the bloodstream of these animals and thus it is difficult to draw any conclusions 
from this experiment.  
This novel finding of a CCR2 dependent population of DCs was not specific 
to the intestine, as the number of splenic DCs was also reduced in CCR2-/- mice 
although in this case, both CD11b+ and CD11b- subsets were affected. A smaller 
defect was also occasionally seen with CD103+CD11b- DCs amongst migratory 
MLN DCs although this was not consistent and neither was it recapitulated in the 
chimeras or parabionts. For unknown reasons the resident DC populations in the 
MLN were largely unaffected in CCR2-/- mice despite the effects observed in the 
spleen. The reasons for these tissue-specific differences in CCR2 dependence 
remain unclear, although it seems clear that CCR2 is not restricted to the intestine. 
The cellular mechanism may also differ between tissues as although the defect in 
intestinal DCs was clearly cell intrinsic, this appeared not to be the case in the 
spleen, where WT and CCR2-/- BM reconstituted the splenic DCs in these mice 
equally as efficiently. This secondary defect could reflect the reduced population of 
mφs in CCR2-/- mice and the known ability of mφs to produce CCR2 ligands 
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(Tagliani et al., 2011). The exact reasons for these differences require further 
investigation. 
Correlating with their selective and partial reduction in the CCR2-/- LP, a 
proportion of CD103-CD11b+ DCs in the LP expressed this receptor. Because of 
the reported technical difficulties associated with using a CCR2 antibody, I 
examined CCR2 expression using three distinct methods, antibody staining, a 
CCL2 uptake assay (Ford et al., 2013; McKimmie et al., 2008) and using 
CCR2+/RFP mice (Saederup et al., 2010). While all three methods identified a clear 
subset of CCR2-expressing CD103-CD11b+ DCs, the size of this population varied 
depending on the method used. While both the direct CCR2 antibody staining and 
CCL2 uptake assay indicated that approximately 25% of these DCs expressed 
CCR2, over 75% of them were CCR2+ in CCR2+/RFP mice. This discrepancy is 
consistent with the original study of these animals, which identified RFP+ cells in 
the bloodstream that were not detected by CCR2 antibody staining (Saederup et 
al., 2010). I also obtained similar results amongst migratory DCs in the MLN, using 
CCR2 antibody staining or CCL2 uptake only approximately 12% of the CD103-
CD11b+ migratory DCs expressed CCR2 however RFP expression was found in 
over 30% of these DCs in the CCR2+/RFP mice. It has been suggested that the 
explanation for this could be that CCR2 becomes internalised in some cells, due to 
constitutive or ligand induced recycling (Mack et al., 2001; Saederup et al., 2010; 
Volpe et al., 2012), thus preventing its detection on the cell surface by antibody or 
fluorescently-labelled ligand. Alternatively, although the RFP gene is under the 
control of the CCR2 promoter, the half-life of the RFP, which is thought to be 20-
30 hours (Subach et al., 2011), may result in the extended presence of an RFP 
signal in the absence of CCR2 protein expression. Similar reasons may account 
for the fact that the CD103+CD11b+ DCs were also CCR2+ in the CCR2+/RFP mice, 
but not when surface staining methods or ligand uptake was used.  Additionally, 
CD103+CD11b- LP DCs expressed low levels of CCR2 when antibody staining 
was used, but showed considerably more using both the CCL2-uptake assay and 
RFP expression. The reasons for this are unclear, but may represent issues with 
the CCL2-uptake assay, which had not previously been validated in the gut. 
Indeed migratory CD103+CD11b- DCs in the MLN did not express CCR2 by either 
antibody staining or CCL2-uptake. Like the CD103-CD11b+ DCs, the CD103-
CD11b- DCs in the LP expressed CCR2 to some degree using all the methods, but 
the proportion of CCR2+ cells amongst this population was highest when assessed 
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by the CCR2+/RFP mice. As in the LP, all migratory DC populations expressed 
some CCR2 when examined in CCR2+/RFP mice, however only the CD103-CD11b+ 
migratory DCs were CCR2+ as assessed by antibody and CCL2 uptake. Despite 
these technical issues, it is important to note that using the antibody to define 
CCR2+ DCs allowed a functionally distinct population of CD103-CD11b+ DCs in the 
LP to be identified (see below). Furthermore, in collaboration with Pamela Wright, I 
was able to identify a similar population of CCR2+CD103-SIRPα+ DCs in the 
human colonic LP, using an anti-CCR2 antibody. As SIRPα is believed to be a 
cross-species marker for the equivalent of CD11b+ DCs found in mice, these cells 
may be analogous to the CCR2+ subset of CD103-CD11b+ DCs found in mice. 
However, a larger proportion of CD103-SIRPα+ DCs in humans expressed CCR2 
than in mice, while a proportion of CD103+SIRPα+ DCs in humans also expressed 
CCR2. This may reflect a technical issue, as the discrimination between CD103+ 
and CD103- SIRPα+ DCs in the human LP was less discrete than in the mouse. 
Further optimisation of the staining panel may allow for greater resolution between 
the populations and a more detailed assessment of CCR2 expression on the 
different populations in humans. Alternatively, as discussed below, CD103- and 
CD103+ SIRPα+ DCs may be developmentally linked, and, the upregulation of 
CD103 may occur prior to the loss of CCR2 in human but not mouse LP, evidently 
this requires direct investigation. Consistent with my findings in CCR2-/- mice, I 
found that CCR2 expression was not restricted to intestinal DCs, as a proportion of 
both splenic and lung CD11b+ DCs were also found to express the chemokine 
receptor as assessed by antibody staining. This finding was supported by a report 
on splenic DC in CCR2+/GFP mice (Satpathy et al., 2013). 
Because CCR2 is generally associated with the egress of monocytes from 
BM, as well as their accumulation in tissues (Serbina and Pamer, 2006), I thought 
it was important to examine directly if the CCR2+CD103-CD11b+ DCs were bona 
fide pre-DC derived DCs. This was indeed the case, as not only did transferred 
pre-DCs generate CCR2+CD103-CD11b+ DCs in the LP, but this subset expressed 
similar levels of mRNA for Flt3, Zbtb46 and Ccr7 as their CCR2- counterparts and 
the CD103+ DC populations. I then investigated whether CCR2 might be 
expressed by pre-DCs in the BM and if this could be involved in their fate in vivo. 
Pre-DCs in the BM expressed heterogeneous levels of CCR2 as assessed using 
the CCR2 antibody, but unlike monocytes, their egress to the bloodstream was 
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unaffected in CCR2-/- mice, as was the numbers of pre-DCs in the BM. 
Unfortunately, I was unable to sort enough CCR2+ pre-DCs to determine if they 
had a differential ability to generate LP DC subsets and this needs explored in the 
future. Instead I performed competitive adoptive transfers of pre-DCs from WT and 
CCR2-/- mice into WT recipients. Under these conditions, all the subsets of LP DC 
derived preferentially from WT progenitors, suggesting a role for CCR2 in the 
ability of the progenitors to gain access to the LP and leaving open the question of 
why there is a selective defect in the CD103-CD11b+ DCs in the CCR2-/- mouse. 
One explanation could be that those CCR2-/- DCs which do gain access to the 
mucosa undergo enhanced in situ proliferation to fill up the empty niche for most of 
the DC subsets. However, why this would not overcome the defect in CD103-
CD11b+ DCs is unclear and clearly further investigation is required to explain 
these results. 
10.5 Function of Intestinal DC Populations 
Having identified novel subsets of genuine DCs in the intestinal LP, I went on 
to investigate their functions. All four populations of DCs were equally efficient at 
inducing proliferation of naïve antigen-specific CD4+ T cells when pulsed with 
ovalbumin (OVA) in vitro. Although all could also induce proliferation of naïve 
antigen-specific CD8+ T cells when higher DC:T cell ratios were used, only the 
CD103+CD11b- DCs were capable of inducing proliferation of naïve CD8+ T cells 
when lower numbers of DCs were used and these were also the only DCs to drive 
the production of IFNγ under any conditions. The ability of the 
CD8α+CD103+CD11b- DCs to cross-present antigen, coupled with their 
dependence on Batf3 and expression of XCR1 emphasises their relationship to 
the CD8α+ lineage in other tissues, which are often defined as CD103+ (Bachem 
et al., 2010; 2012; Bedoui et al., 2009; Haniffa et al., 2012; Zhan et al., 2011). 
Interestingly, although they were inefficient at cross-presenting antigen, some 
CD103-CD11b- intestinal DCs also expressed XCR1, perhaps indicating some 
relationship with the CD8α+ DC lineage. These cross-presentation results contrast 
with those of Fujimoto and colleagues, who showed that LP DC have little cross-
presentation activity unless they have been stimulated via TLRs in vitro (Fujimoto 
et al., 2011). In addition these authors found that the CD103+CD11b+ DCs had 
equivalent cross presentation activity compared with their CD11b- counterparts 
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under these circumstances (Fujimoto et al., 2011). It is entirely possible that 
following the right signals multiple subsets of DCs may be capable of inducing 
cross-presentation, and indeed mature human lymphoid tissue DCs of multiple 
subtypes have been shown to be equally capable of cross-presenting antigen 
(Segura et al., 2013). Thus examination of the effects of distinct TLR ligation on 
the antigen presenting cell activity of the intestinal DC subsets represents an 
important avenue for investigation in the future.  
Although all intestinal DC subsets were equally efficient at inducing 
proliferation of naïve CD4+ T cells, my results showed that they had distinct effects 
on CD4+ T cell polarisation. Consistent with earlier reports that CD103+ DCs may 
be intrinsically tolerogenic (Annacker et al., 2005; Coombes et al., 2007; Jaensson 
et al., 2008; Scott et al., 2011; Siddiqui and Powrie, 2008; Sun et al., 2007), I 
found that the two subsets of CD103+ DCs induced the differentiation of FoxP3+ 
TReg cells better than the CD103- DC subsets. Although it needs to be confirmed 
with increased sample sizes, the CD103+CD11b- DCs appeared to be slightly 
more efficient than the CD103+CD11b+ DCs in this respect. Interestingly this 
correlated with the finding that the CD103+CD11b- DCs had increased 
ALDEFLUOR activity compared with the other DC subsets (Guilliams et al., 
2010a), and were the only DC subset that expressed the TGFβ-activating integrin 
αvβ8 (Travis et al., 2007). Both TGFβ and RA are essential for the induction of 
TReg cells by DCs (Coombes et al., 2007; Jaensson et al., 2008; Sun et al., 2007) 
and it is interesting to note that my work and that of others shows that 
CD103+CD11b- DCs predominate in the colonic LP where TReg cells are also most 
prominent (Denning et al., 2011). Furthermore, CD11c-driven conditional KOs of 
IRF4 and Notch2, as well as my SIRPα mt mice and mice expressing human 
langerin have normal TReg cells despite all displaying defects in the numbers of 
CD103+CD11b+ DCs (Lewis et al., 2011; Persson et al., 2013b; Welty et al., 2013). 
This apparent association between CD103+CD11b- LP DCs and the generation of 
FoxP3+ TReg cells contrasts with the study by Fujimoto and colleagues where 
CD8α+ LP DCs did not induce FoxP3+ TReg cells in vitro (Fujimoto et al., 2011). In 
addition Batf3KO mice which lack CD103+CD11b- DCs, have normal numbers of 
TReg cells in the intestine (Edelson et al., 2010). This may be because this study 
did not discriminate between populations of inducible (iTReg) versus natural (nTReg) 
cells on the basis of expression of neuropilin and Helios (Thornton et al., 2010; 
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Weiss et al., 2012; Yadav et al., 2012), which is important as intestinal mφs have 
been shown to expand TReg cells locally (Hadis et al., 2011) and thus any defect in 
priming iTReg cells might be missed due to the increased local expansion of nTReg 
cells. Nevertheless, my findings showed that CD103+CD11b+ DCs were also 
capable of inducing TReg cells from naïve CD4+ T cells in vitro and thus taken 
together these findings may suggest a level of redundancy in the ability of the 
CD103+ DCs subsets to induce TReg cells. While I was finalising this discussion, a 
report was published demonstrating such redundancy where hu-
LangerinDTAxBatF3 mice, which lack both CD103+CD11b+ and CD103+CD11b- 
DCs were found to have reduced TReg cells in the LP despite the individual strains 
having normal numbers of these cells (Welty et al., 2013). 
As well as their cross-priming activity and slightly enhanced ability to induce 
FoxP3+ TReg cells, CD103+CD11b- DCs were also the most efficient at priming 
IFNγ producing Th1 cells in vitro, possibly due to their production of IL12p40. 
Although my initial studies shown in Chapter 6 did not reveal clear patterns of Th1 
generation by the other subsets, later experiments I carried out in Chapter 9, using 
optimised DC:T cell ratios and improved intracellular cytokine staining protocols 
showed that CD103+CD11b+ DCs did not induce significant Th1 responses and the 
CD103- DC subsets were poor inducers of IFNγ production.  Although this result is 
consistent with findings from my SIRPα mt mice and from CD11c-driven 
conditional KOs of IRF4 that CD103+CD11b+ DCs are dispensable for the 
presence of Th1 cells in the intestine (Persson et al., 2013b), it contrasts with 
results using DCs isolated from intestinal lymph, which suggested CD103-CD11b+ 
DCs to be the main inducers of IFNγ from CD4+ T cells in vitro (Cerovic et al., 
2013). These differences may be due to the cells used in each study, and in 
particular, it may be that the CD103-CD11b+ DCs isolated from lymph are more 
activated than the equivalent subset in the LP. This could be because the DCs 
have received the signals needed to make them enter lymph, or because of 
inflammatory stimuli released during the surgical procedures needed to isolate 
DCs from intestinal lymph. Indeed my experiments on post-operative ileus show 
that even minor handling of the intestine can lead to an inflammatory infiltrate in 
the mucosa and therefore it would be interesting to examine how that might alter 
the T cell polarising functions of DCs. It would also be interesting to investigate 
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how migratory DC populations in the MLN polarise T cells in vitro in comparison 
with those I have isolated from the LP.  
CD103+CD11b+ DCs have recently been associated with the induction of 
Th17 responses in vivo (Lewis et al., 2011; Persson et al., 2013b; 2013a; Satpathy 
et al., 2013; Schlitzer et al., 2013; Welty et al., 2013) and consistent with this, I 
found this subset to be more effective than their CD103+CD11b- counterparts at 
inducing Th17 differentiation from naïve CD4+ T cells in vitro. At first sight these 
results seem to contradict my experiments in which administration of a broad-
spectrum antibiotic cocktail reduced the numbers of intestinal Th17 cells but led to 
increased numbers of CD103+CD11b+ DCs in the LP. One possibility could be that 
the antibiotics had a selective effect on a certain bacterial strain which induce Th17 
responses such as segmented filamentous bacteria (SFB) (Denning et al., 2011; 
Gaboriau-Routhiau et al., 2009; Ivanov et al., 2008; 2009). Thus while more 
CD103+CD11b+ DCs are present, they may not receive the signals required for 
inducing Th17 cells. Of course this does not explain why there are more 
CD103+CD11b+ DCs in the LP but as discussed earlier this could be a separate 
phenomenon where the presence of these DCs is also linked to a specific bacterial 
strain, which is perhaps resistant to the antibiotic regime. Alternative hypotheses 
also exist. It is possible that the antibiotic treatment affects more than just the 
intestinal DCs and perhaps may alter the presence or function of a number of 
innate cells such as mφs and innate lymphoid cells (ILCs) which function in the 
maintenance of Th17 cells in the LP (Hepworth et al., 2013; Shaw et al., 2012). 
Finally, CD103+CD11b+ DCs may not be the only DC subset involved in the 
induction of Th17 cells in vivo. Consistent with this hypothesis, I found that CD103-
CD11b+ DCs were more effective than CD103+CD11b+ DCs at inducing Th17 cell 
polarisation in vitro and this was especially true of the CCR2+ fraction of CD103-
CD11b+ DCs. The presence of a pro-inflammatory CD103- ‘DC’ subset has been 
proposed on numerous occasions (Cerovic et al., 2013; Rivollier et al., 2012; Scott 
et al., 2011; Siddiqui et al., 2010; Varol et al., 2009; Zigmond et al., 2012) and 
although most of these previous studies used imprecisely gated populations of 
MPs, a recent study of intestinal lymph also found genuine CD103- DCs to be the 
most effective inducers of Th17 cells in vitro (Cerovic et al., 2013). Importantly, I 
found that this was not just an in vitro phenomenon, as the defect in CD103-
CD11b+ DCs in CCR2-/- mice was associated with impaired Th17 priming in the 
MLNs following infection with C. rodentium or after priming of antigen-specific T 
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cells in vivo using LPS and α-CD40 as adjuvants. Although, infection with C. 
rodentium also correlated with a selective increase in the proportion of CD103-
CD11b+ DCs in the LP I did not examine specifically if there was a reduced 
population of Th17 cells in the LP of infected CCR2-/- mice. This was because 
these animals are monocytopenic and thus have reduced populations of mφs in 
the gut (Bain et al., 2013) and I was concerned that the lack of these cells might 
compromise the accumulation or maintenance of local Th17 cells as has been 
described previously for both Th17 and TReg cells (Hadis et al., 2011; Shaw et al., 
2012).  
To try and understand why CD103-CD11b+ DCs drove such robust Th17 
responses, I examined their expression of the cytokines IL6, TGFβ, IL1β and IL23, 
all of which are known to be involved in Th17 polarisation (McGeachy and Cua, 
2008; Shaw et al., 2012). I found all DC subsets from the LP to express mRNA for 
Tgfβ, but the significance of this is unclear as it does not measure the presence of 
bioactive TGFβ and several other cell types also make this cytokine. Recently it 
has been shown that IL6 production may be crucial for the induction of Th17 cells 
by CD103+CD11b+ MLN DCs (Persson et al., 2013b), but I found that all subsets 
of LP DCs produced identical amounts of both mRNA and protein. If anything the 
CCR2+CD103-CD11b+ DCs produced slightly less than the CCR2- fraction. It has 
been suggested that production of IL1β by mucosal mφs may maintain previously 
primed Th17 cells in the LP and that this is a mφ-dependent process (Shaw et al., 
2012), although the imprecise gating strategies employed in this study could not 
exclude a role for CD103-CD11b+ DCs. Consistent with their enhanced ability to 
induce Th17 differentiation, CD103+CD11b+ and both CD103- DC subsets 
expressed similar levels of IL1β mRNA, and these were 10-fold more than 
produced by CD103+CD11b- DCs. The one feature I did find was different for the 
CCR2+CD103-CD11b+ DCs was that they expressed significantly more 
IL12/IL23p40 protein by intracellular cytokine staining than any other subset. This 
difference was maintained and greatly enhanced by in vitro stimulation with the 
TLR4 agonist LPS. As I hypothesised that this IL12/IL23p40 protein might 
represent production of IL23, I attempted to measure IL23p19 in steady state DC. 
Despite spending some time trying to optimise primers and protocols for detecting 
IL23p19, I was unable to detect any IL23p19 using either qPCR or intracellular 
cytokine staining from steady state LP DCs. I was also unable to measure IL12p35 
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by qPCR, but as CCR2+CD103-CD11b+ DCs were poor inducers of IFNγ 
production by T cells, I would propose that the IL12/IL23p40 I detected reflected 
IL23, rather than IL12 production by the DCs and that this helps explain the Th17 
priming properties of these DCs. It would be important to prove this by blocking 
IL23 during the DC:T cell co-cultures.  
10.6 Intestinal DC Subsets in Inflammation 
Having identified distinct DC subsets in the steady state intestinal LP which 
appeared to function differentially in the induction of adaptive immune responses, I 
went on to examine how these subsets behaved during inflammation. To address 
this, I employed two models of sterile inflammation, DSS colitis and post-operative 
ileus (POI), together with C. rodentium infection. Although the two sterile models 
resulted in significant inflammation in the LP characterised by neutrophils and 
monocytes, these did not alter the balance between the DC populations in the LP. 
While it is possible that the POI model may be too acute to see changes in the DC 
populations, similar results were obtained in DSS colitis, which lasts for several 
days. Although it would be interesting to follow up these studies by examining 
events in the MLN and carrying out functional analyses of the DC subsets, I 
decided not to pursue these models because of the apparent lack of DC 
involvement.  
However, an important result from the DSS model was that the lineage 
restriction of pre-DCs and monocytes remained faithful during inflammation. Thus 
adoptively transferred pre-DCs gave rise to all subsets of DCs I had identified 
previously, while previous work in the lab had demonstrated that monocytes solely 
generated mφs under these conditions (Bain et al., 2013). Thus my work shows 
that a new population of monocyte-derived DCs does not appear to be recruited to 
the mucosa during inflammation, contrasting with previous studies (Rivollier et al., 
2012; Serbina et al., 2003; Zigmond et al., 2012).  
Unlike sterile inflammation, C. rodentium infection did alter the relative 
frequencies of the DC subsets in the LP with a selective increase in the number of 
CD103-CD11b+ DCs being observed. This further supports that these DCs may 
play a role in Th17 cell induction as C. rodentium also increases the numbers of 
Th17 cells selectively (Geddes et al., 2011; Satpathy et al., 2013). Again, it will be 
 322 
necessary to examine the specific functions of the DC populations during infection 
with C. rodentium, especially in view of my later findings in SIRPα mt mice, which 
have reduced populations of CD103+CD11b+ DCs and Th17 cells (see below). 
10.7 Role of SIRPα  Signalling in Intestinal DCs 
My studies characterising intestinal DC subsets and their origins had 
indicated that their properties might be determined after the arrival of their 
precursors in the mucosa and thus it was of interest to try and identify the factors 
involved. When I began my PhD, SIRPα had been shown to discriminate between 
the two genuine intestinal DC subsets, CD103+CD11b+ and CD103+CD11b- that 
were known at that time. As SIRPα is thought to be an inhibitory receptor, I 
hypothesised that the expression of SIRPα by CD103+CD11b+ DCs might 
contribute to their proposed tolerogenic function. Thus the original aim of my PhD 
was to characterise the DCs in the intestinal LP of mice with a point mutation in 
the cytoplasmic signalling domain of SIRPα, which abolishes intracellular 
signalling. It was while carrying out my initial studies into these mice that I found 
the four clear populations of bona fide DCs, whose characterisation became a 
substantial part of my project. In parallel, I continued my work on the SIRPα mt 
mice and found that the CD103+CD11b+ and CD103-CD11b+ DCs expressed 
SIRPα homogeneously, while the CD103-CD11b- DCs were heterogeneous for 
this molecule and CD103+CD11b- DCs were entirely negative. Mφs and a host of 
other myeloid cells, including neutrophils, monocytes and eosinophils also 
expressed SIRPα. 
A few months into my project, two studies reported that the SIRPα mt mice 
had a selective defect in CD4+CD11b+ DCs in the spleen (Saito et al., 2010), as 
well as a relative lack of a poorly characterised CD11b+CD11cint cell in the SI LP 
(Kanazawa et al., 2010). Thus, to begin to examine the role of SIRPα in the 
intestine, I first enumerated the DC and mφ populations in SIRPα mt mice using 
the precise gating strategies I had developed. Consistent with previous results, I 
found a considerable reduction in the proportions and number of CD11b+ DCs in 
the spleen and amongst resident CD11b+ DCs in the MLN. This was not 
unexpected, given that CD11b+ cells in all tissues express SIRPα. However, the 
mt mice had a selective reduction in CD103+CD11b+ DCs in both the SI and 
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colonic LP as well as amongst CD103+CD11b+ migratory DCs in the MLN. In 
contrast, the CD103-CD11b+ DCs and other SIRPα+ myeloid populations were 
unaffected. This selective defect was probably not observed in the previous report 
because it used CD11c and CD11b to identify ‘DCs’ and thus they were unable 
discriminate between CD103+CD11b+ DCs, CD103-CD11b+ DCs and F4/80+ mφs 
(Kanazawa et al., 2010). Furthermore, the CD11b+CD11c+ ‘DCs’ identified in that 
paper would also include eosinophils, which were later shown to be defective in 
the intestine of SIRPα mt mice (Verjan Garcia et al., 2011). Interestingly, in my 
studies, SIRPα mt mice did not display any eosinophil phenotype. This may be a 
result of the different protocols used to isolate leukocytes from the intestine and 
the use of Percoll gradients by the other groups, or to differences in the microbiota 
in the different mice. I did not follow this up and therefore the role of SIRPα in the 
homeostasis of intestinal eosinophils needs further investigation.  
The selective defect in CD103+CD11b+ DCs in the LP and amongst 
migratory DCs in the MLN was recapitulated in CD47KO mice, supporting previous 
results in the spleen (Saito et al., 2010) and suggesting that signalling through the 
SIRPα-CD47 axis is involved in regulating DC homeostasis. As CD47 is 
expressed ubiquitously in the intestine, it was unclear which CD47-expressing 
cells interact with SIRPα+ DCs, or at which stage of the DC lifespan this interaction 
occurs. I therefore set out to explore how SIRPα might act in the homeostasis of 
CD103+CD11b+ DCs by examining its role in their development, proliferation, 
migration and survival. As I had shown previously that all DC subsets arise from a 
common BM progenitor which uniformly expressed intermediate levels of SIRPα, it 
seemed unlikely that the lack of SIRPα signalling could affect the generation of 
these precursors, without having knock-on effects on all intestinal DC populations. 
Consistent with this hypothesis, I found WT and SIRPα mt mice had similar 
proportions of pre-DCs in the BM and there appeared to be no defect in the egress 
of progenitors from the BM into the bloodstream. Next, I investigated whether 
SIRPα mt pre-DCs could gain entry to the intestinal LP and develop normally into 
the various DC populations. Competitive adoptive transfers using a 50:50 mix of 
WT and SIRPα mt pre-DCs demonstrated that the pre-DCs from SIRPα mt mice 
could enter the LP and were capable of generating all DC subsets once there. 
However SIRPα mt pre-DCs generated CD103+CD11b+ DCs more rapidly than 
their WT counterparts, with a clear population of SIRPα mt BM-derived 
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CD103+CD11b+ DCs being present in the intestine 3 days after transfer, whereas 
this did not occur until day 5 for the WT-derived CD103+CD11b+ DCs. As I 
reasoned that these findings might indicate that SIRPα signalling might act as a 
brake on the maturation of CD103+CD11b+ DCs, including their acquisition of 
CD103. To investigate this further, I examined whether other facets of 
activation/maturation were affected in CD103+CD11b+ DCs from SIRPα mt mice. 
This showed that this population selectively expressed increased levels of the co-
stimulatory molecule CD86 in the steady state compared with WT counterparts, 
consistent with the proposed role of SIRPα in dampening inflammatory responses 
(Braun et al., 2006).  
Emigration from tissue to draining LN is a classical indicator of DC activation 
and a number of studies have implicated the SIRPα-CD47 axis in DC migration. 
However it is unclear whether SIRPα signalling induces or prevents this process 
(Hagnerud et al., 2006; Motegi et al., 2003; Van et al., 2006). Whereas one study 
demonstrated that ligation of SIRPα by an agonist antibody or CD47-Fc fusion 
protein impaired DC migration (Motegi et al., 2003), others have suggested that 
the reduction in DCs observed in the draining LNs of CD47KO mice reflects 
reduced migration (Hagnerud et al., 2006; Van et al., 2006). To explore this 
directly in the intestine, I collaborated with Dr. Simon Milling’s group and examined 
the DC populations present in pseudo-afferent intestinal lymph from SIRPα mt 
mice. Interestingly, this demonstrated no differences in the proportions of any of 
the SIRPα-expressing DCs, but there was a slight increase in the proportion of 
CD103+CD11b- DCs. At first sight this result seemed surprising in view of the 
sizeable reduction in the proportion of CD103+CD11b+ DCs in the LP, which is the 
main source of these DCs in intestinal lymph. However, putting these findings 
together could suggest that there is actually an underlying increase in the rate of 
migration of this DC population out of the mucosa into the lymph. Future studies 
will examine the DCs in both the LP and the lymph simultaneously allowing the 
severity of the defect in the LP to be assessed alongside the proportions of the DC 
subsets in lymph. 
Despite the inconclusive nature of my experiments in lymph, my results so 
far suggested that the lack of SIRPα-CD47 signalling in the DCs may cause over-
activation of CD103+CD11b+ DCs in LP. As a consequence the last stage of 
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mucosal DC development (CD103+CD11b+ DCs) occurs more quickly than normal 
and these are then triggered to migrate to the MLNs. As this idea would seem to 
be at odds with the defect in CD103+CD11b+ DCs in the MLN, I reasoned that the 
over-activated DCs might be more susceptible to death by apoptosis after their 
arrival in the MLN. Annexin V staining in the MLN supported this idea, by showing 
an increased proportion of apoptotic DCs in SIRPα mt MLN, which was selective 
for the CD103+CD11b+ subset. I did attempt to determine if a similar phenomenon 
occurred in the LP, but these studies were inconclusive perhaps because the 
extensive enzymatic digests, required to isolate the cells from the LP, kill any 
apoptotic cells and thus remaining cells appear to be normal. Alternatively, DCs 
arriving in the LN are known to die rapidly in the absence of cognate T cells, 
possibly explaining the increased apoptosis in the MLN. Additionally CD47 is 
expressed on T cells and the SIRPα/CD47 axis is proposed to be involved in the 
DC:T cell interaction in a manner analogous to the co-stimulatory molecule:CD28 
interaction (Matozaki et al., 2009). Thus inefficient interactions between 
CD103+CD11b+ DCs and T cells might result in the induction of apoptosis in the 
DCs, although I would expect the latter to also induce apoptosis in the other 
SIRPα-expressing migratory DCs in the MLN. 
Because these results might indicate that CD103+CD11b+ DCs in the LP of 
SIRPα mt mice are hyper-activated, I thought it important to assess whether these 
animals might develop spontaneous IBD. As my initial studies in young adult mice 
revealed no evidence of inflammation such as increased neutrophils or monocytes, 
I left a cohort of SIRPα mt mice to age for 11 months. Although this experiment 
was only performed once and hence requires further investigation, the mice 
displayed no clinical signs of IBD or ill-health during this time had no evidence of 
inflammatory infiltrates in the SI LP. However, I found that the aged SIRPα mt 
mice no longer had the defect in CD103+CD11b+ DCs seen in the 6-8 week old mt 
mice I had used previously. This was not due to significant changes in the DC 
populations in aged WT mice and therefore could suggest that regulatory 
mechanisms may come into play to prevent continued over-activation of 
CD103+CD11b+ DCs in the SIRPα mt intestine. This idea remains to be explored 
and intriguingly, the resolution of the DC defect was specific to the intestine and 
MLN, as the splenic defect remained in the aged SIRPα mt mice. The reasons for 
this discrepancy require further investigation, but could indicate a different role for 
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SIRPα in the different tissues, perhaps related to the distinct DC subtypes found in 
these locations. It is important to note that this effect of age on the DC defect in 
the intestine of SIRPα mt mice may have influenced the results obtained from the 
experiments on pseudo-afferent intestinal lymph. For technical reasons, the MLNx 
procedure needed for this protocol cannot be undertaken before 6 weeks of age 
and the mice then have to be left at least 6 weeks to allow reanastomosis of the 
lymphatics before the thoracic duct can be cannulated. Thus the mice used in this 
study were some 6-8 weeks older than those I normally used for phenotyping, 
raising the possibility that these mice had already overcome the DC defect and 
thus might explain why the DC subsets were normal in SIRPα mt lymph. As 
mentioned earlier, future studies will directly compare the lymph and LP from the 
same mice to determine the extent of the DC defect in these animals. As this 
finding came towards the end of my PhD, I did not have time to determine if this 
result was consistent between experiments or examine the exact time frame within 
which the SIRPα mt mice might overcome the DC defect. This is currently under 
investigation by a new PhD student in the lab. 
To begin to understand how the SIRPα mutation was exerting its effects on 
the CD103+CD11b+ DCs, I wanted to address whether the requirement for SIRPα 
was intrinsic to the DCs. To examine this, I generated mixed BM chimeras in 
which WT mice were lethally irradiated before being reconstituted with WT and 
SIRPα mt BM in a 50:50 ratio. This showed no apparent defect in the ability of 
SIRPα mt BM to reconstitute haematopoietic cells in the intestine or MLN, 
including the CD103+CD11b+ DCs. This was not the case in the spleen, where the 
defect in CD4+CD11b+ DCs found in the SIRPα mt mouse was recapitulated by 
SIRPα BM, confirming a previous report (Saito et al., 2010). This result further 
highlights the differences between the requirements for SIRPα-CD47 signalling by 
DCs in the spleen and intestine. When I first carried out this experiment, I 
interpreted the result as showing that the DC defect in the intestine and MLNs of 
SIRPα mt mice was not cell intrinsic, however, again this conclusion may need to 
be reassessed in light of the possible age-related resolution of the DC defect in 
SIRPα mt mice as BM used to reconstitute the irradiated mice were from 8 week 
old animals and the chimeric mice were then left for a further 8 weeks to allow 
reconstitution. Thus it is possible that the defect had already been recovered by 
the time these mice were examined. To investigate this further it could be useful to 
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generate conditional SIRPα mt mice in which the SIRPα mutation has been 
specifically targeted to DCs, perhaps by using a Zbtb46cre-SIRPαflox system. 
Alternatively BM chimeras could be generated using BM from 1-2 week old 
animals. However first we will investigate the time course of the DC defect to 
ascertain at what age the mice recover the DC defect. If it turns out that the DC 
defect is not cell intrinsic, it will be interesting to examine the requirements for 
SIRPα in the non-haematopoietic compartment and I have made straight WT into 
SIRPα mt and SIRPα mt into WT chimeras to examine this in the near future. 
Having identified a defect in intestinal CD103+CD11b+ DCs in SIRPα mt mice, 
I went on to explore its consequences for T cell function. These mice had normal 
numbers of Th1 and TReg cells in the LP under steady state conditions, but had a 
selective reduction in the proportion and number of Th17 cells. Although previous 
studies have observed a reduction in Th17 cells in the spleen, lymph nodes and 
intestine of SIRPα mt mice (Kanazawa et al., 2010; Matozaki et al., 2009; 
Okuzawa et al., 2008; Tomizawa et al., 2007), this was not related to a DC defect 
and therefore I thought it important to rule out the possibility that the SIRPα mt 
mice had an intrinsic inability to generate Th17 cells. This was not the case, as 
similar numbers of Th17 cells could be generated in vitro from WT and SIRPα mt 
naïve CD4+ T cells that were stimulated with α-CD3 and α-CD28 under Th17 cell 
polarising conditions. 
 Interestingly, my finding that a defect in CD103+CD11b+ DCs in the SIRPα 
mt mice correlated with reduced Th17 cells in the steady state mucosa is 
supported by five recent papers (Lewis et al., 2011; Persson et al., 2013b; 
Satpathy et al., 2013; Schlitzer et al., 2013; Welty et al., 2013). To explore this 
further, I next assessed the generation of antigen-specific CD4+ T cells in SIRPα 
mt mice in vivo in response to oral or systemic administration of OVA. Consistent 
with the normal numbers of TReg cells in the SIRPα mt LP, the animals developed 
systemic tolerance as assessed by measurement of antigen-specific DTH 
responses after feeding OVA. However, OVA-specific CD4+ TcR transgenic T cells 
showed defective proliferative responses in the MLNs of SIRPα mt mice after 
feeding OVA, suggesting the initial interaction between antigen-carrying DCs and 
transferred T cells in the MLNs may be impaired in these animals. This could be a 
result of the reduced total DC pool in the MLNs of these mice or alternatively due 
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to a poor interaction between SIRPα on the DCs and CD47 on the T cells. Despite 
this, similar proportions of antigen-specific TReg and Th1 cells developed in SIRPα 
mt MLNs, but there was a trend towards fewer Th17 cells. This experiment could 
be further optimised by blocking output of activated T cells to the LP using FTY720 
as this might have obscured any differences in T cell priming. In addition, feeding 
OVA alone would not be expected to induce significant differentiation of Th17 cells. 
To overcome these issues, I next transferred OTII cells into mice that were then 
immunised with OVA, together with LPS and α-CD40 as adjuvants to deliberately 
drive Th17 polarisation (Persson et al., 2013b). Furthermore, the mice received 
two doses of FTY720 to block T cell egress from the MLN. Under these conditions, 
there was a clear reduction in the clonal expansion of donor T cells and defect in 
the generation of Th17 cells in the MLNs of SIRPα mt mice, while the relative 
proportions of TReg and Th1 cells were increased. These results suggest that the 
lack of CD103+CD11b+ DCs in the MLNs of SIRPα mt mice results in reduced 
Th17 cell priming. Similarly, SIRPα mt mice demonstrated a reduced ability to clear 
the C. rodentium infection and this was associated with impaired Th17 cell 
differentiation in the MLN. This is consistent with previous studies suggesting that 
SIRPα mt mice are less susceptible to Th17-mediated CHS and EAE (Motegi et 
al., 2008; Tomizawa et al., 2007).  
Although consistent with a number of reports which have suggested 
intestinal CD103+CD11b+ DCs to be the main inducers of mucosal Th17 responses 
(Lewis et al., 2011; Persson et al., 2013b; Schlitzer et al., 2013), this finding 
contrasts with a recent report which demonstrated that CD103+CD11b+ DCs did 
not directly prime Th17 cells as MHCII expression by these cells was not required 
for the presence of Th17 cells in the LP (Welty et al., 2013). Thus an alternative 
explanation for this result, is that instead of CD103+CD11b+ DCs priming Th17 
cells and hence there being less of these T cells due to the reduction in this DC 
population in SIRPα mt mice, the interaction between SIRPα-expressing DCs and 
CD47-expressing T cells may be impaired in these mice and hence antigen-
presentation by the SIRPα-expressing DCs is impaired. As my other studies found 
the CCR2+CD103-CD11b+ intestinal DCs to be the main inducers of Th17 cells and 
these DCs also express SIRPα, this is a valid second hypothesis. Additionally, this 
would be consistent with my findings that CD103+CD11b+ DCs FACS-purified from 
SIRPα mt LP were equally as capable of generating Th17 cells in vitro as their WT 
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counterparts, while the CD103-CD11b+ DCs FACS-purified from SIRPα-mice 
appeared to be less efficient at inducing Th17 cells than their WT controls. 
Although, this experiment requires repetition, it suggests that the defect in 
CD103+CD11b+ DCs and Th17 cells in SIRPα mt mice may be a combined effect 
of reduced Th17 cell priming in the MLNs by CD103-CD11b+ DCs and impaired 
maintenance of the Th17 cell pool in the LP by the reduced population of 
CD103+CD11b+ DCs. This model would also begin to explain the discrepancies I 
had seen with Th17 cell and CD103+CD11b+ DC numbers in the LP following 
antibiotic administration. That the effect on CD103+CD11b+ DCs may not explain 
fully the T cell phenotype in SIRPα mt mice is supported by my findings that 
SIRPα mt CD103+CD11b+ DCs from the SI LP produced normal amounts of the 
Th17 polarising cytokines IL6 and IL1β. Conversely, there was a decrease in the 
overall levels of these cytokines when total SIRPα mt DCs were used and this 
slightly reduced IL6 and IL1β may demonstrate that the reduction in 
CD103+CD11b+ DCs leads to less overall Th17 polarising cytokines within the DC 
pool as hypothesised in a recent study using a CD11c-driven conditional KO of 
IRF4 (Persson et al., 2013b). Again, these studies need to be repeated and 
CD103-CD11b+ DCs particularly the CCR2+ fraction will also be examined for their 
cytokine profile. Performing similar in vivo priming experiments to those described 
above in CD47KO mice could also test the requirement for a SIRPα-CD47 
interaction between DCs and T cells. These mice have a similar defect in 
CD103+CD11b+ DCs, however the remaining DCs have functional SIRPα. While 
the endogenous T cells lack CD47 expression in these mice, the transferred OTII 
cells will express this molecule and hence if normal priming occurs following OVA 
and adjuvant administration, it would suggest that it is the interaction between 
SIRPα on the DCs and CD47 on the T cells that contributes to this Th17 
phenotype rather than the correlative reduction in CD103+CD11b+ DCs. These 
experiments are currently ongoing in the lab. Moreover, it will be important to 
perform the in vitro co-culture assays using DCs FACS-purified from the MLNs 
rather than the LP of WT or SIRPα mt mice as these are the ones involved in T 
cell priming.  
In addition to examining the DC defect, as well as its causes and 
consequences, I tried to connect the CD103+CD11b+ DC defect in the SIRPα mt 
mice to those reported in other models.  Interestingly, my results indicate that 
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there may be a feedback loop between SIRPα and IRF4, as the expression of Irf4 
mRNA was increased amongst CD103+CD11b+ DCs in SIRPα mt mice. However, 
I could find no evidence for a direct link between SIRPα and IRF4 signalling 
pathways in the literature and nor could I find a link between SIRPα and Notch2 
signalling, despite conditional CD11c-driven KOs of both these molecules causing 
a reduction in the numbers of CD103+CD11b+ DCs and Th17 cells in the LP (Lewis 
et al., 2011; Persson et al., 2013b; Schlitzer et al., 2013). 
As DCs are also essential for IgA production in the gut (Bergtold et al., 2005; 
Castigli et al., 2005; Massacand et al., 2008) and Th17 cells are also implicated in 
this (Hirota et al., 2013), I also examined if the defects in these populations played 
any part in this process by assessing total faecal IgA levels in WT and SIRPα mt 
mice. While no differences were observed, it will be important to examine antigen-
specific IgA responses in these animals, especially as it has been reported that 
CD47KO mice have decreased production of IgA following oral immunisation 
(Westlund et al., 2011).  
Finally I examined the role played by SIRPα signalling and CD103+CD11b+ 
DCs during DSS colitis. When I began my PhD, others had reported that CD47KO 
mice were protected from TNBS-induced colitis due to a failure to recruit CD103-
SIRPα+ monocyte-derived ‘DCs’ (Fortin et al., 2009). However as noted earlier, 
these were identified as ‘DCs’ solely on the basis of CD11c expression and so 
would have included macrophages and eosinophils. In my hands, the SIRPα 
mutation had no effects on disease progression or clinical score during DSS colitis. 
This may be due to the differences between these two models of IBD, but may 
also reflect a role for an additional ligand for CD47 such as surfactant proteins 
(Akiyama et al., 2002; Fournier et al., 2012; Gardai et al., 2003; Janssen et al., 
2008; Madsen et al., 2000). Alternatively, the extracellular SIRPα region, which is 
still present in SIRPα mt mice, although expressed at lower levels, may enable 
active CD47 signalling which is required for protection from colitis. Indeed while 
preparing this thesis, I found CD47KO mice to be less susceptible to DSS colitis 
that WT controls. 
My findings that SIRPα plays an important role in the activation of certain 
DCs and the generation of Th17 responses may have therapeutic implications. 
 331 
Indeed it has been shown ligating SIRPα with a CD47-Fc fusion protein can 
dampen IL1β and TNFα production (Baba et al., 2013). I did obtain CD47-Fc 
fusion protein to study this, but as it is a human homolog it did not bind murine 
SIRPα and these studies were unsuccessful. We are currently devising methods 
and applying for ethical approval to investigate this in vitro with human samples.  
10.7.1 Proposed Model for the Role of SIRPα Signalling  
My results suggest that SIRPα signalling may have a number of effects on 
intestinal DCs, the overall results culminating in a selective defect in the 
CD103+CD11b+ subset. Firstly, it appears to control their development, with 
CD103+CD11b+ DCs appearing in the mucosa more rapidly when pre-DCs lack 
the ability to signal via SIRPα. This suggests that SIRPα on arriving pre-DCs may 
interact with CD47 in the mucosa, acting as a brake on the differentiation of 
CD103+CD11b+ DCs (Fig. 10.1). Although it is possible that SIRPα ligands other 
than CD47 might be involved in this process, this seems unlikely, as the defect in 
CD103+CD11b+ DCs is phenocopied in CD47KO mice. The CD47-expressing cell 
responsible for the local ligation of SIRPα is unclear and given the complex 
strategies which will be needed to identify the relevant cell amongst the wide 
range that expresses CD47, this is a major challenge for the future.  
The idea that SIRPα normally acts as an inhibitory factor for a specific 
subset of intestinal DCs is supported by the fact that those CD103+CD11b+ DCs 
that appear in SIRPα mutant mice appear to be more activated than WT DCs, as 
indicated by their expression of higher levels of CD86. Although not proven, it 
seems likely this role of SIRPα requires direct interaction with yet to be identified 
CD47+ cells in the mucosa. If this increased activation of CD103+CD11b+ DCs can 
be confirmed, I hypothesise that it could be at least part of the explanation for the 
decreased population of CD103+CD11b+ DCs in the SIRPα mt LP, as it may lead 
to more rapid emigration of the CD103+CD11b+ DCs to the MLN and/or enhanced 
apoptosis of CD103+CD11b+ DCs in SIRPα mt intestine. As discussed above, 
although I tried to examine both these possibilities, further investigation is required 
before any conclusions can be drawn. However, despite being unable to obtain 
meaningful results from apoptosis assays using LP DCs, I was able to confirm that 
CD103+CD11b+ DCs from SIRPα mt MLNs are indeed more apoptotic than WT 
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counterparts. This increased susceptibility to apoptosis has also been suggested 
to control the CD11b+ DC defect in the spleen (Saito et al., 2010) and more 
recently, the lack of IRF4 signalling in CD11c-expressing cells has also been 
suggested to cause the apoptosis of CD103+CD11b+ DCs (Persson et al., 2013b).   
A universal feature of all the recent studies including my own in which there 
is a selective reduction in CD103+CD11b+ DCs is poor priming of Th17 cells in the 
MLN and a smaller than normal population of Th17 cells in steady state LP (Fig. 
10.1). One possibility is that this reflects a specific role for the SIRPα - CD47 axis 
in co-stimulation of Th17 cell differentiation, as was suggested by early studies of 
SIRPα function on DCs (Matozaki et al., 2009). My experiments attempting to 
explore these issues were relatively inconclusive, although my findings that the 
loss of CD103+CD11b+ DCs reduced IL6 production by the total intestinal DC pool 
are consistent with similar conclusions from CD11c-cre-IRF4 KO mice (Persson et 
al., 2013b). Together with the fact that the remaining CD103+CD11b+ DCs appear 
to function normally in both cases, this could suggest that the lower levels of Th17 
priming may simply reflect the lower numbers of the DCs, rather than a role for 
SIRPα in DC function. This idea would also be consistent with a very recent paper 
which shows that selective deletion of CD103+CD11b+ DCs in the LP by targeting 
them with diphtheria toxin A driven by the human langerin promoter also results in 
a reduced population of LP Th17 cells (Welty et al., 2013). Interestingly however, 
this study also suggested that cognate interactions between CD103+CD11b+ DCs 
and Th17 were not involved in the link between these cells, as the presence of 
Th17 cells in the LP did not require MHCII expression on the CD103+CD11b+ DCs 
(Welty et al., 2013). Thus is it is possible that the absence of CD103+CD11b+ DCs 
influences the behaviour of other cells involved in priming of Th17 cells, perhaps 
acting as sources of polarizing cytokines such as IL6 or IL23, or by providing a 
depot for antigen. Alternatively, the lack of SIRPα signalling may directly affect the 
function of the other SIRPα expressing DCs such as the CCR2+CD103-CD11b+ 
DCs, which I have demonstrated to be the most potent inducers of mucosal Th17 
responses. Further studies are required to explore these issues. 
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Figure 10.1: Working model for the role of the SIRPα-CD47 axis in CD103+CD11b+ DC 
homeostasis and function 
 
10.8 An Overview of Intestinal DC Subsets 
The results of my project have shown that DCs in the intestinal mucosa are 
much more heterogeneous than previously thought at least at the phenotypic level. 
An important question raised by this study is whether the intestinal DC subsets I 
identified are distinct populations or rather simply represent different maturation 
states of the same lineage. My findings confirm other work indicating that the 
CD103+CD11b-CD8α+ DCs are a distinct population from the CD11b+ DCs, having 
different behaviour and being dependent upon distinct transcription factors 
(Edelson et al., 2011; Schraml et al., 2013), as mentioned above, this raises the 
important question of distinct precursor subsets giving rise to these distinct DC 
lineages and this will be a focus of future studies, potentially using the barcoding 
system recently described by Naik and colleagues, in which the fate of transferred 
progenitors can be tracked at the single cell level (Naik et al., 2013).  
The relationship between the CD103+ and CD103- subsets of CD11b+ DCs 
is less well defined, as is the position of the minor CD103-CD11b- DCs in any 
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developmental scheme. While a recent report has suggested the presence of 
CD103-CD11b- DCs in LP preparations is due to contamination by ILFs, these 
DCs were not completely absent from LP digests from RORγt-deficient animals 
(Cerovic et al., 2013), suggesting that a proportion may be also present in the LP. 
These cells are heterogeneous for many of the markers I examined, thus they may 
represent a mixture of follicle-derived and genuine mucosal DCs.  Interestingly, 
they were the first to appear in the LP following adoptive transfer of pre-DCs. This 
could suggest that they are an intermediary phenotype in DC development and 
this may also explain their heterogeneity, as a proportion express markers 
consistent with the CD103+CD11b- lineage, including CD8α and XCR1 (Bachem et 
al., 2012; Crozat et al., 2011; Edelson et al., 2010), while others express 
SIRPα, which is typically associated with CD11b+ DCs (Persson et al., 2013b; 
Schlitzer et al., 2013). It could also be argued that the other subsets develop from 
a second wave of pre-DCs which take longer to enter the mucosa than the CD103-
CD11b- DC precursors, but this seems unlikely as I could not find donor cells in 
the bloodstream 24hours after injection, whereas the CD103-CD11b+ and 
CD103+CD11b- DC subsets were not detected in the mucosa until days 3-5 post 
transfer. Intestinal CD103+CD11b+ DCs were found in the mucosa even later, with 
these cells not appearing until days 5-7 after transfer of pre-DCs, providing indirect 
evidence that a lineage relationship might exist between the CD103-CD11b+ and 
CD103+CD11b+ DC subsets. Additionally, these CD103+CD11b+ DCs do not 
appear in the intestine until day 7 of life while the other populations are present in 
neonatal animals from birth. While I was finalising this discussion, I received 
preliminary data from my microarray analyses, which demonstrated that only 127 
genes are differentially regulated between these subsets, including CD103 and 
CCR2. This high degree of similarity between the two subsets further supports the 
hypothesis that these may be developmentally related. A recent report that loss of 
IRF4 on CD11c-expressing cells affects both the CD103+CD11b+ and CD103-
CD11b+ DCs in the MLN also supports such a relationship (Persson et al., 2013b). 
Further evidence for a developmental link between these two CD11b+ DC subsets 
comes from my functional studies which suggest both may be involved in the 
generation of mucosal Th17 responses, albeit with the CD103-expressing CD11b+ 
DCs also inducing FoxP3+ TReg cells. Perhaps along this differentiation process the 
cells are imprinted with a tolerogenic phenotype, explaining their specificity in the 
gut, which is continuously exposed to a number of harmless antigens?  
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While there are a number of lines of evidence that suggest a developmental 
relationship may exist between the CD103- and CD103+ CD11b+ DCs, evidence 
also exists to the contrary. The main point against such a relationship is that all 
four mucosal DC populations are capable of migrating to the MLN, being present 
both in intestinal lymph (Cerovic et al., 2013) and amongst MHCIIhi DCs in the 
MLN suggesting that at least some of them are terminally differentiated and ready 
to prime naïve T cells. Additional evidence against such a linear relationship 
comes from the studies of the CCR2-/- mice which have a selective reduction in 
CD103-CD11b+ DCs with CD103+CD11b+ DCs being unaffected. My BrdU studies 
also might argue against an ontogenical relationship between the subsets, as all 
the populations showed parallel uptake of BrdU at both 3 hours and 3 days after 
BrdU administration. However, this could reflect the rapid kinetics of DCs, meaning 
that the long term feeding protocol would achieve maximal labelling quickly and 
hence any differences at earlier points may be missed. This could potentially be 
examined by analysing a number of intermediate time points such as after 12 
hours of feeding. However, the definitive proof that CD103-CD11b+ DCs could 
become CD103+CD11b+ DCs would need to involve transfer of CD103-CD11b+ 
DCs, which would then need to acquire CD103 in vivo. Such an experiment is 
technically challenging as it is unclear if these short-lived DCs would travel to the 
intestine and if enough cells could be transferred to allow a significant population 
to be identified in the LP enabling assessment of CD103 expression. Alternatively, 
the presence of a developmental relationship could be assessed using a novel fate 
mapping system in which a gene could be identified that is expressed by CD103-
CD11b+ DCs but not by pre-DCs (or earlier progenitors) and CD103+CD11b+ DCs. 
With such a gene, a fate mapping mouse could be generated using Cre 
recombinase-mediated excision with a ROSA26-reporter mouse (Luche et al., 
2007; Mao et al., 2001). Thus any cell that has once expressed the gene will be 
labelled and hence any labelled CD103+CD11b+ DCs will have come through a 
CD103-CD11b+ intermediate step. This approach is obviously limited by our 
identification of a suitable gene, perhaps my microarray analyses of the distinct 
subsets coupled with previously analyses of pre-DCs might allow for such a gene 
to be identified. However, fate-mapping mice are not devoid of technical 
challenges, as these often have issues with the labelling efficiencies. This was 
recently demonstrated in the DNGR-1 fate mapping mouse where CD11b+ DCs 
were only 50% labelled compared to the CD11b- DCs which were almost 100% 
labelled, despite progenitors being uniformly DNGR-1+ (Schraml et al., 2013). 
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My identification of CCR2- and CCR2+ fractions of CD103-CD11b+ DCs adds 
a further level of complexity to this maturation hypothesis. While pre-DCs in the 
BM are heterogeneous for CCR2, competitive adoptive transfers of pre-DCs from 
WT and CCR2-/- mice, showed that the CCR2-/- progenitors were outcompeted by 
their WT counterparts in generating all DC subsets, despite there only being a 
reduction in the CD103-CD11b+ DCs in the CCR2-/- mice LP. My functional data 
may shed some light on the relationship. The CCR2+ fraction of CD103-CD11b+ 
DCs is more pro-inflammatory, being the most efficient at Th17 cell priming. 
Although both the CCR2-CD103-CD11b+ and CD103+CD11b+ DCs also appear to 
be capable priming Th17 cells, they were less efficient than the CCR2+CD103-
CD11b+ DCs and recent data suggest that the CD103+CD11b+ DCs are in fact 
dispensable for Th17 cell priming (Welty et al., 2013). It is possible that the DC 
progenitors enter the gut and first develop into CCR2+CD103-CD11b+ pro-
inflammatory DCs, these then lose CCR2 expression and acquire CD103 
expression, as well as the ability to induce TReg cells. However, this hypothesis is 
purely speculative and experiments will need to be designed as described above 
to directly examine this.  
While CCR2 and CD103 may be useful markers for delineating the 
differentiation process, a number of questions remain, for example little is known 
about the role of these markers. CCR2 is known to be involved in monocyte 
egress from the BM (Serbina and Pamer, 2006), however the CCR2+ DCs are not 
monocyte-derived and my results to date suggest that CCR2 is not required on 
pre-DCs for their egress to the blood. While my data suggest CCR2 on pre-DCs 
may be involved in their ability to access tissues, this remains to be verified. 
Experiments examining the effects of exogenous CCL2 on the DC subsets could 
help to elucidate the role of this receptor and this will be examined in the future. 
Similarly the role of CD103 remains unclear. CD103 as it is expressed on TReg 
cells was originally thought to contribute to their function. Although demonstrating 
it was dispensable for this, Annacker and colleagues reported its presence on a 
CD11c-expressing cell and showed that these cells were required for protection 
from T-cell mediated colitis (Annacker et al., 2005). However, this probably does 
not require CD103 itself. Additionally although CD103+ DCs are reported to drive 
the expression of the gut homing receptor, CCR9, on interacting naïve T cells and 
induce FoxP3+ TReg cells (Coombes et al., 2007; Johansson-Lindbom et al., 2005; 
Siddiqui and Powrie, 2008; Sun et al., 2007), CD103 also appears dispensable for 
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this (Jaensson et al., 2008). Interestingly and consistent with CD103+ DCs being 
more tolerogenic, it has recently been shown that CD103 is also dispensable on 
DCs for immunity against helminth infection (Mullaly et al., 2011).  
Another important question is whether once the DCs acquire CD103 and 
their seemingly tolerogenic phenotype can they revert to their previous more pro-
inflammatory phenotype if this is so desired? It has been previously been reported 
that intestinal inflammation can re-programme the tolerogenic nature of MLN 
CD103+ DCs (Laffont et al., 2010) and thus it is possible that while the default 
property of steady state CD103+CD11b+ DCs is to drive FoxP3+ TReg cell priming, 
exposure to pathogens can cause them to revert to a more pro-inflammatory 
phenotype inducing Th17 cells (Satpathy et al., 2013). This would be consistent 
with a recent study by Kinnebrew and co-workers, which showed that following 
stimulation with the TLR5 agonist the CD103+CD11b+ DCs could be induced to 
produce IL23p19 (Kinnebrew et al., 2012). Single cell transfers, mature DC 
transfers, fate-mapping, transcriptome studies and in vitro cultures with various 
microbial-derived such as TLR ligands would help to investigate this in the future. 
Regardless of whether a developmental relationship exists it will be 
interesting to elucidate the signals involved in the differentiation of CD103+CD11b+ 
DCs and why these are specific to the intestine in the steady state, but can also be 
found in the lung during inflammation (Guilliams et al., 2013a). Also it remains 
unclear if the same signal induces CD103 expression on both CD11b- and CD11b+ 
DCs. It is possible that the microbiota are involved in the development of 
CD103+CD11b+ DCs, although then one might expect there to be more 
CD103+CD11b+ DCs in the colon given the higher microbial burden. Additionally, 
studies in germ-free animals, although inaccurately identifying intestinal MPs, have 
not reported on the absence of CD103-expressing DCs (Rivollier et al., 2012). As 
these studies did not discriminate between CD11b+ and CD11b- CD103+ DCs 
based on the gating strategies used, further experiments are required to directly 
investigate this possibility. Perhaps specific bacterial strains are involved in the 
generation of CD103+CD11b+ DCs. This may explain why administration of 
antibiotics appeared to affect their prevalence in the SI LP and why new-born mice 
lack these DCs.  Another candidate is CSF-2 (Greter et al., 2012), but this also 
seems to affect CD103+CD11b- DCs in other tissues and my studies using CSF-
2RKO or exogenous administration of CSF-2 were inconclusive. Furthermore, as 
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discussed above my preliminary data have found CSF-2 levels to be quite low in 
the intestine in comparison to other tissues, such as the lung where 
CD103+CD11b+ DCs are usually absent. A recent study has suggested that 
retinoic acid may be the signal involved in CD103+CD11b+ DC development in the 
gut (Klebanoff et al., 2013), However, this report is in direct contrast to previously 
published studies which suggested RA to be dispensable for the phenotype of gut-
derived DCs in the MLN (Jaensson-Gyllenbäck et al., 2011) and thus this requires 
further examination. Finally, my results using the SIRPα mt mice suggest a role for 
the SIRPα-CD47 axis in the generation of CD103+CD11b+ DCs, although whether 
this can be manipulated to generate or prevent the generation of CD103+CD11b+ 
DCs remains to be investigated.  
Identifying the localisation of the distinct DC populations in the mucosa may 
help to delineate the factors involved in the generation of CD103+CD11b+ DCs, as 
it is possible that their phenotype and function is controlled by their location. It 
takes 8 fluorescent labels to identify accurately the different DC populations in the 
SI LP by flow cytometry, and thus as currently there has only been one report of 
immuno-histochemistry with this many fluorochromes (Gerner et al., 2012), this 
represents a long-term goal for the future. Interestingly, since completing my 
project, I have found that the CD103+ DC subsets can also be isolated from the 
epithelial fraction of mucosal isolates. This is particularly the case for 
CD103+CD11b+ DCs, while CD103- DCs could not be found in these isolates. As 
the ligand for CD103 is E-cadherin, which is expressed by epithelial cells, this 
could suggest a preferential association between these cells and perhaps CD103 
acts to keep the DCs in this location. However, the reasons for the presence of 
DCs in this location and hence the specific need for CD103+CD11b+ DCs in the 
intestine remains unclear. It is possible that the epithelial cell interaction might be 
responsible for the terminal differentiation of CD103+CD11b+ DCs as they produce 
a number of immunomodulatory molecules as discussed in Chapter 1. The specific 
compounds that may be involved however, requires direct investigation. 
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10.8.1 A Proposed Scheme 
Taken together, it is clear that no definitive conclusions can be drawn 
regarding the inter-relationship between DC subsets at this time, largely because 
the techniques are not yet available to complete the analysis required to 
specifically address these issues. However based on the evidence available from 
my thesis and elsewhere a tentative scheme could be proposed, as shown in Fig. 
10.2. In this scheme, pre-DCs enter the mucosa and first acquire CD11c and 
MHCII expression to become CD103-CD11b- DCs. Following CD11c and MHCII 
acquisition, the DCs begin to divide in situ and continue to do so throughout their 
development. These may then subsequently acquire either CD11b or CD103 to 
become CD103-CD11b+ or CD103+CD11b- DCs respectively. Alternatively, 
although not shown in the scheme, these phenotypes may develop from the pre-
DCs without a CD103-CD11b- intermediate step, as these DCs may be restricted 
to the ILFs and be contaminants of the LP digests as previously described 
(Cerovic et al., 2013). The next stage of differentiation sees the development of 
CD103+CD11b+ DCs presumably from the closely related CD103-CD11b+ DCs. 
This appears to be regulated through the SIRPα-CD47 axis, with more efficient 
generation of CD103+CD11b+ DCs in the absence of SIRPα signalling. Again, 
while not shown in the scheme, the development of CD103+CD11b+ DCs may 
occur independently of CD103-CD11b+ DCs. 
As pre-DCs are heterogeneous for CCR2 expression, the CCR2- and 
CCR2+ pre-DCs may preferentially generate CCR2- and CCR2+ CD103-CD11b- 
and CCR2- and CCR2+ CD103-CD11b+ DCs respectively. The relationship 
between CCR2- and CCR2+ pre-DCs and maturing DCs remains to be examined, 
but the CCR2+ DCs may subsequently downregulate CCR2 to give rise to CCR2- 
counterparts. The CD103+CD11b+ DCs then develop from the CD103-CD11b+ 
DCs by downregulating CCR2 and upregulating CD103 expression also acquiring 
a more tolerogenic phenotype in the process. Additionally at each stage of 
differentiation some DCs may migrate to the MLN if they receive the correct 
signals, which remain to be identified. These could begin to be elucidated by 
examining the transcriptional differences between DCs in the LP, lymph and MLN.  
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Figure 10.2: Inter-relationship between DC subsets 
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10.9 Concluding Remarks 
While these studies have increased our understanding of intestinal DCs and 
their functions, a number of questions remain to be addressed. From my extensive 
phenotyping analysis, it is now clear that there are multiple populations of genuine 
DCs in the gut, including previously undescribed CD103- DCs, the presence of 
which has recently been confirmed in two separate studies while I was preparing 
this thesis (Schlitzer et al., 2013; Schraml et al., 2013). Interestingly I have 
uncovered a novel role for CCR2 in intestinal DCs with CCR2 expression 
delineating functionally distinct subsets. Furthermore, I have shown the SIRPα-
CD47 axis to be involved in the development and maturation of CD103+CD11b+ 
DCs. As discussed above, one of the main questions arising from these studies is 
the nature of the relationship between the DCs subsets. If we can identify a gene 
from our microarray analyses that is expressed exclusively in the CD103-CD11b+ 
DCs but turned off in the CD103+CD11b+ DCs, it may be possible to generate a 
fate-mapping mouse system to directly investigate such a relationship.  
In addition to the outstanding questions surrounding DC ontogeny, the role 
for SIRPα remains to be elucidated. My studies implicate the SIRPα-CD47 axis in 
the development of CD103+CD11b+ DCs, but how it functions in this regard 
remains to be seen. Moreover considerable work is required to elucidate if the 
SIRPα mutation affects the function of the CD103-CD11b+ DCs or if the Th17 
defect is a consequence of the reduced population of CD103+CD11b+ DCs seen in 
SIRPα mt mice. The ageing phenomenon in these mice also requires further 
investigation and this is currently underway in the laboratory.  
The overall importance of my findings is that we can now accurately 
discriminate CD103- and CD103+ DCs from other intestinal MPs and so we can 
begin to address their selective roles in regulating immune homeostasis. While I 
have begun to elucidate the functional specialisations of each DC population in the 
steady state gut and during C. rodentium infection, future studies can focus on 
identifying their functions in disease states. Furthermore, as I have shown in 
collaboration with Dr. Simon Milling’s group that it might be possible to extrapolate 
these findings to the human gut and it would be interesting to compare these cells 
in healthy humans and in patients with IBD. As my findings suggest that the 
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SIRPα-CD47 axis may regulate at least one of these DC populations, future work 
could focus on targeting this pathway to enhance or retard CD103+CD11b+ DC 
development as appropriate in various disease settings. Given their apparent dual 
ability to induce TReg and Th17 responses, manipulation of these DCs may be 
beneficial in both the development of oral vaccines and IBD therapeutics. As 
targeting SIRPα through the use of CD47-Fc fusion proteins has already been 
reported (Baba et al., 2013), this may be a viable therapeutic strategy in the near 
future. 
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